[{"Name":"P53","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":1451055,"Description":"The p53 gene is located on chromosome 17p and encodes for a 53-kd nuclear phosphoprotein. The 3-year survival rate was 96.7% of 39 patients with p53-negative carcinomas and 61.8% for the patients with p53-positive tumors; there was a significant difference in the rate between the two groups of patients (P < 0.05). These results suggest that the immunoreactivity of p53 may be a biologic marker of prognostic significance.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":1},{"Name":"Sialosyl-Tn","Molecular type":"Protein","Location":"Colon","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":2224793,"Description":"Multivariate regression analysis revealed that tumor ploidy (P less than 0.001) and sialosyl-Tn expression (P less than 0.05) were the two variables of most importance for predicting both disease-free and overall survival. The authors conclude that sialosyl-Tn expression is an independent predictor of poor prognosis in colon cancer","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":2},{"Name":"Tumour-associated trypsin inhibitor (TATI)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Blood","Assay\/Test":"Radioimmunoassay","Usage":"DiagnosticBM","Pmid":7667604,"Description":"The tumour-associated trypsin inhibitor (TATI) is a peptide which was initially detected in patients with gynaecological malignancies The results suggest that TATI is a very sensitive marker in colorectal cancer, but its utility is limited because of its low specificity in symptomatic patients. The results suggest that TATI is a very sensitive marker in colorectal cancer, but its utility is limited because of its low specificity in symptomatic patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":3},{"Name":"Sialyl Lewis(a) antigen(SLA)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":7697593,"Description":"Sialyl Lewis(a) antigen (SLA) is considered to be a cancer-associated carbohydrate antigen. As determined by multivariate analysis, SLA expression in the primary tumor correlated strongly with recurrence (P = 3.0E-6) and survival (P = 6.9E-3). Sialyl Lewis(a) antigen expression in primary tumors and metastases to regional lymph nodes is a useful marker for evaluating tumor aggressiveness and prognosis in patients with advanced colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":4},{"Name":"Urokinase-type plasminogen activator (uPA)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":7777251,"Description":"Prognosis was poorer in the uPA-positive patients than in the uPA-negative patients. Therefore, uPA may be a good predictor of metastasis and prognosis.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":5},{"Name":"IGF-1 receptors (IGF-1R)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Blood","Assay\/Test":"Immunoradiometric assay","Usage":"PrognosticBM","Pmid":7851547,"Description":"We conclude that there was a trend of better overall survival in patients with IGF-1R+ tumours, and PRL < 20.0 ng\/ml plasma when compared to patients with IGF-1R- tumours, and PRL > 20.0 ng\/ml plasma. IGF-1R negativity in conjunction with hyperprolactinemia could be used as an indicator of unfavourable prognosis in patients with Dukes B or C colon\/rectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":6},{"Name":"E-cadherin","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"In situ hybridisation","Usage":"PrognosticBM","Pmid":7880746,"Description":"Patients surviving 5 years or longer (n = 31) exhibited significantly higher levels of E-cadherin mRNA than those surviving less than 5 years (n = 18, P = 0.003).\u00a0 These preliminary results from this small sample suggest that E-cadherin expression may be a useful prognostic marker in colorectal cancer patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":7},{"Name":"Proliferating cell nuclear antigen (PCNA)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PredictiveBM","Pmid":7908689,"Description":"Two features were independently associated with the likelihood of marked pathologic regression after preoperative irradiation: lesion size and PCNA\/mitotic activity. When stratified by tumor size, marked tumor regression occurred most frequently in smaller tumors with high PCNA\/mitotic activity compared with larger tumors with lower PCNA\/mitotic activity. Intermediate downstaging rates were seen for small or large tumors with moderate PCNA\/mitotic activity Tumor PCNA\/mitotic activity predicts the likelihood of response to irradiation, which may aid in formulating treatment policies for patients with rectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":8},{"Name":"P53","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":7931472,"Description":"The p53 gene is located on chromosome 17p and encodes for a 53-kd nuclear phosphoprotein. By multivariate analysis, p53 overexpression was found to be an independent predictor for disease-free and disease-specific survival. In node-positive colorectal cancer patients with low preoperative CEA levels, nuclear p53 overexpression as determined by immunohistochemistry on archived tissue is an independent predictor for prognosis.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":9},{"Name":"Gp78","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":8082090,"Description":"Multivariate analysis with the Cox regression model indicated that gp78 positivity was a good predictor of disease recurrence, ranking with extent of tumor invasion (T classification) and lymph node status (N classification). Increased expression of gp78 is correlated with a high incidence of recurrence and, consequently, with decreased survival of patients with colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":10},{"Name":"Proliferating cell nuclear antigen (PCNA)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":8095176,"Description":"The proliferation indexes in both cancer cells and epithelial cells of adjacent nonneoplastic crypts were elevated significantly in those who died compared with survivors; this finding was independent of other variables.\u00a0 Proliferation indexes in neoplastic and adjacent normal mucosa, as defined by PCNA immunohistochemical analysis, are independent predictors of recurrence and poor survival in patients with colorectal cancer, indicating that they may be helpful as predictors of long-term survival and in planning prophylactic adjuvant therapy.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":11},{"Name":"Prolactin (PRL)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Blood","Assay\/Test":"Radioimmunoassay","Usage":"PrognosticBM","Pmid":8299078,"Description":"Patients with preoperative levels of prolactin greater than 20.0 ng\/ml had shorter overall survival times than did those with prolactin levels less than 20.0 ng\/ml plasma; such a trend was not observed for patients with CEA levels less than 5.0 ng\/ml and those with CEA levels greater than 5.0 ng\/ml plasma. Prolactin is a better overall marker than is CEA in patients with Dukes B or C colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":12},{"Name":"Small Intestinal Mucin Antigen (SIMA) ","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Blood","Assay\/Test":"ELISA","Usage":"DiagnosticBM","Pmid":8509213,"Description":"In a sample of 113 patients with colorectal cancer, SIMA serum levels were elevated in 15% of patients with Dukes' Stage A, 38% with Stage B, 32% with Stage C and 75% with Stage D colorectal cancer. We propose that SIMA will prove to be a valuable serological tumor marker, in combination with CEA and other tumor markers, for the detection of colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":13},{"Name":"CD44v","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"DiagnosticBM","Pmid":8527042,"Description":"CD44 is a glycoprotein expressed in a wide variety of cell types. Recently expression of some alternatively-spliced variants of CD44 transcripts (CD44v) has been suggested to play a potential role in tumor metastasis and the detection of CD44v containing exon 6 to 11 may be helpful for the diagnosis of cancers. CD44v containing exon 6 to 11 was expressed in 18 cases of colorectal cancers (sensitivity = 90%), 3 out of 4 cell lines, and one normal tissue (specificity = 95%). These results suggest that the expression of CD44v containing exon 6 to 11 can be regarded as tumor specific and that this marker may be helpful for the early diagnosis of colon cancers, if specimens from the early stage are available.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":14},{"Name":"CD44v8-10","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":8648366,"Description":"The CD44 molecule also binds the extracellular matrix components hyaluronic acid, fibronectin, and collagen In multivariate analysis using the Cox regression model, CD44v8-10 expression emerged as an independent prognostic indicator. The results suggest that CD44v8-10 plays a role in metastasis of colorectal cancer, and tha CD44v8-10 expression may be a biologic marker of prognostic significance.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":15},{"Name":"P53 ","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":8874329,"Description":"The p53 gene is located on chromosome 17p and encodes for a 53-kd nuclear phosphoprotein. By multivariate analysis, p53 protein status was the single best predictor of survival, with a relative risk of 6.312. Our results indicate that nuclear p53 protein status in primary CRC is similar to that in metastatic sites and may be the dominant predictor of survival in patients with advanced hepatic metastases","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":16},{"Name":"CD44 v6","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":8883258,"Description":"The CD45 molecule also binds the extracellular matrix components hyaluronic acid, fibronectin, and collagen The 5-year survival rate was significantly higher in patients with CD44 v6 negative cancer (84%) than in those with CD44 v6 positive cancer (31%). Thus, we concluded that CD44 v6 could be a reliable prognostic indicator, as well as a predictor of metastatic potential after curative surgery for colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":17},{"Name":"DCC (deleted in colorectal cancer) ","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":8929264,"Description":"The expression of DCC was a strong positive predictive factor for survival in both stage II and stage III colorectal carcinomas. DCC is a prognostic marker in patients with stage II or stage III colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":18},{"Name":"Fecal CA II","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Feces","Assay\/Test":"ELISA","Usage":"DiagnosticBM","Pmid":9036892,"Description":"Several studies have demonstrated a relationship between mucosal carbonic anhydrase (CA) isoenzymes, particularly CA II, and cancer of the large intestine. The fecal CA II test was similar in sensitivity and specificity to the immunochemical fecal occult blood test (65 vs 48%; 96 vs 100%).\u00a0 Measurement of fecal CA II might be useful in screening for colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0001988","Id":19},{"Name":"KRAS","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":9042267,"Description":"The relative risk of mortality in the stratum of stage A or B was 7.74 (95% confidence interval: 1.72-34.89) by Cox regression analysis. We thereby conclude that K-ras gene mutation is a usefull predictor of the survival of early stage colorectal cancers.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":20},{"Name":"CD44","Molecular type":"Protein","Location":"Colon","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"DiagnosticBM","Pmid":9117309,"Description":"The CD44 gene codes for a family of heavily glycosylated cell surface proteins that have been linked with tumour metastasis.\u00a0 All samples of tumour and metastatic tissue showed complex overexpression of many alternatively spliced products of the CD44 gene. Normal colon, liver and lymphocytes predominantly expressed the standard form of the CD44 molecule (CD44S) with low levels of two or three variants hybridizing to exons v2 and v7. The analysis of CD44 gene expression may provide a promising marker for the early detection of colonic tumours.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":21},{"Name":"Nm23-H1","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":9219795,"Description":"Therefore, nm23-H1 expression within the primary tumor indicated the lymph node status with a sensitivity of 93% and a negative predictive value of 92%. The classic pathohistological factors (high risk vs low risk) had a sensitivity of 78% and a negative predictive value of 77%, respectively. Reduced expression of nm23-H1 within primary colorectal carcinomas could serve as an additional independent marker in estimating the nodal metastatic potential of these tumors.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":22},{"Name":"Tenascin","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":9275031,"Description":"In a multivariate analysis, the Dukes' stage and age were independent prognostic factors, whereas the tenascin expression did not retain a clear independent relationship to survival (P = 0.06). the tumour expression of tenascin may be a potential prognostic marker in colorectal cancer","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":23},{"Name":"Loss of heterozygosity (LOH)","Molecular type":null,"Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":9287966,"Description":"Deletion of 1p sequence was detected in 22 of 82 tumors. Deletions of the microsatellite markers D1S228 (1p36) and HY-TM1 (1p32) were significantly associated with poor survival (P < 0.05): relative risk, 4.1; 95% confidence interval, 1.25-9.23 for D1S228; and relative risk, 6.6; 95% confidence interval, 1.4-19 for HY-TM1. Loss of heterozygosity at D1S228 was also associated with shorter disease-free interval: relative risk, 4.5; 95% confidence interval, 1.3-11. Allelic loss in the 1p36 and 1p32 regions of chromosome 1 appears to be an independent predictor of poor prognosis in patients with adenocarcinoma of the colon.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":24},{"Name":"Vascular endothelial growth factor (VEGF)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Blood","Assay\/Test":"ELISA","Usage":"PrognosticBM","Pmid":9468253,"Description":"The expression of vascular endothelial growth factor (VEGF), a glycoprotein that selectively promotes proliferation of endothelial cells, has been associated with cancer development. In patients with colorectal cancer, serum VEGF levels were significantly associated with Dukes stage (p < 0.01) and with carcinoembryonic antigen levels (r = 0.725, p < 0.001). Patients with hepatic and\/or lymph node metastasis had higher serum VEGF levels than those without. Surgical resection of the colorectal tumor led to a decrease in serum VEGF levels whether or not metastasis was present (p < 0.05).\u00a0 VEGF is involved in the development of colorectal cancer. Measurement of VEGF in the serum may be a useful noninvasive clinical marker for \nevaluating the disease status.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":25},{"Name":"C-myc","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":9468576,"Description":"The disease-free survival rate at 5 years was significantly lower in patients with c-myc overexpression than in those without it (70% versus 100%, p<0.05).\u00a0 These results demonstrate that c-myc mRNA overexpression as assessed by semi-quantitative RT-PCR may be a useful prognostic indicator in patients with colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":26},{"Name":"CD44 variant 6 (CD44v6)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":9489913,"Description":"Splice variants of CD44 play a causal role in the metastatic spread of pancreatic carcinoma in the rat. In previous studies we have shown that homologues of these CD44 isoforms (CD44v6) are overexpressed during colorectal tumorigenesis in man and that CD44v6 overexpression is associated with an unfavorable prognosis in this disease Analysis of CD44v6 expression by means of a combined scoring system, on the basis of a panel of three different monoclonal antibodies (mAbs), makes CD44v6 a highly significant prognostic marker that is independent of Dukes stage, tumor grade, or tumor localization. Assessment of CD44v6 expression by a combination of mAbs yields an independent prognosticator that may be of value in identifying patients with a high propensity to develop distant metastasis.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":27},{"Name":"CD44","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":9548625,"Description":"CD44 is a cell adhesion molecule often expressed in the form of various splice variants. The role of standard CD44 isoform (CD44s) and its variants in colorectal carcinogenesis is partly conflicting. In the multivariate analysis the CD44v6 expression intensity in tumour epithelium predicted independently both cancer-related and recurrence-free survival in T1-4N0-3M0 and T1-3N0M0 cases. In addition, the CD44v3 expression intensity in tumour epithelium was a significant predictor of RFS in T1-3N0M0 cases. These results strongly suggest that the CD44 splice variants v6 and v3 have prognostic significance in colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":28},{"Name":"Loss of heterozygosity (LOH)","Molecular type":null,"Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PredictiveBM","Pmid":9609754,"Description":"Loss of heterozygosity (LOH) on chromosome 18q is frequent in colorectal cancer (CRC) and has been associated with poor prognosis in stage II tumors.\u00a0 Multivariate analysis showed that tumor side (P = 0.0001) and 18q LOH (P = 0.01) were the only independent prognostic factors. Examining markers individually showed that only the lost of D18S474 had a significant influence on survival in patients with stage II CRC (P = 0.016). Microsatellite analysis may be useful in identifying high-risk patients who might benefit from adjuvant therapy.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":29},{"Name":"Alpha-Catenin","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":9624037,"Description":"Reduced alpha-catenin expression was found in 32\/82 (39%) colorectal cancers examined, which was associated with de-differentiation (P < 0.01), lymph node metastasis (P < 0.025), and poor clinical outcome (P < 0.012). Our findings demonstrate a significant down-regulation of alpha-catenin expression in colorectal cancer which is associated with poor differentiation, higher metastatic potential and unfavorable prognosis.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":30},{"Name":"Deleted in colorectal cancer (DCC)\n","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":9645744,"Description":"The DCC protein--for which a gene has been located on chromosome 18q--has recently been reported to have a prognostic value in colorectal cancer.\u00a0 The DCC protein was found to be expressed in 64.9 percent of tumor samples. Nonexpression of DCC protein had an negative influence on survival (P = 0.03). For all tumor stages together, sensitivity of the test for subsequent occurrence of distant metastases was 42 percent and specificity was 71 percent. In Stage II cancers, the positive predictive value was 19 percent, and the negative predictive value was 88 percent. Our results confirm that DCC protein is a useful prognostic marker in patients with rectal carcinomas","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":31},{"Name":"CD44v8-10","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Blood","Assay\/Test":"ELISA","Usage":"PrognosticBM","Pmid":9658313,"Description":"CD44 is a cell adhesion molecule often expressed in the form of various splice variants. The role of standard CD44 isoform (CD44s) and its variants in colorectal carcinogenesis is partly conflicting. In addition, serum CD44v8-10 levels were significantly higher in carcinomas associated with lymph node or liver metastasis than in those without metastasis.\u00a0 These findings suggest the usefulness of serum CD44v8-10 level in the prediction of colorectal cancer metastasis.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":32},{"Name":"TP53, K-ras","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":9659162,"Description":"By log rank test, survival was significantly reduced in subjects with TP53 mutations (p = 0.003) but was not significantly related to acetylator status or the presence of K-ras mutations. After adjustment for tumour stage, subjects with both TP53 and K-ras mutations had a 4.2-fold case fatality (95% confidence interval 1.5 to 11.6) when compared with that of a TP53 negative reference group. The presence of both TP53 and K-ras mutations in colorectal tumours is an adverse prognostic marker which is independent of tumour stage.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":33},{"Name":"HLA-DR antigen, Proliferating cell nuclear antigen labeling index (PCNA-LI) ","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":9663422,"Description":"Five-year survival rates of patients with and without HLA-DR antigen expression were 50 and 19%, respectively. Lesions combining HLA-DR antigen expression and a relatively low PCNA-LI had the best prognosis. These results indicate that HLA-DR antigen expression, particularly combined with a low PCNA-LI, is an important outcome predictor in colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":34},{"Name":"CD44v8-10, Sialyl LeX (SLX)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":9732216,"Description":"In a multivariate analysis using the Cox regression model, the combined expression of SLX and CD44v8-10 emerged as an independent prognostic indicator.\u00a0 These results suggested that the combined expression of CD44v8-10 and SLX may be a biologic marker of prognostic significance.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":35},{"Name":"CD44","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":9754757,"Description":"CD44 is a cell adhesion molecule often expressed in the form of various splice variants. The role of standard CD44 isoform (CD44s) and its variants in colorectal carcinogenesis is partly conflicting. In univariate analysis, a significantly longer relapse-free time (CD44: P = .0004; FVIII-RA: P = .0006) and overall survival time (CD44: P = .0001; FVIII-RA: P = .001) were observed for patients with CD44-negative tumors and MVC below 4 as compared to those with CD44-positive tumors and MVC greater than 4. Univariate analysis showed CD44 and MVC to be independent predictors of prognosis in colorectal carcinomas. Multivariate analysis showed that CD44 positivity was the most important indicator of an unfavorable prognosis for relapse-free and overall survival in patients with colorectal cancer. ","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":36},{"Name":"C-erbB-2","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":9778622,"Description":"Multivariate regression analysis showed cytoplasmic c-erbB-2 overexpression to be an independent prognostic factor for colorectal cancer. These results suggest that overexpression of cytoplasmic c-erbB-2 protein plays an important role in the progression of colorectal cancer and is considered to be an independent prognostic indicator of this lesion.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":37},{"Name":"Interleukin-2 (IL-2R)","Molecular type":null,"Location":"Colon, Rectum","Source":"Blood","Assay\/Test":"ELISA","Usage":"PrognosticBM","Pmid":9786595,"Description":"55-kDa IL-2R-\u03b1 is cleaved from the cell surface and a 45-kDa soluble form of IL- 2R-\u03b1 (sIL-2R-\u03b1) is produced Moreover, the prognosis of patients with low levels of IL-2R (<531 U\/ml) was significantly better than that of those with high levels (P < 0.05). These findings demonstrate that an elevated concentration of soluble IL-2R might be a useful indicator of liver metastasis and poor prognosis in patients with colorectal carcinoma.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":38},{"Name":"P53","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":9797697,"Description":"Mutations of the p53 tumour suppressor gene are the most common genetic abnormalities to be found in human neoplasms At multivariate analysis p53 protein status was the single best predictor of survival (P = 0.0079); the odds ratio of death among patients with p53-positive tumours was 2.53. Nuclear p53 protein expression in hepatic metastases from CRC is an independent prognostic factor of survival following liver resection. ","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":39},{"Name":"Bcl-2","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":9863484,"Description":"Bcl-2 is a cytoplasmic protein which localises to mitochondria, endoplasmic reticulum, and the nuclear envelope. A statistically significant inverse association was found between Bcl-2 score and tumour recurrence (median Bcl-2 score of 6 (interquartile range (IQR) 2-9) in patients with recurrent disease; median Bcl-2 score of 8 (IQR 6-10) in those without recurrence; p = 0.03).\u00a0 Results suggest that, when controlled for differentiation, Bcl-2 expression is a prognostic marker and may be useful as an adjunctive test in clinical decision making.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":40},{"Name":"DCC gene","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":9949300,"Description":"In multivariate analysis using the Cox regression model, DCC protein expression emerged as an independent prognostic indicator. These findings suggested that a decrease in DCC expression may have an important role in the progression of colorectal cancers and may be a biologic marker of prognostic significance.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":41},{"Name":"P27 (Kip1)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM|PredictiveBM","Pmid":10030411,"Description":"The p27Kip1 protein regulates the G1 to S phase transition of cell cycle by binding to and inhibiting the cyclin E\/Cdk2 complex. At multivariate analysis, tumor stage (III vs. I-II) and p27Kip1 protein status (absence vs. presence) were found to be independent prognostic factors for DFS and OS. Lack of p27KiP1 protein expression in CRC is a negative prognostic marker and may therefore be useful in selecting early-stage patients more likely to benefit from adjuvant treatment.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":42},{"Name":"Vascular endothelial growth factor (VEGF)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Blood","Assay\/Test":"ELISA","Usage":"PrognosticBM|PredictiveBM","Pmid":10070308,"Description":"Vascular endothelial growth factor (VEGF) is the most potent angiogenesis factor and has been detected in many human tumours It was significantly longer in the patients with low VEGF levels (below the cut-off) than in those with high VEGF levels (logrank test, P = 0.042). 34 patients with metastasis (19 gastric cancer and 15 colorectal cancer) were treated with systemic chemotherapy, and their pretreatment levels of plasma VEGF and conventional tumour markers (CEA and CA19-9) were evaluated in relation to response. The response to chemotherapy was significantly higher in patients with low VEGF levels (< or = 108 pg\/ml) than in those with high VEGF levels (P = 0.047). In conclusion, plasma VEGF is a useful marker for tumour metastasis and patient survival, and a possible predictive factor for the response of patients with gastrointestinal cancer to chemotherapy.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":43},{"Name":"High mobility group I(Y) [HMGI(Y)]","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"DiagnosticBM|PrognosticBM","Pmid":10096541,"Description":"High mobility group I(Y) [HMGI(Y)] proteins are architectural factors abundantly expressed during embryogenesis, and their overexpression is known to be closely associated with neoplastic transformation of cells. Clinicopathological analysis revealed that the level of HMGI(Y) protein expression was significantly correlated with parameters known to be indicative of a poor prognosis in colorectal cancer patients. These findings indicate that the determination of the HMGI(Y) protein expression level could be a potential marker for the diagnosis of colorectal neoplasias and can be of great value in predicting the prognosis of patients with colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":44},{"Name":"Soluble CD44 splice variants containing exon v6 (sCD44v6)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":10202279,"Description":"The expression of CD44v6 is well known as a useful marker of tumor progression and prognosis in colorectal cancer. The 5-year survival rate was significantly lower in patients with high serum levels of sCD44v6 (52.4%) than in those with low levels of sCD44v6 (78.0%; p < 0.05), and it was also significantly lower in patients with CD44v6-positive cancer (42.1%) than in those with CD44v6-negative cancer (84%; p < 0. 01). We concluded that preoperative elevation in the serum levels of sCD44v6 might be a prognostic indicator for patients with colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":45},{"Name":"Bax ","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":10334520,"Description":"BAX protein is a key promoter of apoptosis Low BAX expression was an independent negative prognostic marker in multivariate regression analysis for all patients independent of the p53 status (relative risk, 3.03, P = .03), especially for p53 wild-type tumors (relative risk, 8.21; P = .0095). We conclude that low BAX expression is an independent negative prognostic marker in patients with hepatic metastases of colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":46},{"Name":"P27 (Kip1)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":10398135,"Description":"Expression of p27 was a strong predictor of survival, both in univariate and in multivariate survival analyses; patients with tumours of p27 LI less than 50 per cent had an impaired prognosis (p=0.0069). p27 expression did not correlate with tumour cell proliferation, or with expression of cyclin D1 or the retinoblastoma protein (pRb). These findings support the view that p27 not merely controls cell cycle progression, but might be associated with other mechanisms responsible for aggressive tumour behaviour in colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":47},{"Name":"P53","Molecular type":"Protein","Location":"Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PredictiveBM","Pmid":10435809,"Description":"The p53 gene is located on chromosome 17p and encodes for a 53-kd nuclear phosphoprotein. The p53 negative patients treated with preoperative radiotherapy had a significant reduction of local failure compared with the non-irradiated p53 negative patients (P = 0.0008). In contrast, p53 positive patients showed no benefit from preoperative radiotherapy. The interaction between p53 status and the benefit of radiotherapy was statistically significant (P = 0.018). Expression of nuclear p53 protein in rectal carcinoma seems to be a significant predictive factor for local treatment failure after preoperative radiotherapy. ","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":48},{"Name":"P16 hypermethylation","Molecular type":null,"Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Methylation-specific polymerase chain reaction (PCR)","Usage":"PrognosticBM","Pmid":10461063,"Description":"Survival analysis revealed a significant survival disadvantage of p16-hypermethylated versus non-p16-hypermethylated tumors (p = 0.0001). the presence of p16 hypermethylation predicts shorter survival in T3N0M0 stage colorectal cancers.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":49},{"Name":"NuMA","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Enzyme immunoassay","Usage":"DiagnosticBM","Pmid":10470167,"Description":"By the first method, NuMA and CEA both had approximately 20% sensitivity for colorectal cancer. By the second method (which generated lower reference values), NuMA was more sensitive than CEA for colorectal cancer. This improved sensitivity was most evident in Dukes B subjects. By either analysis method, NuMA was more sensitive than CEA for subjects at risk for developing colorectal cancer","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":50},{"Name":"P21","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":10487624,"Description":"p21\/WAF1 was first isolated as one of the cyclin-dependent kinase (cdk) interacting proteins induced by wild-type p53 In the multivariate analysis, p21 percentage distribution independently predicted cancer-related survival in all cases, and p21 expression intensity in T1-4\/N0-3\/M0 and T1-3\/N0\/M0 cases. p21 percentage distribution was an independent predictor of RFS in all and T1-3\/N0\/M0 cases. These results suggest that the immunohistochemical detection of cyclin-dependent kinase inhibitor p21 could be used to predict more precisely the outcome of colorectal cancer patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":51},{"Name":"Liver fatty acid-binding protein (L-FABP)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":10518104,"Description":"Liver fatty acid-binding protein (L-FABP) is reported as a biological marker for enterocytic differentiation. Multivariate analysis revealed that the prognostic effect of L-FABP expression in primary colorectal cancers was exerted independently and that its impact was larger than conventional pathological prognosticators. L-FABP expression is suitable for use as a new presurgical prognostic factor for patients undergoing hepatic surgery for colorectal cancer metastases.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":52},{"Name":"Thymidylate synthase (TS)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PredictiveBM","Pmid":10561213,"Description":"Thymidylate synthase (TS) is the rate-limiting enzyme in the synthesis of pyrimidine nucleotides, required for DNA synthesis, and is also a critical target for fluoropyrimidines, which are widely used in the treatment of gastrointestinal tumours. In patients with low and high TS expression, the median time to progression was 9.6 months v 6.2 months (P =.005) and the median survival time 18.4 months v 15.4 months (P =.02), respectively. Two- and 3-year survival rates were 41% v 15% and 19% v 0% (P =.02), respectively. In this cohort of homogenously treated patients, intratumor TS content was a major predictor of clinical outcome. Immunohistochemical TS quantitation provides a convenient, low-cost technique for identifying patients unresponsive to TS inhibitors who may be candidates for alternative chemotherapy \nregimens.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":53},{"Name":"Microvessel count (MVC)","Molecular type":null,"Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":10601549,"Description":"The significant risk factors in order of poorer prognosis by the multivariate analysis among these factors including routinely used clinicopathologic factors were the high MVC, E-cadherin reduced expression, and lymph node metastasis. These findings indicate a high MVC at the site of deepest tumor invasion to be the most important predictor of colorectal cancer prognosis among the factors studied here.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":54},{"Name":"CD44v2","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PredictiveBM","Pmid":10650786,"Description":"Expression of CD44 variant isoforms has been reported to be correlated with faster progression of neoplastic diseases, metastasis and reduced survival period. On the other hand, v2 expression was correlated significantly with recurrence rate and poorer prognosis in Dukes B colorectal cancer although there was no correlation between v2 expression and prognosis in Dukes C patients. CD44v2 expression may be an indication for adopting adjuvant chemotherapy in patients without lymph node metastasis.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":55},{"Name":"P53, Bcl-2","Molecular type":"Protein","Location":"Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":10708936,"Description":"Bcl-2 is an intracellular membrane protein capable of inhibiting programmed cell death Multivariate logistic regression analysis demonstrated that gender (P=0.0136), UICC stage (P=0.0002), p53 expression (P=0.0002) and Bcl-2 expression (P=0. 0243) were independent factors predictive of recurrence. Immunohistochemical assessment of both p53 and Bcl-2 status may be valuable in predicting recurrence and survival after curative surgery for rectal cancer. ","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":56},{"Name":"Interleukin-6 (IL-6)","Molecular type":null,"Location":"Colon, Rectum","Source":"Blood","Assay\/Test":"Enzyme immunoassay","Usage":"PrognosticBM","Pmid":10761792,"Description":"Interleukin-6 (IL-6) is an important proinflammatory cytokine that has multiple effects on stimulating inflammation and cell growth. By using multivariate analysis, an IL-6 concentration of more than 10 pg\/ml was an independent prognostic factor of survival (relative risk = 1.820; P = .020). Furthermore, an IL-6 concentration of more than 10 pg\/ml is an independent negative prognostic marker of survival.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":57},{"Name":"Anti-survivin antibodies","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"ELISA","Usage":"DiagnosticBM","Pmid":10766164,"Description":"Antibody reactivity against survivin, a recently identified tumor-associated protein, was determined in sera from patients with lung (n = 51) or colorectal cancer (n = 49). The increase in prevalence when anti-survivin and anti-p53 antibodies were determined in parallel was statistically significant (29.4% versus 7.8%, P = 0.005 in lung cancer population; 26.6% versus 8.2%, P = 0.015 in colorectal cancer population). The high prevalence of anti-survivin antibodies makes these antibodies an attractive novel marker for the diagnosis of lung and colorectal cancer","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":58},{"Name":"CD44","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":10769701,"Description":"CD44 is a cell adhesion molecule often expressed in the form of various splice variants. The role of standard CD44 isoform (CD44s) and its variants in colorectal carcinogenesis is partly conflicting. In the multivariate analysis, the CD44 expression was suggestive of an independent prognostic factor. It was suggested that CD44 expression could be used as a possible independent predictor of survival.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":59},{"Name":"P21","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PredictiveBM","Pmid":10789738,"Description":"p21\/WAF1 was first isolated as one of the cyclin-dependent kinase (cdk) interacting proteins induced by wild-type p53 Only p21 expression was individually associated with response to radiation (56 vs. 30 percent; P = 0.03). Tumors that were p53-negative\/p21-positive or p21-positive\/bcl-2-positive were also more likely to respond to radiation (83 vs. 35 percent; P = 0.03 and 71 vs. 31 percent; P = 0.01, respectively). p21 expression is a marker of tumor radiosensitivity in patients with rectal cancer. ","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":60},{"Name":"Metalloproteinases (MMPs)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":10794801,"Description":"MMP-1 is a member of collagenases, a family of MMPs that degrades collagens type I, II, and III, main components of the interstitial stroma. MMP-1 expression significantly correlated with hematogenous metastasis of colorectal cancer MMP-1 expression may be a novel marker for hematogenous metastasis of colorectal cancer, and its inhibition may be a strategy for prevention of metastasis.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":61},{"Name":"CDC25B","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR|Immunohistochemistry","Usage":"PrognosticBM|PredictiveBM","Pmid":10850455,"Description":"In  the  CDC25  family,CDC25A  and  CDC25B  types  appear  to  be  potential  oncogenes  be-cause they have been found to transform primary murine fibroblasts incooperation  with  either  mutatedHa-rasor  loss  ofRb1 Multivariate analysis indicated that CDC25B was an independent prognostic marker (risk ratio for death, 3.7; P < 0.0001) even after controlling for various factors such as lymph node metastasis, tumor size, degree of differentiation, and depth of invasion.\u00a0 Our findings suggest that CDC25B is a novel independent prognostic marker of colorectal carcinoma and that it may be clinically useful for selecting patients who could benefit from adjuvant therapy.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":62},{"Name":"P53","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM|PredictiveBM","Pmid":10885605,"Description":"The p53 gene is located on chromosome 17p and encodes for a 53-kd nuclear phosphoprotein. In multivariate analysis, only p53 immunoreactivity emerged as an independent marker for prognosis hazard ratio (HR) = 2.16, 95% confidence interval (CI) 1.12-4.11, P = 0.02). Assessment of p53 protein expression is more discriminative than TP53 mutation to predict the outcome of Dukes' stage B tumours and could be a useful tool to identify patients who might benefit from adjuvant therapy.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":63},{"Name":"Telomerase ","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":10914712,"Description":"Telomeres  are  specialized  structures  containing  uniqueguanine-rich hexameric repeat sequences at the ends of humanand  other  eukaryotic  chromosomes  and  are  important  in  theprotection and replication of chromosomes  The prognosis of the patients with high telomerase activity was significantly worse than that for patients with moderate and low telomerase activity (P < 0.01). Among the 87 patients with curative surgery, disease-free survival rate of those with high telomerase activity was also significantly poorer (P < 0.01). High telomerase activity is an independent prognostic indicator of poor outcome in colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":64},{"Name":"Antigens A, B, H","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":10929759,"Description":"The expression of ABH isoantigens was an independent prognostic variable, in addition to T (depth of tumor invasion), N, and M (distant metastasis) factors, as shown by means of Cox regression analysis. Expression of blood group antigens A, B and H in carcinoma tissue correlates with\na poor prognosis for colorectal cancer patients.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":65},{"Name":"Insulin-like growth factor I (IGF-I)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"DiagnosticBM","Pmid":10999841,"Description":"INSULIN-LIKE growth factor I (IGF-I) and IGF-II are mitogenic and antiapoptotic polypeptides that have properties both as systemic hormones and as local tissue growth factors. Immunohistochemical studies demonstrated IGF-II expression in 83% of all adenomas, which contrasted with absent expression in normal colonic expression and hyperplastic polyps. This study has shown for the first time that serum IGF-II may be a tumor marker in individuals with colorectal adenomas.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":66},{"Name":"Endothelin-1 (ET-1)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Blood","Assay\/Test":"Immunohistochemistry","Usage":"DiagnosticBM","Pmid":11044168,"Description":"The presence of microvascular invasion in the tumour specimens was associated with a significantly raised portal plasma level of Big ET-1 (1.6 (1.5-2.1) versus 1.1 (0.8-1.3) fmol\/ml; P = 0.04). Immunohistochemistry localized Big ET-1 to the cancer epithelial cells. The plasma level of Big ET-1 is significantly raised in patients with colorectal cancer. ","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":67},{"Name":"Interleukin-12 (IL-12)","Molecular type":null,"Location":"Colon, Rectum","Source":"Blood","Assay\/Test":"Quantitative sandwich enzyme immunoassay technique","Usage":"DiagnosticBM","Pmid":11131678,"Description":"Interleukin 12 (IL-12) is a heterodimeric cytokine that has potent anti-tumor and anti-metastatic activities. Although not statistically significantly, high plasma levels of VEGF and low serum levels of IL-12 tended to occur with more advanced colorectal cancer. Plasma levels of VEGF in patients who had circumferential involvement of the tumor greater than 1\/2 were only significantly increased. These results suggest that high plasma levels of IL-12 or low serum levels of IL-12 may be observed in more advanced colorectal cancer patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":68},{"Name":"Ki-67","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":11237496,"Description":"Patients with high Ki-67 scores (> or = 50%) had significantly shorter median survival compared with those with low scores (30 vs 44 months, log-rank P=0.02). A high Ki-67 score was an independent negative prognostic factor by multivariate regression analysis (relative risk=3.04, P=0.036). These findings suggest that the tumour proliferative index is a useful predictor of aggressive tumour behaviour and an indicator of patient survival.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":69},{"Name":"c-Myb, Bcl-x","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":11290547,"Description":"Kaplan-Meier's analysis showed an increased risk of relapse and death in patients whose tumor specimens displayed high c-Myb levels and Bcl-x positivity. These results provide direct evidence of an association between c-Myb and Bcl-x expression and suggest that expression of both molecules might be a useful prognostic marker in CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":70},{"Name":"P53 mutation","Molecular type":"DNA","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":11295071,"Description":"The p53 gene is located on chromosome 17p and encodes for a 53-kd nuclear phosphoprotein. Multivariate analysis of all tumors, p53 mutation and liver metastasis were independent indicators of poor survival (p = 0.0223 for p53 mutation, p = 0.0254 for liver metastasis) We think that p53 mutation is a very useful prognostic indicator when distal colorectal cancers are considered.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":71},{"Name":"Bax ","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":11299743,"Description":"Multivariate analysis for disease free and overall survival showed that bax expression and high Duke's stage were independent prognostic parameters associated with an unfavourable outcome (p = 0.009 and p = 0.0001, respectively).\u00a0 It was concluded that the immunohistochemical expression of bax is a marker of poor prognosis and of a higher risk of local relapse in patients with colorectal adenocarcinomas.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":72},{"Name":"Ki-67","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PredictiveBM","Pmid":11395233,"Description":"The interaction between Ki-67 status and the benefit of radiotherapy was significant for the reduced recurrence rate (p = 0.03), with a trend toward improved disease-free survival (p = 0.08). Many Ki-67 stained tumor cells in the preoperative biopsy predicts an increased treatment failure rate after preoperative radiotherapy of rectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":73},{"Name":"Angiomodulin (tumor-derived adhesion factor\/mac25) ","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":11400113,"Description":"Angiomodulin (tumor-derived adhesion factor\/mac25\/insulin-like growth factor binding protein-7), a cell-adhesive glycoprotein, is secreted by cancer cells and vascular endothelial cells.\u00a0 Multivariate analysis with logistic regression indicated that only angiomodulin expression in cancer cells, lymph node metastasis and age remained significant prognostic variables for survival (p < 0.05). Expression of angiomodulin (tumor-derived adhesion factor\/mac25) in invading\ntumor cells correlates with poor prognosis in human colorectal cancer.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":74},{"Name":"MMP-2:TIMP-2 ratio","Molecular type":null,"Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Enzyme-linked immunosorbent assay|Western blot|in situ hybridization","Usage":"DiagnosticBM","Pmid":11459286,"Description":"Therefore an increased ratio of MMP-2 to TIMP-2 is strongly associated with advanced tumor stages, but a decreased ratio was observed in metastases. These findings suggest that the MMP-2:TIMP-2 ratio may prove useful as a marker of local invasion but not of metastasis in colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":75},{"Name":"Cytokeratin 19, 20","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Blood","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":11459287,"Description":"The detection of cytokeratin 19 or 20 mRNA in peripheral or mesenteric blood is thus associated with the prognosis for colorectal cancer patients undergoing curative surgery. Although the presence of these mRNAs in blood samples is a prognostic marker, the clinical utility of this assay is questionable because of the low recurrence rate in the positive group.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":76},{"Name":"Matrilysin","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":11494227,"Description":"Patients with matrilysin-positive cancer had a significantly shorter overall survival time than those with matrilysin-negative cancer. For patients with intermediate invasive tumor (T2 or T3), only matrilysin was a significant prognostic variable for predicting overall survival in multivariate analysis. Matrilysin expression at the invasive front could be an important marker, predicting an unfavorable prognosis after surgical treatment in patients with colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":77},{"Name":"Faecal calprotectin","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Feces","Assay\/Test":"Faecal occult NA tests","Usage":"DiagnosticBM","Pmid":11511563,"Description":"The overall sensitivity and specificity of calprotectin for colorectal cancer and adenomatous polyps as a combined group was 79% and 72%, respectively, compared with a sensitivity and specificity of faecal occult blood of 43% and 92%. Faecal calprotectin is a simple and sensitive non-invasive marker of colorectal cancer and adenomatous polyps.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0001988","Id":78},{"Name":"Metallothionein (MT)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":11528256,"Description":"The survival rate in the patients with MT-negative tumors was significantly better than that in those with MT-positive tumors as primary sites (p = 0.0198). MT expression in colorectal cancer may be a potential marker affecting lymph node metastases and may be a predictor of a poor prognosis, particularly in patients with synchronous liver metastases.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":79},{"Name":"Pyrimidine nucleoside phosphorylase (PyNPase)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":11696620,"Description":"In multivariate analyses, expression in cancer cells was the strongest predictor of prognosis. PyNPase expression appears to be a relevant factor for predicting\nthe prognosis of colorectal cancer.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":80},{"Name":"P53 antibody","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Blood","Assay\/Test":"Immunohistochemistry","Usage":"DiagnosticBM","Pmid":11706527,"Description":"Mutation of the p53 gene is a genetic alteration found in human cancers. Overexpression of p53 has been found to induce antibody production in serum, and, recently, the simple detection of serum antibody has been made possible. The serum p53 antibody status was strongly correlated with p53 immunostaining in adenocarcinoma (P = 0.0065), but there was no significant correlation in adenoma (P = 0.973). The detection of serum p53 antibody is expected to serve as a new genetic marker, determined by serological analyses, for aiding in the early diagnosis of superficial colorectal cancer and indicating its local curability after endoscopic treatment.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":81},{"Name":"Carcinoembryonic antigen (CEA)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":11712806,"Description":"Carcinoembryonic antigen (CEA) is of prognostic value in colorectal cancer and has been shown to be related to the ability of colorectal cancer cells to implant and to metastasise and to have an effect on immune function. By Cox's regression analysis, high T-CEA concentration was an independent variable for poor outcome (Hazard ratio, 3.15), while S-CEA and N-CEA were not. In conclusion, a high T-CEA concentration was the only independent predictor of poor outcome after resection for colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":82},{"Name":"Beta-catenin","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":11751495,"Description":"Beta-catenin is a member of the cadherin-catenin complex that mediates homotypic cell-cell adhesion In multivariate analysis, only stage and phospho-beta-catenin were independently predictive of overall survival (P < 0.001 and P = 0.0034, respectively). These findings support a role for beta-catenin overexpression in colorectal tumorigenesis and provide initial evidence that phospho-beta-catenin may be a marker for improved overall survival independent of stage and grade.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":83},{"Name":"Bcl-2","Molecular type":"Protein","Location":"Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PredictiveBM","Pmid":11759059,"Description":"In each tumor, the bcl-2\/bax ratio was calculated dividing the percentage of bcl-2-positive cells by the percentage of bax-positive cells. The bcl-2\/bax ratio was greater in group A (1.3 +\/- 0.1) compared with group B (0.49 +\/- 0.1), and was correlated with poor responsiveness to radiotherapy. The current study indicates that in patients with rectal carcinoma an elevated bcl-2\/bax ratio in tissue specimens suggests increased tumor resistance to adjuvant radiotherapy. Thus, in such patients, the bcl-2\/bax ratio may serve as a potential molecular marker for prediction of tumor prognosis.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":84},{"Name":"Cyclooxygenase-2 (COX-2)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":11786771,"Description":"Cyclooxygenase (COX) is a rate-limiting enzyme in prostaglandin biosynthesis Multivariate analysis for factors associated with metachronous liver metastasis showed that cyclooxygenase-2 expression was one of the independent risk factors, second only to lymph node metastasis. Patients with cyclooxygenase-2 expression showed a significantly poorer outcome compared with those without cyclooxygenase-2 expression (P = 0.002). Cyclooxygenase-2 expression in the primary lesion may be a useful marker for evaluating prognosis and liver metastasis in patients with colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":85},{"Name":"Tissue inhibitor of metalloproteinases-1 (TIMP-1)","Molecular type":"Protein","Location":"Colon","Source":"Tissue","Assay\/Test":"ELISA","Usage":"DiagnosticBM","Pmid":11801553,"Description":"TIMP-1, an Mr28,000 glycoprotein present invarious nonmalignant and malignant human tissues and bodilyfluids Total TIMP-1 levels identified patients with CC with a sensitivity of 63% at 98% specificity, patients with early CC (Dukes' A+B) with a sensitivity of 56% at 98% specificity, and patients with right-sided CC with a sensitivity of 72% at 98% specificity. Combining carcinoembryonic antigen and TIMP-1 measurements increased the sensitivities obtained from TIMP-1 measurements alone. Sensitivity and specificity were both sufficiently high to consider TIMP-1 as a marker for the early identification of  CC patients, in particular, those with right-sided CC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":86},{"Name":"PGP9.5","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"DiagnosticBM","Pmid":11801558,"Description":"PGP9.5  is  a  ubiquitin  hydrolase  and  widely  expressed  inneuronal tissues at all stages of neuronal differentiation  Of 74 colorectal cancer specimens examined, 33 cases (46%) showed positive staining with PGP9.5 in most tumor cells, whereas no PGP9.5 expression was detected in adjacent normal epithelium. Subsequently, we correlated PGP9.5 expression in tumors with the clinicopathological features of affected patients and found two significant differences in maximal tumor size and the extent of tumor (P = 0.035 and 0.019, respectively). This result suggests that PGP9.5 expression is related to tumor progression and may be useful as a marker for invasive colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":87},{"Name":"Granulocyte-macrophage-colony stimulating factor (GM-CSF)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Blood","Assay\/Test":"ELISA","Usage":"DiagnosticBM","Pmid":11820563,"Description":"Granulocyte-macrophage-colony stimulating factor (GM-CSF) belongs to the group of glycoproteins called colony-stimulating factors (CSFs). The sensitivities of CEA (63%) and CA 19-9 (56%) were lower than the GM-CSF sensitivity (80%). The specificities of tumour markers were 70% (CEA, GM-CSF) and 75% for CA 19-9. The GM-CSF predictive v values were higher than the CEA and CA 19-9 values.\u00a0 These results suggest that GM-CSF may be useful as tumour marker in colorectal cancer, but further studies are needed.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":88},{"Name":"KAI1\/CD82","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":11848527,"Description":"On multivariate analysis, KAI1\/CD82 expression and Dukes' stage were identified as significant and independent prognostic factors (p=0.006 and 0.045, respectively). KAI1\/CD82 expression appears to be a useful prognostic marker.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":89},{"Name":"Apoptosis","Molecular type":null,"Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM|PredictiveBM","Pmid":11872273,"Description":"Tumors with complete (n = 3) or good (n = 28) response to RCT showed significantly higher pretreatment levels of apoptosis (mean AI: 2.06%) than tumors with moderate (n = 7), minimal (n = 5), or no regression (n = 1) from RCT (AI: 1.44%, p = 0.003). The AI was significantly related to Ki-67 (p = 0.05), but not to p53 and bcl-2 status. Tumor regression and AI best predicted relapse-free survival after combined modality treatment and curative surgery. Spontaneous apoptosis in rectal cancer may serve as an important predictor of tumor regression from RCT in rectal cancer and as a significant prognosticator of relapse-free survival.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":90},{"Name":"Vascular endothelial growth factor (VEGF)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Blood","Assay\/Test":"ELISA","Usage":"PrognosticBM","Pmid":11875709,"Description":"Vascular endothelial growth factor (VEGF) is one of the strongest promoters of angiogenesis, and it has been indicated, that the preoperative serum VEGF concentration is a prognostic marker in a variety of solid tumours In multivariate survival analyses, high serum vascular endothelial growth factor (>533 pg ml(-1)) independently predicted a reduced survival (HR=1.65, P=0.015), while high plasma vascular endothelial growth factor (>112 pg ml(-1)) did not (HR=1.27, P=0.23). This study indicates that preoperative serum vascular endothelial growth factor apparently is a better predictor of overall survival than the preoperative plasma vascular endothelial growth factor.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":91},{"Name":"Thymidylate synthase (TS)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM|PredictiveBM","Pmid":11919227,"Description":"Thymidylate synthase (TS) is the rate-limiting enzyme in the synthesis of pyrimidine nucleotides, required for DNA synthesis, and is also a critical target for fluoropyrimidines, which are widely used in the treatment of gastrointestinal tumours. The group whose tumors expressed the highest TS grade, grade 3 (34% of the patients), had a significantly longer disease-free survival if they were treated with adjuvant therapy compared with surgery alone (multivariate analyses, P =.02), whereas patients whose tumors expressed low TS levels (28% of the patients) had an impaired outcome after adjuvant therapy (multivariate analyses: disease-free survival, P =.01; overall survival, P =.01). TS expression predicts for survival independent of Dukes' stage in patients with CRC treated with surgery alone. The study indicates that patients with high TS levels may benefit from adjuvant 5-FU-based chemotherapy.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":92},{"Name":"Intercellular adhesion molecule-1 (ICAM-1)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":11956618,"Description":"Intercellular adhesion molecule-1 (ICAM-1) is a 90-kDa cell surface glycoprotein and is known to be a member of the immunoglobulin gene superfamily of adhesion molecules. The prognosis of the patients with ICAM-1-negative tumors was significantly poorer than that of those with ICAM-1-positive tumors. In conclusion, these findings suggested that ICAM-1 expression is closely associated with metastasis and may be a useful indicator of prognosis in patients with colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":93},{"Name":"Cytokeratin 20 (CK20) ","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Blood","Assay\/Test":"qRT-PCR","Usage":"DiagnosticBM","Pmid":12032226,"Description":"Cytokeratin 20, an intermediate filament of epithelial cells, is expressed particularly in the urinary tract. CK20 expression was detected in nine of 30 and nine of 19 of the blood and bone marrow samples from patients with colorectal cancer, respectively. In non-cancer control blood and bone marrow samples, CK20 expression was detected in 10 of 47 and four of 15, respectively. A difference between patient and control samples may be observed in terms of frequency of positive PCR tests. In tissue samples, CK20 mRNA expression was downregulated in tumour compared with normal colon tissue. These results, together with other reports in the literature, suggest that CK20 may still be a suitable marker.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":94},{"Name":"Transforming growth factor-beta1(TGFbeta1)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"DiagnosticBM","Pmid":12046078,"Description":"Transforming growth factor(TGF)-b1 is a 25-kd polypeptides.\nThis growth factor regulates cell growth and differentiation in\nboth normal and transformed cells. The expression of TGF beta(1) was correlated significantly with the depth of invasion, stage of disease, lymph node metastasis, VEGF expression and MVD. Patients in T3-T4, stage III-IV and with lymph node metastasis had much higher expression of TGF beta(1) than patients in T1-T2, stage I-II and without lymph node metastasis (P<0.05). TGF beta(1) might be associated with tumor progression by modulating the angiogenesis in colorectal cancer and TGF beta(1) may be used as a possible biomarker.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":95},{"Name":"Angiogenin (ANG)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":12168899,"Description":"Survival analyses revealed a significant correlation between higher serum ANG concentrations (> or = 400ng\/ml) and worse disease-free (p=0.003) or disease-specific (p=0.03) survivals. serum levels of ANG reflect the degree of tissue ANG expression that could be a predictor of postoperative outcome.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":96},{"Name":"Cystatin-like metastasis-associated protein (CMAP)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":12171889,"Description":"Furthermore, the prognosis of the patients with a higher expression of CMAP was significantly worse than those with a lower expression (5-year survival rate; 49.7% and 75.0%, respectively, P = 0.038). These findings imply that the expression level of CMAP in human\ncancer may be a new biomarker for both liver metastasis and the patient'soutcome.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":97},{"Name":"Transforming growth factor-beta1(TGFbeta1)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Blood","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":12174377,"Description":"Transforming growth factor(TGF)-b1 is a 25-kd polypeptides.\nThis growth factor regulates cell growth and differentiation in\nboth normal and transformed cells. Serum TGFbeta1 levels and TGFbeta1 expression in colorectal cancer tissues were correlated significantly with depth of tumor invasion, stage and metastasis. These results suggest that transforming growth factor-beta1 is closely related to the invasion and metastasis of colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":98},{"Name":"Vascular endothelial growth factor (VEGF)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Blood","Assay\/Test":"The quantitative sandwich-enzyme immunoassay technique","Usage":"PrognosticBM","Pmid":12174940,"Description":"Vascular endothelial growth factor (VEGF) is a potent mediator of tumor angiogenesis Plasma levels of VEGF were only significantly increased in patients who had recurrence and a worsening of colorectal cancer.\u00a0 These results suggest that high plasma levels of VEGF may be observed in more advanced colorectal cancer patients, especially in patients who develop recurrence or a worsening of their condition. ","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":99},{"Name":"C-erbB","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":12198768,"Description":"Overexpression of the c-erbB-2 protein (also called HER-2\/neu) is observed in a variety of malignancies including colorectal cancer (CRC).\u00a0 Furthermore Kaplan-Meier analysis showed that overexpression of c-erbB-2 was significantly associated with poor survival and thus could serve as a prognostic marker. Overexpression of c-erbB-2 protein correlates with chromosomal gain at the\nc-erbB-2 locus and patient survival in advanced colorectal carcinomas.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":100},{"Name":"SMAD4","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PredictiveBM","Pmid":12237773,"Description":"SMADs form a family of structurally related proteins initially identified for their role in embryonic development of Drosophila (Raftery et al, 1995) and of C. elegans (Savage et al, 1996). Patients with normal SMAD4 diploidy turned out to have a three-fold higher benefit of 5-fluorouracil-based adjuvant chemotherapy with a border line significance (overall survival: 3.23, P=0.056; disease-free survival: 2.89, P=0.045). SMAD4 is a predictive marker for 5-fluorouracil-based chemotherapy in patients\nwith colorectal cancer.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":101},{"Name":"Survivin","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM|PredictiveBM","Pmid":12240548,"Description":"Low survivin expression was significantly related to an increased disease-free survival rate (77% vs 18% at 5 years in tumors with high survivin expression, p = 0.02) and to a reduced risk for distant metastases (18% vs 78% at 5 years in tumors with high survivin expression, p = 0.05) and local failure (6% vs 37% at 5 years in tumors with high survivin expression, p = 0.07). High survivin expression is associated with reduced apoptosis in rectal cancer\nand may predict disease-free survival after preoperative radiochemotherapy and\nsurgical resection.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":102},{"Name":"Peripheral benzodiazepine receptor (PBR)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":12374690,"Description":"The peripheral benzodiazepine receptor (PBR) has been implicated in the growth control of colorectal cancer, where PBR-specific ligand-binding is increased 3-4-fold. Univariate and multivariate analyses revealed that high PBR overexpression is an independent unfavorable prognostic factor in stage III colorectal cancer. In stage IV, however, the PBR status did not correlate with different survival times. Strong PBR overexpression is a new independent prognostic marker in stage III colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":103},{"Name":"Thymidine phosphorylase (TP)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":12375032,"Description":"As for 5-year survival rate, TP positive group showed a significantly lower rate (29%) than TP negative group (52%) (p=0.05) indicating that TP expression level was an important prognostic factor in colorectal cancer patients. These findings suggest that TP is an important prognostic factor for colorectal cancer patients, and p53, in conjunction with other factors, is also a prognostic indicator.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":104},{"Name":"Thymidylate synthase (TS)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PredictiveBM","Pmid":12394256,"Description":"Thymidylate Synthase (TS) is a rate-limiting enzyme in the DNA synthetic pathway and represents the cellular target of the antimetabolite drug 5-fluorouracil (FUra). The rate of 5-year disease-free survival was significantly higher in the UFT group than in the group receiving no adjuvant chemotherapy ( =0.0055). The difference in survival became more marked among patients whose tumors had diffuse TS expression ( =0.0027). We conclude that, although unrelated to outcome, TS activity may be useful in predicting the response to adjuvant chemotherapy with UFT in patients with curatively resected Dukes' stage B or C colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":105},{"Name":"Decoy receptor 3 (DcR3)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PredictiveBM","Pmid":12397645,"Description":"A secreted member of the TNF receptor superfamily, the decoy receptor 3 (DcR3), was reported to be amplified in colorectal cancer as a negative regulator of Fas-mediated apoptosis. However, adjuvant chemotherapy was significantly more beneficial in patients with normal DcR3 gene copy number than in patients with amplification (DFS: HR 2.84, 95% CI 1.16-6.98, p = 0.02; OS: HR 3.15, 95% CI 1.19-8.32, p = 0.02), whereas DcR3 protein overexpression did not influence the effect of adjuvant chemotherapy (DFS: HR 1.02, 95% CI 0.65-1.60, p = 0.95; OS: HR 0.95, 95% CI 0.61-1.49, p = 0.83).\u00a0 We conclude that amplification  of the 20q13 locus is a predictive marker for adjuvant chemotherapy in colorectal cancer.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":106},{"Name":"Calcium-binding protein S100A4","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":12404222,"Description":"In multivariate regression analysis, S100A4 expression emerged as a highly significant independent parameter (P < 0.001) with the highest relative-risk factor among other covariates. S100A4 expression represents a highly significant prognostic marker in colorectal carcinoma, which is able to identify a subset of patients at high\nrisk.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":107},{"Name":"Cyclooxygenase-2 (COX-2)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":12405290,"Description":"Cyclooxygenase (COX) is a rate-limiting enzyme in prostaglandin biosynthesis Univariate analysis showed that significant prognostic variables for survival were tumor size, lymph node involvement, lymphatic invasion, vascular invasion, liver metastasis, high uPAR level, and COX-2 expression, but only liver metastasis was an independent prognostic factor (P = 0.0065) in multivariate analysis. COX-2 expression was a more important prognostic indicator than any other factor except liver metastasis (P = 0.0526).\u00a0 Cyclooxygenase-2 expression correlates with uPAR levels and is responsible for\npoor prognosis of colorectal cancer.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":108},{"Name":"Epidermal growth factor receptor (EGFR)\u00a0","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PredictiveBM","Pmid":12459370,"Description":"Epidermal growth factor receptor (EGFR) expression is observed in 50%-70% of colorectal carcinomas and is associated with poor prognosis. Preoperative treatment resulted in pathologic complete remission in 7 patients (15%), downstaging in 13 patients (29%), and no response in 25 patients (56%). EGFR+ was observed in 29 of 45 tumors (64%) and was associated with neither clinical tumor stage nor clinical nodal stage. The overall response rate was 34% in EGFR+ patients vs. 62% in those who were EGFR- (p = 0.07). Only 1 of the 7 pathologic complete remission patients was EGFR+ (p = 0.003). EGFR is expressed in a significant number of locally advanced rectal tumors. EGFR expression is an indicator for poor response to preoperative radiotherapy in advanced rectal carcinoma.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":109},{"Name":"Endothelin-1 (ET-1)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Blood","Assay\/Test":"Immunohistochemistry|in situ hybridisation","Usage":"DiagnosticBM","Pmid":12521131,"Description":"The median (range) plasma concentration of big ET-1 in controls was 2.1 pg\/mL (1.2-13.4 pg\/mL). The median (range) plasma concentration of big ET-1 in colorectal cancer patients with no overt hepatic metastases was 3.8 pg\/mL (1.2-15.8 pg\/mL), p=0.002, and the median (range) plasma concentration of big ET-1 in colorectal cancer patients with hepatic metastases was 5.2 pg\/mL (1.7-30 pg\/mL), p=0.0001; both were significantly elevated compared to the control group. A significant difference in immunostaining for big ET-1 was noted between paired normal colonic mucosa (median score-1) and tumour sections (median score-3), p=0.01. Therefore, plasma big ET-1 levels should be evaluated as a potential tumour marker for the identification of hepatic metastases at an earlier stage.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":110},{"Name":"KAI1","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"In situ hybridisation|Immunohistochemistry","Usage":"PrognosticBM","Pmid":12530084,"Description":"Multivariate analysis (Cox proportional hazards model) confirmed high KAI1 mRNA expression was an independent prognostic indicator of distant metastasis (p < 0.0001), cancer-specific survival (p < 0.0001) and overall patient survival (p < 0.0001). These data indicate a complex relationship between KAI1 and\nprogression of human CRC, in which expression is reduced in localised primary\ntumours, but regained in disease associated with metastasis\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":111},{"Name":"Thymidylate synthase (TS)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":12560427,"Description":"Thymidylate synthase (TS), the target enzyme of fluorouracil (FU)-based chemotherapy, is commonly reported to correlate with response and survival in these settings, along with p53. In multivariate analyses, TS overexpression was found to be an independent factor of poor prognosis in OS (P <.01), PFS (P =.06), and HPFS (P <.01). TS levels in hepatic tumors and resection margin are independent predictors of survival and progression in patients with metastatic colorectal cancer","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":112},{"Name":"Vascular endothelial growth factor (VEGF)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":12660643,"Description":"Vascular endothelial growth factor (VEGF) is a potent mediator of tumor angiogenesis The VEGF-C mRNA level in primary tumors correlated with VEGF-C protein expression, lymph node metastasis, and lymphatic invasion. Sixteen of 24 patients with lymph node metastasis showed VEGF-C mRNA overexpression. Morphologically, VEGF-C protein expression in primary tumors showed a statistically significant relationship with lymph node metastasis and lymphatic invasion. Furthermore, the expression levels of VEGF-C mRNA and protein in colorectal\ncancer are correlated with lymph node metastasis and lymphatic invasion.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":113},{"Name":"Tumor necrosis factor receptor type 1 (TNFR1)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":12680198,"Description":"Also in the multivariate analysis, TNFR1 expression was an independent prognostic factor. A high TNFR1 expression in Dukes' stage C colorectal cancer could be a favorable indicator of prognosis.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":114},{"Name":"c-MET","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":12684423,"Description":"Both c-MET and vascular endothelial growth factor (VEGF)-C expression are important factors in primary carcinoma progression. c-MET mRNA copies in CRC specimens was significantly higher than that from normal colon mucosal epithelium (P = 0.0001). c-MET mRNA copies significantly correlated with the depth of invasion: T(1) versus T(2), P = 0.007; T(1) versus T(3)\/T(4), P = 0.0001; T(1) versus T(2) versus T(3)\/T(4), P = 0.0005; and T(1)\/T(2) versus T(3)\/T(4), P = 0.011. This study indicates c-MET mRNA overexpression in primary CRC may be an important prognostic marker for early stage invasion and regional disease metastasis.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":115},{"Name":"Polo-like kinase 1 (PLK1)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":12708489,"Description":"PLK (polo-like kinase), the human counterpart of polo in Drosophila melanogaster and of CDC5 in Saccharomyces cerevisiae, belongs to a family of serine\/threonine kinases. Elevated expression of PLK1 was observed in 57 (73.1%) of the colorectal cancers, statistically significant associations being evident with pT (primary tumor invasion) (P=0.0006, Mann-Whitney U test), pN (regional lymph nodes) (P=0.008, chi2 test) and the Dukes' classification (P=0.0005, Mann-Whitney U test). Our results suggest overexpression of\nPLK1 might be of pathogenic, prognostic and proliferative importance, so that\nthis kinase might have potential as a new tumor marker for colorectal cancers.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":116},{"Name":"CD105","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":12778073,"Description":"CD105 (endoglin) is abundantly expressed in angiogenic EC, and antibodies to it preferentially bind to EC of angiogenic tissues Kaplan-Meier survival analysis revealed that only MVD values obtained using CD105 Mab correlated with survival. Patients with a high MVD, above the median (3.10), showed the worst prognosis. Both high intratumoral microvessel density determined using CD105 antibody and\nelevated plasma levels of CD105 in colorectal cancer patients correlate with poor\nprognosis.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":117},{"Name":"CD55","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":12811528,"Description":"CD55 is a complement regulatory protein that binds to C3 convertases of both the classical and alternative complement pathways and protects cells against bystander attack from complement. Patients with tumours expressing high levels of CD55 had a significantly worse survival (24%) than patients with low CD55 levels (50%, p<0.02). Enhanced expression of the complement regulatory protein CD55 predicts a poor\nprognosis in colorectal cancer patients.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":118},{"Name":"Fecal DNA","Molecular type":"DNA","Location":"Colon, Rectum","Source":"Feces","Assay\/Test":"qRT-PCR","Usage":"DiagnosticBM","Pmid":12816901,"Description":"DNA fragments isolated from CRC patients were of higher molecular weight (>18 bands detected of a total of 24 possible bands) than fragments isolated from fecal DNA of the colonoscopy-negative control group. An assay of fecal DNA integrity may be a useful biomarker for the detection of CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0001988","Id":119},{"Name":"P53","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":12818291,"Description":"Tumor suppressor genes, including p53, act as a G1 checkpoint in the cell replication cycle for cells with abnormal DNA until DNA repair can occur, or until apoptosis ensues in the event of excessive DNA damage. Among 75 patients entered in the study, 38 (50.7%) had p53 positive tumors. Fourteen patients (36.8%) with p53 positive tumors died from colorectal cancer, compared to five (13.5%) with p53 negative tumors (p < 0.04, log-rank test). The adjusted relative risk of cancer-related death among patients with p53 positive tumors was 3.03 (95% CI = 1.05-8.73). Abnormal p53 immunohistochemistry of tumors is associated with a poor prognosis among ulcerative colitis patients who develop colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":120},{"Name":"Tumor M2 Pyruvate Kinase (Tumor M2-PK) ","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Feces","Assay\/Test":"ELISA","Usage":"DiagnosticBM","Pmid":12820312,"Description":"Fecal Tumor M2-PK concentrations could be quantified. A significant difference between cancer patients and controls was found. The highest concentrations were observed in colorectal cancer. However, fecal Tumor M2-PK was not detectable in 5 tumor patients. The measurement of fecal Tumor M2-PK concentrations might provide an interesting screening tool for colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0001988","Id":121},{"Name":"Carcinoembryonic antigen (CEA)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Blood","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":12820382,"Description":"Carcinoembryonic antigen (CEA) is of prognostic value in colorectal cancer and has been shown to be related to the ability of colorectal cancer cells to implant and to metastasise and to have an effect on immune function. In the blood samples of cancer patients, the CEA mRNA level was significantly higher in Dukes' D patients than in the other clinical stages of colorectal cancer. This indicates that quantification of CEA mRNA is useful for the evaluation of colorectal cancer progress and that the post-operative increase of CEA mRNA can be a predictive marker for micrometastasis.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":122},{"Name":"Microsatellite instability (MSI)","Molecular type":null,"Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PredictiveBM","Pmid":12820457,"Description":"Microsatellite instability\u00a0(MSI) is a tumor phenotype linked to somatic or germline (Lynch syndrome) inactivating alterations of DNA mismatch repair genes. Tumours of 7 patients (16%) were highly instable (MSI-H). These patients had a better response rate (72% vs. 41%; p = 0.072) and a significantly better median survival (33 months, [95% CI 20-46] vs. 19 months, [95% CI 10-28]; p = 0.021) than microsatellite stable (MSS) patients (n = 36). Furthermore, MSI status was shown to be an independent predictive marker for survival (p = 0.037). These data provide further support for the hypothesis that MSI-H CRC might have a better response and survival than (MSS) CRC in palliative first-line treatment.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":123},{"Name":"Vascular endothelial growth factor (VEGF)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Blood","Assay\/Test":"ELISA","Usage":"PrognosticBM","Pmid":12875855,"Description":"Vascular endothelial growth factor (VEGF) is a potent mediator of tumor angiogenesis From the survival analysis, a higher serum VEGF-A and sTie-2 receptor level is associated with an earlier development of metastases. Using multivariate Cox's regression analysis, the only independent predictors of outcome were sTie-2 receptor (P=0.038) and VEGF-A (P=0.006). sTie-2 receptor and VEGF-A appear to associate independently with the development of metastases, with VEGF-A being the most powerful predictor of outcome. ","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":124},{"Name":"Thioredoxin-1","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":12878985,"Description":"Thioredoxins are low molecular weight (10\u2013 to 12 kD) redox proteins found in both prokaryotic and eukaryotic cells.There are two known forms of human thioredoxin: thioredoxin-1, which has a predominantly cytoplasmic but also nuclear localization and thioredoxin-2, which is found in the mitochondria When adjusted for Dukes stage, thioredoxin-1 expression showed a statistically significant association with survival (P =.012). thioredoxin-1\nexpression may be an independent marker of patient prognosis.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":125},{"Name":"Thymidylate synthase (TS) ","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":12883662,"Description":"The expression levels of thymidylate synthase (TS) affect the sensitivity of tumor cells to fluorinated pyrimidine cytotoxic agents and determine the response of patients with colorectal cancer to fluorinated-pyrimidine-based chemotherapy. In a subset analysis of Dukes' stage C patients, the survival and DFS rates were 44.0% and 40.0% in the high TS expression group, and 73.5% and 67.4% in the low TS expression group, respectively. Significant differences were observed in both survival (p=0.0048) and DFS (p=0.0054) rates. Significantly poorer prognosis of\ncuratively resected colon cancer in patients with high TS expression levels in\ntumor tissue was confirmed by a double-blind prospective study conducted on\nsamples obtained from patients enrolled in an adjuvant immunochemotherapy\nrandomized clinical trial.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":126},{"Name":"Cyclooxygenase 2 (COX-2)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":14510747,"Description":"Cyclo-oxgenase 2 (COX-2) is involved in prostaglandin synthesis in central nervous system, and it also plays a role in human carcinogenesis. Cyclo-oxygenase-2 over-expression was an independent predictor of a poor prognosis.\u00a0 Cyclo-oxygenase-2 over-expression is not associated with tumour\nphenotype, but is indicative of a poorer clinical outcome in patients with\nnon-advanced colorectal carcinoma.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":127},{"Name":"MMP-2, MMP-9","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Blood","Assay\/Test":"qRT-PCR|Immunohistochemistry","Usage":"PrognosticBM","Pmid":14520690,"Description":"Matrix metalloproteinases, and notably the gelatinases MMP-2 and MMP-9, have important roles in tumour invasion, metastasis and angiogenesis.\u00a0 Plasma MMP-2 levels were also significantly elevated in patients with colorectal cancer, with significant reductions following curative resections at all stages. Similarly, MMP-9 expression was significantly increased in colorectal cancer tissues, predominantly in the tumour stroma.\u00a0 Plasma levels of these enzymes may therefore have potential as a noninvasive indicator of invasion or metastasis in colorectal cancer or as a marker of disease status during follow-up.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":128},{"Name":"Cyclin-dependent kinase 4 (CDK4), p16","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR|Immunohistochemistry","Usage":"PrognosticBM","Pmid":14562378,"Description":"Strong immunostaining of p16 was a predictor for better prognosis whereas strong cytoplasmic immunostaining of CDK4 was a predictor for poor prognosis. Both p16 and CDK4 immunostainings were correlated with histological grade or Dukes' stage. the expression patterns of CDK4 and p16 may be imperative in the development of\ncolorectal carcinoma, thus becoming a new prognostic marker in colorectal cancer.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":129},{"Name":"Disseminated tumor cells (DTC)","Molecular type":null,"Location":"Colon, Rectum","Source":"Blood","Assay\/Test":"PCR-RFLP","Usage":"PrognosticBM","Pmid":14634776,"Description":"Disseminated tumor cells (DTC) are therefore thought to be precursors of micro- and macrometastasis. Colorectal tumor cells that are shed into the blood are filtered by the liver and lungs before they reach more distant organs such as bone marrow At follow-up only 10 of 40 patients (25%) with DTC-free liver had died of their disease but 9 of the 14 patients with hepatic DTC. Among the 14 patients with hepatic DTC 10 (71%) had developed new liver metastasis, compared to 12 of 40 (30%) in those without hepatic DTC. Hepatic DTC in colorectal cancer patients is associated with reduced \noverall survival and increased risk of hepatic metastasis development. \n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":130},{"Name":"Decay-accelerating factor (DAF)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Feces","Assay\/Test":"ELISA","Usage":"DiagnosticBM","Pmid":14638362,"Description":"Decay-accelerating factor (DAF; CD55) is a membrane-bound glycoprotein that regulates the activation of the autologous complement activation by inhibiting the formation and promoting the catabolism of C3 and C5 convertases Testing of two samples from each patient significantly increased the sensitivity (72%) of the stool DAF test without significantly decreasing its specificity (92%). The stool DAF test was positive in more than one half of patients with colorectal cancer at a relatively early TNM stage or with negative fecal occult blood test. These findings suggest that stool DAF is a marker of colorectal cancer independent of fecal occult blood and testing of two samples increases the sensitivity of the stool DAF test.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0001988","Id":131},{"Name":"Laminin 5 ","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"DiagnosticBM","Pmid":14645697,"Description":"Laminins are a group of matrix proteins localised at the basement membrane where they are involved in cell adhesion. The laminin (ln) family consists of cross shaped heterotrimers composed of \u03b1, \u03b2, and \u03b3 subunits. Ten polyps stained positive and the number of polyps expressing the laminin 5 gamma 2 chain increased significantly as the phenotype of the adenomas became more atypical: none of the 15 hyperplastic polyps, two of the 16 tubular adenomas (12.5%), and six of the 24 adenomas with a villous component (25%) were positive. Two of 12 (17%) serrated adenomas, regarded as a distinct form of colorectal neoplasia, showed gamma 2 chain expression.\u00a0 Laminin 5 gamma 2 chain expression was found to increase\nprogressively towards a more atypical phenotype of adenoma. The results suggest\nthat, in the future, laminin 5 gamma 2 chain expression may be used as an\nindicator of incipient malignant transformation of a benign colorectal adenoma.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":132},{"Name":"Beta-catenin","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"DiagnosticBM|PrognosticBM","Pmid":14645698,"Description":"Beta catenin was first identified as a protein associated\nwith E-cadherin in maintaining cell\u2013cell interactions. Moreover, those patients with colorectal cancer and high nuclear beta catenin expression had a higher incidence of lymph node metastasis (chi(2) = 16.99; p < 0.005) and shorter overall survival (p < 0.0001). Nuclear beta catenin expression is a potential prognostic factor in \npatients with colorectal cancer, and together with CK20, it could be used to\nidentify colorectal carcinoma in the Hong Kong population.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":133},{"Name":"17beta-hydroxysteroid dehydrogenase (17HSD)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"In situ hybridization","Usage":"PrognosticBM","Pmid":14672733,"Description":"The enzymes of the 17-hydroxysteroid dehydrogenase (17HSD) family are involved in the regulation of bioavailability of steroid hormones by catalyzing key steps in the formation and primary metabolism of active estrogens, androgens and progestins In colorectal tumors, 17HSD type 2 expression was in most cases downregulated. Female patients had significantly more cancers with high 17HSD type 2 mRNA expression (n=11\/35; 31%) than male patients (n=3\/39; 8%) (P=0.02). We observed a significant impact of 17HSD type 2 mRNA expression on survival in female patients with distal colorectal cancer (n=24), with an overall cumulative 5-year survival rate of 54% in those with low 17HSD type 2 mRNA expression.\u00a0 Our data provide evidence\nsuggesting that low 17HSD type 2 mRNA expression is an independent marker of\nfavorable prognosis in females with distal colorectal cancer\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":134},{"Name":"Cyclooxygenase 2 (COX-2)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":14719154,"Description":"Cyclo-oxgenase 2 (COX-2) is involved in prostaglandin synthesis in central nervous system, and it also plays a role in human carcinogenesis. Kaplan-Meier analysis showed that overexpression of cyclooxygenase-2 was significantly associated with poor survival and thus could serve as a prognostic marker. We conclude that cyclooxygenase-2 is related with tumor progression and metastasis in colorectal cancer, which can be observed on protein level, and reflects chromosomal gain at the locus at 1q25.2-q25.3.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":135},{"Name":"Dihydropyrimidine dehydroganase (DPD) ","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Enzyme-linked immunosorbent assay","Usage":"PrognosticBM|PredictiveBM","Pmid":14744539,"Description":"Dihydropyrimidine dehydrogenase (DPD) is an enzyme that catabolizes 5-fluorouracil (5-FU), which is widely used for chemotherapy in patients with advanced colorectal cancer (CRC).\u00a0 In the adjuvant chemotherapy group, high tumor DPD levels were associated with poor survival (HR, 5.24; P = 0.03). In the surgery alone group, high tumor DPD levels were associated with better survival (HR, 0.32; P = 0.02). In conclusion, tumor DPD level is an efficacious marker in \noral 5-FU based-adjuvant chemotherapy for colorectal cancer; however, low tumor\nDPD predicts reduced survival in patients treated with curative surgery alone.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":136},{"Name":"Dihydropyrimidine dehydrogenase (DPD)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":15015608,"Description":"Dihydropyrimidine dehydrogenase (DPD) is an enzyme that catabolizes 5-fluorouracil (5-FU), which is widely used for chemotherapy in patients with advanced colorectal cancer (CRC).\u00a0 Tumor DPD expression appeared to be an important poor prognostic factor in patients with Dukes' C CRC by multivariate analysis (p=0.013). Immunohistochemical DPD expression in tumors is a useful prognostic parameter in patients with Dukes' C CRC treated with postoperative adjuvant FU-based chemotherapy.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":137},{"Name":"P65","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":15028307,"Description":"P65 protein\/gene is a potential, non-specific tumour marker expressed by different types of neoplasms. p65 Gene expression was associated with more advanced tumours (T3, T4; p=0.0003) with metastases to lymph nodes (N1, N2; p=0.0003) and distant metastases (p=0.0005). p65 Gene expression in primary tumour tissue is associated with poor prognosis for the patients with colorectal cancer in this series.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":138},{"Name":"Platelet-derived endothelial cell growth factor (PD-ECGF)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Enzyme-linked Immunosorbent assay","Usage":"PrognosticBM","Pmid":15028312,"Description":"Platelet-derived endothelial cell growth factor (PD-ECGF) is an angiogenic factor that undergoes increased expression in colorectal carcinomas, but its prognostic value is a topic of debate. A multivariate Cox's regression analysis revealed that high PD-ECGF expression is an independent factor for better outcome. The PD-ECGF expression originated from stromal macrophages was a predictor for favorable outcome after curative resections for colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":139},{"Name":"C-peptide","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Blood","Assay\/Test":"Enzyme-linked immunosorbent assay","Usage":"DiagnosticBM","Pmid":15069117,"Description":"C-peptide (an indicator of insulin production)\u00a0 An increased concentration of plasma C-peptide was statistically significantly associated with an increased risk of colorectal cancer (relative risk [RR] for the highest versus lowest quintile of plasma C-peptide = 2.7, 95% confidence interval [CI] = 1.2 to 6.2; P(trend) =.047), after adjusting for age, smoking status, fasting, BMI, alcohol consumption, vigorous exercise, and aspirin assignment in the Physicians' Health Study. Elevated insulin production, as reflected by elevated concentrations \nof plasma C-peptide, may predict the risk of developing colorectal cancer,\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":140},{"Name":"PRL-3","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"ELISA|Western blot","Usage":"PrognosticBM","Pmid":15133662,"Description":"PRL-3 is a newly identified metastasis-related gene, which codes a 22 KDa nonclassical protein tyrosine phosphatase with a C-terminal prenylation motif. PRL-3 expression was significantly associated with the liver metastasis of colorectal cancer (P = 0.004) and tended to shorten survival time (P = 0.0145). This is the first study demonstrating that PRL-3 is a potential\nmarker for liver metastasis of colorectal cancer and negatively influences the\nprognosis of colorectal cancer patients.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":141},{"Name":"Dipeptidase 1 (DPEP1)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"DiagnosticBM","Pmid":15145522,"Description":"From these analyses we identified dipeptidase 1 (DPEP1) as a potential tumor-specific marker. DPEP1 has been previously found to be a zinc metalloprotease Using immunobead RT-PCR, a technique that first enriches for epithelial cells, we found DPEP1 positive cells in intra-peritoneal lavage and venous blood samples from 15\/38 (39%) colorectal cancer cases. This is the first report of\nDPEP1 as a marker for disseminated colon tumor cells.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":142},{"Name":"The deleted in colorectal cancer (DCC)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":15148649,"Description":"Deletion involving chromosome 18q has been identified in colon carcinoma and was termed deleted in colorectal cancer (DCC) gene. Patients in Stage III who were DCC+\/ CHEMO+ had survival and disease-free survival of 100 percent, whereas in DCC+\/CHEMO- both dropped to zero ( P = 0.0002). On the other hand, in the DCC- tumors, there was no statistical significant relationship between chemotherapy and survival or disease-free survival (DCC-\/CHEMO- had 57 percent survival; DCC-\/CHEMO+ had 52 percent survival). Deleted in colorectal cancer protein expression as a possible predictor of\nresponse to adjuvant chemotherapy in colorectal cancer patients.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":143},{"Name":"Tumor M(2)-PK","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"ELISA","Usage":"DiagnosticBM","Pmid":15162541,"Description":"The concentration of dimeric pyruvate kinase M2 isoenzyme is dramatically increased in a metabolic state characteristic for tumor cells. It is thus called tumor M2-PK The overall sensitivity of tumor M(2)-PK for colorectal cancer was 68.52%, while that of CEA was 43.12%. Tumor M(2)-PK has a higher sensitivity than markers CEA and CA72-4,and is a valuable tumor marker for the detection of gastrointestinal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":144},{"Name":"Tenascin-C (TN-C) ","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":15239346,"Description":"Tenascin-C (TN-C) is a glycoprotein of the ECM related to cell adhesion and detachment Diffuse stromal TN-C immunostaining was found to be significantly correlated with advanced stage and shorter survival time (p = 0.002 and 0.02, respectively). Our findings suggest that TN-C expression may be a potential\nprognostic marker in colorectal carcinoma.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":145},{"Name":"Cyclooxygenase 2 (COX-2)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Feces","Assay\/Test":"qRT-PCR","Usage":"DiagnosticBM","Pmid":15300574,"Description":"Cyclo-oxgenase 2 (COX-2) is involved in prostaglandin synthesis in central nervous system, and it also plays a role in human carcinogenesis. The sensitivity and the specificity of fecal COX-2 assay for CRC were 90% (95% confidence interval [CI], 73%-98%) and 100% (95% CI, 85%-100%), respectively, whereas those of the fecal CEA assay for CRC were 100% (95% CI, 88%-100%) and 5% (95% CI, 2%-23%), respectively.\u00a0 This fecal COX-2 assay had high sensitivity and high specificity for detecting CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0001988","Id":146},{"Name":"Thymidylate synthase (TS)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":15309465,"Description":"Thymidylate synthase (TS) is the rate-limiting enzyme in the synthesis of pyrimidine nucleotides, required for DNA synthesis, and is also a critical target for fluoropyrimidines, which are widely used in the treatment of gastrointestinal tumours. TS expression was highly significantly associated with poor survival and was the strongest independent prognostic factor in multivariate analysis, followed by lymph node status. Thymidylate synthase expression seems to be an independent prognostic factor and a possible predictor of tumor recurrence in patients with colorectal\ncancer.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":147},{"Name":"Dihydropyrimidine dehydrogenase (DPD)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Enzyme-linked immunosorbent assay","Usage":"PredictiveBM","Pmid":15309506,"Description":"5-Fluorouracil (5-FU) is one of the most widely used chemotherapeutic agents for colorectal cancer. More than 80% of an administered dose of 5-FU is eliminated by catabolism via dihydropyrimidine dehydrogenase (DPD, EC 1.3.12), the rate-limiting enzyme In a multivariate analysis, low DPD expression was significantly and independently associated with better survival. Tumor DPD expression is a useful marker for use with adjuvant\nchemotherapy with oral fluoropyrimidines after curative resection of colorectal\ncancer.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":148},{"Name":"Heparanase","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR|Immunohistochemistry","Usage":"PrognosticBM","Pmid":15334632,"Description":"Theheparanase cDNA contains an open reading frame of1,629 bp encoding a 61.2-kDa polypeptide of 543 aminoacids. In multivariate analysis using the Cox regression model, heparanese expression emerged as an independent prognostic indicator. These results indicated that Heparanase expression may be an\nimportant role in invasion and hematogenous metastasis, and may be a biologic\nmarker of prognostic significance in colorectal cancer patients.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":149},{"Name":"Survivin","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"DiagnosticBM","Pmid":15334693,"Description":"Among molecules of the IAP family, survivin, a novel anti-apoptosis gene is prominently expressed in CRC and several other malignancies The expression of survivin mRNA was detected in a significantly greater proportion of colorectal carcinoma samples than in adjacent normal colorectal tissues (67.3% vs 25%; P<0.01). Survivin is a special tumor marker independent of histopathological\ncharacteristics.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":150},{"Name":"A3 adenosine receptors","Molecular type":"Protein","Location":"Colon","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"DiagnosticBM","Pmid":15355922,"Description":"Adenosine, a ubiquitous nucleoside released from metabolically active or stressed cells, is known to act as an important regulatory molecule through its activation of cell surface receptors named A1, A2A, A2B, and A3, all of which belong to the G-protein\u2013coupled superfamily of receptors As measured by receptor binding assays, the density of A(3) receptor was higher in colon carcinomas as compared with normal mucosa originating from the same individuals (P < 0.05). This study provides the first evidence that A(3) receptor plays a\nrole in colon tumorigenesis and, more importantly, can potentially be used as a\ndiagnostic marker or a therapeutic target for colon cancer.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":151},{"Name":"Endothelial cell nitric oxide synthase (ecNOS)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":15500954,"Description":"Nitric oxide (NO) is generated from L-arginine by three nitric oxide synthase (NOS) isoenzymes, neuronal NOS (nNOS), inducible NOS (iNOS) and endothelial cell NOS (ecNOS) Studies of a retrospective material of 186 colorectal tumors (Duke's stage B) now show that PEMVD is a significant and independent prognostic indicator for disease-free survival also in these patients. High expression of endothelial cell nitric oxide synthase in peritumoral\nmicrovessels predicts increased disease-free survival in colorectal cancer\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":152},{"Name":"Activated leucocyte cell adhesion molecule (ALCAM)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":15509676,"Description":"The activated leucocyte cell adhesion molecule (ALCAM; CD166) is a cell adhesion molecule that belongs to the immunoglobulin superfamily and is widely expressed in a variety of normal tissues In survival analyses, membranous ALCAM expression correlated significantly (Cox's regression, p=0.028; relative risk, 2.3) with shortened patient survival. ALCAM is frequently upregulated in colorectal cancer and is a new independent prognostic marker, underscoring the importance of ALCAM in tumour progression in this disease.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":153},{"Name":"Microsatellite instability (MSI)","Molecular type":null,"Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PredictiveBM","Pmid":15510606,"Description":"High microsatellite instability (MSI-H) as a marker for the DNA mismatch repair deficient \"Mutator Pathway\" of carcinogenesis and immunohistochemical expression of cell cycle-related proteins have been found to predict a favorable outcome in colorectal cancer patients Tumors with high microsatellite instability showed CR (3\/5, 60%) more often than PR, whereas tumors with stable microsatellites showed PR (26\/36, 80%) more often than CR (p=0.099). We conclude that a molecular profile characterized by high\nmicrosatellite instability with loss of mismatch repair protein expression and\np21WAF1\/C1PI is predictive of an improved response to neoadjuvant treatment with \n5-FU, CPT-11 and radiation therapy.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":154},{"Name":"P27 (Kip1)","Molecular type":"Protein","Location":"Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PredictiveBM","Pmid":15525823,"Description":"p27(Kip1) is an inhibitor of a broad spectrum of cyclin-dependent kinases (CDKs), and the loss of a single\u00a0p27(Kip1) allele is thereby sufficient to increase tumor incidence via CDK-mediated cell cycle entry. On multivariate analysis, positive p27 expression remained an independent negative prognostic factor for RFS (P = .04). None of the other proteins was significantly associated with RFS. Our results indicate that positive p27 expression in rectal cancer\nafter preoperative chemoradiation is an independent negative predictor of RFS.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":155},{"Name":"Matrix metalloproteinase (MMPs), Tissue inhibitors of matrix metalloproteinases (TIMPs)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":15623598,"Description":"The matrix metalloproteinases (MMPs) are a family of proteolytic enzymes involved in tumor invasion; several individual members of which have been implicated in tumor prognosis. These enzymes and their physiologic inhibitors, the tissue inhibitors of matrix metalloproteinases (TIMPs), act in a coordinated manner to form an integrated system.\u00a0 The MMP\/TIMP profile defined by hierarchical cluster analysis of the immunohistochemical score identifies a distinct group of colorectal cancers with poor prognosis (log-rank test, 12.22, P = 0.0005). The median survival time of patients in this survival group was 18 months compared with a median survival of 49 months in the \"good\" survival group. Multivariate analysis showed that this profile was independently the most significant prognostic factor (P = 0.001). This study has identified that the MMP\/TIMP profile is an\nindependent indicator of poor prognosis in colorectal cancer.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":156},{"Name":"Cyclooxygenase-2 (COX-2)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":15623626,"Description":"Cyclooxygenase (COX) is a rate-limiting enzyme in prostaglandin biosynthesis Cox-2 was an independent prognostic factor (P = 0.0103; relative risk 4.114; 95% confidence interval, 1.397-12.120). Elevated Cox-2 expression, but not that of Cox-1, was significantly \nassociated with reduced survival and recognized as an independent prognostic\nfactor in our cohort of colorectal cancer patients.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":157},{"Name":"Heparanase","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":15625607,"Description":"Heparanase cleaves carbohydrate chains of heparan sulphate proteoglycans and is an important component of the extracellular matrix. Expression of heparanase was significantly more frequent in tumors of higher TNM stage (P=0.0481), higher Dukes stage (P=0.0411), higher vascular infiltration (P=0.0146), and higher lymph vessel infiltration (P=0.0010). Heparanase expression in colon cancers correlated significantly with poor survival (P=0.0361). Heparanase-transfected colon cancer cells exhibited significant invasion compared with control-transfected colon cancer cells (P=0.001), and the peritoneal dissemination model also showed the malignant potential of heparanase-transfected cells, as assayed by number of nodules (P=0.017) and survival (P=0.0062).\u00a0 Heparanase is a marker for poor prognosis of patients with colon\ncancer and could be a suitable target for antitumor therapy in colon cancer.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":158},{"Name":"Connective tissue growth factor(CTGF)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":15633118,"Description":"Connective tissue growth factor (CTGF) has been shown to be implicated in tumor development and progression. Patients with stage II and stage III CRC whose tumors displayed high CTGF expression had a significantly higher overall survival and a disease-free advantage over patients with CRC with low CTGF expression. Our results implicate CTGF as a key regulator of CRC invasion and metastasis, and it appears to be a useful and better prognosis factor for patients with stage II and stage III CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":159},{"Name":"Cathepsin H","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Blood","Assay\/Test":"ELISA","Usage":"PrognosticBM","Pmid":15646835,"Description":"Cathepsin H is a lysosomal cysteine protease that may participate in tumor progression. In survival analysis a significant difference was found between the group of patients with low cathepsin H (first tertile) who had a poor prognosis and the remaining patients (p = 0.03). The risk of patients was further stratified when cathepsin H levels were combined with CEA. Patients with high CEA and low cathepsin H had the highest risk of death with a hazard ratio of 2.72 (95% CI 1.73-4.28), p < 0.0001 Our results show that the prognostic\ninformation of cathepsin H differs from that of the related cathepsins B and L\nand suggest different roles during the progression of malignant disease\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":160},{"Name":"Bcl-2 ","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Blood","Assay\/Test":"ELISA","Usage":"PrognosticBM","Pmid":15655644,"Description":"Bcl-2 is a proto-oncogene originally identified at the breakpoint of a chromosomal translocation (t14:18) in human follicular B-cell lymphomas. Bcl-2 was detected in the serum of patients with CRC. A significantly higher proportion of patients with non-metastatic disease (61%), had high serum bcl-2 values, compared to patients with metastatic disease (28%, p<0.0001). Serum bcl-2 in patients with CRC may reflect the degree of Bcl-2\nexpression in cancer tissue. Serum bcl-2 is easily determinable, and could be\nuseful as a prognostic marker in CRC.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":161},{"Name":"Alphavbeta6 integrin ","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR|Immunohistochemistry","Usage":"PrognosticBM","Pmid":15668738,"Description":"The \u03b1v\u03b26 integrin promotes the activation of autocrine TGF-\u03b2 that sustains the EMT and is also required for the migration of post-EMT cells on fibronectin. Kaplan-Meier analysis of beta6 expression in 488 colorectal carcinomas revealed a striking reduction in median survival time of patients with high beta6 expression. Elevated receptor expression did not simply reflect increasing tumor stage, since log-rank analysis showed a more significant impact on the survival of patients with early-stage, as opposed to late-stage, disease. Cox regression analysis confirmed that this integrin is an independent variable for these tumors. These findings define the alphavbeta6 integrin as an important risk factor for early-stage disease and a novel therapeutic candidate for colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":162},{"Name":"Thymidine phosphorylase (TP)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":15706408,"Description":"Thymidine phosphorylase (TP) is a unique enzyme involved not only in angiogenesis, but in 5-fluorouracil (5-FU) metabolism as well.\u00a0 High stromal TP status was also a strong prognostic factor in the group receiving adjuvant 5-FU derivatives (p=0.0222). Importance of thymidine phosphorylase expression in tumor stroma as a prognostic \nfactor in patients with advanced colorectal carcinoma\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":163},{"Name":"Particularly interesting new cysteine-histidine-rich protein (PINCH)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Feces","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":15720806,"Description":"Particularly interesting new cysteine-histidine-rich protein (PINCH), a LIM domain adapter protein that functions in the integrin and growth factor signal transduction pathway, is upregulated in stroma associated with many common cancers Strong stromal immunostaining for PINCH was shown to predict a worse outcome (rate ratio 2.1, 95% CI 1.16-3.37, P=.01), independent of Dukes stage, growth pattern, and tumor differentiation.\u00a0 Interestingly, stromal staining for PINCH was an\nindependent prognostic indicator in colorectal cancer.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0001988","Id":164},{"Name":"Cyclooxygenase-2 (COX-2)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"DiagnosticBM","Pmid":15754389,"Description":"Cyclooxygenase (COX) is a rate-limiting enzyme in prostaglandin biosynthesis The expression of cyclooxygenase-2 was significantly correlated with the depth of invasion, stage of disease, and metastasis (lymph node and liver). Cyclooxygenase-2 may be associated with tumor progression by\nmodulating the angiogenesis and cancer cell motility and invasive potential in\ncolorectal cancer and it can be used as a possible biomarker.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":165},{"Name":"Thymidine phosphorylase (TP)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PredictiveBM","Pmid":15756433,"Description":"Thymidine phosphorylase (TP) is a unique enzyme involved not only in angiogenesis, but in 5-fluorouracil (5-FU) metabolism as well.\u00a0 In Dukes' C stage colon patients with high TP expression, the 5'-DFUR group had slightly better survival than the 5-FU group.\u00a0 These findings suggest that TP may be a chemosensitive marker for 5'-DFUR as postoperative adjuvant chemotherapy for advanced colon cancer patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":166},{"Name":"Thymidylate synthase (TS)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PredictiveBM","Pmid":15770397,"Description":"Thymidylate synthase (TS) is the rate-limiting enzyme in the synthesis of pyrimidine nucleotides, required for DNA synthesis, and is also a critical target for fluoropyrimidines, which are widely used in the treatment of gastrointestinal tumours. A significant increase in the TS expression score was observed in 5-FU-sensitive colorectal cancers (0.57 +\/- 0.19) compared to 5-FU-resistant ones (1.16 +\/- 0.98; P = 0.029), whereas no significant differences in DPD expression scores were observed in 5-FU-sensitive colorectal cancers (0.86 +\/- 1.19) compared to 5-FU-resistant ones (0.56 +\/- 1.05; P = 0.603). TS mRNA may be useful as a predictor of the 5-FU chemosensitivity of colorectal cancers.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":167},{"Name":"Interleukin 6 (IL-6), C-reactive protein (CRP)","Molecular type":null,"Location":"Colon, Rectum","Source":"Blood","Assay\/Test":"ELISA","Usage":"PrognosticBM","Pmid":15786541,"Description":"C-reactive protein (CRP), a protein synthesized in the hepatocytes, has also been reported to be related both to the malignant potential of the neoplasms and to physical cachexia Median IL-6, TNFalpha and CRP levels were significantly higher in CRC patients than in normal controls. High levels of serum IL-6, TNFalpha and CRP were correlated with larger tumor size. Furthermore, high IL-6 and high CRP levels were associated with reduced overall survival. Serum IL-6, TNFalpha and CRP levels definitely increase in CRC\npatients. Pre-operative serum elevation of IL-6 and CRP was thus found to be\npredictor of the prognosis of CRC patients. The clinical value of TNFalpha in CRC\nneeds to be further investigated.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":168},{"Name":"Microsatellite instability (MSI)","Molecular type":null,"Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Methylation Specific PCR|Immunohistochemistry","Usage":"PrognosticBM","Pmid":15800322,"Description":"Microsatellite instability\u00a0(MSI) is a tumor phenotype linked to somatic or germline (Lynch syndrome) inactivating alterations of DNA mismatch repair genes. We showed that MSI-L defines a group of patients with poorer survival (P = .026) than MSS patients, and that MSI-L was an independent prognostic indicator (P = .005) in stage C colon cancer. Loss of MGMT protein expression was associated with the MSI-L phenotype but was not a prognostic factor for overall survival in colon cancer. p16 methylation was significantly less frequent in MSI-L than in MSI-H and MSS tumors and was not associated with survival. MSI-L characterizes a distinct subgroup of stage C colon cancer\npatients, including the MSI-L subset of proximal colon cancer, who have a poorer \noutcome. \n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":169},{"Name":"Von Willebrand factor (vWF)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Blood","Assay\/Test":"Immunoturbidimetric assay","Usage":"PrognosticBM","Pmid":15810086,"Description":"Von Willebrand factor (vWF) is a glycoprotein that synthesized mainly in endothelial cells and in megakaryocites By multivariate analysis, plasma vWF levels (P<0.001), the extent of metastasis (P = 0.012), and the performance status (P = 0.014) were identified as independent prognostic factors. Our data indicates that high plasma vWF concentrations correlate with advanced diseases and significantly poor prognosis of patients with metastatic\ncolorectal carcinoma. It may serve as a potential biological marker of disease\nprogression in these patients.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":170},{"Name":"SMAD4","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":15814640,"Description":"SMAD4 is an important tumor suppressor gene that mediates transforming growth factor-beta superfamily signaling and is located in chromosome 18q21, a region with frequent genetic losses in these tumors. Patients with tumors expressing high SMAD4 levels had significantly better overall (P < 0.025) and disease-free (P < 0.013) survival than patients with low levels.\u00a0 In conclusion, the level \nof expression of SMAD4 was found to be a more sensitive marker than 18q21 allelic\nimbalance and SMAD4 mutations, which were of no prognostic significance for these\npatients.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":171},{"Name":"Epidermal growth factor receptor (EGFR)","Molecular type":"Protein","Location":"Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM|PredictiveBM","Pmid":15816107,"Description":"Expression of epidermal growth factor receptor (EGFR) is observed in 50-70% of colorectal carcinoma and is associated with poor prognosis.\u00a0 EGFR positive expression was linked to a lack of pathologic complete response to preoperative radiotherapy (P=0.006). Disease-free survival was lower among patients with EGFR positive status before radiotherapy (P=0.003). In a multivariate analysis EGFR expression at biopsy was a statistically significant predictor of disease-free survival, RR=2.88(1.1-7.8), P=0.036. EGFR is expressed in a significant number of rectal tumors.\nEGFR-positive expression before radiotherapy is an indicator for poor response\nand low disease-free survival\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":172},{"Name":"Ornithine decarboxylase (ODC)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR|Immunohistochemistry","Usage":"DiagnosticBM|PredictiveBM","Pmid":15818733,"Description":"Ornithine decarboxylase (ODC) is the first ratelimiting enzyme in the polyamine biosynthesis pathway[8], and plays a critical role in cell transformation RT-PCR showed that the ODC mRNA level increased greatly in colon cancer tissues (P<0.01). Immunohistochemical staining showed that colorectal carcinoma cells expressed a significantly higher level of ODC than normal colorectal mucosa (98.6+\/-1.03% vs 5.26+\/-5%, P<0.01). ODC gene overexpression is significantly related to human colorectal carcinoma. ODC gene expression may be a marker for the gene diagnosis and therapyof colorectal carcinoma.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":173},{"Name":"Placenta growth factor (PlGF)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR|Immunohistochemistry","Usage":"PrognosticBM","Pmid":15831913,"Description":"Placenta growth factor (PlGF), a dimeric glycoprotein with 53% homology to VEGF,10 11 binds to VEGF receptor 1, but not to VEGF receptor 2, and may function by modulating VEGF activity.1 Patients with more tumour PlGF mRNA had shorter survival (p = 0.028). Our results suggest that PlGF expression correlates with disease progression and patient survival and may be used as a prognostic indicator for colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":174},{"Name":"Zeste homolog 2(EZH-2) ","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":15837043,"Description":"Enhancer of zeste homolog 2 (EZH-2) is a polycomb group (PcG) protein, and the clinical significance of this protein has not yet been determined in colorectal cancer (CRC) cases.\u00a0 Among the CRC cases, 32 patients whose tumour tissue showed overexpression of EZH-2 also had a significantly worse prognosis than did 29 patients whose tumour tissue showed low EZH-2 expression (p<0.05). In addition, a significant correlation between EZH-2 and HDAC-1 expression was observed in 61 CRC cases (p<0.05). Moreover, 20 cases of both high EZH-2 and high HDAC-1 expression showed poor prognoses than did 19 cases in which there was low EZH-2 and low HDAC-1 expression (p<0.05). The abundant expression of EZH-2 in CRC cases indicated that EZH-2 may be an oncogene and a prognostic marker for CRC cases.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":175},{"Name":"Bax","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PredictiveBM","Pmid":15891997,"Description":"BAX, the BCL-2-associated X protein, is a cardinal proapoptotic member of the BCL-2 family, which regulates the critical balance between cellular life and death. We further compared the expressions of these molecular markers with the pathological responses of the tumors after therapy. We found that Bax expression, among the markers studied, was exclusively related to tumor regression. Its expression was significantly higher in the complete response group as compared with the partial response group (54% versus 29%, P = .017). his result confirms that apoptosis plays an important role in tumor\nresponse to CRT and provides evidence that Bax may serve as a predictable\nmolecular marker for chemoradiosensitivity in rectal carcinoma.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":176},{"Name":"CYP51","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":15897573,"Description":"The cytochromes P450 (P450) are a multigene family of enzymes with a central role in the oxidative metabolism of a wide range of xenobiotics, including anticancer drugs, carcinogens, and endogenous compounds. The presence of strong CYP51 (log-rank = 12.11, P = 0.0005) or strong CYP2S1 (log-rank = 6.72, P = 0.0095) immunoreactivity were associated with poor prognosis. CYP51 was also an independent marker of prognosis (P = 0.009). High expression of CYP51 or CYP2S1 were associated with poor prognosis and CYP51 is an independent marker of prognosis.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":177},{"Name":"Ku, p53, p21,, p16","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PredictiveBM","Pmid":15966178,"Description":"Univariate analysis showed a correlation between the expression patterns of Ku, p53, p21, and p16 and tumor radiosensitivity, while multivariate analysis showed that the expression pattern of Ku and p16 significantly correlated with tumor radiosensitivity. The combination of Ku and p16, or Ku, p53, p21 and p16 was therefore a good predictive marker for tumor radiosensitivity. These findings tend to support the hypothesis that the combination\nof Ku, p53, p21, and p16 expression after radiotherapy can act as a marker for\nradiosensitivity.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":178},{"Name":"Soluble FAS\/soluble FASL ratio\n","Molecular type":null,"Location":"Colon, Rectum","Source":"Blood","Assay\/Test":"Immunohistochemistry","Usage":"PredictiveBM","Pmid":16000573,"Description":"FAS (CD95) and FAS ligand (FASL; CD95L) have been implicated in chemosensitivity through leading to apoptosis in response to DNA-damaging drugs. A significant increase in the soluble FASL levels up to 9 months (fourth to fifth extractions; 0.26 ng\/mL) of therapy compared with first to third extractions (0.11 ng\/mL; P=0.003) was also found. A random effect regression statistical model determined that >1.2-fold increase in soluble FAS\/soluble FASL ratio was a marker of chemosensitivity (P = 0.001). These data strongly indicate that an increment of soluble FAS\/soluble FASL ratio after treatment could be an excellent marker of chemosensitivity in colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":179},{"Name":"Telomerase reverse transcriptase ","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PredictiveBM","Pmid":16001613,"Description":"Telomerase reverse transcriptase expression and histopathological grade were significant prognostic variables for disease-free survival in the multivariate analysis (P=0.0003, P=0.0091). Telomerase reverse transcriptase\nmight be a useful parameter for patient selection for preoperative radiotherapy\nin rectal carcinoma.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":180},{"Name":"Ku70","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":16001615,"Description":"Ku protein stimulates DNA repair and signals the damage\/stress responses, which may affect apoptosis and cell proliferation. \u00a0Ku70 was a significant variable for prognosis of survival in the multivariate analysis. This is the first report correlating reduced survival with elevated \nexpression of Ku protein in colorectal adenocarcinoma. Ku may be a new prognostic\nmarker useful for selecting adjuvant treatment strategies.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":181},{"Name":"Epidermal growth factor receptor (EGFR)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PredictiveBM","Pmid":16010411,"Description":"Expression of epidermal growth factor receptor (EGFR) is observed in 50-70% of colorectal carcinoma and is associated with poor prognosis.\u00a0 Cytoplasmic expression of EGFR (p = 0.0141) or EGFRvIII (p = 0.005) was, however, associated with improved survival in patients receiving radiotherapy. Our results suggest that coexpression of cytoplasmic EGFR and EGFRvIII occurs in a significant proportion (34%) of Dukes' C colorectal cancer and the cytoplasmic expression of EGFR or EGFRvIII is a good indicator of response to radiotherapy.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":182},{"Name":"Cytokeratin 20 (CK20)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Blood","Assay\/Test":"qRT-PCR","Usage":"DiagnosticBM","Pmid":16048578,"Description":"Cytokeratin 20, an intermediate filament of epithelial cells, is expressed particularly in the urinary tract. In the patient group, CK20 mRNA was detected in 80.0%, 82.5% and 72.5% of patients when CD45, Ber-EP4, and CD45\/Ber-EP4 immunomagnetic beads were used, respectively. The positive detection rates of patients with colorectal carcinoma at Dukes A, B, C, and D stage were 0.0% (0\/2), 33.3% (3\/9), 86.7% (13\/15), and 92.9% (13\/14), respectively. The CK20 mRNA positive detection rate in peripheral blood was significantly correlated with tumor diameter (P < 0.01, chi(2)), lymphatic metastasis (P < 0.05) and hepatic metastasis (P < 0.05), but not with the differentiation of tumor cells. The combined use of negative and positive immunomagnetic beads\nfollowed by amplification of CK20 mRNA by means of RT-PCR is a non-invasive,\nsensitive, and specific assay for the detection of circulating colonic cancer\ncells.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":183},{"Name":"Thymidylate synthase (TS)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":16077970,"Description":"Thymidylate synthase (TS) is the rate-limiting enzyme in the synthesis of pyrimidine nucleotides, required for DNA synthesis, and is also a critical target for fluoropyrimidines, which are widely used in the treatment of gastrointestinal tumours. A significant association was found between tumour TS expression and response to treatment with 5-FU plus FA with irinotecan (p=0.05). Sixty-four percent of patients with TS expression levels below the median showed an objective (complete or partial) response to treatment while, 38% with TS expression levels above the median responded. Immunohistochemical TS expression\nlevels might be used both as a prognostic marker and to help identify patients\nwho would benefit from 5-FU based regime.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":184},{"Name":"Galectin-3","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":16080575,"Description":"The endogenous \u201a-galactoside-binding protein galectin-3 is a member of a gene family of widely distributed carbohydratebinding proteins that have been implicated in cell growth, differentiation, adhesion, malignant transformation While univariate analysis showed that survival in patients with galectin-3-positive expression was significantly poorer than in galectin-3-negative cases (p = 0.0027), galectin-3 expression was a prognostic factor independent of Dukes' stage and lymph node metastasis by multivariate analysis. We propose that galectin-3 expression is an independent factor for\nprognosis in colorectal cancer.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":185},{"Name":"Plasminogen activator inhibitor-1 (PAI-1)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":16091756,"Description":"Plasminogen activator inhibitor-1 (PAI-1), a 45-kDa serine proteinase inhibitor with a reactive peptide bond, Arg345\u2013Met346, is a multifaceted proteolytic inhibitor that not only functions as a fibrinolytic inhibitor, but also plays an important role in signal transduction, cell adherence, and cell migration. Moreover, multivariate analysis revealed the PAI-1 expression score to be a strong and independent prognostic factor for CRC (P = 0.0432). These results suggested that PAI-1 might \nserve as a new parameter for the prediction of prognoses in CRC.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":186},{"Name":"Thymidine phosphorylase (TP), Dihydropyrimidine dehydrogenase (DPD), Thymidylate synthase (TS)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":16132996,"Description":"The enzymes thymidine phosphorylase (TP), dihydropyrimidine dehydrogenase (DPD) and thymidylate synthase (TS) are involved in the metabolism of pyrimidines Correlation to histopathological parameters revealed a significant association between tumor stage and the TP mRNA level (T and N category and UICC) as well as the TP:DPD (T and N category and UICC) and TS:DPD (T category) ratio. In addition, tumor differentiation was correlated to the TS mRNA level and the TS:DPD ratio. Finally, the TS:DPD ratio was a prognostic marker for overall survival in patients receiving resection alone (p=0.032). Moreover, a high TP:DPD ratio (>8.1; p=0.002) and, marginally, low DPD (<8.2; p=0.05) mRNA levels significantly correlated to disease-free survival. Correlations to histopathological parameters and\nclinical follow-up revealed an association of TP, DPD and TS mRNA expression\npatterns with tumor stage and suggested new prognostic and predictive markers for\npatients with colorectal cancer.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":187},{"Name":"Ki-67","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":16151588,"Description":"The proliferative marker,\u00a0Ki-67, is a human nuclear antigen, and forms an integral part of cell division in both normal and malignant tissue. In colorectal cancer, but not in gastric cancer, high levels of Ki67LI have been correlated with poor survival. Ki-67 staining is a simple and useful method for estimating proliferative activity.\u00a0 In colorectal cancer this index may be used as a\nmarker of prognosis.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":188},{"Name":"CD59","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":16151805,"Description":"The mCRP CD59 is a 18\u201320 kDa glycosyl-phosphatidylinositol-anchored cell membrane glycoprotein, which has been widely identified on human cells exposed to complement On survival analysis, a further correlation was observed between expression of CD59 by the colorectal tumours and a reduction in disease-specific patient survival. This observation was strongest for patients with early stage disease.\u00a0 This study has identified CD59 expression as a marker of poor prognosis in colorectal cancer patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":189},{"Name":"CD24","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":16166435,"Description":"CD24 is a cell adhesion molecule that has been implicated in metastatic tumor progression of various solid tumors. In survival analysis, strong cytoplasmic CD24 expression correlated significantly (Cox's regression: P = 0.012, relative risk = 3.7) to shortened patient survival in the group of cases without distant metastases. CD24 is commonly up-regulated in colorectal cancer and is a new\nindependent prognostic marker which corroborates the importance of CD24 in tumor \nprogression of this disease.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":190},{"Name":"DNA methylation","Molecular type":null,"Location":"Colon, Rectum","Source":"Blood","Assay\/Test":"qRT-PCR","Usage":"PredictiveBM","Pmid":16181380,"Description":"Promoter hypermethylation is a common molecular alteration of human colorectal cancer that could be detected in the bloodstream In total, 28 patients with colorectal cancer and 4 controls had methylated DNA detected in at least one marker, which gave a sensitivity of 57% and specificity of 90%. All patients with methylation in two methylation markers had advanced (stage III\/IV) cancer (p= 0.006) and patients with methylation in at least one marker tended to have a lower probability of survival (p= 0.08). The quantitative detection of aberrant DNA methylation in serum may be a promising high-throughput approach for the noninvasive screening and\nmonitoring of colorectal cancer.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":191},{"Name":"Cyclooxygenase-2 (COX-2)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PredictiveBM","Pmid":16213106,"Description":"Cyclooxygenase-2 (COX-2), which is an important mediator of tumor invasiveness and metastasis, is one of three known isoforms of the enzyme that catalyzes the conversion of arachidonic acid to prostaglandins (PG) Good response (TRG 1+2), moderate response (TRG 3), and poor response (TRG 4+5) were seen in 21 patients (42%), 11 patients (22%), and 17 patients (34%), respectively. Patients with COX-2 overexpression in PTB were more likely to demonstrate moderate or poor response (TRG 3+4) to treatment than were those with normal COX-2 expression (p=0.026, chi-square test). Similarly, poor response was more likely if patients had low levels of spontaneous apoptosis in PTBs (p=0.0007, chi-square test). COX-2 overexpression and reduced apoptosis in PTB can predict poor response of rectal cancer to RCT. ","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":192},{"Name":"Vascular endothelial growth factor (VEGF)","Molecular type":"Protein","Location":"Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PredictiveBM","Pmid":16222693,"Description":"Vascular endothelial growth factor (VEGF) is a potent mediator of tumor angiogenesis The mean VEGF expression in nonresponsive tumors (NR) was significantly greater than in completely responsive tumors (CR) (P = 0.0035). Nearly half (47%) of all CR tumors had a VEGF expression of 10% or less. Eleven tumors were negative (0% immunoreactivity) for the protein and all of these (100%) were complete responders. Fifty-two percent of the NR tumors had VEGF scores of 80% or greater. The four scoring methods used to determine the association between VEGF and tumor response each produced significant results (P < 0.05). The results of this study indicate that VEGF assessed\nimmunohistochemically from preirradiation tumor biopsies may be a useful marker\nof rectal tumor response to preoperative radiotherapy\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":193},{"Name":"Migration inhibitory factor(MIF)","Molecular type":"Protein","Location":"Colon","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PredictiveBM","Pmid":16243796,"Description":"MIF is released from the anterior pituitary in response to physiologic stress, including endotoxic shock, hypersensitivity, and adult respiratory distress syndrome, as well as in immune disorders, such as glomerulonephritis and arthritis In an analysis of 12 unrelated colon tumor cell lines, MIF expression and response to hypoxia varied widely. Cell lines in which MIF was inducible by hypoxia were more sensitive to oxaliplatin. In human colon tumor specimens analyzed by immunohistochemistry, MIF expression was similarly variable. We suggest that MIF expression in colorectal cancer may be a marker of susceptibility to therapies that may depend on induction of hypoxia, possibly including antiangiogenic therapy.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":194},{"Name":"Tumour matrilysin","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"DiagnosticBM","Pmid":16284286,"Description":"Matrilysin is one of the targets transactivated by b-catenin, a key mediator in the Wnt pathway, interacting with the family of Tcf\/Lef1 transcriptional factors Tumour matrilysin expression emerged as a stage independent risk factor for nodal metastasis, resulting in a similar predictive performance in receiver operating characteristic curve analysis in the two models. We have provided evidence that tumour matrilysin expression is a\npromising biomarker predicting nodal metastasis of colon and rectal cancer.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":195},{"Name":"Janus kinase 3 (JAK3)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":16308103,"Description":"Janus tyrosine kinases (JAKs) are cytoplasmic protein tyrosine kinases that play a crucial role in the initial steps of cytokine signaling. JAK3, a member of JAK kinase family of four (JAK1, JAK2, JAK3 and TYK2), is abundantly expressed in lymphoid cells. In multivariate analysis, JAK3 immunoreactivity showed independent prognostically unfavorable predictors. These data suggest that JAK3, in particular, is a highly significant,\nprognostic immunohistochemical marker in CRC.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":196},{"Name":"Angiogenesis","Molecular type":null,"Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":16325858,"Description":"Angiogenesis has emerged as a major prognostic factor in many human malignancies and it is a prospective target for cancer therapy. A high vascular density at the invading tumor front was directly related to nuclear p53 accumulation, and inversely to cytoplasmic expression of bcl-2. Furthermore, high angiogenic activity was significantly associated with lymph node metastasis. Survival analysis showed that Dukes stage and vascular density were the most important and independent prognostic factors in colorectal cancer. It is believed that angiogenesis at the invading tumor edge can be\nused as an independent prognostic marker to identify subgroups of colorectal\ncancer patients with an unfavorable post-operative outcome.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":197},{"Name":"Glutathione\u00a0S-transferase P1 (GSTP1)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":16425401,"Description":"Glutathione\u00a0S-transferase P1 (GSTP1) plays a central role in the inactivation of toxic and carcinogenenic electrophiles GSTP1 G-type predicted a worse prognosis in the patients independently of gender, age, Dukes' stage, growth pattern, and differentiation (P=0.03). Polymorphism in SULT1A1 may predispose to colorectal cancer and GSTP1 may be a biological indicator of prognosis in the patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":198},{"Name":"Cathepsin D (CD)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"DiagnosticBM","Pmid":16471040,"Description":"Cathepsin D (CD) is one of the main proteolytic enzymes contributing to the development of cancer.\u00a0 CD activity decreased significantly (p < or = 0.0001) with the distance from the tumour border 2 cm (12.7 fold) and 5 cm (5.7 fold) in comparison to the centre of the tumour. In immunohistochemical examinations CD was detected as diffuse cytoplasmic as well as fine granular staining of the cytoplasm, with occasional coarse cytoplasmic granules staining in the same cases that were positive for both. Positive staining was observed in 2 of 3 in well-differentiated (66%), 4 of 10 in moderately-differentiated (40%) and 4 of 5 in poorly-differentiated (80%), tubular adencarcinomas represented: 3 of 7 (42%) and 9 of 13 in invasive adencarcinoma (69%). We have observed a wide range of cathepsin D and their antigen\nexpressions patterns in colorectal tumours with the development the disease\nstage, this finding may be used as a daignostic tumor marker in colorectal\ncancer.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":199},{"Name":"Bcl-2 ","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":16477877,"Description":"Multiple molecular abnormalities, including abnormal expression of the anti-apoptotic protein Bcl-2, have been implicated in human carcinogenesis. Bcl-2 onco-protein also plays a vital role in tumor progression When entered into a multivariate analysis model, which also included p53 and stage, bcl-2 staining emerged as a prognostic indicator variable. Expression of bcl-2 appears to be useful in selecting a group of colorectal cancer patients with a better prognosis.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":200},{"Name":"Bcl-2 ","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":17192048,"Description":"Multiple molecular abnormalities, including abnormal expression of the anti-apoptotic protein Bcl-2, have been implicated in human carcinogenesis. Bcl-2 onco-protein also plays a vital role in tumor progression Decreased expression of Bcl-2 was associated with an increased rate of recurrence in patients with Stage II CRCs (5-year log-rank test P=0.0015; Hazard Ratio (HR)=3.90, 95%C.I.:1.55-9.77) but not with Stage III CRCs (5-year log-rank test P=0.6058; HR=1.07, 95%C.I.:0.47-2.45) after adjusting for other demographic and clinicopathological features. Furthermore, decreased expression of Bcl-2 was an indicator of short survival in patients with Stage II CRCs but not with Stage III CRCs.\u00a0 decreased or lack of Bcl-2 expression in primary CRCs may serve as a molecular biomarker of high risk of recurrence for Caucasian patients with Stage II CRCs. \n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":201},{"Name":"Thymidylate synthase (TS)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PredictiveBM","Pmid":17520254,"Description":"Thymidylate synthase (TS), the target enzyme of the antimetabolite 5-FU, has been shown to be an independent prognostic marker of 5-FU chemotherapy in gastrointestinal tumours The TS mRNA expression level inversely correlated with the sensitivity to the latter 5-FU regimen (R = 0.577, p < 0.01). The TS mRNA expression level might be a good marker of chemosensitivity to 5-FU in primary colorectal cancer, especially the sensitivity to low dose 5-FU with a long duration.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":202},{"Name":"Bcl-2","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":17562177,"Description":"Bcl-2 protein acts as an inhibitor of apoptosis P53 and bcl2 protein expression was higher in adenomas >or=1 cm (P < 0.03) and tubulovillous-villous adenomas (P < 0.03), and correlated with dysplasia (P < 0.03). In Cox regression analysis, Dukes' stage was the most significant independent prognostic indicator of a worse survival (P < 0.019), whereas when stage was eliminated, bcl-2 expression was also a powerful predictor for bad prognosis (P = 0.02). bcl-2 could be used in combination with Dukes' stage as a predictor of prognosis in colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":203},{"Name":"SFRP2","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Feces","Assay\/Test":"qRT-PCR","Usage":"DiagnosticBM","Pmid":17639423,"Description":"Furthermore, it has been reported that secreted frizzledrelated proteins (SFRPs) known to be involved in Wingless\/ Wnt signaling are also affected by DNA methylation SFRP2 methylation in stool samples was found in none of the healthy controls, in 33% (2 of 6) patients with hyperplastic polyps, and in 46% (6 of 13) patients with adenomas. Statistical analysis revealed that the frequency of SFRP2 methylation increased significantly (P=0.028) from healthy controls to patients with hyperplastic polyps and to patients with adenomas. SFRP2 methylation may serve as a marker for molecular stool-based adenoma and CRC screening.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0001988","Id":204},{"Name":"Vascular endothelial growth factor (VEGF)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":17655863,"Description":"VEGF-A gene is located on chromosome 6p21.3 and undergoes alternative splicing yielding isoforms of 121, 165, 189, and 206 amino acids Survival analysis showed a significant correlation between high levels of VEGF staining intensity and poor disease-specific survival (P < 0.0001), with independent prognostic significance in multivariate analysis (RR = 3.5, P < 0.0001). In addition, patients with Stage II disease and high staining intensity of VEGF had a significantly worse disease-specific survival than those with low staining intensity (P = 0.001). VEGF expression in colorectal cancer seems to be an independent prognostic marker of tumor behavior and may be useful to identify patients with unfavorable clinical outcome.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":205},{"Name":"Colon cancer-specific antigen (CCSA)-2","Molecular type":"Protein","Location":"Colon","Source":"Blood","Assay\/Test":"Immunohistochemistry","Usage":"DiagnosticBM","Pmid":18044711,"Description":"CCSA-2was isolated by excising gel spots from nega-tively staine d two-dimensional gels.  The immunoassay showed a sensitivity of 88.8% (24\/27) and an overall specificity of 84.2% (106\/127). This initial study showed the potential of CCSA-2 to serve as a highly specific blood based marker for colon cancer. ","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":206},{"Name":"Thymidylate synthase (TS)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PredictiveBM","Pmid":18087284,"Description":"Thymidylate synthase (TS), the target enzyme of the antimetabolite 5-FU, has been shown to be an independent prognostic marker of 5-FU chemotherapy in gastrointestinal tumours Multivariate analysis confirmed a significant interaction between nodal status and the probability of achieving a pathological response (P=0.023) and between TS expression and treatment, indicating that a high TS level is predictive of a higher pathological response in the RCT subset (P=0.007). Thymidylate synthase expression assessed immunohistochemically from pretreatment tumour biopsies may be a useful predictive marker of rectal tumour response to preoperative RCT.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":207},{"Name":"Methyl-CpG binding domain protein 4 (MBD4)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":18097604,"Description":"Kaplan-Meier survival analysis indicated that MBD4 is a significant prognostic factor for patient survival (p=0.03). MBD4 was a key protein involved in DNA methylation. MBD4 may be a potential novel prognostic marker for predicting patient survival for colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":208},{"Name":"C-reactive protein (CRP)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Blood","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":18172726,"Description":"C-reactive protein (CRP), a nonspecific acute phase response protein, has been one of the most commonly used markers to evaluate systemic inflammatory responses Analysis of disease-free interval showed C-reactive protein was significant (P = 0.03): as level rose, prognosis worsened. The quiescent inflammation-response group (< or =0.1 mg\/dl) had excellent outcomes. Postoperatively, the C-reactive protein levels declined at the third postoperative month. Preoperative C-reactive protein is an independent prognostic factor.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":209},{"Name":"Epidermal growth factor receptor (EGFR), Vascular endothelial growth factor (VEGF)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PredictiveBM","Pmid":18182986,"Description":"Epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), the p53 tumour suppressor and key mediators of cell-cycle arrest (p21, p27) and apoptosis (Bcl-2, apoptosis protease-activating factor-1 (APAF-1)) are among the immunohistochemical protein markers currently of interest as potential predictors of pathologic response, prognosis and recurrence-free survival in rectal cancer following neoadjuvant therapy In multivariable analysis, loss of VEGF (P-value=0.009; odds ratio (OR) (95% CI)=0.24 (0.08-0.69)) and positive EGFR (P-value=0.01; OR (95% CI)=3.82 (1.37-10.6)) both demonstrated independent predictive value for complete pathologic response. The odds of complete response were 12.8 for the multi-marker combination of VEGF-negative and EGFR-positive tumours. Combined analysis of VEGF and EGFR predicts complete tumour response in rectal cancer treated with preoperative radiotherapy.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":210},{"Name":"CDA, MGC20553,BANK1, BCNP1, MS4A1","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Blood","Assay\/Test":"qRT-PCR","Usage":"DiagnosticBM","Pmid":18203981,"Description":"We validated the predictive power of these five genes with a novel third set of 92 samples, correctly identifying 88% (30 of 34) of CRC samples and 64% (27 of 42) of non-CRC samples.\u00a0 Our results indicate that the five-gene biomarker panel can be used as a novel blood-based test for CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":211},{"Name":"BMP7","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":18259822,"Description":"The BMP family includes more than 15 members in mammals.BMPs are secreted signaling molecules belonging to the transforming growth factor (TGF)-b superfamily A multivariate analysis showed that BMP7 expression status was an independent prognostic factor of overall survival (relative risk, 2.29; 95% confidence interval, 1.08-5.30; p < 0.05). Expression of BMP7 in colorectal tumors correlates with parameters of pathological aggressiveness such as liver metastasis and poor prognosis.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":212},{"Name":"Human leukocyte antigen-DR (HLA-DR)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":18281539,"Description":"CD8+ T cells are activated by antigen presented by human leukocyte antigen (HLA) class I molecules whereas CD4+ T cells are activated by antigen presented by HLA class II molecules, normally expressed on professional antigen-presenting cells such as dendritic cells and macrophages. Patients with HLA-DR-positive tumors developed less frequent local and distant recurrences [1.6% versus 9.1% (P = 0.0015) and 15.3% versus 29.9% (P < 0.0001), respectively, after 5 years of follow-up] and had better survival (78.6% versus 61.3%; P < 0.0001) than patients with HLA-DR-negative tumors. Epithelial HLA-DR was more often found in lower tumor-node-metastasis (TNM) stages.\u00a0 Epithelial human leukocyte antigen-DR expression predicts reduced recurrence rates and prolonged survival in rectal cancer patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":213},{"Name":"Orptate phosphoribosyl transferase (OPRT)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":18288408,"Description":"The initial metabolism of 5-FU into\nnucleotides is essential for its action by one or more of the\nfollowing pathways: directly to 5-fluorouridine-5'-monophosphate\n(FUMP) by orotate phosphoribosyl transferase\n(OPRT); indirectly to FUMP in a sequence of reactions with\nconversion of 5-FU to 5-fluorouridine phosphorylated by\nuridine phsophorylase (UP); indirectly to FdUMP by 2'-deoxy-\n5-fluorouridine (FUdR) catalyzed by thymidine phosphorylase\n(TP) In a multivariate Cox regression analysis, it was demonstrated that the OPRT mRNA level is an independent prognostic variable for disease-free and overall survival.\u00a0 These results suggest that the OPRT mRNA is a useful indicator in the prediction of disease-free and overall survival in Dukes' B and C stage CRC patients treated with oral 5-FU-based adjuvant chemotherapy.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":214},{"Name":"CD44 variant 6 (CD44v6)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PredictiveBM","Pmid":18303484,"Description":"One of the widely studied biomarkers, CD44 variant 6 (CD44v6), a widely distributed transmembrane glycoprotein on cancer cells, was suggested preliminarily to predict the prognosis of patients, especially those with locoregional and distant metastases for several types of commonly diagnosed adenocarcinomas such as breast, gastric, and colorectal cancers. CD44v6 is significantly associated with locoregional recurrence in stage III rectal cancer (hazard ratio 6.02, 95% confidence interval 1.25-29.0; P = 0.018), and the overall locoregional recurrence was significantly higher for patients with positive expression of CD44v6 than for those with negative expression (17.63% vs 6.62%; P = 0.026). CD44v6 expression in cancer cells is a sensitive marker for predicting the treatment outcome in patients with stage II and III adenocarcinoma of the rectum after TME and may be used to determine the necessity of adjuvant treatment. ","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":215},{"Name":"KRAS","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PredictiveBM","Pmid":18316791,"Description":"KRAS, the human homolog of the Kirsten rat sarcoma-2 virus oncogene, encodes a small GTPbinding protein that acts as a self-inactivating signal transducer by cycling from GDP- to GTP-bound states in response to stimulation of a cell surface receptor,including EGFR. KRAS status was ascertained in 427 (92%) of 463 patients (208 panitumumab, 219 BSC). KRAS mutations were found in 43% of patients. The treatment effect on PFS in the wild-type (WT) KRAS group (hazard ratio [HR], 0.45; 95% CI: 0.34 to 0.59) was significantly greater (P < .0001) than in the mutant group (HR, 0.99; 95% CI, 0.73 to 1.36). Median PFS in the WT KRAS group was 12.3 weeks for panitumumab and 7.3 weeks for BSC. Response rates to panitumumab were 17% and 0%, for the WT and mutant groups, respectively. WT KRAS patients had longer overall survival (HR, 0.67; 95% CI, 0.55 to 0.82; treatment arms combined). Consistent with longer exposure, more grade III treatment-related toxicities occurred in the WT KRAS group. No significant differences in toxicity were observed between the WT KRAS group and the overall population. KRAS status should be considered in selecting patients with mCRC as candidates for panitumumab monotherapy.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":216},{"Name":"Beta-catenin ","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":18365911,"Description":"Beta-catenin is a component of the Wingless\/Wnt signaling pathway and can activate target genes associated with proliferation and invasion, linking with the APC gene. Kaplan-Meier analysis showed a significantly worse survival rate for CRC patients with altered expression of beta-catenin (p<0.05, log-rank test).\u00a0 Altered distribution of beta-catenin occurs in the early stage of\ncolorectal carcinogenesis and has a parallel relationship with COX-2 overexpression. It may serve as a potential marker for the progression and prognosis of CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":217},{"Name":"Matrix metalloproteinase-9 (MMP-9)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":18376229,"Description":"Matrix metalloproteinases (MMPs) are a key family of\nproteolytic enzymes involved in extracellular matrix\ndegradation. Multivariate analysis indicated that positive MMP-9 expression was an independent predictor of reduced overall survival (P = 0.0103) and reduced disease-free survival (P = 0.0360).\u00a0 MMP-9 expression was observed in the tumors of patients with Stage II and III rectal carcinoma in comparable values and was characterized by poor overall survival and disease-free survival.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":218},{"Name":"Survivin ","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PredictiveBM","Pmid":18406888,"Description":"Survivin, originally identified in the late 1990s, shows regulatory functions for both control of cell division and inhibition of apoptosis In the translational study of 20 patients with rectal cancer, increased survivin levels were associated with significantly greater risk of local tumor recurrence (p = 0.009). Treatment of SW480 cells with survivin ASOs and irradiation resulted in an increased percentage of apoptotic cells, caspase 3\/7 activity, fraction of cells in the G(2)\/M phase, and H2AX phosphorylation. Clonogenic survival decreased compared with control-treated cells. Furthermore, in vitro and in vivo data suggest a potential role of survivin as a molecular target to improve treatment response to radiotherapy in patients with rectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":219},{"Name":"Amphiregulin (AR)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":18413824,"Description":"AR has been implicated in the growth and regeneration of intestinal mucosa and might be related to the development and progression of gastrointestinal tumors A multivariate analysis of liver metastasis proved that AR expression was an independent prognostic factor of liver metastasis from colorectal cancer (P = 0.0217). AR expression in primary lesions of colorectal cancer is an important predictive marker of liver metastasis.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":220},{"Name":"P16 hypermethylation","Molecular type":null,"Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":18418463,"Description":"The tumor suppressor gene p16 is a cyclin-dependent kinase inhibitor that acts as a negative regulator of cell growth and proliferation in the G1 phase of the cell cycle Cox regression analysis showed that Dukes' A-C patients with p16 hypermethylation in mucosa had an increased risk of cancer-related death (hazard ratio = 2.9, P = 0.007) and shorter disease-free survival (hazard ratio = 2.5, P = 0.015) compared with patients with no p16 hypermethylation.\u00a0 In conclusion, p16 hypermethylation in mucosa of CRC patients was identified as an independent prognostic parameter for cancer-specific survival as well as an independent predictor of DFS.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":221},{"Name":"Matrix metalloproteinase-2 (MMP-2)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":18425389,"Description":"Matrix metalloproteinases (MMPs) are a key family of\nproteolytic enzymes involved in extracellular matrix\ndegradation. MMP-2 expression correlated with the depth of invasion, venous invasion and liver metastasis MMP-2 gene expression was considered a useful predictor of liver metastasis from colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":222},{"Name":"macrophage migration inhibitory factor (MIF)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"DiagnosticBM","Pmid":18426738,"Description":"Compared with CEA, MIF was more sensitive in early cancer detection (47.3% vs 29.5%). However, the specificity was not as high as that of CEA (90.6% vs 100.0%).\u00a0 Our findings indicate that MIF may be used as a diagnostic marker in colorectal carcinomas.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":223},{"Name":"Selenium-binding protein 1 (SBP1)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR|Immunohistochemistry","Usage":"PrognosticBM","Pmid":18435490,"Description":"The human SBP1 (also called SELENBP1 orhSP56), which binds covalently to selenium, was clonedand characterized in 1997. The SBP1 gene is located atchromosome 1q21-22 and encodes a protein of 472 aminoacids that is present as at least four different phosphorylatedisofor ms in membrane-enriched cellular compartments \u00a0Downregulation (approximately 50%) of SBP1 expression by small interfering RNA in colonic cancer cells was associated with reduced expression of another epithelial differentiation marker, carcinoembryonic antigen (CEA), although PCNA and p21(WAF1\/cip1 )expression were not altered.\u00a0 These data demonstrate that higher expression of SBP1 is associated with differentiation of the normal colonic epithelia and may be a positive prognostic factor for survival in stage III colorectal carcinoma.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":224},{"Name":"Receptor for hyaluronic acid mediated motility (RHAMM)","Molecular type":null,"Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":18436576,"Description":"To the standard prognostic features, only six markers added independent prognostic information including receptor for hyaluronic acid mediated motility (RHAMM) (HR = 2.39 (1.88 to 3.05)) RHAMM should be considered a more important prognosticator than tumour grade,tumour budding and vascular invasion in patients with CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":225},{"Name":"PTEN","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":18440486,"Description":"PTEN is a tumor-suppressor gene located on chromosome 10. Deficient PTEN expression leads to activation of the phosphoinositide 3-kinase (PI3K)\/Akt (pAkt) signaling pathway, which may contribute to multiple human cancers.\u00a0 In colorectal cancer patients, PTEN expression showed a negative correlation with young age, female sex, and left-sided (distal) tumors. On multivariate analysis, low PTEN expression (PTEN loss) was noted as an independent parameter for local recurrence (P = .024). The current study suggests that the PTEN loss-PI3K\/pAkt pathway may play an important role in sporadic colon carcinogenesis and that reduced PTEN expression may predict relapse in colorectal cancer patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":226},{"Name":"Regenerating islet-derived 1 alpha (REG1A)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":18452172,"Description":"Human REG1A is a secreted protein spanning 166 amino acidsand belongs to the superfamily of calcium dependent (C-type) lec-tins.  Determination of REG1A expression might be useful for early tumor diagnosis with a sensitivity of 90.6%, and a specificity of 77.9%. REG1A expression was significantly increased in tumors with peritoneal carcinomatosis (p < 0.01). Moreover, REG1A turned out to be a significant predictor of disease-free survival (p < 0.05).\u00a0 REG1A expression is a prognostic marker in colorectal cancer and associated with peritoneal carcinomatosis.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":227},{"Name":"Extramural vascular invasion (EVI) ","Molecular type":null,"Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":18462242,"Description":"There are two types of blood vessel invasion: that ofblood vessels within the bowel wall is defined as intramu-ral vascular invasion and invasion of blood vessels outsidethe bowel wall (in the pericolonic fat or adventitia),defined as extramural vascular invasion (EVI)  Survival curves with and without EVI, unadjusted for nodal status and T stage, were significantly different (P = 0.0001) with 5-year survivals of 52% and 73% respectively. Survival curves for T3 and T4 tumours stratified with and without EVI also showed significantly different survival distributions (P = 0.007). A significant difference in frequency of EVI year on year was seen (P < 0.001), ranging from 8.5% to 46.7%, whereas the number of T3 and T4 tumours in each year was not significantly different (P = 0.677). EVI is an adverse prognostic indicator for survival in patients undergoing potentially curative resection of colorectal cancer,","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":228},{"Name":"Platelet-derived growth factor BB (PDGF-BB)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR|Immunohistochemistry","Usage":"PrognosticBM","Pmid":18478301,"Description":"Platelet-derived growth factor (PDGF) was identified as the serum component responsible for the proliferation of arterial smooth muscle cells.1 A multivariate analysis demonstrated that PDGF-BB expression was an independent prognostic factor.\u00a0 PDGF-BB expression may be a new prognostic indicator for patients with colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":229},{"Name":"hMLH1","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PredictiveBM","Pmid":18497967,"Description":"The defect of the MMR system in\nsporadic CRC is generally caused by promoter hypermethylation\nof the hMLH1 gene, which in turn results in\ntranscriptional silencing, thus leading to MSI Moreover, a multivariate analysis revealed that hMLH1 mRNA expression was a significant independent prognostic factor for tumor recurrence in CRC patients treated with adjuvant 5-FU. Expression of the hMLH1 gene is a possible predictor for the clinical response to 5-fluorouracil after a surgical resection in colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":230},{"Name":"\u03b22microglobulin (B2M)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":18506145,"Description":"We also observed that the expression ratio of B2M\/Spint2 had the highest prognostic accuracy (AUC=0.87; 95% CI=0.71-0.96) of all potential two-gene combinations. These studies are the first to demonstrate a prognostic role of B2M at the mRNA level and suggest that low B2M expression levels might be useful for identifying patients with lymph node metastasis and\/or poor survival.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":231},{"Name":"Mitotic centromere-associated kinesin (MCAK)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR|Immunohistochemistry","Usage":"PrognosticBM","Pmid":18506187,"Description":"Mitotic centromere-associated kinesin (MCAK) is a microtubule depolymerase that is essential for proper kinetochore-microtubule attachment during spindle formation. Patients with high MCAK mRNA expression also showed a far poorer survival rate than those with low MCAK mRNA expression (P<0.01). Elevated MCAK expression was an independent predictor of overall survival and lymph node metastasis. These data suggest that MCAK expression may serve as a good marker of prognosis and lymph node metastasis in colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":232},{"Name":"Apoptotic body index (ABI)","Molecular type":null,"Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":18507083,"Description":"The overall survival (OS) was significantly associated with ABI (P<0.01) The apoptotic body index (ABI) is a favorable prognostic factor and may be used as a stratification parameter especially the high ABI in bcl-2 +ve CRCs.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":233},{"Name":"Carcinoembryonic antigen (CEA)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Blood","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":18513194,"Description":"Carcinoembryonic antigen (CEA) is the most commonly used tumour marker for the diagnosis of CRC and evaluation of prognosis or recurrence after treatment. The multivariate analysis demonstrated that the T-CEA was an independent prognosis factor in CRC. Our study suggests that a high T-CEA concentration may be a useful and independent predictor for poor outcome after surgery in CRC patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":234},{"Name":"GSTP1 Ile105Val polymorphism","Molecular type":null,"Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PredictiveBM","Pmid":18540691,"Description":"At multivariate analysis, GSTP1 Ile105Val polymorphism (p = 0.041) was the only factor found to be associated with haematological toxicity. Patients carrying the Val\/Val genotype in the GSTP1 gene had a lower risk of haematological toxicity (odds ratio = 0.322, 95% CI 0.101, 0.957) than patients with the Ile\/Ile genotype. GSTP1 Ile105Val polymorphism is a promising marker of potential haematological toxicity in elderly patients with rectal cancer receiving preoperative CRT.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":235},{"Name":"Vascular endothelial growth factor (VEGF)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":18546269,"Description":"The secreted mitogen, vascular endo-thelial growth factor A, VEGF-A (commonly referred to as VEGF),seems to play a pivotal and irreplaceable role in the regulation ofphysiological and pathological angiogenesis. Our data support the role of VEGF(165)b as a tumor suppressor factor in colorectal carcinogenesis and its possible prognosis value. Our data support the role of VEGF(165)b as a tumor suppressor factor in colorectal carcinogenesis and its possible prognosis value.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":236},{"Name":"CK20","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":18587323,"Description":"CKs are intermediate filament proteins and 20 subtypes have been classified based on isoelectric pH (focusing) and molecular weight. Two of the most used stains are CK20 and CK7.5 Loss of CDX2 and CK20 is more frequently encountered in mismatch repair-deficient colorectal cancer, which should be taken into consideration to differentiate between primary and metastatic colorectal cancer in daily practice. CK20 overexpression is an independent adverse prognostic factor in mismatch repair-proficient colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":237},{"Name":"Microsatellite instability (MSI)","Molecular type":null,"Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PredictiveBM","Pmid":18594845,"Description":"One of these potential prognostic factors is high-level microsatellite instability (MSI-H). MSI-H is related to a deficient mismatch repair (MMR) system The incidence of MSI-H was 4%. MSI-H was correlated with a lower rate of disease control compared to non-MSI-H patients (p = 0.02). However, there was no correlation between MSI-H and progression-free survival or overall survival. Our data suggest that MSI-H may be correlated with a poorer response to a 5-FU\/oxaliplatin treatment.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":238},{"Name":"Beta-catenin","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"DiagnosticBM","Pmid":18609711,"Description":"Beta-catenin is a component of the Wingless\/Wnt signaling pathway and can activate target genes associated with proliferation and invasion, linking with the APC gene. Membranous beta-catenin expression was found in the normal colorectal epithelium. Almost 100% of CRC cases showed membranous and cytoplasmic expression, and 55 (58%) cases showed nuclear expression. In univariate (Kaplan-Meier) survival analysis, only the nuclear index (NI) was a significant predictor of disease free survival (DFS) (P = 0.023; n = 35), with a NI above the median associated with longer DFS (34.2 mo) than those with a NI below the median (15.5 mo) (P = 0.045, ANOVA). The other indices were not significant predictors of DFS, and none of the three tested indices (for membranous, cytoplasmic, or nuclear expression) predicted disease-specific survival (DSS). However, when dichotomized as positive or negative nuclear expression, the former was a significant predictor of more favorable DFS (P = 0.041) and DSS (P = 0.046). Nuclear beta-catenin expression provides additional information in predicting patient outcome in advanced CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":239},{"Name":"DYX1C1","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"DiagnosticBM","Pmid":18618141,"Description":"The DYX1C1\u00a0gene maps to chromosome 15q21 and consists of 10 exons dispersed over about 78\u00a0kb of genomic DNA. The protein sequence encoded by\u00a0DYX1C1\u00a0is 420 aa in length and the protein sequences of the nonhuman primate homolog are 98.6\u201399.5% similar to that of humans\u00a0 Four new alternative transcripts were identified by RT-PCR analysis with various human tissue samples including 10 normal and adjacent tumor tissue sets. Semi-quantitative RT-PCR analysis showed the transcriptional activity of V3 and V2 was higher in tumor than in normal tissue samples, especially in the colorectal tissue samples. Our results indicated that alternatively spliced transcript variants of the DYX1C1 gene could be used as cancer biomarkers to detect colorectal cancer. ","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":240},{"Name":"Beta-catenin","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":18630466,"Description":"Beta-catenin is a component of the Wingless\/Wnt signaling pathway and can activate target genes associated with proliferation and invasion, linking with the APC gene. In 73.1% of primary tumors, positive staining for beta-catenin was detected in the membranes at the tumor center and in the nuclei at the invasive front. In 32 patients (26.9% of all cases), beta-catenin was expressed exclusively in the nuclei of the carcinoma cells throughout the tumors. Significant differences in expression of nuclear beta-catenin in the primary tumors were detected between the liver metastasis and non-liver metastasis groups at the tumor center (p=0.004), invasive front (p=0.021) and in the vessels (p<0.0001). Nuclear accumulation of beta-catenin in cellular cells at the invasive front and in the vessels was the most powerful predictor of liver metastasis in colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":241},{"Name":"Formin-like 2 (FMNL2)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR|Immunohistochemistry","Usage":"DiagnosticBM","Pmid":18665374,"Description":"Formin-like 2 (FMNL2) is a member of diaphanous-related formins which can control the actin-dependent processes such as cell motility and invasion. The immunohistochemical analysis showed FMNL2 expression was considerably higher in CRC tumors and corresponding metastatic lymph nodes than in normal colorectal mucosa (P < 0.05, respectively). Elevated FMNL2 expression was significantly correlated with lymphatic metastasis of CRC (P < 0.05). Real-time RT-PCR analysis confirmed the results obtained by immunohistochemistry. At mRNA and protein levels, FMNL2 expression was substantially upregulated in cell lines derived from CRC metastases (SW620, SW480\/M5, and LoVo) compared to ones derived from primary CRC (HT29, LS174T, and SW480; P < 0.05). In vitro cell invasive assay demonstrated that the former three cell lines had higher invasive ability than the latter cell lines. FMNL2 may play an important role in the metastasis of CRC and may be a useful marker for metastasis of CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":242},{"Name":"Microtubule associated protein 7 (Map7)\/B2M","Molecular type":null,"Location":"Colon","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":18695889,"Description":"Further, using Kaplan-Meier survival analysis, we observed significantly different curves as a function of marker positivity for the Map7\/B2M (p=0.0001; HR=11) expression ratio. The expression ratio of Map7\/B2M is prognostic for survival in patients with stage II colon cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":243},{"Name":"CD133","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":18781171,"Description":"CD133 is a five-transmembrane domain molecule with a molecular weight of 120\u2009kDa Moreover, we show that CD133 expression in colorectal cancer is an independent prognostic marker that correlates with low survival in a stratified patient collective.\u00a0 CD133 expression is an independent prognostic marker for low survival in colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":244},{"Name":"CpG island methylator phenotype (CIMP), BRAF","Molecular type":null,"Location":"Colon","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":18832519,"Description":"A subset of colon cancers exhibit widespread promoter methylation, referred to as the CpG island methylator phenotype (CIMP), which is associated with microsatellite instability (MSI). After adjustment for other predictors of patient survival, patients with CIMP-high cancers (126 (19%) tumours with >or=6\/8 methylated CIMP-specific promoters) experienced a significantly low colon cancer-specific mortality (multivariate HR 0.44, 95% confidence interval (CI) 0.22 to 0.88), whereas the BRAF mutation was significantly associated with a high cancer-specific mortality (multivariate HR 1.97, 95% CI 1.13 to 3.42). A trend toward a low cancer-specific mortality was observed for MSI-high tumours (multivariate HR 0.70, 95% CI 0.36 to 1.37). CIMP-high appears to be an independent predictor of a low colon cancer-specific mortality, while BRAF mutation is associated with a high colon cancer-specific mortality.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":245},{"Name":"RHAMM, CD8(+) TILs","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":18985041,"Description":"The receptor for hyaluronic acid-mediated motility (RHAMM) mediates both Ras and TGF-b signalling pathways and is associated with poor prognosis in a variety of tumour entities (Wang et al, 1998; Maxwell et al, 2004; Hamilton et al, 2007). Finally, CD8 \u00fe tumour infiltrating lymphocytes (TILs) have been linked to improved survival in colorectal cancer patients (Chiba et al, 2004; Galon et al, 2006) The 5-year cancer-specific survival of T1\/T2\/RHAMM+\/TIL- patients was 48% (20-72%) and significantly worse compared to T3\/T4\/RHAMM-\/TIL+ patients (71% 95% CI 56-82%); P=0.039). Stratifying by nodal status, only N+\/RHAMM+\/TIL- patients demonstrated a significantly worse prognosis than N0\/RHAMM+\/TIL- patients (P=0.005). Loss of CD8(+) TILs was predictive of local recurrence in RHAMM+ tumours (P=0.009) only RHAMM and CD8(+) TILs may assist in identifying early stage rectal cancer patients facing a particularly poor prognosis and who may derive a benefit from preoperative therapy.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":246},{"Name":"HuR","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":19009247,"Description":"HuR, a ubiquitously expressed protein of the embryonic lethal abnormal vision (ELAV) family first isolated from D. melanogaster, is involved in mRNA stability and turnover. In patients in the highest quartile of total HuR expression, survival was 22.8 months less than those in the lower quartiles (40.6 versus 63.4 months, p = 0.04). Furthermore, HuR levels correlate positively with expression of vascular endothelial growth factor (VEGF) and CD31, a marker for vascular endothelium.\u00a0 High expression of HuR predicts poor survival.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":247},{"Name":"hTERT transcripts (hTERT-AT)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR|Immunohistochemistry","Usage":"DiagnosticBM","Pmid":19010861,"Description":"Telomerase, a ribonucleoprotein complex containing an internal RNA template (hTR) and a catalytic protein with telomere-specific reverse transcriptase activity (hTERT), extends telomeres at the end of eukaryotic chromosomes, thus preventing cell senescence and death. Using the cutoff value of 180 copies hTERT-AT\/mL, the sensitivity and specificity of the assay for CRC detection were 92% and 100%, respectively.\u00a0 These findings indicate that quantification of hTERT mRNA in plasma may be used as a marker for detection and monitoring of neoplastic colorectal\ndisease.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":248},{"Name":"Cyclooxygenase-2 (COX-2)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PredictiveBM","Pmid":19015468,"Description":"Cyclooxygenase-2 (COX-2) is an important\nmediator of tumor invasiveness\nand metastasis. Patients with COX-2 overexpression were more likely to show a poor TRG (P = .003) and were less likely to achieve histopathologic nodal downstaging (P = .03) than those with normal COX-2 expression. Vascular endothelial growth factor overexpression was found to be associated with COX-2 overexpression (P = .02). Cyclooxygenase-2 expression in pretreatment biopsy as a predictor of tumor responses after preoperative chemoradiation in rectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":249},{"Name":"Insulin-like growth factor-1 receptor (IGF-1R)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PredictiveBM","Pmid":19033715,"Description":"Insulin-like growth factor-1 receptor (IGF-1R), epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER)-2 are transmembrane receptors which are overexpressed in many cancers, including CRC Multivariate analysis of potential prognostic factors showed that IGF-1R expression and worsened performance status were independent predictors of poor outcomes. Our results suggest that anti-IGF-1R strategies may offer a useful approach in molecular therapy for CRC, which has the potential to improve outcomes.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":250},{"Name":"Leptin","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":19050975,"Description":"Leptin, the product of the obese (ob) gene, is the 167- amino-acid cytokine-like peptide that regulates food intake and energy expenditure via interaction with specific receptors in the hypothalamus.1 In multivariate survival analysis with Cox proportional hazards model, leptin expression was an independent prognostic marker of disease-free survival (p = 0.009).\u00a0 In addition, high leptin expression was an indicator of favorable tumor features and better survival of colorectal cancer patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":251},{"Name":"Circulating DNA","Molecular type":"DNA","Location":"Colon, Rectum","Source":"Blood","Assay\/Test":"qRT-PCR","Usage":"PredictiveBM","Pmid":19096128,"Description":"Meantime, it is widely accepted that a substantial proportion of circulating cell-free DNA in plasma of cancer patients originates from tumor cells At the end of treatment responders showed a further decrease in circulating DNA, whereas in nonresponders the circulating DNA manifestly increased (P = 0.006).\u00a0 This study demonstrates that circulating DNA in plasma of rectal cancer patients undergoing preoperative chemoradiation might serve as a surrogate marker to discriminate between responders and nonresponders.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":252},{"Name":"CXCR4","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR|Immunohistochemistry","Usage":"PrognosticBM","Pmid":19308676,"Description":"Chemokines and their receptors are implicated in formation of colorectal cancer metastases. Especially CXCR4 is an important factor, determining migration, invasiveness, metastasis and proliferation of colorectal cancer cells. Using RT-PCR we found that a high expression of CXCR4 in the primary tumor was an independent prognostic factor for a poor disease free survival (p = 0.03, HR: 2.0, CI = 1.1-3.7). Immunohistochemical staining showed that nuclear distribution of CXCR4 in the tumor cells was inversely associated with disease free and overall survival (p = 0.04, HR: 2.6, CI = 1.0-6.2), while expression in the cytoplasm was not associated with prognosis. In conclusion, our study showed that a high expression of nuclear localized CXCR4 in tumor cells is an independent predictor for poor survival for colorectal cancer patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":253},{"Name":"Cyclin D2 ","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":19508551,"Description":"The\u00a0protein\u00a0encoded by this gene belongs to the highly conserved\u00a0cyclin\u00a0family, whose members are characterized by a dramatic periodicity in protein abundance through the\u00a0cell cycle.\u00a0 Elevated cyclin D2 and D3 were associated with vascular invasion (P = 0.014 and 0.028 respectively), liver metastasis (P = 0.001 and 0.007 respectively) and reduced disease specific survival (Cyclin D2, P < 0.022). These findings suggest that cyclin D2 expression at the invasive margin of CRCs is associated with liver metastasis and may serve as a useful prognostic marker and indicator of the need for adjuvant therapy.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":254},{"Name":"Urokinase-type plasminogen activator (uPA)","Molecular type":"Protein","Location":"Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":19740518,"Description":"Urokinase-type plasminogen activator (uPA) is a member of the serine protease family and a key regulator of biologic processes implicated in tumor cell migration, invasion, and metastasis. The presence of vascular invasion (P\u00a0= .038) was associated with uPAR overexpression as was an infiltrating tumor border configuration (P\u00a0= .033). Our findings suggest that uPA, but not uPAR, is an independent prognostic factor.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":255},{"Name":"Osteopontin (OPN)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"qRT-PCR|Western blot","Usage":"PrognosticBM","Pmid":19763701,"Description":"Osteopontin (OPN) is a phosphorylated glycoprotein which is associated with tumor progression, development, and metastasis. The status of OPN mRNA expression was an independent prognostic factor for the prognosis of CRC patients (P = 0.008; RR, 2.775; 95% confidence interval, 2.334-3.811). The status of OPN mRNA expression could be a novel prognostic molecular marker for CRC patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":256},{"Name":"UbcH10 gene","Molecular type":"DNA","Location":null,"Source":"Tissue","Assay\/Test":"qRT-PCR|Immunohistochemistry|Western blot","Usage":"DiagnosticBM|PrognosticBM","Pmid":19779934,"Description":"UbcH10 is the cancer-related E2 ubiquitin-conjugating enzyme. Our study suggests that UbcH10 gene may be a new marker in diagnosis and prognosis of colorectal cancer,","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":257},{"Name":"CXCL10","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Real-time RT-PCR","Usage":"PrognosticBM","Pmid":19821051,"Description":"CXC chemokine ligand 10 (CXCL10), human interferon-inducible protein 10 (IP-10), acts through their putative receptor CXC receptor 3 (CXCR3), and promotes cell-mediated immunity and inhibits angiogenesis.\u00a0 Kaplan-Meier curves comparing different CXCL10 expression levels with survival showed highly significant separation (P < 0.05, log-rank test).\u00a0 We concluded that detection of CXCL10, as a prognostic marker for stage II and III CRC patients, may contribute to predicting clinical outcome.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":258},{"Name":"IQGAP1","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry|qRT-PCR|Western blot","Usage":"PrognosticBM","Pmid":19856315,"Description":"IQGAP1 is a 189-kDa scaffolding protein that contains multiple protein-interacting domains, such as a calponin homology domain, a polyproline-binding domain, four calmodulin-binding motifs and a Ras-GAP-related domain. Patients with IQGAP1 overexpression and diffuse pattern had significantly shorter survival (p < 0.0001) than others. Diffuse and high expression of IQGAP1 predicts poor prognosis in patients with colorectal carcinoma.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":259},{"Name":"High-mobility group box 1 (HMGB1)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"RT-PCR|Western blot|Immunohistochemistry","Usage":"PrognosticBM","Pmid":19898867,"Description":"High-mobility group box 1, an important member of the high-mobility group protein superfamily, has been implicated in a variety of biologically important processes. The expression of HMGB1 in CRC was significantly correlated with overall survival (log-rank test statistic\u00a0=\u00a07.388,\u00a0P\u00a0=\u00a00.007).\u00a0 Our results suggest that HMGB1 protein is a valuable marker for progression of CRC patients. ","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":260},{"Name":"Survivin","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry|RT-PCR|Western blot","Usage":"PrognosticBM","Pmid":19921309,"Description":"Survivin, an important member of the IAP family, inhibits caspase activation by interacting with caspases via baculovirus IAP repeat domains, therefore leading to negative regulation of apoptosis. Univariate and multivariate analyses indicated that that the level of survivin expression was an independent prognostic factor of overall survival for CRC patients (P\u00a0=\u00a00.042, 0.011, respectively). Survivin might be an independent prognostic factor and a potential target for the chemoradiotherapy of CRC patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":261},{"Name":"Transgelin-2 (TAGLN2)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Western blot|Immunohistochemistry","Usage":"PrognosticBM","Pmid":19930159,"Description":"The protein encoded by this gene is a homolog of the protein transgelin, which is one of the earliest markers of differentiated smooth muscle. Over-expression of TAGLN2 may serve as a new biomarker for predicting progression and prognosis of CRC","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":262},{"Name":"P73","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":19956069,"Description":"p73\u00a0is a protein related to the\u00a0p53\u00a0tumor protein. Because of its structural resemblance to p53, it has also been considered a\u00a0tumor suppressor All these findings prove that p73 expression should be considered as a valuable poor prognostic marker.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":263},{"Name":"Thymidylate synthase (TS)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM|PredictiveBM","Pmid":19956517,"Description":"Thymidylate synthase (TS) is the rate-limiting enzyme in the synthesis of pyrimidine nucleotides, required for DNA synthesis, and is also a critical target for fluoropyrimidines, which are widely used in the treatment of gastrointestinal tumours. There was a significant difference in the intensity of TS expression between the clinical responders and non-responders (p=0.036). In terms of the staining pattern of TS expression, diffuse staining was correlated with a poor response (p=0.012) and poor survival (p=0.045).\u00a0 These results suggest that the expression of TS in primary colorectal\ncancer might be an important prognostic factor for chemotherapy response and\nsurvival, and might be a useful therapeutic marker for the response of\nchemotherapy.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":264},{"Name":"S100A14, S100A4","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"RT-PCR|Immunohistochemistry","Usage":"PrognosticBM","Pmid":19956863,"Description":"Among the S100 family members, S100A4, a known metastasis-associated gene, was isolated by subtractive hybridization of non-metastatic cells from metastatic mouse mammary adenocarcinoma cells. Patients with S100A14- tumors had significantly reduced overall survival compared with those with S100A14+ tumors (P<0.001). The signature derived from the combined expression status of S100A14 and S100A4 could be a valuable prognostic indicator in CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":265},{"Name":"Transglutaminase 2 (TGM2)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM|PredictiveBM","Pmid":20033322,"Description":"Transglutaminase 2,\u00a0TGM2, is a family of enzymes that catalyzes the formation of an amide bond between the \u03b3-carboxamide groups of peptide-bound glutamine residues and the primary amino groups in various compounds. Patients in the high TGM2 expression group showed a poorer overall survival rate than those in the low expression group (P = .001). TGM2 is a novel marker for prognosis and therapeutic target in colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":266},{"Name":"Secernin 1 (SCRN1)","Molecular type":null,"Location":null,"Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":20039278,"Description":"Secernin 1 (SCRN1) is a member of the secernin family and is reported to be a tumor-associated antigen.\u00a0 The overall survival rate was lower in the SCRN1 high-expression group than the low-expression group ( P \u00bc 0.049). SCRN1 is a novel marker for prognosis in colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":267},{"Name":"ATP11A","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":20043114,"Description":"The adenosine triphosphate-binding cassette (ABC) transporter-homologous gene ATP11A belongs to an extended family of ABC transporters that confer multi-drug resistance to cancer cells. Patients with high ATP11A expression showed a poorer disease-free survival rate compared to those with low expression (P<0.001). ATP11A is a useful predictive marker of metastasis in colorectal cancer patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":268},{"Name":"Notch1","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":20058190,"Description":"Notch1 signaling plays a paradoxical role, either as a tumor suppressor or oncogene, depending on the tissue type. Notch1 was positively correlated with depth of invasion (P = 0.005), lymph node metastases (P = 0.03), and tumor-node-metastasis (TNM) stage (P < 0.001) Notch1 might serve as a novel prognostic marker that is independent of, and additive to, the TNM staging system.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":269},{"Name":"TLR4, myeloid differentiation factor 88 (MyD88)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":20145615,"Description":"MyD88\u00a0adaptor-like, Toll\/IL1R\u00a0domain-containing adaptor molecule inducing interferon-\u03b2, and\u00a0TRIF-related adaptor molecule. The high combined expression of TLR4 and MyD88 was also significantly associated with poor DFS and OS (HR: 2.25; 95% CI: 1.27-3.99; P=0.0053 and HR: 2.97; 95% CI: 1.64-5.38; P=0.0003). High expression of TLR4 and MyD88 is associated with liver metastasis and is an independent predictor of poor prognosis in patients with CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":270},{"Name":"Cellular apoptosis susceptibility (CSE1L\/CAS) protein","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Blood","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":20150437,"Description":"The cellular apoptosis susceptibility (CSE1L\/CAS) protein is the human homologue of the yeast chromosome segregation gene product, CSE1. Serum cellular apoptosis susceptibility protein is a potential prognostic marker for metastatic colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":271},{"Name":"MUC12","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR|Immunohistochemistry","Usage":"PrognosticBM","Pmid":20162577,"Description":"MUC12\u00a0was reported as a novel membrane-associated mucin gene located on chromosome 7q22. Multivariate analysis disclosed that MUC12 expression status was an independent prognostic factor in Stages II and III CRC (relative risk, 8.236; 95% confidence interval, 1.702-39.849 p = 0.009).\u00a0 MUC12 mRNA expression is an independent marker of prognosis in stage II and stage III colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":272},{"Name":"Thymidylate synthase (TS) ","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":20332484,"Description":"TS is also the intracellular target enzyme for 5-FU where the main antitumoral effect is a competitive inhibition of TS. TS, immunohistochemically assessed, is a prognostic factor in CRC patients treated with surgery alone. ","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":273},{"Name":"CD95","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":20339853,"Description":"The expression of CD97, a member of the EGF-TM7 family with adhesive properties, is proportional to the aggressiveness and lymph node involvement in thyroid tumors. Univariate analysis revealed that lymph node metastasis (P = 0.001), stages II-IV (P = 0.026), and strong CD97 expression at tumor invasion front (P = 0.002) were shown to have a significant adverse impact on the postoperative survival rate. CD95 may be a poor prognostic factor for rectal adenocarcinoma.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":274},{"Name":"hMLH1","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PredictiveBM","Pmid":20368829,"Description":"The overall survival was better in patients responsive to CPT-11-based chemotherapy compared to non-responders. Our results suggest that hMLH1 protein expression may be a\npredictor for CPT-11 responsiveness in patients with colorectal cancer.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":275},{"Name":"NGX6","Molecular type":"DNA","Location":null,"Source":"Tissue","Assay\/Test":"Luciferase-reporter|RT-PCR","Usage":"DiagnosticBM|PrognosticBM|PredictiveBM","Pmid":20423473,"Description":"NGX6\u00a0is a novel\u00a0EGF-like domain-containing gene identified by a location candidate cloning strategy. A trend was shown toward metastasis status and primary site in colorectal carcinomas with NGX6 promoter methylation (p = 0.056 and P = 0.067, respectively). DNA methylation of NGX6 promoter might be a potential molecular marker for diagnosis or prognosis, or serve as a therapeutic target.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":276},{"Name":"ABCB1\/MDR1 gene polymorphisms","Molecular type":"DNA","Location":null,"Source":"Tissue","Assay\/Test":"PCR","Usage":"PrognosticBM","Pmid":20533057,"Description":"The ABCB1\/MDR1\u00a0gene seems to play an important role in tumour progression Multivariate analysis according to Cox's proportional hazard model indicated that the T(1236) allele is a good, independent prognostic factor and the presence of this allele decreases the risk of death in comparison with a group without this allele (HR = 0.26; p = 0.0424). ABCB1\/MDR1 gene polymorphisms as a prognostic factor in colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":277},{"Name":"Stomatin-like protein 2","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Western blot","Usage":"PredictiveBM","Pmid":20533595,"Description":"Stomatin-like\u00a0protein\u00a02\u00a0is a\u00a0protein\u00a0that in humans is encoded by the STOML2\u00a0gene. The differentially expressed proteins identified were associated with CRC and may act as drug target.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":278},{"Name":"Prefoldin 4 (PFDN4)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"qRT-PCR|Immunohistochemistry","Usage":"PrognosticBM","Pmid":20552408,"Description":"The human\u00a0PFDN4\u00a0gene, prefoldin 4, is a subunit of the heterohexameric chaperone protein and belongs to the prefoldin family.\u00a0 The multivariate regression analysis indicated that inclusion in the\u00a0PFDN4\u00a0high-expression group (relative risk, 2.68; 95% confidence interval, 1.37\u20135.49;\u00a0P\u00a0=\u00a00.003) was an independent predictor of overall survival, as was venous invasion (relative risk, 2.10; 95% confidence interval, 1.01\u20134.21;\u00a0P\u00a0=\u00a00.045).\u00a0 The data strongly suggest that PFDN4 expression is a prognostic factor in CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":279},{"Name":"Prion protein, PrP(C)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM|PredictiveBM","Pmid":20564346,"Description":"The cellular prion protein, PrPC, is a glycoprotein whose possible physiological functions include roles in cell adhesion, signal transduction, regulation of copper metabolism as well as protection from apoptosis and oxidative stress. Protein levels were correlated with disease recurrence (P = 0.007).\u00a0 PrP(C) overexpression may constitute a prognostic marker for disease recurrence and potentially a new target for anticancer therapy.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":280},{"Name":"P16","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":20572035,"Description":"p16, is a\u00a0tumor suppressor\u00a0protein, that in humans is encoded by the\u00a0CDKN2A\u00a0gene. MUC1, pERK and p16 in LN (P=.002, P=.014, and P=.002, respectively) had independent prognostic value. The current results support the investigation of p16 as a prognostic and potential predictive biomarker for future randomized trials of patients with stage III colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":281},{"Name":"Polo-like kinase 1 (PLK1)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Western Blot|qPCR","Usage":"PredictiveBM","Pmid":20581060,"Description":"PLK1\u00a0kinase activity is inhibited by DNA damaging agents, in an\u00a0ataxia telangiectasia mutated\u00a0or Rad3-related kinase-dependent manner. High\u00a0PLK1\u00a0expression was associated with a nonsignificant trend for reduced overall survival (5-year rate 54.2 versus 84.4%, for high and low\u00a0PLK1\u00a0expression, respectively,\u00a0P\u00a0= 0.059).\u00a0 Polo-like kinase 1 as predictive marker and therapeutic target for radiotherapy in rectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":282},{"Name":"Prohibitin (PHB)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Western blot","Usage":"DiagnosticBM","Pmid":20596663,"Description":"PHB is an evolutionarily conserved and ubiquitous protein that may be involved in tumorigenesis and development of CRC. PHB is a potential diagnostic and differentiation biomarker of CRC in the clinic.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":283},{"Name":"Dermokine (DK)","Molecular type":null,"Location":null,"Source":"Blood","Assay\/Test":"qRT-PCR|Immunohistochemistry","Usage":"DiagnosticBM","Pmid":20652332,"Description":"Dermokine (DK)-\u03b1\/-\u03b2 (sk30\/89) as a novel keratinocyte-secreted peptide, as well as identifying the formation of a new stratified epithelium-secreted gene complex (SCC) with two other keratinocyte-secreted peptides, Kdap and suprabasin.\u00a0 Serum DK-\u03b2\/\u03b3 is the most promising of the existing tumor biomarkers for the diagnosis of early-stage colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":284},{"Name":"Cyclin E","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":20677343,"Description":"Cyclin E binds to\u00a0G1\u00a0phase\u00a0Cdk2, which is required for the transition from G1\u00a0to\u00a0S phase\u00a0of the\u00a0cell cycle\u00a0that determines initiation of DNA duplication.\u00a0 Cyclin E might be a poor prognosis factor.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":285},{"Name":"Metastasis-associated in colon cancer 1 (MACC1)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":20682999,"Description":"MACC1\u00a0induces cell proliferation, motility, HGF-triggered scattering in cell cultures, tumor growth, and metastasis in xenograft models MACC1 might serve as a new parameter for the prognostic prediction of colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":286},{"Name":"S100A4","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":20712050,"Description":"The\u00a0S100\u00a0family of proteins has emerged as an important group with the capacity to promote invasiveness and metastasis of many human neoplasms. Positive immunoreactivity of protein S100A4 was found to be associated with tumor recurrence (P = 0.004), and was also associated with significantly worse overall survival in the Kaplan-Meyer survival analysis (P = 0.044). Expression of protein S100A4 is a predictor of recurrence in colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":287},{"Name":"S100A4","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":20719498,"Description":"One potential prognostic factor is S100A4, a small, calcium-binding protein belonging to the S100 protein family. In multivariate analysis, nuclear localisation was inversely associated with metastasis-free (P=0.03) and overall survival (P=0.02) Nuclear S100A4 is a novel prognostic marker in colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":288},{"Name":"ESM-1","Molecular type":"Protein","Location":null,"Source":"Blood","Assay\/Test":"RT-PCR|Immunohistochemistry|Western blot","Usage":"DiagnosticBM","Pmid":20735430,"Description":"This gene encodes a secreted protein which is mainly expressed in the\u00a0endothelial cells\u00a0in human lung and kidney tissues. The accuracy, sensitivity, and specificity of ESM-1 for CRC were 0.94, 99%, and 73%, respectively, by receiver operating characteristics curve analysis. ESM-1 can be used as a potential serum marker for the early detection of CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":289},{"Name":"\u03b3-Catenin","Molecular type":null,"Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":20737155,"Description":"Subsequent TMA analysis showed that upregulation of cytoplasmatic \u03b3-catenin in the invasive fronts of curatively resected early T2 and T3 colorectal carcinomas was associated with shortened disease-free survival and an increased risk of death (p=0.003; hazard ratio = 2.98; 95% confidence interval, 1.44-6.18). We found that upregulation of cytoplasmatic \u03b3-catenin was associated with significantly impaired cancer-specific survival (p\u2009=\u20090.001) and disease-free survival (p\u2009=\u20090.012). \u03b3-Catenin is an independent prognostic marker in early stage colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":290},{"Name":"Jumonji domain containing 1A (JMJD1A)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"qRT-PCR|Immunohistochemistry|Western blot","Usage":"PrognosticBM|PredictiveBM","Pmid":20823141,"Description":"Jumonji domain containing 1A\u00a0(JMJD1A), a histone H3 Lys\u00a0demethylase, was a useful biomarker for\u00a0hypoxic\u00a0tumor cells and a poor prognosis of\u00a0CRC.\u00a0 JMJD1A was a novel independent prognostic factor for CRC (P = 0.013). JMJD1A is a useful biomarker for hypoxic tumor cells and a prognostic marker that could be a promising therapeutic target against CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":291},{"Name":"C4.4A","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Western blot|Immunohistochemistry|qRT-PCR","Usage":"PrognosticBM","Pmid":20825414,"Description":"The C4.4A protein was identified in a highly metastasizing rat pancreatic adenocarcinoma cell line, but not in locally growing rat tumors. The membranous staining with enhanced intensity at the invasive front of the primary colorectal cancer (Type A: 34\/132, 25.6%) was associated with depth of invasion (P = 0.033) and venous invasion (P = 0.003), and was a significant independent prognostic factor (5-year overall survival in the entire series [n = 132; P = 0.004] and disease-free survival in stage II and III colorectal cancers [n = 82; P = 0.003]). Our data indicate that expression of the C4.4A protein at the invasive front acts as a novel prognostic marker in colorectal cancer,","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":292},{"Name":"Tumour-associated trypsin inhibitor (TATI) ","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Blood","Assay\/Test":"Immunofluorometric assay","Usage":"PrognosticBM","Pmid":20849596,"Description":"Increased levels of s-TATI were associated with a reduced DFS (HR = 2.00; 95% CI 1.40-2.84, P < 0.001) and OS (HR = 2.40; 95% CI 1.74-3.33, P < 0.001). (HR = 2.89; 95% CI 1.96-4.25).\u00a0 High preoperative s-TATI levels predict a poor prognosis in patients with CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":293},{"Name":"CCT\u03b6-1","Molecular type":null,"Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Western blot|Immunohistochemistry","Usage":"PrognosticBM","Pmid":20872946,"Description":"CCT (chaperonin containing t-complex polypeptide 1, or TCP1) is a 16 subunit complex composed of two back-to-back stacked rings, each enclosing a substrate binding site and each containing eight different subunits \u03b1, \u03b2, \u03b3, \u03b4, \u03b5, \u03b7, \u03b8, and \u03b6\u00a02,\u00a03. CCT\u03b6-1 could be a new prognostic marker for CRC and involve in tumorigenesis. ","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":294},{"Name":"Ankyrin repeat, SOCS box-containing 9 (ASB9)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"qRT-PCR|Immunohistochemistry","Usage":"PrognosticBM","Pmid":20878058,"Description":"ASB9 is involved in the negative regulation of cytokine signaling.  A multivariate analysis showed that ASB9 expression status was an independent prognostic factor of overall survival (relative risk, 4.09; 95% confidence interval, 1.47-11.88; P=0.007).\u00a0 The results of the present study suggest that ASB9 is a useful prognostic marker for CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":295},{"Name":"Matrix metalloproteinase 13 (MMP13)","Molecular type":"Protein","Location":null,"Source":"Blood","Assay\/Test":"RT-PCR","Usage":"PrognosticBM","Pmid":20878116,"Description":"Matrix metalloproteinase 13 (MMP13), a member of the matrix metalloproteinase family, is considered to play a role in the tumor cell proliferation and invasion.\u00a0 Patients with MMP13 mRNA overexpression have a higher risk of postoperative relapse (P<0.0001; OR=7.989; 95% CI, 2.607-24.481).\u00a0 MMP13 is a potential prognostic marker for colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":296},{"Name":"microRNA-221 (miR-221)","Molecular type":"MicroRNA","Location":null,"Source":"Blood","Assay\/Test":"qRT-PCR|Immunohistochemistry","Usage":"DiagnosticBM|PrognosticBM","Pmid":20880178,"Description":"Mir-221 is an\u00a0oncogenic\u00a0microRNA. It targets CD117, which then prevents\u00a0cell migration\u00a0and\u00a0proliferation\u00a0in endothelial cells. When the cutoff value for miR-221 is 1.69, the sensitivity is 86% with the specificity of 41%. The direct amplification of plasma miR-221 can be used as a potential noninvasive molecular marker for diagnosis and prognosis of CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":297},{"Name":"Phospholipid scramblase 1 (PLSCR1)","Molecular type":"Protein","Location":null,"Source":"Blood","Assay\/Test":"Western Blot|Immunohistochemistry","Usage":"DiagnosticBM|PrognosticBM","Pmid":20927484,"Description":"Phospholipid scramblase 1\u00a0(PLSCR1), a newly identified calcium-dependent plasma-membrane protein, has been revealed to be important in the transbilayer movement of\u00a0phosphatidylserine\u00a0and other aminophospholipids to the plasma membrane outer leaflet. When cutoff values of 5 ng\/mL and 13.9 AU were applied for CEA and\u00a0PLSCR1, respectively, the overall\u00a0CRC\u00a0diagnostic sensitivity and specificity of\u00a0PLSCR1\u00a0were 80% and 60%, respectively, and those of CEA were 37% and 87%, respectively. PLSCR1 might be used as a noninvasive serological diagnostic and prognostic biomarker for CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":298},{"Name":"Toll like receptor 4 (TLR4)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":21059221,"Description":"TLR-4\u00a0is a transmembrane pattern recognition receptor that provides a critical link between immune stimulants produced by microorganisms, in particular\u00a0lipopolysaccharide, and the initiation of the innate immune reaction to foreign agents, but also to tumor cells. Those with a percentage of TLR-4+ cells expression less than 50% relapsed much later (within 40 months, RR 3.15; log rank chi-square 4.03, p < 0.05). The tumor microenvironment of colorectal cancer: stromal TLR-4 expression as a potential prognostic marker.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":299},{"Name":"Long interspersed nucleotide element-1 (LINE-1)","Molecular type":"DNA","Location":null,"Source":"Tissue","Assay\/Test":"Northern blot|Western blot","Usage":"PrognosticBM","Pmid":21087350,"Description":"Long interspersed nuclear element-1 (LINE-1) is a non-long-terminal-repeat class of retroposon that is the most successfully integrated mobile element and accounts for approximately 18% of the human genome. High LINE-1 methylation was associated with a trend for longer survival in the overall patient group (P=0.055). These results suggest that LINE-1 methylation is a novel predictive marker for survival benefit from adjuvant chemotherapy with oral fluoropyrimidines in CRC patients. ","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":300},{"Name":"Survivin","Molecular type":"protein","Location":"t","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":21118954,"Description":"Survivin, the smallest member of the inhibitor-of-apoptosis (IAP) family is a multifunctional protein that is reported to interact at the crossroads of disparate molecular networks of cellular division, intracellular signaling, and apoptosis. A higher survivin expression correlated with advanced ypT (P = 0.026) and ypUICC (P = 0.05) stage as well as DFS (P = 0.038) after preoperative RCT. Survivin expression displays a marker with prognostic utility in rectal cancers.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":301},{"Name":"PTPRG","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Real-time RT\u2013PCR","Usage":"DiagnosticBM","Pmid":21150880,"Description":"PTPs are known to be signaling molecules that regulate a variety of cellular processes including cell growth, differentiation, mitotic cycle, and oncogenic transformation.\u00a0 Validation of this region in an additional cohort of 103 sporadic colorectal tumours and 58 paired normal mucosa tissue samples showed 94% sensitivity and 96% specificity The high sensitivity and specificity for the PTPRG intron 1 methylation in both sporadic and hereditary colon cancers support biomarker potential for early detection of colon cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":302},{"Name":"Peroxisome proliferator-activated receptor \u03b3 (PPARG)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"ChIP|Western blot|Immunohistochemistry|MTT|qRT-PCR","Usage":"PrognosticBM","Pmid":21151932,"Description":"Consistently, variations in\u00a0PPARG\u00a0expression or gene mutations have been associated with tumorigenesis Our findings provide a novel mechanistic insight into epigenetic silencing of PPARG in CRC that may be relevant as a prognostic marker of tumor progression.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":303},{"Name":"NHERF1 ","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Immunofluorescence","Usage":"DiagnosticBM","Pmid":21170265,"Description":"NHERF1 is a 50-kDa adaptor protein composed of two tandem PSD-95\/Disc-large\/ZO-1 (PDZ) domains and a carboxyl (C)-terminal ERM-binding region.\u00a0 This study identifies NHERF1 as a new player in CRC progression and supports the notion that the expression or subcellular distribution of NHERF1 may be used as diagnostic marker for CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":304},{"Name":"Mus81","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":21175991,"Description":"The\u00a0Mus81\u00a0gene encodes a critical endonuclease involved in DNA repair and tumor suppression.\u00a0 Multivariable Cox regression analysis identified Mus81 downregulation as an independent prognostic factor for colorectal carcinoma (hazard ratio, 1.678; P = 0.040). Downregulation of Mus81 as a novel prognostic biomarker for patients with colorectal carcinoma.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":305},{"Name":"Matrix metalloproteinase-7 (MMP-7)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":21207220,"Description":"MMP-7, also called matrilysin, is able to degrade collagenes, proteoglycans, elastine, laminin, fibronectin, entactin, tenascin, and casein. High MMP-7 immunoexpression was associated with poor 5-year survival (P\u2009=\u20090.028), but during longer follow-up, the difference in prognosis between patient groups disappeared (P\u2009=\u20090.308). MMP-7 as a prognostic marker in colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":306},{"Name":"STOML2","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"DiagnosticBM","Pmid":21209152,"Description":"Increased expression of\u00a0STOML2\u00a0was associated with decreased\u00a0CRC-related survival; the mean survival period was 34.77 \u00b1 2.03 months in patients with high\u00a0STOML2\u00a0expression. STOML2\u00a0and\u00a0CEA\u00a0had statistically significant AUC values of 0.74 and 0.69, respectively STOML2 may be a noninvasive serological biomarker for early CRC diagnosis.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":307},{"Name":"S100A4","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Western blot|Immunohistochemistry|qRT-PCR","Usage":"PrognosticBM","Pmid":21218086,"Description":"S100A4 was significantly upregulated in LNM\u00a0CRC\u00a0compared with non-LNM\u00a0CRC. Univariate and multivariate analyses indicated that S100A4 expression was an independent prognostic factor for recurrence and survival of CRC patients (P<0.05). S100A4 might serve as a powerful biomarker for LNM and a prognostic factor in CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":308},{"Name":"Brachyury","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":21220197,"Description":"Brachyury, also known as T, is a member of the T-box family, whose expression is regulated by the Wnt signalling pathway which in turn is mediated by the \u03b2-catenin\/TCF4 complex. In multivariate analyses (Cox regression) brachyury expression was an independent prognostic marker if brachyury expression was compared with tumour grade in Cox regression analysis in Dukes A (p\u00a0=\u00a00.028) stages only. Brachyury expression predicts poor prognosis at early stages of colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":309},{"Name":"NDRG2 (N-Myc downstream-regulated gene 2)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"RT-PCR","Usage":"PrognosticBM","Pmid":21220491,"Description":"NDRG2\u00a0(N-Myc downstream-regulated gene 2) is a member of the\u00a0NDRG\u00a0gene family, composed of 4 members named\u00a0NDRG1,\u00a0NDRG2,\u00a0NDRG3, and\u00a0NDRG4, which have been implicated in the regulation of cell differentiation and proliferation. NDRG2 mRNA expression significantly correlated with differentiation status (P < 0.001), lymph node metastasis (P < 0.001), and tumor node metastasis stage (P < 0.001). NDRG2 mRNA level was found to be an independent prognostic factor for both disease-free survival and overall survival of CRC patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":310},{"Name":"Second mitochondria-derived activator of caspase (Smac)\u00a0","Molecular type":"Protein","Location":"Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":21264534,"Description":"Smac is a novel pro-apoptotic protein, first reported by Du et al. in 2000 High expression of Smac before CRT, and high Dworak's tumor regression grade (TRG) were significantly associated with improved 5-year disease-free survival (P < 0.05). Multivariate analysis confirmed that the pretreatment expression of Smac and Lymph nodal status were independent prognostic factors.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":311},{"Name":"Osteoprotegerin (OPG)","Molecular type":null,"Location":null,"Source":"Tissue","Assay\/Test":"qRT-PCR|Immunohistochemistry","Usage":"PrognosticBM|PredictiveBM","Pmid":21270110,"Description":"OPG\u00a0helps cancer cells survive by providing resistance to apoptosis induced by the\u00a0TNF-related apoptosis-inducing ligand. The overall survival (OS) rate was significantly lower (P\u00a0< 0.001) in patients with high\u00a0OPG protein\u00a0expression than in those with low\u00a0OPG\u00a0expression. Overexpression of OPG may be a predictive biomarker of CRC recurrence and a target for treatment of this disease.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":312},{"Name":"Bcl-Xl","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":21277008,"Description":"The Bcl-2 protein family is the best characterized protein family involved in the regulation of apoptotic cell death, consisting of pro-apoptotic and anti-apoptotic proteins. Univariate and multivariate analysis indicated that the status of Bcl-xL protein expression might be an independent prognostic marker for CRC patients (P=0.032) The status of Bcl-xL protein expression might be an independent prognostic marker for CRC patients","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":313},{"Name":"Forkhead box M1 (FOXM1)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PredictiveBM","Pmid":21281787,"Description":"Forkhead box protein M1 (FoxM1) is a member of the FoxM family and its deregulation has been implicated in pathogenesis of many cancers because of its ability to drive cell cycle progression and evasion of growth arrest. FOXM1 gene may serve as a useful molecular biomarker and potential therapeutic target.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":314},{"Name":"Sperm-associated antigen 9 gene (SPAG9)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"RT-PCR|Immunohistochemistry|ELISA","Usage":"DiagnosticBM","Pmid":21356354,"Description":"Sperm-associated antigen 9 gene, newly identified as a member of the CT antigen family, as associated with various malignancies. Anti-SPAG9 antibodies could be a novel serum biomarker for early diagnosis.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":315},{"Name":"CK2\u03b1","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"qRT-PCR|Immunohistochemistry","Usage":"PrognosticBM","Pmid":21359197,"Description":"Protein kinase CK2\u00a0(formerly known as\u00a0casein kinase\u00a02) is a highly conserved serine\/threonine kinase. In multi-variate analysis, overexpression of nuclear\u00a0CK2\u03b1\u00a0was prognostically independent (hazard ratio \u200a=\u200a4.53, 95% confidence Interval \u200a=\u200a2.46 to 8.32,\u00a0P<0.0001). Overexpression of nuclear CK2\u03b1 was proven to be an independent prognostic marker for CRC. ","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":316},{"Name":"Methylation of DSC3","Molecular type":"DNA","Location":null,"Source":"Tissue","Assay\/Test":"RT-PCR|Western blot|Immunohistochemistry","Usage":"PrognosticBM","Pmid":21364582,"Description":"Desmocollin 3 (DSC3), a member of the cadherin superfamily and integral component of desmosomes, is involved in carcinogenesis. Methylation of DSC3 genomic sequences was found in 41% (41 out of 99) of primary CRC, being associated with poor prognosis (P=0.002). Methylation status of DSC3 DNA is a prognostic marker for CRC. ","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":317},{"Name":"Adrenomedullin (ADM)","Molecular type":null,"Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":21378331,"Description":"Adrenomedullin\u00a0(ADM\u00a0or\u00a0AM) is a\u00a0vasodilatorpeptide hormone\u00a0of uncertain significance in human health and disease. ADM was a novel independent prognostic factor for CRC (p = 0.027). ADM was a novel independent prognostic factor for CRC","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":318},{"Name":"microRNA-195 (miR-195)","Molecular type":"MicroRNA","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":21390519,"Description":"MiR-195, one of the miR-16\/15\/195\/424\/497 family members, has been shown to play an important role in tumorigenesis, as a tumor suppressor.\u00a0 Kaplan-Meier survival analysis indicated that patients with reduced miR-195 had a poor overall survival (P < 0.01). Our data indicate the potential of miR-195 as a novel diagnostic or prognostic biomarker for CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":319},{"Name":"Interleukin 17 (IL-17)","Molecular type":null,"Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry|qRT-PCR|ElISA","Usage":"PrognosticBM","Pmid":21396350,"Description":"IL-17, which exerts strong pro-inflammatory effects, has emerged as an important mediator in inflammation-associated cancer.\u00a0 Multivariate Cox regression analyses confirmed that higher expression of IL-17 [hazard ratio (HR)\u00a0=\u00a04.024, 95% confidence interval (95% CI)\u00a0=\u00a01.561\u201310.375] were independent prognostic factors. IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":320},{"Name":"Matrix metalloproteinase-9 (MMP-9)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":21455597,"Description":"MMP-9, also known as\u00a092 kDa type IV collagenase,\u00a092 kDa gelatinase\u00a0or\u00a0gelatinase B\u00a0(GELB), is a matrixin, a class of\u00a0enzymes\u00a0that belong to the\u00a0zinc-metalloproteinases\u00a0family involved in the degradation of the\u00a0extracellular matrix. MMP-9 staining in colorectal cancer tissues had shorter disease-free survival than those with lower MMP-9 staining (log-rank test:\u00a0P\u00a0<\u00a00.001). It could also serve as a novel prognostic marker that is independent of, and additive to, the tumor-node-metastasis (TNM) staging system.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":321},{"Name":"Growth differentiation factor 15 (GDF15)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":21468045,"Description":"Growth differentiation factor 15\u00a0(GDF15) belongs to the\u00a0transforming growth factor beta\u00a0superfamily and has a role in regulating inflammatory and apoptotic pathways in injured tissues and during disease processes. Patients with CRC with moderate to high intensity of GDF15 immunostaining had a higher recurrence rate compared with patients with no or low intensity in all stages (stages I-III) (HR, 3.9; 95% CI, 1.16-13.15) and in stage III (HR, 10.32; 95% CI, 1.15-92.51) Growth differentiation factor 15 serves as a negative prognostic marker in CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":322},{"Name":"HOXB7","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry|Western blot|RT-PCR","Usage":"PrognosticBM","Pmid":21474578,"Description":"HOXB7, a member of class I homeobox, plays an important role in tumorigenesis. HOXB7 protein level was significantly correlated with advanced Dukes stage (P < 0.001), T stage (P = 0.012), distant metastasis (P = 0.042), higher proliferation index (P = 0.007) and poor survival of patients (P = 0.005) Our findings suggest that HOXB7 protein, as a valuable marker of CRC prognosis, plays an important role in the development and progression of human CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":323},{"Name":"Kallikrein-related peptidase 10 (KLK10)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":21487810,"Description":"KLK10\u00a0gene contains six exons and five introns and codes for a secreted protein.The expression of KLK10 is regulated by steroid hormones, which implies that KLK10 plays an important role in the initiation and progression of endocrine-related cancers. Cox proportional hazard regression model using univariate analysis revealed for the first time that high status KLK10 expression is a significant factor for disease-free survival (DFS; p=0.002) and overall survival (OS; p=0.026) of patients. Kaplan-Meier survival curves demonstrated that KLK10 expression of low status is significantly associated with longer DFS (p=0.001) as well as OS (p=0.021). KLK10 gene expression may be used as a marker of unfavorable prognosis for CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":324},{"Name":"SPG20 (spastic paraplegia-20)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Real-time quantitative gene expression","Usage":"DiagnosticBM","Pmid":21499309,"Description":"The SPG20 gene is located in chromosome band 13q13.3 and a one base deletion in exon-4 (1110delA) resulting in loss of expression of the mutated protein has been shown to cause the autosomal recessive\u00a0spastic paraplegia-20. For the combined test and validation series, Receiver Operating Characteristics (ROC) curves showed an area under the curve (AUC) of 0.947 (P=2.87E-37; asymptotic 95% confidence interval: 0.919\u20130.975) for carcinomas versus normal mucosa and 0.913 (P=2.66E-26; asymptotic 95% confidence interval: 0.872\u20130.954) for\u00a0adenomas\u00a0versus normal mucosa. SPG20, a novel biomarker for early detection of colorectal cancer, encodes a regulator of cytokinesis.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":325},{"Name":"Urokinase-type plasminogen activator (uPA), Proliferating cell nuclear antigen labeling index (PCNA-LI)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":21533355,"Description":"The combination of u-PA expression and elevated PCNA-LI at the deepest invasive portion correlated significantly with prognosis. These results indicate that u-PA expression is an important predictor of CRC development and liver metastasis. Furthermore, combined analysis of u-PA expression and PCNA-LI at the deepest invasive portion is very useful in predicting CRC prognosis.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":326},{"Name":"Rabphilin-3A-like (RPH3AL)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Western blot","Usage":"DiagnosticBM","Pmid":21536019,"Description":"Rabphilin-3A-like (RPH3AL) is a protein that consists of 302 amino acids (38\u00a0kDa) and has 77.9% similarity to the Rabphilin-3A protein. The value of the area under the receiver operating characteristic curve of RPH3AL autoantibody was 0.84. Circulating RPH3AL autoantibodies are prevalent in patients with CRC, and detection of these autoantibodies might provide a novel non-invasive approach for CRC diagnosis.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":327},{"Name":"ADAMTS12","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":21559743,"Description":"ADAMTS12 participates in the initiation and progression of arthritis by degrading the cartilage oligomeric matrix protein.\u00a0 Kaplan\u2013Meier analysis showed that the colorectal cancer patients who showed low ADAMTS12 expression had a poor survival rate (P\u00a0<\u00a00.001). ADAMTS12 expression may be a good prognostic marker for colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":328},{"Name":"Metastasis suppressor 1 (MTSS1)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Western Blot|Immunohistochemistry","Usage":"PrognosticBM","Pmid":21562916,"Description":"This gene, located on human chromosome 8q24.1, encodes a 5.3\u00a0kb mRNA and a polypeptide predicted to be an actin-binding protein of 356 amino acids with homology to the WASp (Wiskott\u2013Aldrich Syndrome protein) family. In multivariate analysis, MTSS1 expression maintained independent prognostic influence on overall survival (P\u2009=\u20090.004). MTSS1 may be a good biomarker to be applied in the clinical setting to predict the prognosis of CRC patients with completely resected.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":329},{"Name":"MGb2-Ag\/TRAK1","Molecular type":null,"Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry|Western blot","Usage":"PrognosticBM","Pmid":21573901,"Description":"Both univariate and multivariate analyses showed that tumor differentiation and MGb2-Ag\/TRAK1 expression were two independent and prognostic factors for CRC (p\u2009<\u20090.001). MGb2-Ag\/TRAK1 may play an important role in the development of CRC and may be a valuable prognostic indicator of CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":330},{"Name":"Matrix metalloproteinase-21 (MMP-21)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":21590459,"Description":"The encoded protein may play an important role in\u00a0embryogenesis, particularly in\u00a0neuronal\u00a0cells, as well as in\u00a0lymphocyte\u00a0development and survival. The unadjusted HR of weak positive (+), moderate positive (++) and strong positive (+++) groups were 3.15 (95% CI, 1.61\u20136.18;\u00a0P\u2009<\u20090.05), 6.13 (95% CI, 3.09\u201312.15;\u00a0P\u2009<\u20090.001) and 7.71 (95% CI, 5.10\u201318.48;\u00a0P\u2009<\u20090.001), respectively. MMP-21 might also serve as a novel prognostic marker that is independent of, and additive to, the TNM staging system.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":331},{"Name":"p53","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":21598212,"Description":"TP53, located on chromosome 17p13, is one of the most mutated genes chromosome 17p13, is one of the most mutated genes. A significant difference between cases and controls was found for the arginine\/arginine genotype compared with (grouped) arginine\/proline and proline\/proline genotypes (Odds Ratio = 1.451 (1.002-2.103), P=0.048) We evaluated the expression patterns of p53 protein, as potential prognostic marker in colorectal cancer specimens by immunohistochemical staining.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":332},{"Name":"Immune cells (iCD10)","Molecular type":null,"Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":21599811,"Description":"CD10 is a 90\u2013100-kDa cell surface\u2013zinc-dependent metalloprotease that has been referred to as neutral endopeptidase (EC 3.4.24.11), enkephalinase, neprilysin, and common acute lymphoblastic leukemia antigen. In multivariate analysis, iCD10 could be an independent prognostic factor for both recurrence-free survival and overall survival in stage I-III CRC (hazard ratio, 2.522 [1.299-4.896], P = 0.006; 2.890 [1.357-6.157], P = 0.006, respectively) The expression level of iCD10 at the tumor invasion front represented an independent prognostic biomarker in stage I-III CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":333},{"Name":"\u03b1(1,6)fucosyltransferase","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":21652057,"Description":"A fucosyltransferase\u00a0is an\u00a0enzyme\u00a0that transfers an L-fucose\u00a0sugar from a GDP-fucose (guanosine diphosphate-fucose) donor substrate to an acceptor substrate. In patients with moderate or strong \u03b1(1,6)fucosyltransferase expression, a significant decrease in the overall (P = .04) and disease-free (P = .03) survival rates was observed. These findings suggest that \u03b1(1,6)fucosyltransferase expression may be a good indicator of poor prognosis in colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":334},{"Name":"MMP-21","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":21656525,"Description":"The encoded protein may play an important role in\u00a0embryogenesis, particularly in\u00a0neuronal\u00a0cells, as well as in\u00a0lymphocyte\u00a0development and survival. Patients with tumors of elevated MMP-21 expression had worse overall survival compared with those with preserved MMP-21 expression (log-rank test:\u00a0P\u2009=\u20090.006).\u00a0 It could also be a novel molecular marker to predict prognosis of patients with stage II and stage III colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":335},{"Name":"Rho GDP dissociation inhibitor 2 (RhoGDI2)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"RT-PCR","Usage":"PrognosticBM","Pmid":21698524,"Description":"Rho GDP dissociation inhibitor 2 (RhoGDI2) was recently shown to act as a metastasis suppressor gene in bladder cancer. RhoGDI2-higher expression tumors had a significant correlation with superior relapse-free survival (RFS) time as compared to RhoGDI2-lower expression tumors in stage III CRC (log-rank test, P\u00a0<\u00a00.05). RhoGDI2 was an independent prognostic factor for RFS.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":336},{"Name":"Neurone glial-related cell adhesion molecule (Nr-CAM) ","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":21718388,"Description":"Neurone glial-related cell adhesion molecule is a 200\u2013220\u00a0kDa transmembrane protein composed of six Ig-like domains and five FnIII repeats in the extracellular region plus a highly conserved cytoplasmic tail, and is known to be involved in the development and function of the mammalian nervous system.( Nr-CAM overexpression correlated with a significant increase in disease-specific (HR 1.66; 95% confidence interval 1.11-2.47; P = 0.014) and overall mortality (HR 1.57; 95% confidence interval 1.07-2.30; P = 0.023) in advanced but not early stage disease. Nr-CAM overexpression is an independent marker of poor prognosis among advanced CRC patients, ","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":337},{"Name":"Epidermal growth factor-like domain 7 (EGFL7)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":21737648,"Description":"The egfl7\u00a0gene is located on chromosomes 9 and 2 in human and mouse, respectively, and is structured in 11 exons and introns, including intron-1a and 1b which are alternatively transcribed from two different promoters. The CRC patients with high EGFL8 down-regulation showed either poorer disease-free survival (p=0.0167) or poorer overall survival (p=0.0310) than those with low EGFL8 down-regulation.Multivariable analysis identified EGFL8 down-regulation as an independent prognostic factor for CRC patients (hazard ratio, 12.974; p=0.037). The down-regulation of EGFL8 as a novel prognostic biomarker for CRC patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":338},{"Name":"Testes-specific protease 50 (TSP50)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"RT-PCR|Western blot|Immunohistochemistry","Usage":"PrognosticBM","Pmid":21765952,"Description":"The\u00a0testes-specific protease 50\u00a0(TSP50) gene was discovered from a human testes cDNA library on a hypomethylated DNA fragment isolated from human\u00a0breast cancer\u00a0cells via the methylation sensitive-representational difference analysis techniqu. Multivariate Cox regression analysis indicated that high TSP50 expression was a statistically significant independent risk factor (hazard ratio \u200a= 2.205, 95% CI = 1.214-4.004, P = 0.009). High expression of testes-specific protease 50 is associated with poor prognosis in colorectal carcinoma.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":339},{"Name":"Notch1","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":21771876,"Description":"Notch signaling is an evolutionarily conserved pathway which regulates critical cellular pathways and plays a key role in the development of normal tissues and cells through various effects on differentiation, proliferation, cell fate decision, and stem cell renewal.\u00a0 Kaplan\u2013Meier survival curves showed that higher\u00a0Notch1\u00a0expression was associated with worse overall survival (log-rank test:\u00a0P\u00a0< 0.001). Notch1 is an independent predictor of prognosis for patients with colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":340},{"Name":"Bag-1","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"RT-PCR|Immunohistochemistry","Usage":"DiagnosticBM|PrognosticBM","Pmid":21809033,"Description":"BAG-1 is a multifunctional binding protein involved in differentiation, cell cycle, and apoptosis. They might be regarded as a biomarker for the diagnosis of the early stages of colorectal cancer. In addition, they have particular significance for the prognosis of colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":341},{"Name":"Eukaryotic initiation factor 5A2 (EIF5A2)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry|Western blot|RT-PCR","Usage":"PrognosticBM|PredictiveBM","Pmid":21813470,"Description":"The authors have previously isolated a putative oncogene, eukaryotic initiation factor 5A2 (EIF5A2) from 3q26. The overexpression of EIF5A2 was examined by immunohistochemistry in 102\/229 (44.5%) CRC patients, and it was significantly correlated with tumour metastasis and determined to be an independent predictor of shortened survival (p<0.05).\u00a0 EIF5A2 could be employed as a novel prognostic marker and\/or effective therapeutic target for CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":342},{"Name":"Podocalyxin-like 1 (PODXL) ","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":21829192,"Description":"Podocalyxin-like 1 (PODXL) is an anti-adhesive transmembrane protein belonging to the\u00a0CD34\u00a0family. A shorter CSS (hazard ratio (HR)=1.98; 95% confidence interval (CI) 1.38-2.84, P<0.001) and 5-year OS (HR=1.85; 95% CI 1.29-2.64, P=0.001); the latter remaining significant in multivariate analysis (HR=1.52; 95% CI 1.03-2.25, P=0.036). Podocalyxin-like 1 expression is an independent factor of poor prognosis in CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":343},{"Name":"CXCL16","Molecular type":"Protein","Location":null,"Source":"Blood","Assay\/Test":"Immunohistochemistry|Western Blot","Usage":"PrognosticBM","Pmid":21845497,"Description":"CXCL16 is composed of a CXC chemokine domain, a\u00a0mucin-like stalk, a\u00a0transmembrane domain\u00a0and a cytoplasmic tail containing a potential\u00a0tyrosine\u00a0phosphorylation\u00a0site that may bind\u00a0SH2. Multivariate analysis identified T classification (T3,4;\u00a0P\u00a0=\u00a00.001), GPS (1,2;\u00a0P\u00a0=\u00a00.026), vessel involvement (P\u00a0=\u00a00.015), liver metastases (P\u00a0<\u00a00.0001), and elevated serum CXCL16 levels (P\u00a0=\u00a00.0025) as independent risk factors for predicting poor prognosis. We identified CXCL16 as a novel prognostic marker.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":344},{"Name":"Transketolase like gene 1 (TKTL1)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"RT-qPCR","Usage":"PrognosticBM","Pmid":21854597,"Description":"The detection of the\u00a0Transketolase-like-1\u00a0(TKTL1) protein and its role in the pentose phosphate pathway (PPP) first described a link between enhanced glycolysis and cancer. The impact of\u00a0VEGFR-2\u00a0expression on DFS failed statistical significance but a trend was observed regarding 3-year DFS in favour of patients with lower\u00a0VEGFR-2\u00a0expression (3-year DFS: 81% versus 53%, n = 32, p = 0.19, HR:0,43) High TKTL-1 expression correlates with poor prognosis in terms of 3 year disease-free survival in patients with LARC treated with intensified neoadjuvant chemoradiotherapy.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":345},{"Name":"Claudin-1 (CL-1)","Molecular type":"Protein","Location":"Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":21873169,"Description":"Claudin-1 (CL-1) and claudin-2 (Cl-2) are transmembrane proteins which are an integral component of tight junction strands. Multivariate Cox analysis revealed that tumor location (p=0.005), venous invasion (p=0.038), PNI (p=0.033), preoperative CEA level (p=0.027) and low level of CL-1 expression (CL-1 PS) (p=0.046) were associated with recurrent disease in the same group (Table III).\u00a0 Loss of claudin-1 expression is a strong predictor of disease recurrence and poor patient survival in stage II and III rectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":346},{"Name":"Secreted Protein Acidic, Rich in Cysteine (SPARC)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"DiagnosticBM|PrognosticBM","Pmid":21887554,"Description":"Secreted Protein Acidic and Rich in Cysteine (SPARC) has been shown to be involved in many physiological functions in cell biology. The difference still existed as a statistical significance even when the value was adjudged with Dukes\u2019 stage (p\u2009=\u20090.01), tumor differentiation (p\u2009=\u20090.047) and both together Dukes\u2019 stages and tumor differentiations (p\u2009=\u20090.006) by Multivariate and Interaction analyses. Expression of SPARCL1 protein might be a valuable biomarker for early diagnosis in colorectal cancers and further predicting patients' prognosis.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":347},{"Name":"Cyclin E","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Western blot","Usage":"PrognosticBM","Pmid":21944050,"Description":"Cyclin E, which includes full-length (FL) cyclin E, low-molecular weight (LMW) cyclin E and total molecular cyclin E (full-length plus low-molecular weight), is known to not only play an important function in G1\u00a0phase and the G1\u2013S transition, but also cause chromosomal instability. Patients with elevated LMW- or total cyclin E levels had a hazard ratio for death from rectal cancer of 6.302 (95% CI, 1.903-17.81, p\u00a0=\u00a00.001) or 4.332 (95% CI, 1.298-16.362, p\u00a0=\u00a00.001). Overexpression of cyclin E isoforms correlates with poor prognosis in rectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":348},{"Name":"RNA-binding motifs 3 (RBM3)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Western blot","Usage":"PrognosticBM","Pmid":21956899,"Description":"RBM3, one of three X-chromosome-related RBM-genes (RBMX, RBM3 and RBM10), was initially identified in a human fetal brain tissue cDNA library and maps to Xp11.23. RBM3 expression as assessed by the polyclonal antibody was significantly associated with a prolonged RFS in both univariate analysis (HR=0.60; 95% CI 0.36\u20130.99,\u00a0p<0.047) and multivariate analysis (HR=0.55; 95% CI 0.33\u20130.92,\u00a0p=0.024). These data demonstrate that high tumor-specific nuclear expression of RBM3 is an independent predictor of good prognosis in colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":349},{"Name":"Rpt4","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":21960357,"Description":"In contrast, in Stage II patients increased Rpt4 staining was significantly associated with disease free survival (Cox proportional hazard ratio 0.605; p = 0.0217) Our data suggest that Rpt4 is an independent prognostic variable for Stage II colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":350},{"Name":"Matrix metalloproteinase-2 (MMP-2)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"RT-PCR|Immunohistochemistry|Western blot","Usage":"PrognosticBM","Pmid":21968416,"Description":"Matrix metalloproteinase-2 (MMP2) is a member of the matrix metalloproteinase (MMP) family, which is involved in the breakdown of extracellular matrix in normal physiological processes. Tumor size, lymph node metastasis, distant metastasis, and\u00a0MMP2\u00a0expression were significantly related to overall survival of CRC patients (P< 0.001,\u00a0P= 0.011,\u00a0P< 0.001,\u00a0P= 0.007, respectively).\u00a0 MMP2 promotes CRC cell growth and invasion by up-regulating VEGF and MT1-MMP expression, which makes this pathway a potential target for cancer treatment.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":351},{"Name":"Fucosylated haptoglobin (Fuc-Hpt)","Molecular type":null,"Location":null,"Source":"Tissue","Assay\/Test":"ELISA","Usage":"PrognosticBM","Pmid":22006099,"Description":"Fucosylation is an important oligosaccharide modification involved in cancer and inflammation. As a result from multivariate logistic-regression analysis for 5 parameters that are significantly elevated by univariate analysis, distant metastasis was chosen as the independent factor for the elevation of Fuc-Hpt (odds ratio of 9.10% and 95% confidence interval [CI] of 1.67-49.59,\u00a0P\u00a0= .011). Fuc-Hpt might be a useful marker for the prognosis of CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":352},{"Name":"CXCL10","Molecular type":"Protein","Location":null,"Source":"Blood","Assay\/Test":"ELISA|Immunohistochemistry","Usage":"PrognosticBM","Pmid":22038159,"Description":"Chemokines are a large family of small chemotactic cytokines with four conserved cysteines linked by disulfide bonds. Kaplan-Meier analysis showed that higher serum CXCL10 level was associated with a poor prognosis (p=0.032, log-rank test). Preoperative high serum levels of CXCL10 were associated with poor prognosis and liver metastasis in CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":353},{"Name":"E-box-binding homeobox 2 (ZEB2)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"qRT-PCR|Immunohistochemistry","Usage":"PrognosticBM|PredictiveBM","Pmid":22042972,"Description":"The ZEB2 protein is a\u00a0transcription factor\u00a0that plays a role in the\u00a0transforming growth factor \u03b2 (TGF\u03b2) signaling pathways that are essential during early fetal development. Expression of\u00a0ZEB2\u00a0at the invasion front was found to be an independent prognostic marker for cancer-specific survival (P\u00a0= 0.02) besides tumor stage (P\u00a0< 0.001) whereas\u00a0ZEB2\u00a0expression at the tumor center failed to be significant (P\u00a0= 0.33). ZEB2 may be interesting as biomarker and potential target for treatment of colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":354},{"Name":"microRNA-150 (miR-150)","Molecular type":"MicroRNA","Location":null,"Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM|PredictiveBM","Pmid":22052060,"Description":"MiR-150\u00a0is a family of\u00a0microRNA\u00a0precursors found in\u00a0mammals, including\u00a0humans.\u00a0 Multivariate Cox regression showed that low miR-150 expression predicted worse prognosis (HR 0.18; 95% CI 0.05 to 0.25; p<0.001) and treatment with adjuvant chemotherapy was also associated with worse survival (HR 0.38; 95% CI 0.19 to 0.79; p=0.009). MiR-150 as a potential biomarker associated with prognosis and therapeutic outcome in colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":355},{"Name":"Visinin-like protein-1 (VSNL-1)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"qRT-PCR|Immunohistochemistry","Usage":"PrognosticBM","Pmid":22052372,"Description":"This gene is a member of the visinin\/recoverinsubfamily of\u00a0neuronal calcium sensor\u00a0proteins. Patients with high VSNL-1 expression had significantly poorer prognosis than those with low expression in stage III disease (p = 0.045). Visinin-like protein-1 overexpression is an indicator of lymph node metastasis and poor prognosis in colorectal cancer patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":356},{"Name":"Pleiotrophin (PTN)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"ELISA|Immunohistochemistry|qRT-PCR|Western blot","Usage":"PrognosticBM|PredictiveBM","Pmid":22065111,"Description":"The proto-oncogene growth factor PTN is a heparin-binding glycoprotein that was purified by the Medical Center of the University of Washington in 1989. The log-rank test revealed that the survival time between the high- and low-expressing PTN groups was significant different (p\u2009<\u20090.001). PTN could serve as a prognostic factor for this cancer. It may represent an attractive new target for CRC therapy.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":357},{"Name":"Glucose transporter 1 (GLUT1)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"qRT-PCR|Immunohistochemistry","Usage":"DiagnosticBM","Pmid":22072148,"Description":"GLUT1, also known as\u00a0solute carrier family 2, facilitated glucose transporter member 1\u00a0(SLC2A1), is a\u00a0uniporterprotein\u00a0that in humans is encoded by the\u00a0SLC2A1gene. An elevated GLUT1 expression may be a useful predictor of distant recurrence and poor prognosis in rectal cancer patients after preoperative CRT.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":358},{"Name":"Indoleamine 2,3-dioxygenase 1 (IDO1)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"RT-qPCR|Western blot|Immunohistochemistry","Usage":"PrognosticBM","Pmid":22108515,"Description":"Indoleamine 2,3-dioxygenase 1 (IDO1) is a tryptophan-catabolising enzyme that induces immune tolerance by modulating T-cell responses. It was associated with overall survival (P=0.001) and with metachronous metastases (P=0.018). IDO1 is an independent prognostic indicator for CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":359},{"Name":"Stathmin-1 (STMN1)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Western blot|Immunohistochemistry","Usage":"PrognosticBM","Pmid":22181002,"Description":"Stathmin is a\u00a0highly conserved\u00a017\u00a0kDa\u00a0protein\u00a0that is crucial for the regulation of the cell\u00a0cytoskeleton.\u00a0 We also showed via tissue microarray analyses of 324 CRC tissues and Kaplan-Meier survival plot that CRC patients with higher expression of STMN1 have poorer prognosis.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":360},{"Name":"CXCL5","Molecular type":"Protein","Location":null,"Source":"Blood","Assay\/Test":"Western blot|Immunohistochemistry","Usage":"PrognosticBM","Pmid":22197219,"Description":"CXCL5 is predominantly produced in colonic epithelial cells, and is a CXC chemokine containing ELR motif, which promotes angiogenesis through interaction with its specific receptor CXCR2. Univariate analysis correlated elevated CXCL5 with poor overall survival (p=0.0002). CXCL5 is a novel serum prognostic marker in patients with colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":361},{"Name":"Ubiquitin-like with plant homeodomain, ring finger domains 1 (UHRF1)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry|Western Blot","Usage":"PredictiveBM","Pmid":22219067,"Description":"UHRF1, also known as ICBP90, was identified as a multidomain protein, which is required for cellular proliferation and epigenetic regulation. UHRF1 may be used as a biomarker or even a therapeutic target for CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":362},{"Name":"Mitochondrial transcription factor A (mtTFA)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":22266811,"Description":"Mitochondrial transcription factor A (mtTFA) is a member of the high mobility group (HMG)-box protein family (2) and stimulates the transcription of mitochondrial genes by binding to the mitochondrial displacement loop (D-loop) region. The survival rate of the patients negative for mtTFA expression was significantly higher than that of patients with positive mtTFA expression (5-year survival rate, 80.5% vs. 60.4%, P=0.0328). The positive mtTFA expression appears to be a useful marker for tumor progression and poor prognosis in patients with CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":363},{"Name":"Kallikrein-related peptidase 6 (KLK6)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":22285222,"Description":"The human kallikrein-related peptidase-6 (KLK6) is a member of the human kallikrein gene family, and is expressed in a wide array of normal tissues. Univariate analysis showed that KLK6 expression and stage had statistically significant correlation with disease-free survival (p=0.045 and p<0.001, respectively) and overall survival (p=0.027 and p<0.001, respectively). KLK6 immunostaining is an independent prognostic marker in patients with CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":364},{"Name":"CD73","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Western blot|Immunohistochemistry","Usage":"PrognosticBM","Pmid":22287455,"Description":"CD73, also known as ecto-5\u2032-nucleotidase (ecto-5\u2032-NT), is a glycosylphosphatidylinositol-linked 70-kDa cell-surface ectoenzyme expressed on many cell types, including subsets of lymphocytes, endothelial cells, and epithelial cells.\u00a0 High expression of CD73 as a poor prognostic biomarker in human colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":365},{"Name":"E-cadherin","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"RT-PCR|Immunohistochemistry|Western blot","Usage":"PrognosticBM","Pmid":22311018,"Description":"Cadherin-1\u00a0also known as\u00a0CAM 120\/80\u00a0or\u00a0epithelial cadherin\u00a0(E-cadherin) or\u00a0uvomorulin\u00a0is a\u00a0protein\u00a0that in humans is encoded by the\u00a0CDH1\u00a0gene. E-cadherin can act as a central modulator of the cell biological phenotypes and a potential prognostic marker in Colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":366},{"Name":"microRNA-10b (miR-10b)","Molecular type":"MicroRNA","Location":null,"Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":22322955,"Description":"MiR-10b\u00a0has been shown to be involved in cancer progression in several kinds of cancers, including those of the breast, pancreas, and central nervous system. MiR-10b is a novel prognostic marker in colorectal cancer. ","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":367},{"Name":"FOXM1","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR|Immunohistochemistry|Western blot","Usage":"PrognosticBM","Pmid":22326401,"Description":"FoxM1 belongs to a large family of Forkhead transcription factors that possesses a winged-helix DNA-binding domain called Forkhead box (FOX). Multivariate analysis showed that the status of FOXM1 expression was an independent prognostic factor for CRC patients (P=0.025). FOXM1 expression correlates with tumor invasion and a poor prognosis of colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":368},{"Name":"Special AT-rich sequence-binding protein 2 (SATB2)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":22333599,"Description":"Special AT-rich sequence-binding protein 2\u00a0(SATB2), a nuclear matrix-associated transcription factor and epigenetic regulator, was initially identified as a gene involved in\u00a0osteoblast differentiation and craniofacial patterning in humans\u00a0 SATB2\u00a0remained an independent prognostic factor for both CSS (HR=0.49, 95% CI 0.25\u20130.96,\u00a0P=0.039) and\u00a0OS\u00a0(HR=0. 37, 95% CI 0.19\u20130.71,\u00a0P=0.003) in patients with\u00a0colon cancer. High SATB2 expression is an independent marker of good prognosis in colon cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":369},{"Name":"ORM2","Molecular type":"Protein","Location":null,"Source":"Blood","Assay\/Test":"ELISA|Western blot","Usage":"DiagnosticBM","Pmid":22363757,"Description":"ORM2 could be used as a potential biomarker in the diagnosis of CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":370},{"Name":"Reversion-inducing cysteine-rich protein with Kazal motif (RECK)\u00a0","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":22397871,"Description":"Reversion-inducing cysteine-rich protein with Kazal motifs (RECK) is a membrane-anchored glycoprotein of approximately 110 kDa.\u00a0 Decreased RECK expression was an independent prognostic factor of poor survival.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":371},{"Name":"CXCR3","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR|Immunohistochemistry|Western blot","Usage":"PrognosticBM|PredictiveBM","Pmid":22401929,"Description":"Chemokine receptor CXCR3\u00a0is a G\u03b1i\u00a0protein-coupled receptor in the\u00a0CXC chemokine receptorfamily. By multivariate analysis, we showed that CXCR3 expression and Dukes\u2019 classification were independent prognostic factors for overall survival of CRC patients (P\u00a0=\u00a00.038 and 0.014, respectively). CXCR3 is an indicator of a poor prognosis and a promising target for cancer therapy in colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":372},{"Name":"Aldehyde dehydrogenase 1 (ALDH1)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PredictiveBM","Pmid":22405917,"Description":"ALDH1 confers resistance to alkylating chemotherapeutic agents and protects against oxidative damage. ALDH1 could be an effective therapeutic target in early CRC but not late-stage disease. ","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":373},{"Name":"Kallikrein-related peptidase 10 (KLK10)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":22437349,"Description":"Kallikrein-10\u00a0is a\u00a0protein\u00a0that in humans is encoded by the\u00a0KLK10\u00a0gene. Cox multivariate analysis showed that both KLK10 expression and stage were independent predictors of unfavorable DFS (p = 0.057 and p = 0.001, respectively) and overall survival (p = 0.009 and p = 0.001, respectively). KLK10 immunostaining is an independent prognostic marker in patients with CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":374},{"Name":"PITX1","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry|RT-PCR","Usage":"PrognosticBM","Pmid":22438068,"Description":"This gene encodes a member of the RIEG\/PITX homeobox family, which is in the bicoid class of homeodomain proteins.\u00a0 Reduced expression of PITX1 was independently correlated to shorter patients survival and could serve as a prognostic marker.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":375},{"Name":"B7-H3","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry|Western immunoblot","Usage":"PrognosticBM","Pmid":22473715,"Description":"B7-H3, an immunoregulatory protein that belongs to the B7 family of T-cell co-regulatory molecules,10\u00a0may be a new potential prognostic marker.\u00a0 Nuclear B7-H3 could become a useful prognostic marker in colon cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":376},{"Name":"microRNA-22 (miR-22)","Molecular type":"MicroRNA","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":22492279,"Description":"Mir-22 was originally identified in\u00a0HeLa\u00a0cells, but was later found to be ubiquitously expressed in various tissues. Our data indicate the potential of miR-22 as a novel prognostic biomarker for CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":377},{"Name":"EFEMP2","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Western Blot|Immunohistochemistry|ELISA","Usage":"DiagnosticBM","Pmid":22506683,"Description":"EGF-containing fibulin-like extracellular matrix protein 2\u00a0is a\u00a0protein\u00a0that in humans is encoded by the\u00a0EFEMP2\u00a0gene. The diagnostic accuracy of EFEMP2 was superior to the established CRC biomarker carcinoembryonic antigen evidenced by the area under the receiver operating characteristic curve for the two biomarkers were 0.923 and 0.728, respectively. These results indicated EFEMP2 is a promising serum biomarker for CRC early detection.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":378},{"Name":"Metallothionein, p53\u00a0","Molecular type":"Protein","Location":"Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":22516242,"Description":"Metallothioneins (MTs) are low-molecular-weight, cysteine-rich stress response proteins that are ubiquitously expressed at low levels in eukaryotes. In univariate analysis, patients with metallothionein(H)\/p53(-) phenotype showed a better overall survival (hazard ratio [HR], 2.83; P < .05) and disease-free survival (HR, 2.03; P < .05).\u00a0 Combined metallothioneins and p53 proteins expression as a prognostic marker in patients with Dukes stage B and C colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":379},{"Name":"FANCJ","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"qRT-PCR|Western blot|Immunohistochemistry","Usage":"PrognosticBM","Pmid":22526901,"Description":"FANCJ\u00a0is one of 14 Fanconi anemia (FA) genes in which mutations have been described in FA patients. Among patients who did not receive adjuvant chemotherapy, FANCJ expression was not correlated with RFS (P = 0.76). FANCJ could be a useful biomarker to predict the response to 5-FU and prognosis of CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":380},{"Name":"RalBP1","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"qRT-PCR|ELISA","Usage":"PrognosticBM|PredictiveBM","Pmid":22549157,"Description":"RalBP1\u00a0is a multifunctional membrane protein that has been implicated in cancer cell proliferation,11\u00a0radiation and chemoresistance,\u00a0and ligand dependent receptor internalization. Multivariate Cox regression analysis including sex, age, stage, grade, and nodal status as covariates showed that overexpression of RalBP1 protein, but not mRNA, was an independent predictor of both decreased disease free survival (p = 0.016, RR = 6.892) and overall survival (p = 0.039, RR = 5.986).\u00a0 RalBP1 represents a promising novel therapeutic target.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":381},{"Name":"S100P","Molecular type":"Protein","Location":"Rectum","Source":"Tissue","Assay\/Test":"Western blot|qRT-PCR","Usage":"PrognosticBM","Pmid":22552710,"Description":"S100 calcium-binding protein P (S100P), a member of S100 protein family, was first isolated from human placenta. The patients with normal serum levels of S100P showed favorable prognosis compared with patients with elevated S100P levels (P=0.008).\u00a0 S100P, a potential novel prognostic marker in colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":382},{"Name":"Cyclooxygenase-2 (COX-2)","Molecular type":"Protein","Location":"Colon","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":22553404,"Description":"It is an\u00a0enzyme\u00a0that in humans is encoded by the\u00a0PTGS2\u00a0gene. In univariate Kaplan-Meier survival analysis, there was a significant (P = 0.026) difference in disease-free survival between COX-2-positive and negative tumors in favor of the latter.\u00a0 COX-2 expression seems to provide useful prognostic information in CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":383},{"Name":"Nanog","Molecular type":null,"Location":null,"Source":"Tissue","Assay\/Test":"Western Blot|RT-PCR|Immunohistochemistry","Usage":"PrognosticBM","Pmid":22562535,"Description":"Nanog is a transcription factor critically involved in the self-renewal of undifferentiated embryonic stem cells, which has been verified to play an important role in maintaining pluripotency. In the Cox regression test, the histological grade, Lymph node metastasis, TNM stage, liver metastasis, and Nanog were detected as the independent prognostic factors (P = 0.02, 0.045, 0.01, 0.001 and 0.001, respectively). Nanog were detected as the independent prognostic factors.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":384},{"Name":"Rsf-1 (HBXAP)","Molecular type":"Protein","Location":"Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":22569540,"Description":"RSF1, also known as hepatitis B X-antigen associated protein (HBXAP), is a member of ATP-dependent chromatin remodelling factors that interact with sucrose non-fermenting protein 2 homologue to form a complex belonging to the ISWI chromatin remodelling family. High-expression of Rsf-1 emerged as an adverse prognosticator for diseases-specific survival (p=0.0092) and significantly predicted worse MeFS (p=0.0006).\u00a0 High-expression of Rsf-1 represents a potential prognostic biomarker in rectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":385},{"Name":"lysosome-associated protein transmembrane-4 beta (LAPTM4B)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Western blot|Immunohistochemistry","Usage":"PrognosticBM","Pmid":22578410,"Description":"This gene maps to 8q22.1, contains 7 exons and 6 introns, and encodes a member of the mammalian 4-tetratransmembrane spanning protein superfamily. The 5-year overall survival (OS) rates for patients with high and low LAPTM4B expression were 37.38% and 98.04%, respectively (hazard ratio = 22.774; 95% confidence interval [CI], 5.287-98.091; P < .0001). The 5-year disease-free survival rate was 21.15% for patients in the high-expression group and 91.82% for patients in the low-expression group (hazard ratio = 11.674; 95% CI, 3.562-38.263; P < .0001). Overexpression of LAPTM4B-35 is associated with poor prognosis in colorectal carcinoma.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":386},{"Name":"Leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5)","Molecular type":"DNA","Location":null,"Source":"Blood","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":22605983,"Description":"The leucine-rich repeat-containing G-protein-coupled receptor 5 (LGR5) also known as G-protein-coupled receptor 49 (GPR49), has been recently reported as a marker for stem cells (SC) in the small intestine and colon. LGR5 indicated a poor prognosis regarding both PFS (p = 0.007; HR, 1.013) and overall survival (p = 0.045; HR, 1.01). LGR5 indicated a poor prognosis regarding both PFS (p = 0.007; HR, 1.013) and overall survival (p = 0.045; HR, 1.01).","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":387},{"Name":"Matrix metalloproteinase-7 (MMP-7)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":22631636,"Description":"Matrix metalloproteinase-7 (MMP-7), also known as matrilysin, is the smallest member of matrix-degrading metalloproteinases (MMPs) which play important role in degradation of extracellular matrix (ECM). There is highly significant difference in overall survival rate between MMP-7 negative group and MMP-7 positive group (Log-rank test=9.957, p= 0.002). Expression and prognostic value of matrix metalloproteinase-7 in colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":388},{"Name":"Activating transcription factor 1 (ATF1)","Molecular type":null,"Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":22631637,"Description":"Activating transcription factor 1 (ATF1) belongs to the ATF\/CREB family of transcription factors, which represents a large group of basic region-leucine zipper (bZip) proteins. Patients with higher ATF1 expression levels have a significantly higher survival rate than that with lower expression (P = 0.026 for overall survival, P = 0.008 for progress free survival). Activating transcription factor 1 is a prognostic marker of colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":389},{"Name":"Amphiregulin (AR)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":22641668,"Description":"Amphiregulin, also known as AREG, is a protein that in humans is encoded by the AREG gene. Amphiregulin was found to be an independent predictor of overall survival [hazard ratio=6.25 (95% confidence interval=1.3-111.5; p=0.0144)] and relapse-free survival [hazard ratio=6.94 (95% confidence interval=1.5-123.2; p=0.0075)]. Amphiregulin is a prognostic factor in colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":390},{"Name":"Circulating tumor cells (CTCs)","Molecular type":null,"Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Tissue","Usage":"PrognosticBM","Pmid":22649166,"Description":"Circulating tumor cells (CTCs) are cells that have shed into the\u00a0vasculature\u00a0or\u00a0lymphatics from a primary\u00a0tumor\u00a0and are carried around the body in the circulation. The median\u00a0OS\u00a0time was also shorter for patients with a CTC count \u22653 than for patients with a lower count\u201417.7 months (95% CI, 12.6\u201323.1 months) versus 25.1 months (95% CI, 21.0\u201328.9 months (p\u00a0= .0059; HR, 1.64; 95% CI, 1.15\u20132.34). The CTC count is a strong prognostic factor for PFS and OS outcomes in metastatic colorectal cancer patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":391},{"Name":"Cyclooxygenase-2 (COX-2)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"RT-PCR|Western blot|Immunohistochemistry","Usage":"DiagnosticBM|PredictiveBM","Pmid":22710400,"Description":"Cox-2 is an inducible enzyme that converts arachidonic acid to prostaglandins.\u00a0 Cox-2 is a promising marker for the diagnosis of colorectal metastasis and a potential therapeutic target for colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":392},{"Name":"Girdin","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"RT-PCR|Immunohistochemistry","Usage":"PrognosticBM","Pmid":22714912,"Description":"Girdin is a novel protein that is found at the crossroad of G protein signaling and tyrosine kinase receptor signaling.\u00a0 After analyzing survival rates, cases with highly expressed Girdin protein were shown to attain a significantly higher rate of liver metastasis and poorer postoperative, disease-specific survival than those with no or low expressed Girdin protein (P = 0.001).\u00a0 The Girdin protein were detected as an independent prognostic factor","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":393},{"Name":"Kallikrein-related peptidase 6 (KLK6)","Molecular type":"Protein","Location":"Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":22727694,"Description":"Human\u00a0tissue kallikrein-related peptidase 6 (KLK6) belongs to the human\u00a0kallikrein gene\u00a0family of\u00a0serine proteases.\u00a0 The KLK6 positivity in lymph nodes with few tumour cells, that is, low CEA mRNA levels, also indicated poor prognosis (hazard ratio 2.8). Lymph node KLK6 positivity indicated presence of aggressive tumour cells associated with poor prognosis and high risk of tumour recurrence.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":394},{"Name":"CD133","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":22739652,"Description":"CD133 (prominin-1) is a five-transmembrane glycoprotein that was described initially as a surface antigen specific to human hematopoietic stem cells. Cytoplasmic CD133 expression level correlated significantly with tumor local recurrence (P = 0.025) and survival of patients with colorectal cancer (P = 0.002), and correlated inversely with tumor regression grading (P = 0.021) after CCRT in patients with rectal cancer. Cytoplasmic CD133 expression is a reliable prognostic indicator of tumor regression after neoadjuvant concurrent chemoradiotherapy in patients with rectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":395},{"Name":"JMJD2B","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Western blot|qRT-PCR|Immunohistochemistry","Usage":"PredictiveBM","Pmid":22745382,"Description":"Our findings suggest that JMJD2B may serve as a potential therapeutic cancer target","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":396},{"Name":"microRNA-92a (miR-92a)","Molecular type":"MicroRNA","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":22772712,"Description":"MiR-92a has been shown to be deregulated in several types of cancers, and upregulation of miR-92a correlates with worse prognosis. Kaplan-Meier analysis indicated that patients with high miR-92a expression had a poor overall survival (p\u2009=\u20090.001) MiR-92a may serve as a molecular prognostic marker for colorectal cancer and disease progression.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":397},{"Name":"MSP5","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":22773039,"Description":"MSP58\u00a0was first identified as a\u00a0nuclear protein\u00a0interacting with the proliferation-related nucleus protein\u00a0p120. The Kaplan-Meier survival analysis demonstrated that the survival time of CRC patients with low expression of MSP58 was longer than those with high expression during the 5-year follow-up period (P < 0.001). Our results demonstrated MSP58 might serve as a novel prognostic marker.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":398},{"Name":"Extracellular matrix metalloproteinase inducer (EMMPRIN)\u00a0","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Western blot|Immunohistochemistry","Usage":"PrognosticBM","Pmid":22782346,"Description":"Another key regulator of MMP activity in both stromal and tumour cells is the extracellular matrix metalloproteinase inducer (EMMPRIN\/CD147\/basigin), a\u00a0cell surface glycoprotein\u00a0belonging to the immunoglobulin superfamily. EMMPRIN\u00a0was also an independent prognostic factor for disease-specific survival (P=0.04; hazard ratio 2.3; 95% confidence interval (CI) 1.0\u20135.0; data not shown), but not statistically significant for overall survival (P=0.07; hazard ratio 1.5; 95%\u00a0CI 1.0\u20132.5). EMMPRIN is a promising prognostic biomarker in colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":399},{"Name":"WRAP53","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":22805008,"Description":"WRAP53\u00a0gene (for WD40-encoding RNA antisense to\u00a0p53) encodes a regulatory RNA essential for\u00a0p53\u00a0function upon DNA damage. Expression of WRAP53 in metastases gave a better outcome (p=0.02, RR, 0.32, 95% CI, 0.13-0.84), and an interaction analysis showed significance between the two groups (p=0.01). WRAP53 may be a new biomarker used to predict prognosis and to select suitable patients for preoperative radiotherapy.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":400},{"Name":"Insulin-like growth factor 2 messenger RNA binding protein 3 (IGF2BP3)\u00a0","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":22840368,"Description":"IGF2BP3\u00a0is expressed by a variety of malignant tumours including pancreatic, lung, oesophageal, thyroid, and gynaecological cancers, and\u00a0melanomas. IGF2BP3 positivity was significantly associated with shorter colorectal cancer-specific [log-rank p<0.0001; multivariate HR, 1.37; 95% confidence interval (CI), 1.02-1.84] and overall survival (log-rank p=0.0004; multivariate HR, 1.32; 95% CI, 1.05-1.66). Our findings support a role for IGF2BP3 as a diagnostic and\/or prognostic biomarker in colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":401},{"Name":"EPAS1","Molecular type":"Protein","Location":"Rectum","Source":"Blood","Assay\/Test":"RT-PCR","Usage":"PrognosticBM","Pmid":22848255,"Description":"EPAS1\u00a0encodes hypoxia inducible factor 2-\u03b1, an important angiogenic factor whose high expression in CRC was shown to play a significant role in tumor progression and to possess prognostic value. Patients with high levels of mRNA showed a 4-year DFS rate of 21.7% (95% CI 0.9\u201342.5), while patients with low levels showed a rate of 73.9% (95% CI 47.8\u201399.9) (p=0.028) Our results suggest that EPAS1 mRNA levels may be an indicator of poor prognosis in colorectal cancer patients at advanced stages.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":402},{"Name":"Phosphatase, tensin homolog (PTEN)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":22848291,"Description":"The role of the lipid phosphatase activity of\u00a0PTEN\u00a0as a negative regulator of the cytoplasmic\u00a0phosphatidylinositol-3-kinase\/Akt pathway is well known. PTEN may have potential as a prognostic marker in human CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":403},{"Name":"Phospho-ERK","Molecular type":null,"Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":22864777,"Description":"Colorectal cancer with wild-typeK-Ras and low phospho-ERK expression had a significantly higher survival rate (log-rank P = 0.04). Phospho-ERK may be a useful marker in combination with K-Ras for improving the prognosis of colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":404},{"Name":"XIAP (X-linked inhibitor of apoptosis)","Molecular type":null,"Location":"Rectum","Source":"Tissue","Assay\/Test":"Western Blot|Immunohistochemistry","Usage":"PrognosticBM","Pmid":22867709,"Description":"XIAP is a member of the\u00a0inhibitor of apoptosis\u00a0family of proteins (IAP). XIAP as a radioresistance factor and prognostic marker for radiotherapy in human rectal adenocarcinoma.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":405},{"Name":"MDM2 SNP309","Molecular type":"DNA","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":22914606,"Description":"An important oncoprotein regulator of p53, the Murine Double Minute2 (MDM2) which was frequently amplified in many cancers, suggesting a mechanism of increasing protein expression. Patients with overexpression of MDM2 had shorter survival compared with patients who had a negative expression of MDM2 (P = 0.002). Effects of\u00a0MDM2\u00a0SNP309\u00a0may be considered a valuable\u00a0prognostic\u00a0marker\u00a0to predict poor outcome for Tunisian patients with\u00a0colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":406},{"Name":"Melanoma antigen D1 (MAGED1) ","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Western blot|RT-PCR|Immunohistochemistry","Usage":"PrognosticBM","Pmid":22935435,"Description":"Melanoma antigen D1\u00a0(MAGED1), also known as Dlxin-1 or NRAGE, is a member of the type II\u00a0MAGE\u00a0family. Univariate and multivariate analyses indicated that MAGED1 expression was an independent prognostic factors (p\u2009<\u20090.001) MAGED1 may serve as a novel prognostic biomarker of human colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":407},{"Name":"RhoE","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Western Blot|Immunohistochemistry","Usage":"PrognosticBM","Pmid":22941156,"Description":"RhoE, an atypical Rho protein, is differently deregulated in some solid tumors, and there are conflicting data describing the role of RhoE in tumor cell migration and invasion.\u00a0 Patients with colorectal cancer with strong RhoE staining had a 6.78-fold higher risk of relapse than those with colorectal cancer with negative RhoE staining (95\u00a0% CI 4.31\u201311.15;\u00a0P\u00a0<\u00a00 0.001).\u00a0 RhoE is associated with relapse and prognosis of patients with colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":408},{"Name":"Matrix metalloproteinase-13 (MMP-13)\u00a0","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":22950625,"Description":"MMP-13 is a member of the matrix-degrading metalloproteinases (MMPs) which have the ability to selectively degrade specific ECM components including collagen fibers, elastin, laminin, gelatin and proteoglycan. The overall survival rate of the MMP-13-negative group was significantly higher than the positive group (Log-rank test\u2009=\u200912.452, p <\u20090.001). We found that MMP-13 was correlated with progression and metastasis of CRC and could be used as a prognostic marker in CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":409},{"Name":"Ras-like nuclear protein (Ran) ","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Western blot|Immunohistochemistry","Usage":"PrognosticBM","Pmid":22956174,"Description":"Ran is a small G protein belonging to the Ras superfamily of small guanosine triphosphatases (GTPases). Ran may play an important role in the development of CRC and may serve as a novel prognostic indicator of CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":410},{"Name":"Monocarboxylate transporter 4 (MCT4)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":22969839,"Description":"MCT4\u00a0is strongly expressed in highly glycolytic cells The survival rate of the patients who had negative\u00a0MCT4\u00a0expression was significantly higher than that of patients with positive\u00a0MCT4\u00a0expression (5-year survival rate, 88.2 vs. 55%, p=0.0001). positive MCT4 expression appears to be a useful marker for tumor progression and prognosis in patients with CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":411},{"Name":"Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6)","Molecular type":"Protein","Location":"Colon","Source":"Tissue","Assay\/Test":"RT-PCT|Luciferase reporter assay|Immunohistochemistry","Usage":"PrognosticBM|PredictiveBM","Pmid":22975528,"Description":"CEACAM6 is a single-chain glycosylphosphoinositol (GPI) anchored immunoglobulin (Ig)-like glycoprotein and is a member of the human CEA family. High expression levels of CEACAM6 were significantly associated with lower overall survival (p<0.001) and shorter recurrence-free survival (p<0.001). CEACAM6 is closely associated with poor prognosis, indicating that CEACAM6 might be a potential therapeutic target for colon cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":412},{"Name":"microRNA-144 (miR-144)","Molecular type":"MicroRNA","Location":null,"Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":22983984,"Description":"MiR-144\u00a0is a family of\u00a0microRNA\u00a0precursors found in\u00a0mammals, including\u00a0humans.\u00a0 Low expression levels of miR-144 were associated with enhanced malignant potential such as venous invasion (P = 0.0013), liver metastasis (P = 0.08), liver recurrence (P = 0.0058) and poor prognosis (P = 0.0041). MiR-144 is a meaningful prognostic marker","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":413},{"Name":"Autophagy-related gene 5 (ATG5)\u00a0","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry|Western blot","Usage":"DiagnosticBM|PrognosticBM","Pmid":22993366,"Description":"It is an E3\u00a0ubiquitin\u00a0ligase\u00a0which is necessary for\u00a0autophagy\u00a0due to its role in\u00a0autophagosome\u00a0elongation. The 5-year DFS and OS rates did not differ in relation to the ATG5 expression (ATG5 \u2013\u00a0vs.\u00a0+: DFS, 72.7%\u00a0vs.\u00a071.6%,\u00a0p=0.816; OS, 72.7%\u00a0vs.\u00a072%,\u00a0p=0.966). ATG5 could be a potential prognostic or diagnostic biomarker.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":414},{"Name":"microRNA-148a (miR-148a)","Molecular type":"MicroRNA","Location":null,"Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":23056401,"Description":"MiR-148a is frequently down-regulated in this disease, and this principally occurs through hypermethylation of its putative promoter region. In multivariate analysis, miR-148a expression was an independent prognostic\/predictive biomarker for advanced CRC patients (DFS in stage III, low vs. high expression, HR 2.11; OS in stage IV, HR 1.93). MiR-148a status has a prognostic\/predictive value in advanced CRC patients treated with conventional chemotherapy.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":415},{"Name":"NUCKS1","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"qRT-PCR|Immunohistochemistry","Usage":"PrognosticBM|PredictiveBM","Pmid":23065711,"Description":"Nuclear ubiquitous casein and cyclin-dependent kinases substrate\u00a0is a\u00a0protein\u00a0that in humans is encoded by the\u00a0NUCKS1\u00a0gene. Multivariate analysis indicated that overexpression of NUCKS1 is a significant prognostic factor of OS for patients with CRC (p\u00a0= 0.024; relative risk (RR) = 0.604; 95% confidence interval = 0.389\u20130.937). The overexpression of NUCKS1 in cancer cells could be used as a CRC prognostic marker and might also be a target for treatment of this disease.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":416},{"Name":"Integrin-linked kinase (ILK)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Western blot|Immunohistochemistry|RT-PCR","Usage":"PrognosticBM","Pmid":23108908,"Description":"Integrin-linked kinase (ILK) is a downstream substrate of the phosphoinositide 3-kinase (PI-3K) pathway located upstream of protein kinase B.\u00a0 Patients with tumors displaying high-level ILK expression showed significantly shorter overall survival (P = 0.028, log-rank test). Our data suggest that ILK overexpression may represent a novel potential prognostic marker for patients with CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":417},{"Name":"microRNA-429 (miR-429)","Molecular type":"MicroRNA","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Western blot|qRT-PCR","Usage":"PrognosticBM","Pmid":23111103,"Description":"MiR-429 is down-regulated and may function as a tumor suppressor by targeting c-myc and PLCG1 in gastric and breast cancers, respectively. Our data suggest for the first time that miR-429 could represent a novel prognostic biomarker for CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":418},{"Name":"Tumor necrosis factor receptor-associated protein 1 (TRAP1)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR|Western blot|Immunohistochemistry","Usage":"PrognosticBM","Pmid":23139614,"Description":"The protein encoded by this gene is a member of the\u00a0tumor necrosis factor receptor\u00a0superfamily, which also contains TNFRSF1B.\u00a0 Univariate and multivariate analyses indicated that TRAP-1 expression was an independent prognostic factor for recurrence and survival of CRC patients (Hazard ratio of 2.445 in recurrence, P = 0.017; 2.867 in survival, P = 0.028). Mitochondria TRAP-1 may be a potential biomarker for LNM and a prognostic factor in CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":419},{"Name":"Aquaporin5 (AQP5)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry|RT-PCR","Usage":"PrognosticBM","Pmid":23148732,"Description":"The aquaporins (AQPs) consist of a family of small membrane transport proteins.\u00a0 AQP5 expression was not significantly associated with the sex or age of the patient with colorectal cancer (P>0.05). AQP5 might be a novel prognostic biomarker for patients with colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":420},{"Name":"Leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5)","Molecular type":"DNA","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM|PredictiveBM","Pmid":23153436,"Description":"Lgr5, which is also known as GPR49, is a member of the\u00a0G-protein-coupled receptor\u00a0(GPCR) family of proteins and is a target of Wnt signaling. Multivariate analysis showed that the effect of Lgr5 on survival was independent of Ki-67 (P=0.037).\u00a0 These findings suggest that Lgr5 may be prognosis of colorectal carcinoma, and may be a potential new therapeutic target for the treatment of colorectal cancer patients","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":421},{"Name":"Deleted in liver cancer 2 (DLC2)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"RT-PCR|Western blot|Immunohistochemistry","Usage":"PrognosticBM","Pmid":23162637,"Description":"Deleted in\u00a0liver cancer\u00a02 (DLC2), also called STARD 13, has been identified as a tumor suppressor gene and is closely related to\u00a0deleted in liver cancer 1\u00a0(DLC1).\u00a0 Our results imply that DLC2 is be a potential prognostic marker for CRC patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":422},{"Name":"BRD7","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Western blot|Immunohistochemistry|RT-qPCR","Usage":"PrognosticBM","Pmid":23215825,"Description":"BRD7 is a member of bromodomain-containing protein and was found to be a cofactor of P53. Univariate and multivariate analyses indicated BRD7 expression was an independent prognostic factor (P\u00a0<\u00a00\u00b7001). BRD7 may serve as a potential prognostic biomarker of human colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":423},{"Name":"Matrix metalloproteinases (MMPs)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":23216739,"Description":"MMPs are zinc-dependent endopeptidases capable of degrading both BM and ECM proteins and extracellular adhesion molecules.\u00a0 In univariate analysis of Dukes' B tumours, MMP-9 negativity associated with poor survival (p\u2009=\u20090.018), and MMP-9 positivity was an independent prognostic marker in multivariate analysis of these tumours (p\u2009=\u20090.034). Negative MMP-9 expression can predict poor prognosis in Dukes' B colorectal tumours.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":424},{"Name":"EGFR, Her2","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"RT-qPCR|Western blot|Immunohistochemistry","Usage":"PrognosticBM","Pmid":23220854,"Description":"Univariate and multivariate analyses indicated that EGFR and Her2 expression were useful independent prognostic factor for recurrence and survival of CRC patients (P < 0.05). EGFR and Her2 might serve as a potential biomarker for LNM and a prognostic factor in CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":425},{"Name":"Ephrin-A1 (EFNA1)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry|qRT-PCR|Western blot","Usage":"PrognosticBM","Pmid":23258614,"Description":"EFNA1 was originally isolated as a secreted protein in conditioned media from cultures of human umbilical vein endothelial cells treated with tumor necrosis factor-\u03b1. EFNA1 was an independent prognostic factor for CRC (p<0.05). Ephrin-A1 mRNA is associated with poor prognosis of colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":426},{"Name":"Hepatitis A virus cellular receptor 1 (HAVcR-1)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"DiagnosticBM|PrognosticBM","Pmid":23267147,"Description":"Hepatitis A virus cellular receptor-1 (HAVcR-1), previously found to be located on mouse chromosome 11 and human chromosome 5q31-33, is associated with disease susceptibility. HAVcR-1 expression was increased in colorectal cancer (p<0.001) and the disease-free time of patients with high levels of HAVcR-1 expression was significantly longer (p=0.045).\u00a0 HAVcR-1 overexpression may be a diagnostic biomarker for colorectal cancer and a prognostic marker for a longer disease-free interval after surgery for colorectal cancer. ","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":427},{"Name":"Paxillin (PXN)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"RT-PCR|Immunohistochemistry|Western blot","Usage":"PrognosticBM","Pmid":23275153,"Description":"PXN\u00a0is a multidomain adaptor protein that integrates multiple signals from\u00a0cell surface receptors, integrins and growth factors. Multivariate analysis showed that\u00a0PXN\u00a0expression and\u00a0TNM\u00a0stage were independent prognostic factors for\u00a0CRC\u00a0patients (P\u00a0= 0.001 and 0.033, respectively). These results demonstrated that overexpression of PXN could serve as an independent prognostic indicator in CRC patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":428},{"Name":"microRNA-362-3p (miR-362-3p)","Molecular type":"MicroRNA","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"RT-qPCR|Western blot","Usage":"PrognosticBM","Pmid":23280316,"Description":"Four miRNAs (miR-362-3p, miR-570, miR-148 a* and miR-944) were expressed at a higher level in tumors from patients with no recurrence (p<0.015), compared with tumors from patients with recurrence. We conclude that miR-362-3p may be a novel prognostic marker in CRC,","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":429},{"Name":"Deleted in breast cancer 1 (DBC1) ","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry|qRT-PCR","Usage":"PrognosticBM","Pmid":23299276,"Description":"Deleted in breast cancer 1 (DBC1) was initially identified during a representative differential analysis searching for candidate breast tumor-suppressor genes which were homozygously deleted in human chromosome 8p21 in breast cancer.\u00a0 Univariate Cox regression suggested that DBC1 expression, poorly differentiation status and the presence of lymph node metastasis predict shorter overall survival in colorectal cancer (P < 0.05).\u00a0 These results suggest that DBC1 is over-expressed in colorectal cancer and that it might serve as a predictor for selecting patients at high risk of poor prognosis.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":430},{"Name":"Alpha 1-antitrypsin, the levels of mRNA expression of MMP7, COX-2, Upar","Molecular type":null,"Location":null,"Source":"Tissue","Assay\/Test":"qPCR","Usage":"DiagnosticBM","Pmid":23300952,"Description":"Those for which the ROC area was over 75% were MMP7 (0.81) and tetranectin (0.80), COX-2 (0.78), uPAR (0.78) and carbonic anhydrase (0.77).\u00a0 Serum alpha 1-antitrypsin and the levels of mRNA expression of MMP7, COX-2 and uPAR have good diagnostic accuracy for CRC, even in the early stages.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":431},{"Name":"SLIT2","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry|Western blot|qRT-PCR","Usage":"PrognosticBM","Pmid":23314850,"Description":"The SLIT2 gene is located on chromosome 4p15.2. SLIT2 exerts its activity by binding to its receptor ROBO1, which activates SLIT2-related cellular signaling. SLIT2 may be a potential clinical prognosis marker in colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":432},{"Name":"Telomere-specific reverse transcriptase (hTERT)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"RT-PCR","Usage":"PrognosticBM","Pmid":23322193,"Description":"hTERT\u00a0is the rate-limiting component of the telomerase complex and its expression, usually absent from normal somatic cells, is essential for unlimited cell growth. High hTERT levels identified patients with a higher risk of disease recurrence (HR=3.06 (95% CI 1.03-9.04), P=0.043) and death (HR=3.24 (95% CI 1.37-7.71), P=0.008). hTERT level is an independent prognostic marker of OS in CRC patients. ","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":433},{"Name":"AC133","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":23322518,"Description":"AC133 was originally generated to target the CD133 surface antigen.\u00a0 High AC133 expression was identified as a significant predictor for poor disease-free survival and overall survival at both univariate (p = 0.009, 0.013, respectively) and multivariate levels (p = 0.022, 0.026, respectively) AC133\u00a0expression associated with poor\u00a0prognosis\u00a0in stage II\u00a0colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":434},{"Name":"S-phase kinase-associated protein 2 (SKP2)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM|PredictiveBM","Pmid":23328995,"Description":"The S-phase kinase-associated protein 2 (SKP2) gene, located at chromosome 5p13, produces a substrate-recognizing E3 ubiquitin ligase and targets p27Kip1\u00a0for degradation by the 26S proteasome. High expression of SKP2 was correlated with the advanced Post-Tx nodal status (p = 0.002), Post-Tx International Union for Cancer Control stage (p = 0.002), and a lower-degree tumor regression grade (p < 0.001).\u00a0 SKP2 overexpression is associated with a poor prognosis of\u00a0rectal cancer\u00a0treated with chemoradiotherapy and represents a therapeutic target with high potential.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":435},{"Name":"Tropomyosin receptor kinases B, C (TrkB, C)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry|qRT-PCR","Usage":"DiagnosticBM|PredictiveBM","Pmid":23332094,"Description":"Members of the tropomyosin receptor kinase (Trk) family have a high affinity for neurotrophins and regulate neuronal survival.\u00a0 TrkB expression was associated with local progression (P = .0284), clinical stage (P = .0026), nodal metastasis (P = .0068), and peritoneal metastasis (P = .0026).\u00a0 These results suggest that TrkB and TrkC have a tumor progressive function and may be a useful diagnostic and therapeutic target in CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":436},{"Name":"TAZ","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Western blot","Usage":"PrognosticBM|PredictiveBM","Pmid":23372686,"Description":"TAZ\u00a0is structurally homologous to\u00a0YAP, is likewise inhibited by the Hippo pathway, and also promotes EMT-mediated cancer progression. By Cox-regression,\u00a0TAZ\u00a0mRNA expression is a predictor of survival in this cohort (HR\u200a=\u200a1.743, 95% CI\u200a=\u200a1.177\u20132.582,\u00a0p\u200a=\u200a0.006). These data suggest that TAZ could be a therapeutic target for the treatment of colon cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":437},{"Name":"Plastin-3 (PLS3)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":23378342,"Description":"Plastin3\u00a0(PLS3) codes for an actin-bundling protein known to inhibit cofilin-mediated depolymerization of actin fibers. The association between PLS3-positive CTC and prognosis was particularly strong in patients with Dukes B (HR = 4.07; 95% CI = 1.50-11.57) and Dukes C (HR = 2.57; 95% CI = 1.42-4.63).\u00a0 PLS3 is a novel marker for metastatic CRC cells, and it possesses significant prognostic value.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":438},{"Name":"Zinc finger E-box binding homeobox 1 (ZEB1) ","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"quantitative real-time RT-PCR","Usage":"PrognosticBM","Pmid":23420790,"Description":"Zinc finger E-box binding homeobox 1\u00a0(ZEB1) encodes a transcription factor that plays a key role in cancer progression by regulating EMT in breast, prostate, ovarian and\u00a0colorectal cancer. The overall survival rate was significantly lower in the patients with high\u00a0ZEB1\u00a0mRNA expression than in those with low expression (P=0.010). Our data indicate the potential of ZEB1 as a novel prognostic biomarker for CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":439},{"Name":"GATA-binding protein 2 (GATA2)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":23423786,"Description":"GATA-binding protein 2 (GATA2) is a nuclear transcription factor that plays a critical role in tumorigenesis.\u00a0 Univariate analysis showed high levels of GATA2 expression to be significantly associated with shorter periods of disease-free survival (HR 2.196; 95 % CI 1.142-4.226; P = 0.018). Multivariate analysis showed GATA2 expression to be an independent prognostic factor for patients with colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":440},{"Name":"TRIM28","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":23425061,"Description":"TRIM28, also known as KAP1 and TIF1\u03b2, is a universal co-repressor, mediating transcriptional control through interaction with Kr\u00fcppel associated box zinc finger proteins. Multivariate analysis showed that the epithelial to stromal TRIM28 expression ratio was an independent predictor of OS (hazard ratio=2.136; 95% confidence interval 1.015-4.498, P=0.046) and RFS (hazard ratio=2.100; confidence interval 1.052-4.191, P=0.035). A high TRIM28 expression ratio between stromal and epithelial compartments in colorectal cancer tissue is an independent predictor of poor prognosis. ","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":441},{"Name":"CCL18","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":23433718,"Description":"CCL18, also known as dendritic cells-chemokine, pulmonary and activation-regulated chemokine, and macrophage inflammatory protein 4, is a chemotactic cytokine that is expressed by a broad range of lymphocytes.\u00a0 Urvival analysis and multivariate analysis revealed that CCL18 was an independent favorable prognostic factor in patients with CRC (P = 0.033). A high CCL18 level might be an independent biomarker for predicting better survival of patients with CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":442},{"Name":"OV-6","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":23445514,"Description":"OV-6, recognized by a monoclonal antibody generated to target cells isolated from carcinogen-treated rat liver, is among the best available markers of liver stem cells. Disease-free survival and overall survival were significantly poorer in patients with high overall OV-6 expression than in those with low overall OV-6 expression (P\u00a0=\u00a00.015 and P\u00a0=\u00a00.029, respectively) OV-6 is not unique to the hepatobiliary system, and may be a novel prognostic marker in colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":443},{"Name":"microRNA-182 (miR-182)","Molecular type":"MicroRNA","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM|PredictiveBM","Pmid":23474644,"Description":"MiR-182 may play important roles in cancer tumorigenesis and progression and exert different effects in various types of cancer. Kaplan-Meier analysis demonstrated that high miR-182 expression predicted poor survival (p = 0.001). MiR-182 might be involved in colorectal cancer progression and could be used as a potential prognostic biomarker and therapeutic target in the management of colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":444},{"Name":"Annexin A2 (ANXA2","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"DiagnosticBM|PrognosticBM","Pmid":23489866,"Description":"Annexin A2 (ANXA2) is known to be a tumourigenic molecule and is highly expressed in colorectal cancer (CRC). Receiver operating characteristic (ROC) (AUC\u00a0=\u00a00.768, 95% CI\u00a0=\u00a00.642-0.894).ANXA2 expression (P < 0.001, HR = 1.445, 95% CI 1.222-1.709) were independent factors predicting recurrence. These results indicate that ANXA2 is a biomarker with diagnostic and prognostic potential for patients with CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":445},{"Name":"Kallikrein-related peptidase (KLK)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":23499583,"Description":"They are located in the chromosomal region 19q13.3\u2013q13.4 and they encode for 15 highly conserved trypsin- or chymotrypsin-like serine proteases. Patients with high KLK10 expression had a shorter disease-free and overall survival rates (P=0.014; P=0.020). Our results suggest that KLK10 may serve as a new marker of unfavourable prognosis of colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":446},{"Name":"BRCA1-associated protein 1 (BAP1)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"RT-PCR|Western blot|Immunohistochemistry","Usage":"PrognosticBM","Pmid":23526420,"Description":"BAP1 is a 91KD nuclear-localized deubiquitinating enzyme (DUB) and has been involved in various biological processes including chromatin dynamics. Multivariate analysis demonstrated that BAP1 expression was an independent prognostic factor for CRC (p = 0.037). BAP1 may serve as a novel prognostic biomarker for CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":447},{"Name":"Yes-associated protein (YAP) ","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":23558963,"Description":"YAP functions as a transcription co-activator interacting with the PPXY motif-containing protein. Univariate and multivariate analyses revealed that YAP expression was an independent prognostic indicator of CRC (p = 0.0207). YAP expression was an independent prognostic indicator of CRC","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":448},{"Name":"p53","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Western blot|RT-PCR","Usage":"PrognosticBM","Pmid":23571142,"Description":"The product of p53 is a nuclear phosphoprotein that regulates cell growth indirectly and inhibits cells with mutagenic damage from entering the S-phase by arresting the cell cycle in G1. In stage III cancers, high wt-p53 expression was associated with better survival than low wt-p53 expression in patients treated with adjuvant chemotherapy (p\u00a0= 0.005). Expression of p53 mRNA is a useful predictor of survival in patients with stage III or rectal cancers.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":449},{"Name":"P27 (Kip1)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":23574593,"Description":"The p27kip1 protein, a negative cellcycle regulator, belongs to the kinase inhibitor proteins(KIP) family and affects the cyclin E-CDK2 and cyclin A-CDK2 complexes required for G1\u00b1S transition  At multivariate analysis, N status, p27(kip1) expression, and intratumoural necrosis were independent risk factors for DFS. Absence of p27(kip1) expression is a useful marker of tumour aggressiveness in rectal carcinoma stages I-III, and an independent predictor for OS and DFS.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":450},{"Name":"Gankyrin","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry|qRT-PCR|ELISA","Usage":"PrognosticBM|PredictiveBM","Pmid":23576566,"Description":"Gankyrin\u00a0consists of 7 ankyrin repeats, which are required for protein\u2013protein interactions. Gankyrin may be a potential prognostic marker and therapeutic target of metastatic CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":451},{"Name":"Calcium activated chloride channel A1 (CLCA1)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Western blot|qPCR","Usage":"PrognosticBM","Pmid":23593331,"Description":"Chloride\u00a0channels (CLCs) form a large functional family with structurally diverse\u00a0members that play an important role in the regulation of epithelial fluid and electrolyte transport. CLCA1 may be a potential diagnostic marker for CRC prognosis.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":452},{"Name":"PLAC1\/CP1","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":23604623,"Description":"PLAC1\/CP 1, a new member of the CT family, encodes a 26-kDa protein primarily localized to both the nucleus and cytoplasm compartments of trophoblastic cells.\u00a0 These results show that the PLAC1\/CP1 antigen is a possible prognostic marker of CRC and that PLAC1\/CP1 p41-50.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":453},{"Name":"Spleen tyrosine kinase (Syk)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR|Westerm Blot|Immunohistochemistry","Usage":"PrognosticBM","Pmid":23609194,"Description":"Spleen tyrosine kinase (Syk) gene is widely expressed in various types of normal and tumor tissues and cancer cells Five-year overall survival in methylated Syk group was significantly lower than that in unmethylated Syk group (59 vs. 80 %, p < 0.001).\u00a0 Syk methylation is correlated with poor overall survival, which acts as an independent prognostic indicator of CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":454},{"Name":"Twist2","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":23613636,"Description":"Twist2\u00a0(Dermo1), a highly homologous protein of\u00a0Twist1, has attracted our attention. Multivariate analysis revealed that bad M-stage [hazard ratio (HR) = 7.694, 95%CI: 2.927-20.224, P < 0.001] and Twist2-positive (HR = 5.744, 95%CI: 1.347-24.298, P = 0.018) were the independent risk factors for poor overall survival (OS), while Twist2-positive (HR = 3.264, 95%CI: 1.455-7.375, P = 0.004), bad N-stage (HR = 2.149, 95%CI: 1.226-3.767, P = 0.008) and bad M-stage (HR = 10.907, 95%CI: 4.937-24.096, P < 0.001) were independently associated with poor disease-free survival (DFS). Twist2 is a valuable prognostic biomarker for colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":455},{"Name":"Cryptochrome 1 (Cry1)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR|Westerm Blot|Immunohistochemistry","Usage":"PrognosticBM|PredictiveBM","Pmid":23626715,"Description":"Cryptochrome 1 is a key regulator of the circadian feedback loop and plays an important role in organisms. High Cry1 expression was associated with poor overall survival in CRC patients (p\u200a=\u200a0.010). These results suggest that Cry1 may be a prognostic biomarker and a promising therapeutic target for CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":456},{"Name":"Carbonic anhydrase II (CA II)\u00a0","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"RT-PCR|Western blot|Immunohistochemistry","Usage":"DiagnosticBM","Pmid":23727877,"Description":"The\u00a0carbonic anhydrases\u00a0(or\u00a0carbonate dehydratases) form a family of\u00a0enzymes\u00a0that\u00a0catalyze\u00a0the rapid interconversion of\u00a0carbon dioxide\u00a0and\u00a0water\u00a0to\u00a0bicarbonate\u00a0and\u00a0protons\u00a0(or vice versa), a\u00a0reversible reaction\u00a0that occurs relatively slowly in the absence of a catalyst. These data suggest that CA II may be a potential biomarker for early diagnosis of CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":457},{"Name":"MPO+ cell infiltration","Molecular type":null,"Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":23734221,"Description":"Myeloperoxidase\u00a0(MPO) is a lysosomal enzyme produced in high amounts by neutrophilic granulocytes (NG), especially during their early maturation phase. MPO+ cell infiltration proved an independent prognostic marker overall (P\u200a=\u200a0.004; HR\u200a=\u200a0.65; CI:\u00b10.15) and in both training (P\u200a=\u200a0.048) and validation (P\u200a=\u200a0.036) sets. High density MPO+ cell infiltration is a novel independent favorable prognostic factor in CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":458},{"Name":"STAT3","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":23756862,"Description":"STAT3\u00a0activity is so far considered to be associated with elevated malignancy and invasive behaviour of\u00a0CRC\u00a0cells STAT3\u00a0expression were found significantly correlated with longer patients' overall survival (P=0.010\/P=0.020) We could show that STAT3 expression and activity constitutes an independent favourable prognostic marker for CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":459},{"Name":"Four-and-a-half LIM domains protein 2 (FHL2)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":23756870,"Description":"Four-and-a-half LIM domains protein 2 (FHL2) is a component of the focal adhesion structures and has been suggested to have a role in cancer progression. Multivariate Cox analysis shows that expression in the tumour invasion front (P<0.001) as well as in the centre of the tumour (P<0.001) was associated with metachronous metastases independently of the clinicopathological variables. FHL2 is an independent adverse prognostic indicator for CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":460},{"Name":"CCL21","Molecular type":null,"Location":null,"Source":"Tissue","Assay\/Test":"Western blot|Immunohistochemistry","Usage":"PrognosticBM","Pmid":23760102,"Description":"CCL21, known as 6Ckine\/SLC, is a CC-type chemokine with specificity to CCR7 receptors via a uniquely long C-terminal tail containing 32 amino acids. CCL21 expression was still found to have an impact on patient survival (OS, P=0.025; DFS, P=0.020). CCL21 as an independent favorable prognostic factor for stage III\/IV colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":461},{"Name":"Yes-associated protein (YAP),\u00a0transcriptional co-activator with PDZ-binding motif\u00a0(TAZ)","Molecular type":null,"Location":"Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry|qRT-PCR|Western blot","Usage":"PrognosticBM","Pmid":23762387,"Description":"Yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ) are nuclear effectors of the Hippo pathway. Expression of both\u00a0YAP\u00a0and\u00a0TAZ\u00a0were associated with significantly poor overall survival, with the adjusted HR being 3.118 (95% CI: 1.017\u20139.559;\u00a0P<0.001).\u00a0 Co-overexpression of YAP and TAZ is an independent predictor of prognosis for patients with CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":462},{"Name":"Leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5)","Molecular type":"DNA","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PredictiveBM","Pmid":23784051,"Description":"The leucine-rich repeat-containing G protein-coupled receptor 5 (Lgr5) is an adult intestinal stem cell marker frequently detected in human colorectal cancers (CRCs). High expression levels of Lgr5 were significantly associated with shorter disease-free survival (P\u2009<\u20090.001) and shorter cancer-specific survival (P\u2009=\u20090.007) in CRC patients. These results suggest that elevated Lgr5 level has the potential to serve as a therapeutic target in CRC patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":463},{"Name":"MUC20","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"RT-qPCR|Western blot|Immunohistochemistry","Usage":"PrognosticBM","Pmid":23787019,"Description":"Mucins\u00a0are large extracellular\u00a0glycoproteins\u00a0that are heavily glycosylated with complex oligosaccharides and are produced by epithelial cells. We further showed that MUC20 overexpression was correlated with recurrence and poor outcome (P\u2009<\u20090.05).\u00a0 MUC20 may serve as an important predictor of recurrence and poor outcome for CRC patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":464},{"Name":"Soluble a-proliferation-inducing ligand (sAPRIL)","Molecular type":"Protein","Location":null,"Source":"Blood","Assay\/Test":"ELISA","Usage":"DiagnosticBM","Pmid":23792260,"Description":"Area under the receiver-operating characteristic (ROC) curve for sAPRIL was 0.854 (95% CI, 0.776-0.933).\u00a0 The results indicated that serum sAPRIL had a positive diagnostic value for colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":465},{"Name":"Toll like receptor 4 (TLR4)","Molecular type":"Protein","Location":"Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":23799413,"Description":"TLR4\u00a0is a transmembrane protein, member of the\u00a0toll-like receptor\u00a0family, which belongs to the\u00a0pattern recognition receptor\u00a0(PRR) family. This same analysis also revealed that TLR4 expression by fibroblasts was a significant and independent factor associated with relapse-free survival [positive: 3.47 (1.75\u20136.88); P= 0.0001], as well as with overall survival [positive: 2.59 (1.25\u20135.47); P= 0.013]. TLR4 expression by fibroblasts could be a useful prognostic marker in CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":466},{"Name":"G-protein-coupled receptor 48 (GPR48)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM|PredictiveBM","Pmid":23803691,"Description":"G-protein-coupled receptor 48 (GPR48) is an orphan receptor belonging to the G-protein-coupled receptors family, which plays an important role in the development of various organs and cancer development and progression such as gastric cancer and colorectal cancer (CRC) Multivariate analysis revealed that GPR48 expression (\u00a0P\u00a0= 0.015, HR: 2.740, 95% CI: 1.219\u20136.158) and lymph node status (\u00a0P\u00a0< 0.001, HR: 4.080, 95% CI: 2.225\u20137.483) were independent prognostic factors that could affect the OS of CRC patients GPR48 could serve as both a prognostic biomarker and a therapeutic target for resectable CRC patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":467},{"Name":"Paired related homoeobox 1 (PRRX1)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"qRT-PCR|Immunoblotting","Usage":"PrognosticBM","Pmid":23807160,"Description":"Paired related homoeobox 1 (PRRX1) has been identified as a new epithelial-mesenchymal transition (EMT) inducer in breast cancer. Kaplan\u2013Meier disease-free survival curves for 226 patients with CRC (GSE 14333) according to\u00a0PRRX1\u00a0expression. *statistically significant (P\u2a7d0.05). PRRX1 is an indicator of metastasis and poor prognosis in CRC cases.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":468},{"Name":"Thymidylate synthase (TYMS)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"RT-qPCR|Western blot|Immunohistochemistry","Usage":"PrognosticBM","Pmid":23810585,"Description":"TYMS is a 74\u00a0kDa protein and forms a homodimer which catalyzes reductive methylation of deoxyuridine monophosphate (dUMP) to generate dTMP using a cofactor, CH2H4-folate. Univariate and multivariate analyses indicated that TYMS expression was an independent prognostic factor for recurrence and survival of CRC patients (P<0.05). TYMS effect on lymph node metastasis in CRC might serve as a potential biomarker for LNM and a prognostic factor in CRC. ","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":469},{"Name":"Podocalyxin-like 1 (PODXL)\u00a0","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM|PredictiveBM","Pmid":23819542,"Description":"Podocalyxin-like protein\u00a0(PODXL) is a\u00a0transmembrane glycoprotein\u00a0with anti-adhesive properties, first identified in the kidney where it plays a vital role in maintaining filtration pathways. PODXL expression in the primary tumour is sufficient for its use as a prognostic and treatment predictive biomarker in CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":470},{"Name":"S100A10","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR|Immunohistochemistry|Western blot","Usage":"PrognosticBM|PredictiveBM","Pmid":23828264,"Description":"S100 proteins constitute a family of intracellular calcium-binding proteins characterized by EF hand motifs. S100A10 positivity was significantly correlated with shortened specific [log-rank p < 0.001; multivariate hazard ratio (HR), 1.49; 95% confidence interval (CI), 1.09-2.04] and overall survival (log-rank p = 0.0012; multivariate HR, 1.34; 95% CI, 1.06-1.73). Our results suggest a role for S100A10 as a prognostic marker and potential therapeutic target in colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":471},{"Name":"G-protein-coupled receptor 120 (GPR120)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PredictiveBM","Pmid":23851494,"Description":"GPR120 was originally described as an orphan receptor before its endogenous ligands, poly-unsaturated long-chain free fatty acids (FFAs), were known. Our results demonstrate that GPR120 shows promise as a new potential target for cancer therapeutics.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":472},{"Name":"Carboxypeptidase E (CPE)-\u0394N","Molecular type":null,"Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR|Western blot","Usage":"PrognosticBM","Pmid":23852859,"Description":"Carboxypeptidase E (CPE), also known as carboxypeptidase H or enkephalin convertase, is a member of the metallocarboxypeptidase gene family. Patients with high CPE-\u0394N expression had a significantly shorter survival (P < 0.001, logrank test). We can conclude that CPE-\u0394N expression might be a potential prognostic marker for colorectal cancer patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":473},{"Name":"microRNA-625 (miR-625)","Molecular type":"MicroRNA","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM|PredictiveBM","Pmid":23861214,"Description":"The overexpression of miR-625 inhibits the proliferation and migration of gastric cancer cells, which suggests that this miRNA may act as a tumor suppressor in gastric cancer cells.\u00a0 The decreased expression of miR-625 was positively associated with advanced lymph node metastasis (P\u2009=\u20090.038), liver metastasis (P\u2009=\u20090.031), poor overall survival (P\u2009=\u20090.002) Our results suggest that miR-625 may serve as an efficient clinical biomarker and a therapeutic tool for the inhibition of metastasis in CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":474},{"Name":"N-myc downregulated gene 1 (NDRG1)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":23874544,"Description":"NDRG1\u00a0exerts its function through modulating the major signaling pathways in a large variety of tumor types including\u00a0CRC. NDRG1 was considered to be an independent prognostic factor for overall survival (p\u200a=\u200a0.001) and recurrence (p\u200a=\u200a0.003). Our study concludes that NDRG1 is a novel favorable predictor for the prognosis in CRC patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":475},{"Name":"Kininogen-1","Molecular type":"Protein","Location":null,"Source":"Blood","Assay\/Test":"Immunohistochemistry|ELISA","Usage":"DiagnosticBM","Pmid":23894665,"Description":"Kininogen-1\u00a0is a multifunctional protein that plays an important role in many pathophysiological processes. The area under the receiver operating characteristic curve (AUC) for serum kininogen-1 in the diagnosis of ACA was 0.635 (P=0.003), and for serum carcinoembryonic antigen (CEA) was 0.453 (P=0.358). The sensitivity, specificity of serum kininogen-1 for diagnosing Duke's stage A and B CRC was 70.13%, 65.88%, respectively. These results suggest that kininogen-1 is a potential serum biomarker for the early detection of advanced colorectal adenoma and CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":476},{"Name":"Claudin-1","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":23898096,"Description":"Claudin-1\u00a0is a\u00a0protein\u00a0that in humans is encoded by the\u00a0CLDN1\u00a0gene. Our study showed the significance of low expression of claudin-1 as a predictor of poor prognosis of colorectal cancer","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":477},{"Name":"DEK","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":23902796,"Description":"The\u00a0DEK gene, on chromosome 6, encodes\u00a0a 375-amino acid protein with an estimated molecular weight of 43kD. DEK\u00a0over expression emerged as a significant independent prognostic factor in\u00a0colorectal cancer\u00a0(HR: 1.805, 95% CI: 1.208\u20132.699, P=0.004). DEK is an independent poor prognostic factor of colorectal cancers.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":478},{"Name":"Hv1","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Western blot|Immunohistochemistry","Usage":"DiagnosticBM|PrognosticBM|PredictiveBM","Pmid":23940591,"Description":"Hv1\u00a0contains three predicted domains: N-terminal acid and proline-rich domain, transmembrane voltage-sensor domain (VSD), and C-terminal domain.\u00a0 Our results suggest that Hv1 may be used as a potential biomarker for diagnosis and prognosis of colorectal carcinoma, and a potential target for anticancer drugs in colorectal cancer therapy.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":479},{"Name":"T-box2 (TBX2)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"qRT-PCR|Western blot|Immunohistochemistry","Usage":"PrognosticBM|PredictiveBM","Pmid":23959449,"Description":"T-box2 (TBX2) is a member of the T-box family of transcription factors, which plays a critical role in embryonic development.\u00a0 TBX2 was a significantly prognostic factor for decreased survival and increased disease recurrence independent of tumor stage(II, III stage) and functioned as a biomarker to identify prognosis of patients with CRC (OS: HR 2.154; 95% CI 1.019-4.551; P = 0.044, DFS: HR 2.253; 95% CI 1.109-4.575; P = 0.025).\u00a0 TBX2 functioned as a biomarker to identify prognosis of patients with CRC. Furthermore, TBX2 could serve as a potential target of cancer drug therapy.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":480},{"Name":"microRNA-21  (miR-21)","Molecular type":"MicroRNA","Location":"Colon, Rectum","Source":"Blood","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":23970420,"Description":"MicroRNA-21 was elevated both in serum and tissue samples of patients with CRC. A Cox regression analysis identified miR-21 expression as an independent predictor of survival (P\u2009=\u20090.048). Our results suggest that circulating serum miR-21 is a promising prognostic marker for CRC prognosis.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":481},{"Name":"microRNA-200c (miR-200c)","Molecular type":"MicroRNA","Location":null,"Source":"Blood","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":23982750,"Description":"The five members of miR-200 are found in two clusters. In humans, miR-200a, miR-200b, and miR-429 are located on\u00a0chromosome 1\u00a0and miR-200c and miR-141 are on\u00a0chromosome 12. Serum miR-200c was an independent predictor for lymph node metastasis (odds ratio: 4.81, 95% confidence interval: 1.98-11.7, P = 0.0005) and tumor recurrence (hazard ratio: 4.51, 95% confidence interval: 1.56-13.01, P = 0.005) and emerged as an independent prognostic marker for CRC (hazard ratio: 2.67, 95% confidence interval: 1.28-5.67, P = 0.01). Serum miR-200c has strong potential to serve as a noninvasive biomarker for CRC prognosis and predicting metastasis.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":482},{"Name":"Protein tyrosine phosphatase 1B (PTP1B)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry|Quantitative RT-PCR|Western blot","Usage":"PrognosticBM","Pmid":23990346,"Description":"The protein tyrosine phosphatase 1B (PTP1B) is a classical non-transmembrane protein tyrosine phosphatase that is an important regulator of signaling pathways involved in human diseases such as obesity, diabetes, and cancer.\u00a0 Patients with higher expressions of PTP1B had the lower survival (P = 0.012).\u00a0 Our results suggest that PTP1B expression may serve as a valuable prognostic biomarker for CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":483},{"Name":"Slug, Vimentin","Molecular type":null,"Location":null,"Source":"Tissue","Assay\/Test":"RT-qPCR|Western blot|Immunohistochemistry","Usage":"DiagnosticBM|PrognosticBM","Pmid":24001454,"Description":"A significant correlation was observed between Slug and Vimentin expression in CRC (messenger RNA: \u03c1 = 0.546, protein: \u03c1 = 0.405). Slug and Vimentin expression as potential predictive biomarkers for identifying patients with lymph node metastasis or poor prognosis in CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":484},{"Name":"Maspin","Molecular type":"Protein","Location":"Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry|Western blot","Usage":"PrognosticBM","Pmid":24002600,"Description":"Maspin\u00a0(mammary\u00a0serine\u00a0protease\u00a0inhibitor) is a\u00a0protein\u00a0that in humans is encoded by the\u00a0SERPINB5gene. Immunohistochemical analysis of Maspin expression on tumour sections revealed that it was an independent predictor of time to recurrence (log-rank P=0.004) and CRC-specific survival (P=0.000) in stage III CRC. Maspin is a marker for early recurrence in primary stage III and IV colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":485},{"Name":"Interleukin 35 (IL-35)","Molecular type":null,"Location":null,"Source":"Blood","Assay\/Test":"Immunohistochemistry|ELISA","Usage":"PrognosticBM","Pmid":24040445,"Description":"Interleukin-35 (IL-35) is a heterodimeric cytokine composed of the\u00a0p35\u00a0subunit of IL-12 and the Epstein-Barr Virus (EBV)-induced gene 3 (EBI3) subunit identified in B lymphocytes based on its induction following EBV infection. Our data support that IL-35 could be a valuable biomarker for assessing CRC progression and prognosis in clinical settings.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":486},{"Name":"HS1-associated protein X-1 (HAX-1)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"RT-qPCR|Immunohistochemistry","Usage":"PrognosticBM|PredictiveBM","Pmid":24057929,"Description":"HS1-associated protein X-1 (HAX-1) is involved in a variety of important physiological and pathological processes including anti-apoptosis, cell migration, and endocytosis. The overall survival rate was significantly lower in patients with high HAX-1 expression compared to those with low expression (P\u2009<\u20090.001).\u00a0 HAX-1 might be an important marker for tumor progression and prognosis, as well as a potential therapeutic target of CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":487},{"Name":"P62\/sequestosome-1","Molecular type":null,"Location":null,"Source":"Tissue","Assay\/Test":"Western blot|RT-PCR|Immunofluorescence","Usage":"PredictiveBM","Pmid":24065390,"Description":"p62\/sequestosome-1 is a multifunctional adapter protein implicated in selective autophagy, cell signaling pathways, and tumorigenesis, and plays an important role at the crossroad between autophagy and cancer.\u00a0 p62 and autophagy will be therapy targets for the treatment of colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":488},{"Name":"Transmembrane protease\/serine 4 (TMPRSS4)","Molecular type":"Protein","Location":"Colon","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":24072509,"Description":"Transmembrane protease\/serine 4 (TMPRSS4), a member of the type II transmembrane serine protease family, is highly expressed in some human cancers and involved in the EMT regulation of cancer cells.\u00a0 Higher TMPRSS4 predicted shorter overall survival (OS) and disease-free survival (DFS) in CRC patients (P < 0.01, both). The findings in our study demonstrated the potential value of TMPRSS4 expression level as a prognostic biomarker for CRC patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":489},{"Name":"Inhibin \u03b2 A (INHBA)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":24085226,"Description":"Inhibin \u03b2 A (INHBA) is a member of the transforming growth factor \u03b2 (TGF-\u03b2) superfamily. Patients in the high expression group showed a poorer overall survival rate when compared to those in the low expression group (P<0.001). The present study suggests that INHBA is useful as a predictive marker for prognosis in CRC patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":490},{"Name":"Serpin B5","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Western blot|Co-IP|ELISA|Immunohistochemistry","Usage":"PrognosticBM","Pmid":24114705,"Description":"Serpin B5 is a candidate tumour suppressor and its function may be affected by protein interactions. Strong expression of serpin B5 was also associated with a reduced DFS (p = 0.001) and OS (p = 0.017).\u00a0 Strong expression of serpin B5 was associated with a worse prognosis in patients with CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":491},{"Name":"Topoisomerase-1 (TOPO1)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":24123038,"Description":"Type I topoisomerases\u00a0are\u00a0enzymes\u00a0that cut one of the two strands of double-stranded DNA, relax the strand, and reanneal the strand. Low TOPO1 expression was statistically favourably associated with overall survival (hazard ratio=0.55; p=0.041). Our data suggest the TOPO1 expression levels to be a prognostic marker in patients with mucinous CRC treated with FU. ","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":492},{"Name":"microRNA-32 (miR-32)","Molecular type":"MicroRNA","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry|Western blot|qRT-PCR","Usage":"PrognosticBM","Pmid":24123284,"Description":"MiR-32 may be a marker of poor prognosis in CRC patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":493},{"Name":"Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)","Molecular type":null,"Location":"Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":24127411,"Description":"DYNAMIC CONTRAST-ENHANCED (DCE) MRI is an in vivo method to characterize microcirculation in human neoplasias, as it assesses the extravasation of paramagnetic contrast agents such as gadolinium-chelates and can be applied to organs with little motion such as the breast, esophagus, or the rectum. A significant correlation was found between DCE-MRI parameter TTP and the expression of EGFR (P = 0.044). DCE-MRI data may constitute a prognostic indicator for lymph node and distant metastases in patients with rectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":494},{"Name":"DVL1","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"DiagnosticBM|PrognosticBM","Pmid":24129181,"Description":"Segment polarity protein dishevelled homolog DVL-1\u00a0is a\u00a0protein\u00a0that in humans is encoded by the\u00a0DVL1gene. Independent predictive value for liver metastasis in CRC patients (OR: 5.764; 95% CI: 2.588-12.837; p < 0.0001 on univariate analysis; OR: 3.768; 95% CI: 1.469-9.665; p = 0.006 on multivariate analysis).\u00a0 DVL1 could be a potential prognostic and predictive marker for CRC patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":495},{"Name":"Anaplastic lymphoma kinase (ALK)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"FISH|Immunohistochemistry|qRT-PCR","Usage":"PrognosticBM","Pmid":24129244,"Description":"Anaplastic lymphoma kinase\u00a0(ALK) is a tyrosine kinase that was first identified as part of chromosomal rearrangement as a fusion partner of nucleophosmin. Increased ALK gene copy number alteration was associated with poor prognosis (P=0.0135) ALK gene amplification is associated with poor prognosis in colorectal carcinoma.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":496},{"Name":"Fibroblast growth factor receptor 1 (FGFR1)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR|Western Blot|Immunohistochemistry","Usage":"PredictiveBM","Pmid":24135816,"Description":"FGFRs are encoded by 4 genes (FGFR1\u20134) and activated after ligand binding. They regulate downstream signaling pathways via two substrates,\u00a0FRS2\u00a0and phospholipase-C\u03b3. FGFR1 is a potential therapeutic target in a subset of CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":497},{"Name":"The dipeptidyl peptidase IV (DPPIV)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":24142639,"Description":"The\u00a0dipeptidyl peptidase IV\u00a0(DPPIV) gene family has garnered increasing interest due to its diverse functions related to pathogenesis of inflammatory, metabolic,\u00a0 Multivariate analysis showed that loss of DPP10 expression was an independent factor for poor patient prognosis (p=0.008). Dipeptidyl peptidase 10, a novel prognostic marker in colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":498},{"Name":"Dachshund homolog 1\u00a0(DACH1)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"qRT-PCR|Immunohistochemistry","Usage":"DiagnosticBM|PrognosticBM","Pmid":24149323,"Description":"Dachshund homolog 1\u00a0(DACH1), a homolog of\u00a0Drosophila dac\u00a0in human, is located in chromosome 13q22.\u00a0 DACH1 may serve as detective and prognostic marker in CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":499},{"Name":"microRNA-21 (miR-21)","Molecular type":"MicroRNA","Location":null,"Source":"Tissue","Assay\/Test":"Quantitative PCR|Western blot|ChIP","Usage":"PrognosticBM","Pmid":24149370,"Description":"MiR-21\u00a0is considered an oncomir; indeed, unlike other miRNAs, it is frequently upregulated in the majority of solid tumors. The best AUC value (>0.86,\u00a0P\u00a0< 0.01) for this group was obtained when\u00a0miR-21,\u00a0ITG\u03b24, and\u00a0PDCD4\u00a0genes were combined using logistic regression in a unique 3-gene prognostic assay MiR-21 could be exploited as a prognostic tool for CRC metastasis.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":500},{"Name":"microRNA-183 (miR-183)","Molecular type":"MicroRNA","Location":null,"Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":24150523,"Description":"MiR-183 is located on human chromosome 7 and has been implicated in key cellular functions such as apoptosis, proliferation, and tumorigenesis. Kaplan-Meier analysis indicated that patients with high miR-183 expression had a poor overall survival (P=0.002).\u00a0 MiR-183 may serve as a predictive biomarker for the prognosis or the aggressiveness of CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":501},{"Name":"Crohn's like lymphoid reaction (CLR)","Molecular type":null,"Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":24154855,"Description":"Quantitative evaluation of CLR density is a relevant prognostic indicator in CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":502},{"Name":"TP53","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Western blot","Usage":"PrognosticBM","Pmid":24158910,"Description":"In humans, the\u00a0TP53\u00a0gene is located on the short arm of\u00a0chromosome 17\u00a0(17p13.1). The frequencies of Pro72Pro (P\u2009=\u20090.0033) genotype and Ser47\/Pro72 (P\u2009=\u20090.00171) haplotype were significantly higher in patients as compared to controls.\u00a0 Elevated TP53 expression appears to be useful prognostic marker for CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":503},{"Name":"Bax-interacting factor-1 (Bif-1)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":24175288,"Description":"Bax-interacting factor-1\u00a0(Bif-1, also known as endophilin B1 and SH3GLB1), a member of the membrane curvature-driving endophilin family of proteins. Stratified multivariate analysis demonstrated that low Bif-1 expression was an independent indicator of poor prognosis (hazard ratio, 0.459; 95% confidence interval, 0.285-0.739; P = 0.001). This suggests that Bif-1 protein expression may be a useful prognostic marker in early-stage CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":504},{"Name":"Epidermal growth factor receptor (EGFR)\u00a0","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":24204699,"Description":"The\u00a0epidermal growth factor receptor\u00a0(EGFR), a target for treatment of advanced\u00a0colorectal cancer, belongs to a\u00a0transmembrane glycoprotein\u00a0of the ErbB tyrosine kinase receptor family.\u00a0 In multivariate analysis, EGFR+\/TATI+ was an independent prognostic factor of favourable prognosis (p<0.001). Concomitant positivity of EGFR and TATI\/SPINK1 predicts favourable prognosis in CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":505},{"Name":"Plastin-3 (PLS3)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"RT-qPCR|Immunocytochemical|Western blot","Usage":"PrognosticBM","Pmid":24217791,"Description":"Plastin-3\u00a0is a highly conserved\u00a0protein\u00a0that in humans is encoded by the\u00a0PLS3\u00a0gene\u00a0on the X chromosome. High expression of PLS3 in CTCs of TDB as well as peripheral blood was established as an independent prognostic factor of overall survival (p\u00a0<\u00a00.001). The aberrant expression of PLS3 contributes to a poor prognosis in CRC patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":506},{"Name":"Cadherin 12 (CDH12)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistological|qRT-PCR|Western blot","Usage":"DiagnosticBM|PrognosticBM|PredictiveBM","Pmid":24237488,"Description":"Cadherin 12\u00a0(CDH12), which encodes a type II classical cadherin from the cadherin superfamily, may mediate\u00a0calcium-dependent cell adhesion. CDH12 is expected to become a new diagnostic and prognostic marker and a novel target of the treatment of colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":507},{"Name":"microRNA-31 (miR-31)","Molecular type":"MicroRNA","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR|Western blot","Usage":"DiagnosticBM|PredictiveBM","Pmid":24242331,"Description":"High miR-31 expression was related to cancer-specific mortality [multivariate hazard ratio = 2.06, 95% confidence interval: 1.36-3.09, P = 0.0008] MiR-31 may be a promising diagnostic biomarker and therapeutic target in colon cancers.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":508},{"Name":"KRAS","Molecular type":"Protein","Location":null,"Source":"Blood","Assay\/Test":"qPCR","Usage":"PrognosticBM","Pmid":24263065,"Description":"KRAS also known as\u00a0V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog, is a\u00a0GTPase\u00a0that in humans is encoded by the\u00a0KRASgene. The median OS was 13.0 mo in pKRAS wt patients and 7.8 in pKRAS-mutated, (HR=2.26, P<0.0001). PFS was 4.6 and 2.7 mo, respectively (HR=1,69, P=0.01).\u00a0 Plasma KRAS status seems to hold important predictive and prognostic information.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":509},{"Name":"Bmal1","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry|Western blot","Usage":"PrognosticBM|PredictiveBM","Pmid":24277452,"Description":"The\u00a0Bmal1\u00a0gene, encodes the\u00a0Bmal1\u00a0protein, is a core component of the circadian\u00a0clock\u00a0in mammals. The overall survival of patients with colorectal cancer with high Bmal1 levels in their primary tumors was significantly longer than that of patients with low Bmal1 levels (27 vs. 19 months; P = 0.043).\u00a0 Bmal1 shows the potential as a novel prognostic biomarker and may represent a new therapeutic target in colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":510},{"Name":"microRNA-25 (miR-25)","Molecular type":"MicroRNA","Location":null,"Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":24293092,"Description":"MiR-25 is 22 nucleotides in length, is hosted by the minichromosome maintenance protein-7 (MCM7) gene and is transcribed as part of the mir-106b-25 polycistron. These results prove that miR-25 is an independent prognostic factor for patients with colorectal cancer. ","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":511},{"Name":"microRNA-30b (miR-30b)","Molecular type":"MicroRNA","Location":null,"Source":"Tissue","Assay\/Test":"RT-PCR|Western blot|Immunohistochemistry","Usage":"PrognosticBM|PredictiveBM","Pmid":24293274,"Description":"MiR-30b is a member of the miR-30 family, which may function as important regulators in human cancer. MiR-30b is a potential prognostic marker or therapeutic target for CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":512},{"Name":"microRNA-218 (miR-218)","Molecular type":"MicroRNA","Location":null,"Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":24294377,"Description":"MiR-218 is downregulated in various types of cancer. Patients with low miR-218 expression had shorter survival time than those with high miR-218 expression (P = 0.036). Decreased expression of miR-218 is associated with poor prognosis in patients with colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":513},{"Name":"Matrilysin-2 (MMP-26)\u00a0","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":24318970,"Description":"Matrilysin-2 (MMP-26) has been proved to play an important role during invasion and metastasis of some human solid tumor. It also provided the first evidence that matrilysin-2 expression was an independent prognostic factor for patients with colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":514},{"Name":"Carbonic anhydrase IX (CA9)\u00a0","Molecular type":"Protein","Location":"Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry|Western blot","Usage":"PrognosticBM","Pmid":24321995,"Description":"Carbonic anhydrase IX (CA9) catalyses the hydration of carbon dioxide to bicarbonate and protons, and in this way represents a linkage of metabolic processes and pH regulation. This study provides first evidence of CA9 expression in pulmonary metastases of CRC and suggests a role of CA9 as a prognostic marker.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":515},{"Name":"microRNA-133b (miR-133b)","Molecular type":"MicroRNA","Location":null,"Source":"Tissue","Assay\/Test":"qRT-PCR|Western blot","Usage":"PrognosticBM","Pmid":24330809,"Description":"MicroRNA-133b (miR-133b), which is a muscle-specific microRNA, has been reported to be downregulated in human colorectal carcinoma (CRC) when compared to adjacent non-tumor tissue.\u00a0 the AUC of\u00a0miR-133b\u00a0reached 0.8081 [95% confidence interval (CI): 0.6857-0.9306, P\u2009<\u20090.001], with a cut-off point of 77.42% sensitivity and 78.95% specificity. MiR-133b is a novel prognostic marker that participates in the progression of human colorectal cancer via regulation of CXCR4 expression.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":516},{"Name":"BIRC5 (Survivin)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Blood","Assay\/Test":"RT-qPCR","Usage":"DiagnosticBM|PrognosticBM","Pmid":24338523,"Description":"BIRC5 (Survivin), a key member of inhibitor of apoptosis family, has been shown in colorectal cancer (CRC) tumorigenesis and progress. ROC curve demonstrated an optimal cut-off value of 0.128, providing a sensitivity of 84.8% and a specificity of 80.0% for discriminating CRC from controls. Serum cell free BIRC5 mRNA is a promising non-invasive biomarker for diagnosis and prognosis of CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":517},{"Name":"AT-rich interactive domain 3A (ARID3A)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":24366420,"Description":"AT-rich interactive domain 3A (ARID3A) is a member of the ARID family of DNA-binding proteins.\u00a0 ARID3A expression was shown to be an independent predictor of better prognosis in CRC (HR\u00a00.653; 95\u00a0% CI 0.44\u20130.97;\u00a0p\u00a0=\u00a00.033) Our data suggested that strong expression of ARID3A may predict a good prognosis in patients with CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":518},{"Name":"Vasohibin-1","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Western blot|Immunohistochemistry|RT-PCR","Usage":"PrognosticBM","Pmid":24366689,"Description":"Vasohibin-1 is a member of Vasohibin protein family. The patients with high Vasohibin-1 expression had significantly worse overall survival (OS) and progression-free survival (PFS) than those with low Vasohibin-1 expression (OS: P\u00a0=\u00a00.001; PFS: P\u00a0=\u00a00.003). Vasohibin-1 might become a new biomarker and provide additional prognostic information in patients with colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":519},{"Name":"Free circulating DNA (FCDNA)","Molecular type":"DNA","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"RT-PCR","Usage":"PrognosticBM","Pmid":24380554,"Description":"This study shows that absolute quantification of FCDNA in CRC patients could have a prognostic value and could be used as potential tool for early detection of recurrences.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":520},{"Name":"S100P","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry|RT-PCR|Western blot","Usage":"PrognosticBM|PredictiveBM","Pmid":24381058,"Description":"S100P is a member of S100 family that impact on various both physically and pathologically cellular processes through its calcium-binding ability. S100P expression in patients with colorectal cancer (log-rank test, P = 0.153) These findings suggested that S100P could serve as a promising candidate for colorectal cancer marker, prognostic indicator, and therapeutic target.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":521},{"Name":"CXCR4","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"RT-PCR|Immunohistochemistry","Usage":"PrognosticBM","Pmid":24395653,"Description":"C-X-C chemokine receptor type 4\u00a0(CXCR-4) also known as\u00a0fusin\u00a0or\u00a0CD184 is a\u00a0protein\u00a0that in humans is encoded by the\u00a0CXCR4\u00a0gene. CXCR4 expression were found to be independent prognostic factors (P\u2009=\u20090.02, 0.045, 0.01, 0.001, and 0.001, respectively). CXCR4 as a novel predictive biomarker for metastasis and poor prognosis in colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":522},{"Name":"microRNA-449a (miR-449a)\u00a0","Molecular type":"MicroRNA","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qPCR","Usage":"PrognosticBM","Pmid":24396489,"Description":"MicroRNA-449a\u00a0(miR-449a) is an miRNA that has been previously identified in cancer studies.\u00a0 These results suggested that miR-449a is involved in the development of colorectal carcinoma and may be a potential prognosis indicator.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":523},{"Name":"TWIST1, SNAI1","Molecular type":null,"Location":"Colon","Source":"Tissue","Assay\/Test":"qRT-PCR|Immunohistochemistry","Usage":"PrognosticBM","Pmid":24402192,"Description":"High TWIST1 and SNAI1 mRNA expression was associated with poor overall survival according to the univariate analysis (P<0.01 and P=0.01, respectively) and the multivariate analysis (P=0.04 and P=0.04, respectively). TWIST1 and SNAI1 as markers of poor prognosis in human colorectal cancer are associated with the expression of ALDH1 and TGF-\u03b21.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":524},{"Name":"microRNA-429 (miR-429)","Molecular type":"MicroRNA","Location":null,"Source":"Tissue","Assay\/Test":"RT-qPCR|Immunochemistry|Luciferase|Western blot","Usage":"PredictiveBM","Pmid":24402783,"Description":"MiR-429 or Onecut2 is the important therapy target for CRC","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":525},{"Name":"The overexpressed in lung cancer-1 (OLC1)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":24403489,"Description":"The overexpressed in lung cancer-1 (OLC1) protein is overexpressed in a variety of human tumors. The 5-year overall survival (OS) rates in patients with strong-positive and weak OLC1 staining were 16.6% and 95.3%, respectively (p<0.0001). Over-expression of the overexpressed in lung cancer-1 is associated with poor prognosis in colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":526},{"Name":"Golgi phosphoprotein 3 (GOLPH3)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR|Immunohistochemistry","Usage":"PrognosticBM","Pmid":24444035,"Description":"Golgi phosphoprotein 3\u00a0(GOLPH3) was initially identified as a Golgi membrane protein.\u00a0 High GOLPH3 expression was significantly associated with prolonged disease-free survival (DFS, P = 0.002) and overall survival (OS, P = 0.011) in patients who received 5-FU-based adjuvant chemotherapy. Our results suggest that\u00a0GOLPH3\u00a0is associated with prognosis in\u00a0CRC\u00a0patients treated with postoperative\u00a05-FU-based adjuvant chemotherapy.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":527},{"Name":"hMOF","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"RT-PCR|Western blot|Immunohistochemistry","Usage":"DiagnosticBM","Pmid":24452485,"Description":"hMOF (hMYST1), a member of the MYST family of HATs, is responsible for histone H4K16ac. Our results suggest that downregulation of hMOF may be common in cancer tissues, and may represent a novel biomarker for tumor diagnosis.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":528},{"Name":"ncRAN (non-coding RNA expressed in aggressive neuroblastoma) ","Molecular type":"RNA","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"RT-qPCR","Usage":"PrognosticBM|PredictiveBM","Pmid":24519959,"Description":"These results suggest that ncRAN might represent a novel prognostic indicator, a biomarker for the early detection of metastasis and a target for gene therapy in CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":529},{"Name":"microRNA-126 (miR-126)","Molecular type":"MicroRNA","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR|Western blot|Immunohistochemistry","Usage":"PrognosticBM","Pmid":24532280,"Description":"MiR-126 is frequently downregulated in a variety of malignancies and acts as a potential tumor suppressor. Low expression of microRNA-126 is associated with poor prognosis in colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":530},{"Name":"Thymine DNA glycosylase (TDG)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Western blot|RT-PCR|ChIP","Usage":"PredictiveBM","Pmid":24532795,"Description":"G\/T mismatch-specific thymine DNA glycosylase is an enzyme that in humans is encoded by the TDG gene. Several bacterial proteins have strong sequence homology with this protein. These results suggest that TDG warrants consideration as a potential biomarker for CRC and as a target for CRC treatment.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":531},{"Name":"HLA class II antigen","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry|qRT-PCR","Usage":"PrognosticBM","Pmid":24563618,"Description":"HLA class II antigens are also expressed in a variety of malignant tumors of different embryological origin.\u00a0 HLA class II antigen expression in CRC tumors is a favorable prognostic marker.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":532},{"Name":"Secretoglobin, family 2A, member 1 (SCGB2A1)\u00a0","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Microarray","Usage":"PrognosticBM","Pmid":24585249,"Description":"Mammaglobin-B\u00a0also known as\u00a0secretoglobin family 2A member 1\u00a0is a\u00a0protein\u00a0that in humans is encoded by the\u00a0SCGB2A1\u00a0gene. The DFS was significantly associated with the depth of invasion (p=0.0082), lymph node metastasis (p<0.0001), histological grade (p=0.0193), vessel invasion (p=0.0001) and the expression of SCGB2A1 (p<0.0001). These results indicated that SCGB2A1 represented a novel, prognostic factor for CRC, and that expression of SCGB2A1 correlated with chemoresistance, radioresistance and cancer cell stemness.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":533},{"Name":"Fusobacterium nucleatum (Fn)","Molecular type":null,"Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"DiagnosticBM|PrognosticBM","Pmid":24599709,"Description":"Fn is a highly invasive, Gram-negative anaerobic bacterium and part of the oral and gut commensal flora. CRC patients with low Fn levels had a significantly longer overall survival time than patients with moderate and high levels of the bacterium (p\u2009=\u20090.008).  Our results highlight the potential of Fn detection as a diagnostic and prognostic determinant in CRC patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":534},{"Name":"Cysteine-rich angiogenic inducer 61 (CYR61)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Western blot|Immunohistochemistry","Usage":"PrognosticBM","Pmid":24606730,"Description":"Cysteine-rich 61 (Cyr61), a member of the CCN protein family, possesses diverse functionality in cellular processes such as adhesion, migration, proliferation, and survival.\u00a0 The duration of survival was significantly lesser in patients with Cyr61 high expression than in patients with Cyr61 low expression (p = 0.001). Cyr61 expression is associated with prognosis in patients with colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":535},{"Name":"Leukocyte RTL","Molecular type":"DNA","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"RT-PCR","Usage":"PrognosticBM","Pmid":24608194,"Description":"patients with short RTL in the testing set also showed worse OS and RFS than those with long RTL (P = 0.007 and P = 0.020, respectively).  Our study for the first time demonstrates that leukocyte RTL is an independent prognostic marker complementing TNM stage and associated with the immune functions in CRC patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":536},{"Name":"microRNA-214 (miR-214)","Molecular type":"MicroRNA","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM|PredictiveBM","Pmid":24616020,"Description":"MiR-214\u00a0is a vertebrate-specific family of\u00a0microRNA\u00a0precursors. The ~22\u00a0nucleotide\u00a0mature miRNA sequence is excised from the precursor hairpin by the enzyme\u00a0Dicer. MiR-214 may serve as a potential marker to predict survival, and the miR-214-FGFR1 axis may be a therapeutic target in CRC patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":537},{"Name":"microRNA-210 (miR-210)","Molecular type":"MicroRNA","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR|Western blot|Luciferase","Usage":"PrognosticBM","Pmid":24632577,"Description":"MiR-210\u00a0may act as an oncogenic miRNA and is associated with a poor prognosis in some human epithelial cancers. The results showed that overall survival was significantly related to the\u00a0miR-210\u00a0expression level (RR\u200a=\u200a2.621; 95% CI, 1.457\u20134.712;\u00a0P\u200a=\u200a0.001)\u00a0 Hypoxia-inducible MiR-210 is an independent prognostic factor and contributes to metastasis in colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":538},{"Name":"Lipocalin-2 (Lcn-2)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Western blot|Immunohistochemistry","Usage":"PrognosticBM","Pmid":24682311,"Description":"Lcn-2 was first identified as a gene that is rapidly induced during SV40 tumor virus-triggered mitosis in quiescent primary murine kidney cells.\u00a0 Survival analysis according to the Kaplan-Meier method revealed a significant association between Lcn-2 overexpressing tumors and overall survival (p < 0.001) and disease-free survival (p < 0.001). Our data provide evidence that Lcn-2 expression is up-regulated with tumor progression and was found to be a predictor of overall survival.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":539},{"Name":"Immunoscore","Molecular type":null,"Location":"Rectum","Source":"Tissue","Assay\/Test":"Microarray","Usage":"PrognosticBM","Pmid":24691640,"Description":"The densities of CD3(+) and CD8(+) lymphocytes and the associated Immunoscore (from I0 to I4) were significantly correlated with differences in disease-free and overall survival (HR, 1.81 and 1.72, respectively; all P < 0.005). The Immunoscore could be a useful prognostic marker in patients with rectal cancer treated by primary surgery.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":540},{"Name":"Lemur tyrosine kinase-3 (LMTK3)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":24695631,"Description":"Lemur tyrosine kinase-3 (LMTK3) is a member of the serine-threonine-tyrosine kinases family. These results suggest that LMTK3 protein could serve as a prognostic marker for CRC patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":541},{"Name":"P21, CD166","Molecular type":null,"Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":24708484,"Description":"high p21 expression level at the pre-treatment biopsy was significantly associated with poor DFS (p\u2009=\u20090.001, HR 6.14; 95% CI 2.03, 18.55). High CD166 expression level at the pretreatment biopsy was also associated with poor DFS (p\u2009=\u20090.003; HR 5.61; 95% CI 1.81, 17.35). These show high p21 and CD166 expression at the pretreatment biopsy were associated with tumor regression and poor prognosis in patients treated with 5-FU based CRT","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":542},{"Name":"Colon cancer-specific antigen-2 (CCSA-2)","Molecular type":null,"Location":null,"Source":"Blood","Assay\/Test":"Enzyme-linked immunosorbent assay(ELISA)","Usage":"DiagnosticBM|PrognosticBM","Pmid":24710115,"Description":"Serum CCSA-2, at the cut-off point of 64.10 ng\/mL, had a sensitivity of 98.10% and a specificity of 97.90% Serum CCSA-2 not only may be a potential biomarker using in screening and surveillance of CRC, but also may be an independent prognostic marker for CRC patients. ","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":543},{"Name":"Nucleolin","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Immunofluorescence|Fluorescence-activated cell-sorting (FACS)|Immunohistochemistry","Usage":"PredictiveBM","Pmid":24713430,"Description":"Nucleolin\u00a0is a\u00a0protein\u00a0that in humans is encoded by the\u00a0NCL\u00a0gene. This indicates that nucleolin may be a novel cancer therapy target and a predictive marker for tumor migration in colorectal carcinoma","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":544},{"Name":"Notch3","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":24728738,"Description":"Neurogenic locus notch homolog protein 3 is a protein that in humans is encoded by the NOTCH3 gene. Coexpression of nuclear Notch1 and Notch3 had an additive effect toward poorer dRFS compared with a negative subtype (HR\u00a0=\u00a02.48; 95\u00a0% CI, 1.41-4.40; P\u00a0=\u00a00.0019). Nuclear Notch3 expression might be a novel predictive marker for recurrence in Stage II and III CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":545},{"Name":"microRNA-20a (miR-20a)","Molecular type":"MicroRNA","Location":null,"Source":"Tissue","Assay\/Test":"qPCR|Western blot","Usage":"PrognosticBM","Pmid":24737193,"Description":"high miR-20a expression was a significant independent predictor of low survival rates of patients with CRC (P=0.045) in addition to the presence of lymph node metastasis (P=0.025) and distant metastasis (P<0.001) MiR\u201120a is an independent prognostic factor in colorectal cancer and is involved in cell metastasis.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":546},{"Name":"Interleukin-like EMT inducer (ILEI)","Molecular type":null,"Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":24738665,"Description":"ILEI overexpression was associated significantly with T-stage, N-stage, TNM stage and EMT phenotype (P = 0.024, <0.001, <0.001 and <0.001, respectively). ILEI is an independent predictive factor associated with poor prognosis in CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":547},{"Name":"Protocadherin 10 (PCDH10)","Molecular type":"Protein","Location":"Colon","Source":"Tissue","Assay\/Test":"RT-PCR","Usage":"PrognosticBM","Pmid":24740680,"Description":"Protocadherin 10 (PCDH10), a novel tumor suppressor gene in human cancers, is located in a common deleted region at chromosome 4q28 in colorectal cancer (CRC). The genetic aberration was significantly associated with tumor progression and distant metastasis (p\u2009=\u20090.021 and p\u2009=\u20090.018, respectively) and was an independent predictor of poor survival for CRC patients (p\u2009=\u20090.005).\u00a0 The genetic deletion of PCDH10 represents an adverse prognostic marker for the survival of patients with CRC","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":548},{"Name":"Leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5)","Molecular type":"DNA","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry|qRT-PCR","Usage":"PrognosticBM","Pmid":24751002,"Description":"Leucine-rich repeat-containing G-protein coupled receptor 5\u00a0(LGR5) also known as\u00a0G-protein coupled receptor 49\u00a0(GPR49) or\u00a0G-protein coupled receptor 67\u00a0(GPR67) is a\u00a0protein\u00a0that in humans is encoded by the LGR5\u00a0gene. patients with low level of Lgr5 expression had significantly longer survival time than patients with high level of Lgr5 expression (log-rank test, P = 0.039).  These results suggest that elevated Lgr5 expression might contribute to the development and progression of CRC, and it could also be used a potential unfavorable prognostic biomarker for CRC. ","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":549},{"Name":"Sirt7","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Quantitative reverse transcription PCR|Western blot|Immunohistochemistry","Usage":"PrognosticBM","Pmid":24771643,"Description":"Sirt7, as a member of this family, is frequently overexpressed in certain carcinomas, but the oncogenic mechanism is seldom reported. In this study, The Sirt7 protein level significantly correlated with tumor stage (P = 0.029), lymph node metastasis (P = 0.046), and poor patient survival (P < 0.05).  Our findings suggest that Sirt7 plays an important role in the development and progression of human colorectal cancer and functions as a valuable marker of colorectal cancer prognosis.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":550},{"Name":"Aldh1, Survivin,, EpCAM","Molecular type":null,"Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Microarrays","Usage":"PrognosticBM","Pmid":24786601,"Description":"Hazard ratios ranged up to 8.3 for overall survival (P<0.001), 36.6 for disease-specific survival (P<0.001), and 27.1 for distant recurrence-free survival (P<0.001). Our data identified combined expression levels of Aldh1, Survivin, and EpCAM as strong independent prognostic factors, with high hazard ratios, for survival and tumour recurrence in colon cancer patients, and therefore reflect tumour aggressiveness.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":551},{"Name":"Tescalcin (TESC)","Molecular type":"DNA","Location":"Colon","Source":"Tissue","Assay\/Test":"RT-PCR","Usage":"DiagnosticBM","Pmid":24811141,"Description":"TESC\u00a0is an autosomal gene that is differentially expressed in mammalian tissues, with high expression in embryonic gonads, in adult mouse heart, brain, stomach, and testis, and in mouse and human primary hematopoietic progenitor cells and cell lines. the area under the curve for serum\u00a0TESC\u00a0was 0.826 for patients with\u00a0CRC\u00a0(95% CI, 0.753-0.899) and the cut-off point was 1.945 ng\/ml. The sensitivity of the ROC curves for\u00a0TESC\u00a0was 94% and the specificity was 54%. TESC is a potential diagnostic marker and oncotarget in colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":552},{"Name":"RAC1b","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"RT-PCR","Usage":"PrognosticBM","Pmid":24833563,"Description":"RAC1b, a RAC1 spliced variant, is over-expressed in colorectal cancer (CRC), and impairs apoptosis by activation of nuclear-factor-KB. RAC1b overexpression was a poor survival factor for OS (HR, 2.35; 95% CI, 1.2-4.59; p=0.01) and progression-free survival (PFS) (HR, 2.4; 95% CI, 1.2-4.78; p=0.01) in KRAS\/BRAF WT mCRC patients. RAC1b overexpression constitutes a marker of poor prognosis in KRAS\/BRAF WT mCRC patients treated with first-line FOLFOX\/XELOX therapy.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":553},{"Name":"LMO1","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"RT-qPCR|Immunohistochemistry|Western blot","Usage":"PredictiveBM","Pmid":24845030,"Description":"Rhombotin-1 is a protein that in humans is encoded by the LMO1 gene. LMO1 encodes a cysteine-rich, two LIM domain transcriptional regulator. LMO1 is a commonly activated tumor promoter that activates AKT signaling in CRC and a new predictive marker for targeted therapy.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":554},{"Name":"Tafazzin (TAZ)","Molecular type":"Protein","Location":"Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":24858921,"Description":"Tafazzin protein\u00a0(TAZ) is encoded by the\u00a0TAZ\u00a0gene functions as a phospholipid-lysophospholipid transacylase. strong TAZ expression in biopsy was related to distant recurrence, independent of gender, age, stages and grade (p\u200a=\u200a0.043, HR, 6.160, 95% CI, 1.063-35.704). Strong expression of TAZ protein seems to be related to rectal cancer development and RT response, it can be a predictive biomarker of distant recurrence in patients with preoperative RT.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":555},{"Name":"CD133","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":24864242,"Description":"CD133 antigen\u00a0also known as\u00a0prominin-1\u00a0is a\u00a0glycoprotein\u00a0that in humans is encoded by the\u00a0PROM1gene. Patients with higher level of CD133 staining in CRC had longer disease free interval (Cox-Mantel P = 0.0244), whereas we found no relation between CD44 expression and overall survival or disease free interval.\u00a0 We have shown that CD133, generally considered to be a negative marker, can bear also clinically positive prognostic information in group of patients with colorectal liver metastases.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":556},{"Name":"Astrocyte elevated gene-1 (AEG-1)","Molecular type":"DNA","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry|Western blot","Usage":"PrognosticBM","Pmid":24874474,"Description":"The oncogene, astrocyte elevated gene-1 (AEG-1, also known as Metadherin (MTDH), and LYRIC) was originally identified and cloned by subtraction hybridisation as a human immunodeficiency virus-1 (HIV-1)-inducible gene in human fetal astrocyte. High AEG-1 expression in the primary tumour of the patients treated with RT correlated independently with higher risk of distant recurrence (P=0.009) and worse disease-free survival (P=0.007).  AEG-1 expression is an independent prognostic factor in rectal cancer patients with preoperative radiotherapy: a study in a Swedish clinical ","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":557},{"Name":"Urokinase-type plasminogen activator receptor (uPAR)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Immunoperoxidase|Immunohistochemistry","Usage":"PrognosticBM","Pmid":24889870,"Description":"The\u00a0urokinase-type\u00a0plasminogen\u00a0receptor (uPAR) is of particular importance for this process, as receptor binding is a prerequisite for pericellular plasmin formation, which is required for tissue remodeling during cancer invasion. including clinical covariates and soluble uPAR(I), the latter was significantly associated to overall survival (HR = 2.68 [95% CI: 1.90-3.79, P < 0.0001]) and uPAR-positive macrophages in the tumor core remained significantly associated to overall survival (HR = 1.81 [95% CI: 1.08-3.01, P = 0.023]). Urokinase-type plasminogen activator receptor (uPAR) on tumor-associated macrophages is a marker of poor prognosis in colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":558},{"Name":"AMP-activated protein kinase (AMPK)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":24892446,"Description":"AMPK is a heterotrimeric serine\/threonine protein kinase, and is activated following its phosphorylation by its upstream kinase liver kinase B1 (LKB1) in response to an increase in cellular AMP\/ATP ratio. Low pAMPK levels were associated with worse OS (P-value 0.0002) but not with PFS, whereas low pACC levels were associated both with worse OS and PFS (P-value 0.0007 and 0.01, respectively). Our findings suggest that high tissue AMPK activation is a prognostic biomarker in this cohort of metastatic colorectal cancer patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":559},{"Name":"\u03b2-Catenin, E-Cadherin","Molecular type":null,"Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":24904831,"Description":"Prognostic Significance of \u03b2-Catenin, E-Cadherin, and SOX9 in Colorectal Cancer: Results from a Large Population-Representative Series","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":560},{"Name":"RP11-462C24.1","Molecular type":"LncRNA","Location":null,"Source":"Tissue","Assay\/Test":"Quantitative RT-PCR","Usage":"PrognosticBM","Pmid":24908062,"Description":"RP11-462C24.1, which could be a biomarker for\u00a0CRC, for the analysis of association between its expression and clinical characteristics and association between its expression and patients\u2019 survival. patients with low expression of RP11-462C24.1 had a poor disease-free survival (P < 0.001). Low expression of novel lncRNA RP11-462C24.1 suggests a biomarker of poor prognosis in colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":561},{"Name":"Vascular endothelial growth factor 1\/Fms-like tyrosine kinase 1 (VEGFR1\/Flt-1)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":24908415,"Description":"Vascular endothelial growth factor 1\/Fms-like tyrosine kinase 1 (VEGFR1\/Flt-1) regulates monocyte migration, recruits endothelial cell progenitors, increases the adhesive properties of natural killer cells and induces of growth factors. Flt-1 overexpression was an independent predictor of positive margin status, positive lymphovascular invasion and local disease recurrence (p\u2009<\u20090.001, p\u2009<\u20090.001 and p\u2009=\u20090.003, respectively). Flt-1 was not associated with survival (log-rank\u2009=\u20090.003, p\u2009=\u20090.959). Expression profiling of Flt-1 seems to have a prognostic potential in CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":562},{"Name":"Ephrin type-B receptor 6 (EphB6)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry|quantitative RT-PCR","Usage":"PrognosticBM","Pmid":24912672,"Description":"Ephrin type-B receptor 6\u00a0is a\u00a0protein\u00a0that in humans is encoded by the\u00a0EPHB6\u00a0gene The patients with lymph node metastasis had a worse prognosis independently of gender, age, tumor site, stage and differentiation (RR = 0.404, CI 0.267-0.213, P < 0.001) EphB6 may represent a novel, useful tissue biomarker for the prediction of survival rate in CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":563},{"Name":"Heme oxygenase-1 (HO-1)\/carbon monoxide (CO)","Molecular type":null,"Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"DiagnosticBM|PrognosticBM","Pmid":24927633,"Description":"HO is the key enzyme involved in the initial and rate-limiting step in heme degradation, in which heme is degraded and converted to biliverdin, carbon monoxide (CO) and iron is released.  These findings strongly suggested HO-1\/COHb is a useful diagnostic and prognostic indicator for CRC, and inhibition of HO-1 may be a option to enhance the chemotherapeutic effects of conventional anticancer drugs toward CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":564},{"Name":"Matrix metalloproteinase-7 (MMP-7)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"RT-PCR|Immunohistochemistry","Usage":"DiagnosticBM","Pmid":24930385,"Description":"MMP-7, one of the members of matrilysins, has only a signal peptide, a prodomain and a catalytic domain.\u00a0 MMP-7 mRNA expression had a sensitivity of 81.3% and a specificity of 81.2% at a cut-off value of 0.0006. We emphasized the significant role of MMP-7 in diagnosis and progression and\/or development of colorectal cance","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":565},{"Name":"microRNA-205 (miR-205)","Molecular type":"MicroRNA","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"quantitative RT-PCR","Usage":"DiagnosticBM|PrognosticBM","Pmid":24935592,"Description":"MiR-205 is a highly conserved microRNA and it has been proved that miR-205 shares a similar expression pattern with miR-200 family. The area under the ROC curve (AROC) is 0.81 and specificity and sensitivity is 91% and 85% respectively. Diagnostic and prognostic value of miR-205 in colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":566},{"Name":"WNT inhibitory factor 1 (WIF1),  secreted frizzled related protein 1 (SFRP1)","Molecular type":null,"Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":24949429,"Description":"Coexpression of SFRP1 and WIF1 as a prognostic predictor of favorable outcomes in patients with colorectal carcinoma.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":567},{"Name":"RAGE","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"qRT-PCR|Western blot|Immunocytochemistry","Usage":"PrognosticBM","Pmid":24952599,"Description":"RAGE is a single membrane spanning protein of the immunoglobulin superfamily.\u00a0 high RAGE expression in primary tumors correlated with metachronous metastasis, reduced overall (P=0.022) and metastasis-free survival (P=0.021). RAGE mediates S100A4-induced cell motility via MAPK\/ERK and hypoxia signaling and is a prognostic biomarker for human colorectal cancer metastasis.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":568},{"Name":"NEDD9","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM|PredictiveBM","Pmid":24966970,"Description":"NEDD9, also called HEF1 and Cas-L, initially identified in neuronal precursor cells in 1992, was down-regulated during the development of early embryonic mouse central nervous system.NEDD9 protein belonging to a member of Crk-associated substrate (CAS) family, is also an integral player in pathological cell biology. Patients with a higher NEDD9 expression had a significantly shorter overall survival (OS) (P<0.01). Our finding demonstrated the potential value of NEDD9 expression level as a prognostic molecular marker and a target for new therapies for CRC patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":569},{"Name":"DEPTOR","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM|PredictiveBM","Pmid":24969890,"Description":"DEP domain-containing mTOR-interacting protein\u00a0(DEPTOR) also known as\u00a0DEP domain-containing protein 6\u00a0(DEPDC6) is a\u00a0protein\u00a0that in humans is encoded by the\u00a0DEPTOR\u00a0gene. DEPTOR is a potential marker for prognostic evaluation and a target for the treatment of CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":570},{"Name":"Glutathione S-transferase \u03c0-1 (GSTP-1)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Western blot|Immunohistochemistry|RT-PCR|ChIP","Usage":"PredictiveBM","Pmid":24970398,"Description":"GST pi-1 (GSTP-1) is encoded by a single gene mapped to chromosome 11q13 (3,4) and is frequently overexpressed in many types of tumors, including colorectal cancers. These data indicate that GSTP-1 may serve as a clinically useful biomarker of colon cancer and a target for anti-colon cancer drugs.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":571},{"Name":"Special AT-rich sequence-binding protein-1 (SATB1)","Molecular type":"Protein","Location":"Rectum","Source":"Tissue","Assay\/Test":"RT\u2013PCR|Western Blot|Immunofluorescence","Usage":"PrognosticBM|PredictiveBM","Pmid":24971456,"Description":"SATB1 (special AT-rich sequence-binding protein-1)\u00a0is a\u00a0protein\u00a0which in humans is encoded by the\u00a0SATB1gene. Kaplan-Meier survival analysis and log-rank test revealed a significant correlation between high SATB1 expression level and shorter survival time (p<0.001\uff09 SATB1 may represent an important prognostic biomarker and therapeutic target for CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":572},{"Name":"NLK","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Western blot|RT-PCR","Usage":"DiagnosticBM|PredictiveBM","Pmid":24972723,"Description":"NLK, a mammalian serine\/threonine protein kinase, belongs to the proline-directed protein kinase superfamily, which is originally identified by the screening of cDNAs coding for protein kinases. low expression of NLK correlated with a shorter overall survival rates of patients with CRC (P<0.05) NLK could be a novel direction for developing diagnostic and therapeutic approaches in colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":573},{"Name":"sphingosine-1-phosphate receptor 1 (S1PR1)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":24972972,"Description":"S1PR1 is a\u00a0G-protein-coupled receptor\u00a0which binds the bioactive signaling molecule\u00a0sphingosine 1-phosphate\u00a0(S1P).\u00a0 We suggest that detection and analysis of S1PR1 expression in colorectal cancer tissue might be used for predicting prognosis of colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":574},{"Name":"microRNA-630 (miR-630)","Molecular type":"MicroRNA","Location":null,"Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":24981248,"Description":"We have investigated the expression level of miR-630 in clinical colorectal and adjacent normal specimens, as well as analyzed its association with overall survival of patients. MicroRNA-630 is a prognostic marker for patients with colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":575},{"Name":"NAT10 (N-acetyltransferase 10)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Immunofluorescent","Usage":"PrognosticBM|PredictiveBM","Pmid":24982245,"Description":"NAT10 (N-acetyltransferase 10) is a nucleolar protein, but may show subcellular redistribution in colorectal carcinoma. NAT10 membrane staining reflected the depth of invasion and tendency to metastasize (all P values<0.001), and was associated with a poorer prognosis (P=0.023; \u03c72=5.161). This finding suggests that NAT10 may be a useful prognostic marker and potential therapeutic target in colorectal carcinoma.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":576},{"Name":"ATG4B","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"RT-PCR","Usage":"PredictiveBM","Pmid":24991826,"Description":"Cysteine protease ATG4B\u00a0is an\u00a0enzyme\u00a0that in humans is encoded by the\u00a0ATG4B\u00a0gene. These results suggest that ATG4B is a potential biomarker and drug target for cancer therapy.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":577},{"Name":"Podocalyxin","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":25004863,"Description":"Podocalyxin, a\u00a0sialoglycoprotein, is thought to be the major constituent of the\u00a0glycocalyx\u00a0of\u00a0podocytes\u00a0in the\u00a0glomerulus. Results remained significant in multivariable analysis (respectively, HR = 1.82; 95% CI 1.15-2.86, p = 0.01; HR = 2.59; 95% CI 1.41-4.88, p = 0.002; and HR = 2.69; 95% CI 1.30-5.54, p = 0.007) Podocalyxin is a marker of poor prognosis in colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":578},{"Name":"Protein phosphatase, Mg2+\/Mn2+ dependent, 1D (PPM1D)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qPCR|Western blot","Usage":"PrognosticBM|PredictiveBM","Pmid":25009596,"Description":"The protein encoded by this gene is a member of the PP2C family of Ser\/Thr protein phosphatases. multivariate analyses demonstrated that high PPM1D expression was an independent prognostic factor for overall survival (hazard ratio = 0.24; 95% confidence interval, 0.13-0.86; P=0.004). PPM1D is a prognostic marker and therapeutic target in colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":579},{"Name":"O6-methylguanine DNA methyltransferase (MGMT), CD133","Molecular type":null,"Location":null,"Source":"Tissue","Assay\/Test":"methylation-specific PCR|Immunohistochemistry","Usage":"PrognosticBM","Pmid":25015560,"Description":"MGMT and CD133 may both be useful for determining the prognosis of colorectal cancer patients and to identify those requiring more aggressive adjuvant therapies","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":580},{"Name":"Leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5)","Molecular type":"DNA","Location":null,"Source":"Tissue","Assay\/Test":"Immunoblotting","Usage":"DiagnosticBM|PredictiveBM","Pmid":25025569,"Description":"Leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5) also known as G-protein coupled receptor 49 (GPR49) or G-protein coupled receptor 67 (GPR67) is a protein that in humans is encoded by the LGR5 gene The findings of this study suggest that LGR5 plays a vital role in CRC pathogenesis and has the potential to serve as a diagnostic marker and a therapeutic target for CRC patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":581},{"Name":"Metastasis associated with lung adenocarcinoma transcript-1 (MALAT1)","Molecular type":"LncRNA ","Location":null,"Source":"Tissue","Assay\/Test":"RT\u2013PCR","Usage":"PrognosticBM","Pmid":25025966,"Description":"Metastasis associated with lung adenocarcinoma transcript-1 (MALAT1) is an evolutionarily highly conserved lncRNA. Our findings implied that\u00a0MALAT1\u00a0might be a potential predictor for tumour metastasis and prognosis.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":582},{"Name":"Zinc-finger protein X-linked (ZFX)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"quantitative RT-PCR|Western blot|Immunohistochemistry","Usage":"PrognosticBM","Pmid":25031734,"Description":"Zinc-finger protein X-linked (ZFX) encoded on the X chromosome, is a member of zinc-finger protein family, all of which are highly conserved in vertebrates. multivariate analysis indicated that ZFX expression, Lymph node metastasis and Dukes\u2019 classification were independent prognostic factors for overall survival of CRC patients (P = 0.039, P = 0.031, and P = 0.010). Zinc-finger protein X-linked is a novel predictor of prognosis in patients with colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":583},{"Name":"MALAT1","Molecular type":"LncRNA ","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"quantitative RT-PCR","Usage":"PrognosticBM","Pmid":25031737,"Description":"MALAT1 also known as NEAT2 is a large, infrequently\u00a0spliced\u00a0non-coding RNA, which is highly conserved amongst\u00a0mammals\u00a0and highly expressed in the\u00a0nucleus. a significantly worse prognosis with a hazard ratio (HR) of 2.863 (95% CI, 1.659 to 4.943; P < 0.001) for DFS and 3.968 (95% CI, 1.665 to 9.456; P = 0.002) for OS The expression of MALAT1 is upregulated in CRC tissues, and a higher expression level of MALAT1 might serve as a negative prognostic marker in stage II\/III CRC patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":584},{"Name":"IL-17, Tr1-positive cells","Molecular type":null,"Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":25034363,"Description":"The average total survival time in patients with high percentage of IL-17-, CD49b-, and LAG-3-positive cells in tumor tissues was significantly shorter than that in patients with low percentage of these cells (p = 0.046, p = 0.016, p = 0.002, respectively). The high percentage of IL-17- and Tr1-positive cells in tumor tissues is a predictive marker for poor prognosis of colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":585},{"Name":"DNAJB6","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry|Western Blot","Usage":"PrognosticBM","Pmid":25044025,"Description":"DNAJB6 is a member of the heat shock protein 40 (Hsp40) family. A Kaplan-Meier survival analysis revealed a correlation between DNAJB6 expression and overall survival (OS) times (P\u2009=\u20090.003). DNAJB6 may be used as a prognostic marker for CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":586},{"Name":"Histone modifications H3K4me3, H3K9me3, H4K20me3","Molecular type":null,"Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":25047223,"Description":"The HR for disease-free survival was 3.81 (1.72-8.45; p = 0.001), for locoregional recurrence-free survival 2.86 (1.59-5.13; p < 0.001) and for distant recurrence-free survival 2.94 (1.66-5.22; p < 0.001). Combined nuclear expression of histone modifications H3K4me3, H3K9me3 and H4K20me3 is prognostic in early-stage colon cancer","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":587},{"Name":"19 genes regulated by TREM1 or CTGF activation (TCA19)","Molecular type":null,"Location":null,"Source":"Tissue","Assay\/Test":"RNA-seq","Usage":"PrognosticBM","Pmid":25049118,"Description":"TCA19 was an independent risk factor (HR = 1.894, 95% CI = 1.227-2.809, P = 0.002) A nineteen gene-based risk score classifier predicts prognosis of colorectal cancer patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":588},{"Name":"Thomsen-Friedenreich (TF) antigen","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"DiagnosticBM","Pmid":25052906,"Description":"Thomsen-Friedenreich (TF) antigen belongs to the mucin-type tumor-associated carbohydrate antigen. These data demonstrate the potential of this novel probe for imaging TF antigen as a biomarker for the early detection and prediction of the progression of CRC at the molecular level.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":589},{"Name":"Bmi1","Molecular type":"Protein","Location":null,"Source":"Blood","Assay\/Test":"quantitative PCR","Usage":"PrognosticBM","Pmid":25054051,"Description":"Polycomb complex protein BMI-1 also known as polycomb group RING finger protein 4 (PCGF4) or RING finger protein 51 (RNF51) is a protein that in humans is encoded by the BMI1 gene. Bmi1 mRNA levels exhibited a significantly higher rate of distant metastasis following primary resection (P=0.017) and a significantly worse prognosis regarding disease-free survival (P=0.016)  Plasma Bmi1 mRNA as a potential prognostic biomarker for distant metastasis in colorectal cancer patients","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":590},{"Name":"Phosphorylated p38 (p-p38)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry|Western blot","Usage":"PrognosticBM","Pmid":25056534,"Description":"P38, one of the components of the mitogen-activated protein kinase (MAPK) family, is an important intracellular signal in the regulation of tumor proliferation, differentiation, and progression . Overexpression of p-p38 predicted poor OS (P\u2009<\u20090.001), DFS (P\u2009=\u20090.002), LFFS (P\u2009=\u20090.016), and DMFS (P\u2009=\u20090.025) in CRC. Our results demonstrated that p-p38 was a negative independent prognostic factor for CRC","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":591},{"Name":"91H","Molecular type":"LncRNA","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":25058480,"Description":"91H, H19 antisense RNA, was a novel lncRNA that was located on the position of the H19\/IGF2 locus (Accession number NC_000011.9) with 119.329 kbs in length.  91H relative expression and distant metastasis were independent prognostic indicators for the overall survival rate of patients with CRC (HR: 3.66, P\u200a=\u200a0.001; HR: 8.97, P<0.001) respectively by multivariate analysis Up-regulation of 91H promotes tumor metastasis and predicts poor prognosis for patients with colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":592},{"Name":"Lysine-specific demethylase 1 (LSD1)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry|q-PCR|Immunoblotting assay","Usage":"PredictiveBM","Pmid":25060070,"Description":"Lysine-specific demethylase 1 (LSD1), the first histone demethylase that was discovered as a flavin adenine dinucleotide (FAD)-dependent amine oxidase, catalyzes the demethylation of histone H3-K4 and K9. LSD1 levels were significantly correlated with an advanced AJCC T stage (P = 0.012) and distant metastasis (P = 0.004). LSD1 and its inhibitor might provide a new target or a useful strategy for therapy of CRC","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":593},{"Name":"Kr\u00fcppel-like factor 4 (KLF4)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Real-time reverse transcription PCR","Usage":"PrognosticBM","Pmid":25060774,"Description":"KLF4 is a member of the KLF family of transcription factors, which belongs to the relatively large family of SP1-like transcription factors. Patients with a high KLF4 level in matched normal tissues were more likely than those with a low KLF4 level to develop recurrence and had poorer overall survival (P\u2009=\u20090.005).  Our data suggest that KLF4 mRNA expression level in normal tissues and tumors may be a useful prognostic marker in patients with CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":594},{"Name":"Stathmin-1 (STMN1)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"qPCR|Western blot","Usage":"PredictiveBM","Pmid":25063586,"Description":"Stathmin is a highly conserved 17 kDa protein that is crucial for the regulation of the cell cytoskeleton. These findings establish STMN1 as a potential target in antimetastatic therapy, ","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":595},{"Name":"FOXC2","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":25069037,"Description":"Forkhead box protein C2 (FOXC2) also known as forkhead-related protein FKHL14 (FKHL14), transcription factor FKH-14, or mesenchyme fork head protein 1 (MFH1) is a protein that in humans is encoded by the FOXC2 gene. Kaplan\u2013Meier survival analysis indicated that patients with high FOXC2 level had significantly poorer overall survival (P\u00a0=\u00a00.002) and disease-free survival (P\u00a0=\u00a00.006,\u00a0Fig. 1D, left panels) than patients with low FOXC2 level. These findings suggest that FOXC2 plays an essential role in CRC progression and may serve as a valuable clinical prognostic marker of this disease","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":596},{"Name":"Phosphorylated focal adhesion kinase (P-FAK)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":25075018,"Description":"PTK2 protein tyrosine kinase 2 (PTK2), also known as focal adhesion kinase (FAK), is a protein that, in humans, is encoded by the PTK2 gene. Positive nuclear P-FAK expression was associated with shorter disease-specific survival in univariate (p=0.005) and multivariate analysis (p=0.016). P-FAK expression is an independent prognostic marker in CRC","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":597},{"Name":"Vimentin methylation","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Blood","Assay\/Test":"Quantitative methylation-specific PCR","Usage":"DiagnosticBM","Pmid":25075038,"Description":"Vimentin is a type III intermediate filament (IF) protein that is expressed in mesenchymal cells. The combination of all three markers yielded similar sensitivity for patients with disease of stage 0: 57.1%, I: 36.1%, II: 45.2%, and III: 55.4%, whereas the sensitivity reached 85.7% for patients with stage IV disease. VIM methylation of serum DNA may be a useful marker for the early detection of CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":598},{"Name":"A disintegrin, metalloprotease 8 (ADAM8)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR|Western blot|Immunohistochemistry","Usage":"PredictiveBM","Pmid":25098630,"Description":"ADAMs (short for a disintegrin and metalloproteinase) are a family of transmembrane and secreted metalloendopeptidases. ADAM8-positive tumors had worse 5-year overall survival (OS, p = 0.037) and 5-year disease free survival (DFS, p = 0.014) compared with those with ADAM8-negative tumors. Our results show that ADAM8 is overexpressed in CRC, promotes cell growth and correlates with worse OS and DFS, and thus could serve as a biomarker for individual CRC patient therapy.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":599},{"Name":"CDC42","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry|Western blot|qRT-PCR","Usage":"PrognosticBM","Pmid":25113996,"Description":"Cell division control protein 42 homolog, also known as\u00a0Cdc42, is a\u00a0protein\u00a0involved in regulation of the\u00a0cell cycle. Our results indicate that early-stage mutant intestinal epithelial cells must recruit the pleiotropic functions of Cdc42 for malignant progression, suggesting its relevance as a biomarker and therapeutic target for selective ","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":600},{"Name":"Melanoma-associated antigen D4 (MAGE-D4)","Molecular type":"Protein","Location":"Colon","Source":"Tissue","Assay\/Test":"RT-PCR|Immunohistochemistry|ELISA","Usage":"PrognosticBM","Pmid":25120768,"Description":"This gene is expressed only in brain and ovary among normal tissues, and two transcript variants of this gene are specifically expressed in glioma cells among cancer cells.  Multivariate analysis exhibited high MAGE-D4 protein expression had a trend toward an independent prognostic factor (hazard ratio: 6.124; P=0.050).  Overexpression of MAGE-D4 in colorectal cancer is a potentially prognostic biomarker and immunotherapy target.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":601},{"Name":"Beclin-1","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":25130795,"Description":"Beclin-1 interacts with either BCL-2 or PI3k class III, playing a critical role in the regulation of both autophagy and cell death. Patients with a high Beclin-1 expression, when compared to those with a lower expression had both a better overall survival (OS, P=0.006) and disease-free survival (DFS, P=0.008). High expression of Beclin-1 predicts favorable prognosis for patients with colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":602},{"Name":"ArhGAP30","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"RT\u2013qPCR|ChIP assay","Usage":"PrognosticBM","Pmid":25156493,"Description":"RhoGAP domain is an evolutionary conserved protein domain of GTPase activating proteins towards Rho\/Rac\/Cdc42-like small GTPases. The overall survival of patients in the ArhGAP30 downregulation group was significantly shorter than in the upregulation group (79.2 versus 96.0 months, P=0.007), and multivariate analysis suggested significant association after adjustment for tumour stage and microsatellite instability (MSI) status (hazard ratio 0.431, 95% confidence interval 0.234\u20130.794; P=0.007). The expression of ArhGAP30 is a potential prognostic marker for CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":603},{"Name":"ALU115","Molecular type":"DNA","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Real-time ALU-PCR","Usage":"DiagnosticBM","Pmid":25157833,"Description":"Circulating cell-free DNA (ccf-DNA) in serum or plasma is a promising candidate biomarker for detection, monitoring and prognostic prediction of malignant tumours The AUC of ALU115, ALU247\/115 and CEA was 0.85 (95% CI: 0.81\u20130.91), 0.89 (95% CI: 0.85\u20130.93) and 0.78 (95% CI: 0.72\u20130.84), respectively. Serum DNA concentrations and integrity index may be valuable in early complementary diagnosis and monitoring of progression and prognosis of CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":604},{"Name":"microRNA-27a (miR-27a)","Molecular type":"MicroRNA","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PredictiveBM","Pmid":25166914,"Description":"MiR-27 is a family of microRNA precursors found in animals, including humans. MiR-27a could be a useful biomarker for monitoring colorectal cancer development and progression, and also could have a therapeutic potential by targeting SGPP1, Smad2 and STAT3 for colorectal cancer therapy.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":605},{"Name":"microRNA-133a (miR-133a)","Molecular type":"MicroRNA","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":25170220,"Description":"MiR-133a was associated with various human malignancies MiR-133a levels and TNM stage were independently associated with OS (HR = 0.590, 95%CI: 0.350-0.995, P < 0.05; and HR = 6.111, 95%CI: 1.029-36.278, P < 0.05, respectively). The downregulation of miR-133a may play an important role in the progression of CRC and can be used as an independent factor to determine CRC prognosis.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":606},{"Name":"Long interspersed nucleotide element-1 (LINE-1)","Molecular type":"DNA","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"LINE-1 Methylation|MSI","Usage":"PrognosticBM","Pmid":25190725,"Description":"Long interspersed nuclear elements (LINEs) are a group of non-LTR (long terminal repeat) retrotransposons which are widespread in the genome of many eukaryotes. The association of LINE-1 hypomethylation with higher mortality (HR = 5.13, 95% CI = 1.99 to 13.2; P < .001) was stronger than that in MSI-high cases without CRC family history (HR = 1.62, 95% CI = 0.89 to 2.94, P = .11) (P interaction = .02, between LINE-1 and CRC family history statuses). Tumor LINE-1 methylation level may be a useful prognostic biomarker to identify aggressive carcinomas among MSI-high CRCs.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":607},{"Name":"Prothymosin-\u03b1 (PTMA)","Molecular type":"Protein","Location":"Colon","Source":"Tissue","Assay\/Test":"Immunohistochemistry|Western blot|RT-PCR","Usage":"PrognosticBM","Pmid":25197357,"Description":"Human prothymosin-\u03b1 (PTMA) is a member of the \u03b1-thymosin family comprising 110 amino acids, and its sequence is highly conserved in mammals. Expression of both PTMA and mutant TP53 was found to be a significant prognostic factor for DFS (hazard ratio [HR] 2.094; 95% confidence interval [CI], 1.457-3.051; P < 0.001) and OS (HR 2.348; 95% CI, 1.493-3.692; P < 0.001). PTMA might play an important role in the progression of CRC, and the assessment of both PTMA and mutant TP53 expression can help predict colon cancer prognosis.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":608},{"Name":"Ribosomal s6 kinase4 (RSK4)","Molecular type":"Protein","Location":"Colon","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":25197367,"Description":"Ribosomal s6 kinase (rsk) is a family of protein kinases involved in signal transduction. Patients with high protein level of RSK4 showed prolonged overall survivals (P<0.05). Low expression of RSK4 predicts poor prognosis in patients with colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":609},{"Name":"Uroplakin Ia(UPK la)","Molecular type":"Protein","Location":"Colon","Source":"Tissue","Assay\/Test":"Real time PCR|Immunohistochemistry","Usage":"PrognosticBM","Pmid":25197375,"Description":"Uroplakins are urothelial differentiation-related membrane proteins that exhibited typical 2D crystals of hexagonally packed 16-nm particles.  Low expression of UPKIa was significantly associated with poorer overall (OS) and recurrent free (RFS) survival (P = 0.017 and P = 0.007, respectively) of colorectal cancer patients. Low expression of UPKIa was a promising predictor for poor outcome of colorectal cancer patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":610},{"Name":"CpG island methylation phenotype (CIMP)","Molecular type":"DNA","Location":"Colon","Source":"Tissue","Assay\/Test":"Methylation Sensitive High Resolution Melting (MS-HRM)","Usage":"PrognosticBM","Pmid":25243122,"Description":"CpG island methylation phenotype (CIMP), characterized by the extensive hypermethylation of multiple CpG islands, is currently recognized as one of the major mechanisms in the colorectal carcinogenesis While comparing with the combine of CIMP-L and CIMP-0 (CIMP-L\/0), CIMP-H also presented a worse prognosis (HR = 2.31; 95% CI: 1.02-5.24; P = 0.04). CIMP-H may be a predictor of a poor prognosis of CRC in Northeast China patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":611},{"Name":"Polycomb-group (PcG)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":25243792,"Description":"The PcG proteins act in large multi-protein complexes and play an important role in embryonic development and cell proliferation. High expression of all four markers in the combined marker analyses was correlated with the best patient survival and the longest recurrence-free survival, with overall survival (p\u200a=\u200a0.01, HR 0.42(0.21-0.84)), disease-free survival (p\u200a=\u200a0.007, HR 0.23(0.08-0.67) and local recurrence-free survival (p\u200a=\u200a0.02, HR 0.30(0.11-0.84)).  We found that expression of PcG proteins and H3K27me3 showed prognostic value in our study cohort. ","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":612},{"Name":"Integrin \u03b1v\u03b26, Ets-1","Molecular type":null,"Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":25264483,"Description":"\u03b1v\u03b26 is a special subtype of integrin that is expressed in epithelial cells only, and its major ligand is fibronectin (FN).Ets-1 is a kind of transcription factor which is present in species ranging from sponges to human.  And Cox model indicated that \u03b1v\u03b26 and Ets-1 were the independent prognostic factors (RR\u2009=\u20092.175, P\u2009=\u20090.012 and RR\u2009=\u20093.903, P < 0.001). Integrin \u03b1v\u03b26 and transcriptional factor Ets-1 act as prognostic indicators in colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":613},{"Name":"microRNA-194 (miR-194)","Molecular type":"MicroRNA","Location":"Colon","Source":"Tissue","Assay\/Test":"Real-time qPCR|Luciferase assay|Western Blot|TUNEL assay","Usage":"DiagnosticBM","Pmid":25285168,"Description":"MiR-194 microRNA precursor is a small non-coding RNA gene that regulated gene expression. Low expression of miR-194 in CRC tissues was associated with large tumor size (P=0.006), lymph node metastasis (P=0.012) and shorter survival (HR =2.349, 95% CI = 1.242 to 4.442; P=0.009). MiR-194 could be a significant diagnostic and prognostic biomarker for CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":614},{"Name":"\u03b2-catenin","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":25295092,"Description":"\u03b2-catenin is a component of the Wingless\/Wnt signaling pathway. The presence of nuclear \u03b2-catenin overexpression at the tumor invasive front was found to be correlated with the tumor, node, metastasis stage (P=0.020), lymph node metastasis (P=0.016) and histological differentiation (P=0.006). IHC staining of \u03b2-catenin is considered to be a useful marker to predict the prognosis in CRC","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":615},{"Name":"Regenerating islet-derived gene4 (REG4) ","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":25295732,"Description":"Regenerating islet-derived protein 4 is a protein that in humans is encoded by the REG4 gene. Univariable hazard ratio (HR)\u200a=\u200a0.57; 95% confidence interval (CI) (0.34-0.94); multivariable HR\u200a=\u200a0.55; 95% CI (0.33-0.92). REG4 independently predicts better prognosis in non-mucinous colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":616},{"Name":"Rs6475526","Molecular type":"DNA","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Genotyping|SNP selection","Usage":"PrognosticBM","Pmid":25350395,"Description":"Interferons (IFNs) are immune-related proteins produced and released by host cells in response to the presence of pathogens. SNP rs6475526 (IFNA7\/IFNA14) was associated with overall survival of the patients (P\u200a=\u200a0.041 and event-free survival among patients without distant metastasis at the time of diagnosis, P\u200a=\u200a0.034) Rs6475526 is an independent prognostic marker for CRC","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":617},{"Name":"Ku70, ataxia-telangiectasia mutated (ATM)","Molecular type":"Protein","Location":"Colon","Source":"Tissue","Assay\/Test":"Real-time qPCR|Western blot|Immunohistochemistry","Usage":"PrognosticBM","Pmid":25368522,"Description":"Ataxia-telangiectasia mutated (ATM) is a serine-threonine kinase that is triggered by DSBs to activate several downstream targets, including those involved in the induction of cell senescence and apoptosis. Ku70 can form a Ku heterodimer complex with Ku80 that binds to DSBs and aids in nonhomologous end joining (NHEJ). Ku70, and ATM expression were correlated to the overall survival (P<0.05\uff09 Loss of Ku70 and ATM expression might act as a biomarker to predict poor prognosis in patients with CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":618},{"Name":"Structural maintenance of chromosomes 4 (SMC-4)","Molecular type":"Protein","Location":"Colon","Source":"Tissue","Assay\/Test":"RT-PCR|Western blot|Immunohistochemistry","Usage":"PredictiveBM","Pmid":25422241,"Description":"Structural maintenance of chromosomes 4 (SMC-4) is a chromosomal ATPase which plays an important role in regulate chromosome assembly and segregation.  The patients with SMC-4 negative expression had a significantly higher overall survival (A) and disease-free survival (B) rate than the SMC-4 positive group (p=0.005, p<0.001, respectively) Our study provides a new therapeutic target for colorectal cancer treatment.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":619},{"Name":"microRNA-376a (miR-376a)","Molecular type":"MicroRNA","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR|Immunohistochemistry","Usage":"PrognosticBM","Pmid":25422250,"Description":"MicroRNA-376a (miR-376a) expression and association with clinical factors in CRC remains unclear. The Overall Survival was Lower in Patients with High miR-376a Expression than in those Patients with Low miR-376a Expression (p=0.0314) Those results demonstrated that miR-376a may be a meaningful prognostic biomarker and potential therapeutic target in colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":620},{"Name":"SH2-containing inositol 5'-phosphatase 2 (SHIP2)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qPCR|Immunohistochemistry","Usage":"PrognosticBM","Pmid":25525286,"Description":"SH2-containing inositol 5\u2032-phosphatase 2 (SHIP2) belongs to the phosphoinositol phosphatases family which plays important role in modulating signaling pathways relevant to both diabetes and cancer and generally regulates insulin signaling, cytoskeleton remodeling, and receptor endocytosis.  The expression of SHIP2 protein in CRC was related to lymph node metastasis (P = 0.036), distant metastasis (P = 0.001), and overall survival (P = 0.009). The findings suggested that SHIP2 may be identified as a useful prognostic marker in CRC and targeting CRC may provide novel strategy for CRC treatment.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":621},{"Name":"microRNA-196a (miR-196a), microRNA-196b (miR-196b)","Molecular type":"MicroRNA","Location":"Colon","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":25525411,"Description":"The miR-196 family consists of miR-196a and miR-196b. This family has been reported to play crucial roles in normal development and cancer pathogenesis by regulating its target genes. High miR-196b expression and miR-196a-high\/miR-196b-high expression tended to be shorter than the corresponding control groups (log-rank statistic, all P\u2009<\u20090.001) Combined expression of miR-196a and miR-196b may be a promising biomarker in identifying a poor prognosis group of CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":622},{"Name":"Interleukin-36\u03b1 (IL-36\u03b1)","Molecular type":null,"Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":25550854,"Description":"Interleukin-36 alpha also known as interleukin-1 family member 6 (IL1F6) is a protein that in humans is encoded by the IL36A gene. The overall survival rate of colorectal cancer patients was significantly decreased in low IL-36\u03b1 expression group compared with high IL-36\u03b1 expression group (P = 0.001). Decreased expression of interleukin-36\u03b1 predicts poor prognosis in colorectal cancer patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":623},{"Name":"Rab27b","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qPCR|Immunohistochemistry","Usage":"PrognosticBM","Pmid":25580113,"Description":"Rab27, which is a special member of the small GTPase Rab family and is widely conserved in metazoans, is composed of two isoforms, Rab27a and Rab27b. Cox multifactor analysis and Kaplan-Meier method suggested that higher Rab27b protein expression (P = 0.041) and tumor differentiation (P = 0.001) Rab27b is a potential predictor for metastasis and prognosis in colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":624},{"Name":"Cryptochrome 2 (CRY2)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Immunoblotting","Usage":"PrognosticBM|PredictiveBM","Pmid":25855785,"Description":"Cryptochromes\u00a0(from the\u00a0Greek\u00a0\u03ba\u03c1\u03c5\u03c0\u03c4\u03cc\u03c2 \u03c7\u03c1\u03ce\u03bc\u03b1, \"hidden colour\") are a class of\u00a0flavoproteins\u00a0that are sensitive to\u00a0blue light. Our findings indicate that the upregulation of CRY2 caused by downregulation of FBXW7 may be a novel prognostic biomarker and may represent a new therapeutic target in colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":625},{"Name":"microRNA-1269a (miR-1269a)","Molecular type":"MicroRNA","Location":"Colon","Source":"Tissue","Assay\/Test":"qRT-PCR|Western Blot|Immunohistochemistry","Usage":"PredictiveBM","Pmid":25872451,"Description":"Our findings suggest that miR-1269a is a potential marker to inform adjuvant chemotherapy decisions for CRC patients and a potential therapeutic target to deter metastasis.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":626},{"Name":"Serine protease inhibitor Kazal-type 1\u00a0(SPINK1)","Molecular type":"Protein","Location":"Rectum, Colon","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":25884558,"Description":"Serine threonine tyrosine kinase 1\u00a0(STYK1), also known as novel oncogene with kinase domain (NOK), was identified as a new member of the RPTK-like protein family and found to be expressed in several normal human tissues. Kaplan-Meier analysis indicated that patients with high intratumoral STYK1 expression had a significantly shorter disease-specific survival (DSS) than those with low expression (p\u2009<\u20090.001).\u00a0 Our results suggest that increased STYK1 protein expression correlates with disease progression and metastasis and may serve as a predictor of poor survival in CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":627},{"Name":"Cancerous inhibitor of protein phosphatase 2A (CIP2A) ","Molecular type":"Protein","Location":"Rectum, Colon","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":25896895,"Description":"Cancerous inhibitor of protein phosphatase 2A\u00a0(CIP2A) is a recently identified oncoprotein that is overexpressed in several malignancies, including\u00a0leukemia, breast, gastric, prostate, lung, ovarian, head and neck carcinoma, and\u00a0colorectal cancer. CIP2A expression was an independent prognostic marker in patients with wild-type KRAS metastatic colorectal cancer after colorectal liver metastasectomy (relative risk\u2009=\u20091.873, P\u2009=\u20090.019).\u00a0 CIP2A is an independent prognostic\u00a0marker\u00a0in patients with wild-type KRAS metastatic\u00a0colorectal cancer\u00a0after colorectal liver metastasectomy.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":628},{"Name":"microRNA-217 (miR-217)","Molecular type":"MicroRNA","Location":null,"Source":"Tissue","Assay\/Test":"qRT-PCR|Western blot","Usage":"PrognosticBM|PredictiveBM","Pmid":26016795,"Description":"MiR-217\u00a0has been reported to play an important role in carcinogenesis.\u00a0 MicroRNA-217 functions as a prognosis predictor and inhibits colorectal cancer cell proliferation and invasion via an AEG-1 dependent mechanism.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":629},{"Name":"Serine protease inhibitor Kazal-type 1\u00a0(SPINK1)","Molecular type":"Protein","Location":"Rectum, Colon","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":26037168,"Description":"Serine protease inhibitor Kazal type-1 (SPINK1), a trypsin kinase inhibitor, is involved in inflammation, cell proliferation and carcinogenesis. In Kaplan-Meier analyses, patients with high SPINK1 intensity tended to have shorter overall survival (p = 0.03).\u00a0 SPINK1 may serve as a prognostic biomarker in therapeutic targeting in the future.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":630},{"Name":"RAD54B ","Molecular type":"Protein","Location":"Rectum, Colon","Source":"Tissue","Assay\/Test":"RT-PCR","Usage":"PrognosticBM","Pmid":26046797,"Description":"Human\u00a0RAD54B\u00a0was first identified in 1999 as a homolog of\u00a0RAD54.\u00a0RAD54B\u00a0belongs to\u00a0SNF2\/SWI2 superfamily, and biochemical studies have shown that\u00a0RAD54B\u00a0is involved in the homologous recombination. Multivariate analysis using Cox proportional-hazards model showed that high RAD54B expression was an independent predictor in both training (hazard ratio, 4.31; 95% CI, 1.53-13.1; P = 0.0060) and validation (hazard ratio, 3.63; 95% CI, 1.23-10.7; P = 0.021) set. This study first demonstrated RAD54B expression has potential to serve as a novel prognostic biomarker, particularly for distant recurrence in CRC patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":631},{"Name":"microRNA-154 (miR-154)","Molecular type":"MicroRNA","Location":null,"Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":26048406,"Description":"The univariate analysis demonstrated that CRC patients with low miR-154 expression had poorer overall survival (P\u2009=\u20090.006). These findings suggested that miR-154 downregulation may be associated with tumor progression of CRC, and that this miR may be an independent prognostic marker for CRC patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":632},{"Name":"microRNA-19a (miR-19a)","Molecular type":"MicroRNA","Location":null,"Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":26057451,"Description":"The CRC patients with high exosomal miR-19a expression showed poorer prognoses than the low expression group (P<0.001). Abundant expression of exosomal miR-19a in serum was identified as a prognostic biomarker for recurrence in CRC patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":633},{"Name":"IncRNA-CCAT1","Molecular type":"LncRNA","Location":"Rectum, Colon","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"DiagnosticBM|PredictiveBM","Pmid":26064266,"Description":"CCAT1 plays an important role in the genesis, development, invasion and metastasis; it mediates the EMT process of colorectal cancer; and it's expected to be a new marker and treatment target in colorectal diagnosis and treatment.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":634},{"Name":"Kinesin superfamily protein 2A (KIF2A)","Molecular type":"Protein","Location":"Rectum, Colon","Source":"Tissue","Assay\/Test":"qRT-PCR|Immunohistochemistry","Usage":"PrognosticBM","Pmid":26070867,"Description":"Kinesin superfamily protein 2A (KIF2A), together with KIF2B, mitotic centromere-associated kinesin (MCAK, also known as KIF2C), constitute the kinesin-13 family. Multivariate Cox regression analyses further showed that high cytoplasmic KIF2A expression (P\u2009=\u20090.001), poor tumor differentiation (P\u2009=\u20090.001), high preoperative CEA levels (P\u2009<\u20090.001), and advanced tumor TNM stage (P\u2009=\u20090.012) were independent prognostic factors for poor overall survival This study demonstrated CRC tissue-preferred expression pattern of the KIF2A and suggested that high KIF2A expression might serve as an independent maker for poor prognosis in CRC patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":635},{"Name":"Rab27A","Molecular type":"Protein","Location":"Rectum, Colon","Source":"Tissue","Assay\/Test":"qPCR|Immunohistochemistry","Usage":"PrognosticBM","Pmid":26070933,"Description":"Rab27A\u00a0is a peculiar member in Rab family for its specific role in human hereditary disease and dysfunction. Cox multi-factor analysis and Kaplan-Meier method suggested Rab27A protein expression (p\u2009=\u20090.012) and tumor differentiation (p\u2009=\u20090.004) were significantly associated with the overall survival of CRC patients. Rab27A may be used as a valuable prognostic biomarker for CRC patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":636},{"Name":"Carbonic anhydrase IV (CA4)","Molecular type":"Protein","Location":"Rectum, Colon","Source":"Tissue","Assay\/Test":"Chromatin immunoprecipitation assay","Usage":"PrognosticBM","Pmid":26071132,"Description":"Carbonic anhydrase IV\u00a0(CA4), located on chromosome 17q22, which is preferentially methylated in human\u00a0colon cancer\u00a0through promoter methylation array. CA4 methylation may serve as an independent biomarker for the recurrence of CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":637},{"Name":"E2F1","Molecular type":null,"Location":"Rectum, Colon","Source":"Tissue","Assay\/Test":"qRT-PCR|Western blot|Immunohistochemistry","Usage":"DiagnosticBM|PrognosticBM","Pmid":26093293,"Description":"E2F is a very important transcription factor in regulating RRM2 gene.\u00a0 The 5-year overall survival (OS) rate of the RRM2 and E2F1 double-high expression group was significantly lower than that of the RRM2 and E2F1 double-low expression group (27.7% vs 55.4%, p\u00a0<\u00a00.001).\u00a0 Understanding the role of E2F1 in activating RRM2 transcription will help to explain the relationship between E2F1 and RRM2 in CRC and provide a novel predictive marker for diagnosis and prognosis of the disease.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":638},{"Name":"mTOR","Molecular type":"DNA","Location":"Rectum, Colon","Source":"Tissue","Assay\/Test":"Western blot|RT-PCR|Immunohistochemistry","Usage":"PrognosticBM","Pmid":26097572,"Description":"Spearman analysis results showed that LC3 expression was positively correlated with Beclin1 but negatively correlated with mTOR (r = 0.593 and -0.165, respectively; P < 0.01).\u00a0 The LC3 and mTOR genes must be simultaneously detected to evaluate progression and prognosis of CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":639},{"Name":"LC3 ","Molecular type":"DNA","Location":"Rectum, Colon","Source":"Tissue","Assay\/Test":"Western blot|RT-PCR|Immunohistochemistry","Usage":"PrognosticBM","Pmid":26097572,"Description":"Spearman analysis results showed that LC3 expression was positively correlated with Beclin1 but negatively correlated with mTOR (r = 0.593 and -0.165, respectively; P < 0.01).\u00a0 The LC3 and mTOR genes must be simultaneously detected to evaluate progression and prognosis of CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":640},{"Name":"MYBL2","Molecular type":"Protein","Location":"Rectum, Colon","Source":"Tissue","Assay\/Test":"RT-qPCR|Immunohistochemistry|Western blot","Usage":"PrognosticBM","Pmid":26101717,"Description":"The MYBL2 gene, which is also known as B-MYB, is a member of the\u00a0MYB\u00a0family that includes\u00a0A-MYB\u00a0and\u00a0C-MYB. Overexpression of\u00a0MYBL2\u00a0was significantly associated with a poorer DFS (P=0.001). MYBL2 is an independent prognostic marker that has tumor-promoting functions in colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":641},{"Name":"microRNA-34a (miR-34a)","Molecular type":"MicroRNA","Location":null,"Source":"Tissue","Assay\/Test":"Western blot|Real time RT-PCR","Usage":"PredictiveBM","Pmid":26103003,"Description":"Establishing a strong potential for the application of miR-34a as a novel therapeutic marker against CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":642},{"Name":"CXCL1","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"ELISA|Immunofluorescence","Usage":"PrognosticBM","Pmid":26104296,"Description":"The chemokine (C-X-C motif) ligand 1 (CXCL1) is a small\u00a0cytokine\u00a0belonging to the CXC\u00a0chemokine\u00a0family that was previously called GRO1 oncogene, GRO\u03b1, KC, neutrophil-activating protein 3 (NAP-3) and melanoma growth stimulating activity, alpha (MSGA-\u03b1). In humans, this protein is encoded by the\u00a0CXCL1\u00a0gene. Highly elevated CXCL1 expression significantly correlated with decreased overall survival in stage IV CRC patients (hazard ratio 0.28; 95% CI 0.11-0.72). High CXCL1 expression is a poor prognostic biomarker in metastatic CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":643},{"Name":"Endothelial cell-specific molecule-1 (ESM-1) ","Molecular type":null,"Location":"Rectum, Colon","Source":"Blood","Assay\/Test":"ELISA","Usage":"PrognosticBM","Pmid":26125749,"Description":"Endothelial cell-specific molecule-1 (ESM-1), also known as endocan, is a dermatan sulfate proteoglycan that was initially cloned in 1996 from a human endothelial cell cDNA library. Multivariate analysis confirmed that the hazard risk of death was significantly higher in patients with high serum ESM-1 expression compared with low expression (hazard risk = 4.09, 95% confidence interval: 2.27-10.88, P < 0.001).\u00a0 Detection of ESM-1 levels in the serum may serve as a tumor biomarker for assessing prognosis in CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":644},{"Name":"Leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5)","Molecular type":"DNA","Location":null,"Source":"Tissue","Assay\/Test":"RT-qPCR","Usage":"PredictiveBM","Pmid":26137160,"Description":"LGR5, also known as HG38 and G protein-coupled receptor 49, is a target gene of the Wnt\/\u03b2-catenin\u00a0signaling pathway (11), acting as receptor for the Wnt\/\u03b2-catenin\u00a0signaling agonist R-spondin. These findings demonstrated that LGR5 expression is critical for the promotion of neoplastic CRC cell proliferation, indicating that LGR5 may be a novel therapeutic target for CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":645},{"Name":"RPS24","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Western blot","Usage":"DiagnosticBM|PredictiveBM","Pmid":26149657,"Description":"Ribosomal protein (RP) is a ubiquitous RNA binding protein, the function of which is not only to participate jointly with ribosome RNA (rRNA) in the synthesis of protein, but also to take part in the regulation of gene transcription and the regulation of cell proliferation and apoptosis through its extra-ribosomal functions. Our findings indicated that RPS24 gene may be a promising biomarker for therapy in human colon cancer and may have a potential application in the diagnosis or treatment of human colon cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":646},{"Name":"microRNA-17-3p (miR-17-3p)","Molecular type":"MicroRNA","Location":"Rectum, Colon","Source":"Blood","Assay\/Test":"RT-qPCR","Usage":"PrognosticBM","Pmid":26250939,"Description":"MicroRNAs (miRNAs) are a class of short (18\u201322 nt in length), evolutionarily conserved, non-protein-coding RNAs that play critical roles in diverse biological processes though negative post-transcriptional regulation. The Kaplan-Meier method and Cox proportional hazards analysis, we found that miR-17-3p and miR-106a were powerful and independent prognostic indicators and that high levels of these miRNAs were associated with shorter disease-free survival (DFS) (P\u2009<\u20090.0001 for miR-17-3p and P\u2009=\u20090.001 for miR-106a). The present study reveals novel serum-miRNA-based biomarkers for monitoring tumor dynamics as well as for predicting disease recurrence in patients with stage II\/III CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":647},{"Name":"Dehydrogenase\/reductase (SDR family) member 9 (DHRS9) ","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"RT-qPCR|Western blot|Immunohistochemistry","Usage":"PrognosticBM","Pmid":26254099,"Description":"Dehydrogenase\/reductase (SDR family) member 9\u00a0(DHRS9), also known as retinol dehydrogenase L (RDHL), has been identified as a member of the short-chain dehydrogenases\/reductase (SDR) family that converts retinol to retinal.\u00a0 Kaplan-Meier analysis indicated that low DHRS9 expression predicted poor disease-free survival (p\u2009=\u20090.003) and disease-specific survival (p\u2009=\u20090.021) Our results suggest that decreased expression of DHRS9 correlates with tumor progression and may serve as a potential prognostic biomarker in CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":648},{"Name":"Interferon-induced transmembrane protein 1 (IFITM1)","Molecular type":"Protein","Location":"Rectum, Colon","Source":"Tissue","Assay\/Test":"Western blot|qRT-PCR|Immunohistochemistry","Usage":"PrognosticBM|PredictiveBM","Pmid":26259513,"Description":"Interferon induced transmembrane protein 1 (IFITM1) belongs to the interferon induced transmembrane protein family. These results suggested that IFITM1 promotes the aggressiveness of CRC cells, and it is a potential prognostic marker and therapeutic target for CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":649},{"Name":"53BP1","Molecular type":"Protein","Location":"Colon","Source":"Tissue","Assay\/Test":"Western blot|qRT-PCR","Usage":"PrognosticBM","Pmid":26261485,"Description":"53BP1\u00a0(P53\u00a0binding protein 1,\u00a053BP1) is a newly discovered tumor suppressor gene, which is an important member of DNA damage response pathway family. Patients with low 53BP1 expression revealed poor survival time in I-IIA stage, T3-T4, N0 (P < 0.05). Our findings suggest 53BP1 may serve as a candidate biomarker for predicting prognosis and disease development in colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":650},{"Name":"MTA2","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM|PredictiveBM","Pmid":26261611,"Description":"MTA2 protein localizes in the nucleus and is a component of the nucleosome remodeling and the deacetylation complex (NuRD). Survival analysis indicated that MTA2 expression in cancer tissues, serving as an independent correlation factor, was significantly correlated with poor prognosis (P = 0.004). MTA2 is a crucial biomarker that is closely related with prognosis of CRC and also a potential molecular target for evaluating the prognosis and treatment of CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":651},{"Name":"Twist-related protein 1 (TWIST1)","Molecular type":"Protein","Location":"Rectum, Colon","Source":"Tissue","Assay\/Test":"RT-PCR|Western blot|Immunohistochemistry","Usage":"PrognosticBM|PredictiveBM","Pmid":26269759,"Description":"Twist-related protein 1 (TWIST1) also known as\u00a0class A basic helix-loop-helix protein 38\u00a0(bHLHa38) is a\u00a0basic helix-loop-helix\u00a0transcription factor\u00a0that in humans is encoded by the\u00a0TWIST1\u00a0gene. Positive Twist1 expression is correlated with poor overall survival in CRC patients (P<0.0001). Twist1 may be a potential prognostic marker and a molecular target for therapies.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":652},{"Name":"Long non-coding RNA Loc554202","Molecular type":"LncRNA","Location":"Rectum, Colon","Source":"Tissue","Assay\/Test":"qRT-PCR|Western blot|Immunohistochemistry","Usage":"PrognosticBM","Pmid":26362196,"Description":"Long non-coding RNAs (lncRNAs, > 200 nucleotides in length) are a class of newly discovered non-coding RNA molecules with limited or no protein-coding capacity\u00a0 Our results suggest that Loc554202 may play an important role in the progression of CRC and could be a candidate prognostic biomarker or a target for new cancer therapies.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":653},{"Name":"Retinoid-interferon-induced mortality-19 (GRIM-19)","Molecular type":"DNA","Location":"Rectum, Colon","Source":"Tissue","Assay\/Test":"Immunohistochemistry|qRT-PCR","Usage":"PrognosticBM","Pmid":26363526,"Description":"Retinoid-interferon-induced mortality-19 (GRIM-19), a recently discovered cell death regulatory gene, may function as a tumor suppressor in many human malignancies.\u00a0 During a mean period of 40 months follow-up, patients without GRIM-19 had a statistically significantly lower rate of recurrence\/metastasis (P < .05) and a shorter overall survival time (P < .01) than the patients with GRIM-19 expression GRIM-19 expression is closely associated with CRC progression and might be a very promising prognostic biomarker for CRC patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":654},{"Name":"PLA2G4C SNP (rs1549637)","Molecular type":"DNA","Location":null,"Source":"Blood","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":26364726,"Description":"The phospholipase A2 (PLA2) family consists of enzymes defined by their ability to catalyze fatty acid from the\u00a0sn-2 position of glycerophospholipids. The cancer-specific survival differed between the genotypes (p\u2009=\u20090.019) and the carriers of the A allele were associated with the highest risk of CRC death, with a hazard ratio (HR) of 1.72 [95% confidence interval (CI) 1.17-2.53, p\u2009=\u20090.006] compared with homozygous carriers of the T allele.\u00a0 The A allele in PLA2G4C SNP (rs1549637) is associated with a worse prognosis in patients with CRC, especially in stage II disease, and it could be a potential prognostic\u00a0biomarker\u00a0in the planning of individual adjuvant therapy in stage II patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":655},{"Name":"Wilms' tumor gene (WT1)","Molecular type":"DNA","Location":null,"Source":"Tissue","Assay\/Test":"qPCR","Usage":"PrognosticBM","Pmid":26406403,"Description":"Wilms\u2019 tumor gene (WT1), 34-kDa translocase of the outer mitochondrial membrane (TOMM34). WT1 is a potential marker for prognosis and tumor progression in CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":656},{"Name":"SDF-1 ","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"RT-PCR|Immunohistochemistry","Usage":"PrognosticBM","Pmid":26406413,"Description":"Stromal cell-derived factor 1, a protein in cell biology Kaplan-Meier survival analysis revealed that high expression of the couple SDF-1\/CXCR4 correlated with poor prognosis of colorectal cancer patients (P < 0.001). Those proteins may potentially be used as an independent biomarker for the prognostic evaluation of colon cancer in the Tunisian cohort.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":657},{"Name":"CXCR4","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"RT-PCR|Immunohistochemistry","Usage":"PrognosticBM","Pmid":26406413,"Description":"C-X-C chemokine receptor type 4\u00a0(CXCR-4) also known as\u00a0fusin\u00a0or\u00a0CD184\u00a0(cluster of differentiation 184) is a\u00a0protein\u00a0that in humans is encoded by the\u00a0CXCR4\u00a0gene. Kaplan-Meier survival analysis revealed that high expression of the couple SDF-1\/CXCR4 correlated with poor prognosis of colorectal cancer patients (P < 0.001). Those proteins may potentially be used as an independent biomarker for the prognostic evaluation of colon cancer in the Tunisian cohort.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":658},{"Name":"Neuron navigator 2 (NAV2) ","Molecular type":"Protein","Location":"Rectum, Colon","Source":"Tissue","Assay\/Test":"Immunohistochemistry|qRT-PCR|Western blot","Usage":"PrognosticBM|PredictiveBM","Pmid":26452645,"Description":"NAV2\u00a0protein contains various functional domains, including a calponin homology (CH) domain, four coiled-coil (CC) domains, a cytoskeletal interacting domain (CSID), and an\u00a0AAA-domain. NAV2-positive tumors had a significantly lower OS rate than those with\u00a0NAV2-negative tumors (log-rank test,\u00a0p\u2009=\u20090.0004). NAV2 could serve as both a prognostic biomarker and a potential therapeutic target for patients with NAV2-positive CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":659},{"Name":"microRNA-144 (miR\u2011144)","Molecular type":"MicroRNA","Location":null,"Source":"Tissue","Assay\/Test":"RT-qPCR","Usage":"PredictiveBM","Pmid":26458302,"Description":"MiR-144\u00a0is a family of\u00a0microRNA\u00a0precursors found in\u00a0mammals, including\u00a0humans.\u00a0 Together, the data of the present study demonstrated that miR\u2011144 acts as a tumor suppressor by targeting ROCK1, and indicates the potential of miR\u2011144 as a novel biomarker and target in the treatment of rectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":660},{"Name":"SNORA42","Molecular type":"Small nucleolar RNAs (snoRNAs)","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":26475630,"Description":"Small nucleolar RNAs (snoRNAs) In the clinical validation cohort, increased SNORA42 expression was an independent prognostic factor for overall survival and disease-free survival, and was a risk factor for distant metastasis. SNORA42 appears to be a novel oncogene and could serve as a promising predictive biomarker for recurrence and prognosis in patients with CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":661},{"Name":"G9a","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT\u2013PCR|Immunohistochemistry","Usage":"PredictiveBM","Pmid":28351524,"Description":"G9a is a protein lysine methyltransferase involved\nin histone methylation and gene expression A significantly positive\ncorrelation was shown between G9a and CSCs marker CD133 in locally advanced rectal cancer patients\nwith CCRT Our study theorized that G9a might serve as a novel target in colon cancer, which offers exciting potential in prediction of response to preoperative chemoradiotherapy in patients with advanced CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":662},{"Name":"SHP-1","Molecular type":"Protein","Location":"Rectum, Colon","Source":"Tissue","Assay\/Test":"Western blot|Immunohistochemistry","Usage":"PrognosticBM|PredictiveBM","Pmid":26476076,"Description":"SH2 domain-containing phosphatase 1\u00a0(SHP-1) is a nonreceptor\u00a0protein tyrosine phosphatase\u00a0(PTP) that was first identified in hematopoietic cells and epithelial cells. Patients with strong SHP-1 and weak p-STAT3(Tyr705) expression had significantly higher overall survival compared with patients with weak SHP-1 and strong p-STAT3(Tyr705) expression (P = .029) SHP-1 is suitable to be a useful prognostic marker and a pharmacological target for CRC treatment.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":663},{"Name":"Hexokinase 1 (HK1)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":26476538,"Description":"The HK1 gene is localized in chromosome 10q22 and encodes a protein composed of 917 amino acids.\u00a0 The univariate analysis demonstrated that pT classification (P\u2009=\u20090.001), pN classification (P\u2009<\u20090.001), and pM classification (P\u2009<\u20090.001) affected the patients\u2019 overall survival. Importantly, multivariate analysis identified HK1 expression in CRC as an independent prognostic factor. Overexpression of HK1 may act as a significant biomarker of poor prognosis for patients with CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":664},{"Name":"Bone marrow stromal antigen 2 (BST2)","Molecular type":"Protein","Location":null,"Source":"Blood","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":26494939,"Description":"BST2, a type II transmembrane protein also known as\u00a0HM1.24\/CD317, has been identified to be overexpressed in a variety of cell lines from different cancer types. Immunohistochemical analysis revealed the overexpression of BST2 in CRC tissues, and higher BST2 expression levels correlated with poorer 5-year survival (46.47% versus 65.57%; p = 0.044). BST2, a membrane protein selectively detected in CRC cell secretome, may be a novel plasma biomarker and prognosticator for CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":665},{"Name":"Growth differentiation factor 15 (GDF15) ","Molecular type":"Protein","Location":"Rectum, Colon","Source":"Tissue","Assay\/Test":"RT-PCR|Immunohistochemistry","Usage":"PrognosticBM","Pmid":26497212,"Description":"GDF15\u00a0is a divergent member of the BMP- subfamily of the\u00a0TGF-\u03b2\u00a0superfamily, which is also designated as macrophage inhibitory cytokine-1 (MIC-1). Multivariate Cox analysis revealed\u00a0GDF15\u00a0as an independent prognostic factor (P\u00a0= 0.039). GDF15 could be considered as a novel prognostic marker for CRC in the clinic.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":666},{"Name":"Rac GTPase activating protein 1 (RACGAP1)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":26508373,"Description":"RACGAP1 belongs to the family of GTPase activation proteins and has an important influence on the initiation of cytokinesis, control of cell growth and differentiation, regulation of spermatogenesis, and tumor metastasis. Patients with high nuclear RACGAP1 expression had poor outcomes, whereas those with high cytoplasmic RACGAP1 expression had favorable prognosis (P = .003 and P = .001, respectively).\u00a0 We suggest that RACGAP1 expression levels in the nucleus and cytoplasm, determined by immunohistochemical staining, predict opposite clinical outcomes and that both could be independent prognostic markers for colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":667},{"Name":"Linc-POU3F3","Molecular type":"LncRNA","Location":null,"Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PredictiveBM","Pmid":26510906,"Description":"Linc-POU3F3 is a potential therapeutic target and novel molecular biomarker for CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":668},{"Name":"NEAT1","Molecular type":"Protein","Location":null,"Source":"Blood","Assay\/Test":"qRT-PCR","Usage":"DiagnosticBM|PrognosticBM","Pmid":26552600,"Description":"NEAT1\u00a0is an essential component of nuclear paraspeckles. NEAT1_v1 and NEAT1_v2 expression were highly accurate in distinguishing colorectal cancer patients from NCs (area under the curve: 0.787 and 0.871, respectively).\u00a0 Whole blood NEAT1 expression is a novel diagnostic and prognostic biomarker of overall survival in colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":669},{"Name":"VE1 antibody","Molecular type":"Protein","Location":"Colon","Source":"Tissue","Assay\/Test":"Immunohistochemistry|PCR","Usage":"PrognosticBM","Pmid":26588428,"Description":"The sensitivity and specificity of VE1 expression in detecting the BRAF mutation was 91.3% and 98.8%, respectively. Immunohistochemistry for VE1 antibody is a sensitive and specific marker for detection of BRAF mutations in CRCs. I","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":670},{"Name":"Serum uric acid ","Molecular type":null,"Location":"Colon","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":26781472,"Description":"Uric acid is a heterocyclic compound of carbon, nitrogen, oxygen, and hydrogen with the formula C5H4N4O3.  There was relationship between increase of uric acid level of third month uric acid level and stable disease (p < 0.001). There was a significant overall survival increased in the group with increased uric acid level (p < 0.001). The decline of CEA level was related to uric acid level (p < 0.022).  This study is the first showing significant increases of serum uric acid in patients with metastatic colorectal cancer who favorably responded to chemotherapy with bevacizumab.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":671},{"Name":"micrometastasis volume","Molecular type":null,"Location":"Colon, Rectum","Source":"Blood","Assay\/Test":"RT-PCR","Usage":"PrognosticBM","Pmid":26831719,"Description":"Multivariate Cox regression analyses revealed that a high micrometastasis volume (high MMV, n = 95) was an independent poor prognostic factor for 5-year disease-free survival (DFS; P = 0.001) and 5-year overall survival (OS; P = 0.016). This prospective clinical trial demonstrates that micrometastasis volume is a useful marker in identifying patients who are at high or low risk for recurrence of stage II colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":672},{"Name":"Amphiregulin (AR)","Molecular type":"Protein","Location":null,"Source":"Blood","Assay\/Test":"Proseek Multiplex Oncology","Usage":"DiagnosticBM","Pmid":26836253,"Description":"Amphiregulin, also known as AREG, is a protein that in humans is encoded by the AREG gene. AUC0.81 Confirmation rates were 50.0%, 84.5%, and 74.2% for one-, two-, and three-marker algorithms identified in the screening setting and were 42.9%, 18.6%, and 25.7% for algorithms identified in the clinical setting.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":673},{"Name":"KCTD12","Molecular type":"Protein","Location":"Rectum, Colon","Source":"Tissue","Assay\/Test":"Immunohistochemistry|qRT-PCR","Usage":"PrognosticBM|PredictiveBM","Pmid":26847701,"Description":"KCTD12\u00a0(potassium channel tetramerization domain containing 12, pfetin), which contains a voltage-gated potassium (K+) channel tetramerization T1 domain and a BTB\/POZ (Bric-a-brac, Tram-track, Broad complex poxvirus and zinc finger) domain, belongs to the KCTD family and was initially identified in cochlea. This report reveals that KCTD12 is a novel regulator of CRC cell stemness and may serve as a novel prognostic marker and therapeutic target for patients with CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":674},{"Name":"lncRNA TUG1","Molecular type":"LncRNA","Location":null,"Source":"Tissue","Assay\/Test":"RT-qPCR|Western blot","Usage":"PredictiveBM","Pmid":26856330,"Description":"LincRNA\u00a0taurine up-regulated gene 1\u00a0(TUG1; also known as TI-227H; Linc00080; ncRNA00080) was originally identified as a transcript up-regulated by\u00a0taurine\u00a0and is found to be expressed in various human cancer cell lines and tumors. TUG1 may have potential roles as a biomarker and\/or a therapeutic target in colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":675},{"Name":"CXCR3 ","Molecular type":"Protein","Location":"Rectum, Colon","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":26870351,"Description":"Chemokine receptor CXCR3\u00a0is a G\u03b1i\u00a0protein-coupled receptor in the\u00a0CXC chemokine receptor\u00a0family. Patients with recurrence exhibited higher CXCR3 (P<0.001) and CXCL10 (P<0.001) expression compared with non-recurrent patients, as determined by IHC. CXCR3 expression may be used as a prognostic marker and may contribute to the prediction of clinical outcome in stage II CRC patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":676},{"Name":"17\u03b2-Hydroxysteroid dehydrogenase type 10 (HSD10)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Real time RT-PCR|Western blot|Immunohistochemistry","Usage":"PrognosticBM","Pmid":26884257,"Description":"7-ketosteroid oxidoreductases,\u00a0HSD17B,\u00a017-ketosteroid reductases,\u00a017-KSR, are a group of\u00a0alcohol oxidoreductases\u00a0which\u00a0catalyse\u00a0the\u00a0dehydrogenation\u00a0of 17-hydroxysteroids\u00a0in\u00a0steroidogenesis. The Kaplan\u2013Meier and log-rank analysis revealed a highly significant association between HSD10 overexpression in the tumor and overall survival (OS) (p\u2009<\u20090.001).\u00a0 HSD10 protein analysis may be of prognostic value.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":677},{"Name":"Interferon-induced transmembrane protein 1 (IFITM1)","Molecular type":"Protein","Location":"Rectum, Colon","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":26884876,"Description":"INF-induced\u00a0transmembrane protein 1\u00a0(IFITM1) is a member of the\u00a0IFN-inducible transmembrane protein family and a component of multimeric complex involved in the transduction of anti-proliferation and cell adhesion signals. Univariate Cox regression suggested that older age and poorly differentiation status predict shorter overall survival in colorectal cancer (P<0.05). IFITM1 may serve as an independent prognostic biomarker for colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":678},{"Name":"Forkhead box C2 (Foxc2)","Molecular type":"DNA","Location":null,"Source":"Tissue","Assay\/Test":"RT-qPCR|Western blot","Usage":"PrognosticBM","Pmid":26893778,"Description":"The forkhead box C2 (Foxc2) gene was first identified in mice during embryogenesis. Foxc2 may serve as a valuable clinical prognostic marker for CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":679},{"Name":"microRNA-21 (miR-21)","Molecular type":"MicroRNA","Location":"Rectum, Colon","Source":"Blood","Assay\/Test":"qRT-PCR","Usage":"DiagnosticBM|PrognosticBM","Pmid":26898324,"Description":"MicroRNA-210 (miR-210), the master hypoxamir, is overexpressed and generally exhibits oncogenic properties in most human solid tumours, including colorectal cancer (CRC).\u00a0 The area under the receiver operating characteristic curve (AUC) of circulating miR-210 to detect CRC was 0.821, with a sensitivity of 74.6% and a specificity of 73.5%.\u00a0 Our data suggested that circulating miR-210 could be a potential non-invasive marker for diagnosis and prognosis of CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":680},{"Name":"Zinc-finger protein X-linked (ZFX)","Molecular type":"Protein","Location":"Rectum, Colon","Source":"Tissue","Assay\/Test":"Western blot|qRT-PCR|Immunohistochemistry","Usage":"PrognosticBM|PredictiveBM","Pmid":26967242,"Description":"Zinc-finger protein X-linked\u00a0(ZFX) is a member of Kr\u00fcppel-type zinc finger protein family and was originally identified as a critical regulator of self-renewal in both embryonic and hematopoietic stem cells. ZFX is a novel prognostic biomarker and potentially useful therapeutic target in stage II\/III CRC patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":681},{"Name":"microRNA-543 (miR-543)","Molecular type":"MicroRNA","Location":null,"Source":"Tissue","Assay\/Test":"Western blot|qRT-PCR|Immunohistochemistry","Usage":"DiagnosticBM|PrognosticBM","Pmid":26968810,"Description":"MiR-543 has been implicated as having a critical role in the development of breast cancer, endometrial cancer and hepatocellular carcinoma.\u00a0 MiR-543 may serve as a novel diagnostic and prognostic biomarker for CRC metastasis.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":682},{"Name":"PRKDC","Molecular type":null,"Location":null,"Source":"Tissue","Assay\/Test":"Immunoblot|qRT-PCR","Usage":"PrognosticBM|PredictiveBM","Pmid":26992638,"Description":"DNA-dependent protein kinase, catalytic subunit, also known as\u00a0DNA-PKcs, is an\u00a0enzyme\u00a0that in humans is encoded by the\u00a0gene\u00a0designated as\u00a0PRKDC\u00a0or\u00a0XRCC7. Kaplan-Meier curves for patients with low or high PRKDC expression in their tumor samples. N=25 for each group. Long-rank test P-value: 0.0062. PRKDC is an essential gene required for CRC cell proliferation\/survival, which may represent as a potential prognostic biomarker and an ideal therapeutic target for CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":683},{"Name":"CYP24A1","Molecular type":"DNA","Location":"Rectum, Colon","Source":"Tissue","Assay\/Test":"Immunohistochemistry|qRT-PCR","Usage":"PrognosticBM","Pmid":26997443,"Description":"24-Hydroxylase, encoded by the\u00a0CYP24A1\u00a0gene, is the key enzyme that catabolizes 1,25(OH)2D3\u00a0to the less active calcitroic acid. A Kaplan-Meier analysis of the CRC patients with high CYP24A1 expression showed significantly reduced overall survival and disease-free survival compared to the patients with low expression (P = 0.026 and .009). CYP24A1 expression is closely associated with CRC progression, and it might be a novel prognostic biomarker for CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":684},{"Name":"RAS mutation","Molecular type":"DNA","Location":"Colon","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":27004837,"Description":"Ras is a family of related proteins which is expressed in all animal cell lineages and organs. With a median follow-up of 84.1 months (57.2-NA) for a survivor, the 4-year OS rate was 65.6% for mCRC with RAS mutation, and 81.3% for mCRC with wild-type RAS (p\u2009<\u20090.05).  RAS mutation is a prognostic biomarker in colorectal cancer patients with metastasectomy.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":685},{"Name":"Cancer susceptibility candidate 11 (CASC11) ","Molecular type":null,"Location":null,"Source":"Tissue","Assay\/Test":"qRT-PCR|Western blot|Immunohistochemistry|COIP|ChIP","Usage":"DiagnosticBM|PredictiveBM","Pmid":27012187,"Description":"Cancer susceptibility candidate 11 (CASC11) located in the chromosome 8q24 gene desert ~2.1\u2009kb upstream of c-Myc. Or findings indicate that the novel lncRNA CASC11 may serve as a candidate diagnostic biomarker and a promising therapeutic target for CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":686},{"Name":"Sciellin (SCEL)","Molecular type":null,"Location":null,"Source":"Tissue","Assay\/Test":"Western blot|Immunohistochemistry","Usage":"PredictiveBM","Pmid":27013588,"Description":"Sciellin\u00a0(SCEL), a precursor of the cornified envelope, contains 16 inexact repeats of 20 amino acids and a\u00a0LIM\u00a0domain that may function as a protein interaction module regulating the localization of\u00a0SCEL\u00a0and protein assembly in the cornified envelope. They suggest SCEL may be a useful therapeutic target for preventing or eliminating CRC hepatic metastasis.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":687},{"Name":"Human homolog of Drosophila prune protein (h-prune; HGNC13420)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry  assay|Western blot|Migration assay|Real-time reverse transcription\u2013polymerase chain reaction (qRT-PCR)|Cytotoxicity assay|In vivo metastasis assays","Usage":"PrognosticBM","Pmid":27037526,"Description":"Human homolog of Drosophila prune protein (h-prune) belongs to the DHH superfamily. The overall survival rate was significantly lower in h-prune-positive cases than in h-prune-negative cases (p\u2009=\u20090.003). h-Prune could be a new prognostic marker and molecular target for CRLM.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":688},{"Name":"h-Prune ","Molecular type":"Protein","Location":"Rectum, Colon","Source":"Tissue","Assay\/Test":"Immunohistochemistry|Western blot|qRT-PCR","Usage":"PrognosticBM","Pmid":27037526,"Description":"Human homolog of\u00a0Drosophila\u00a0prune protein (h-prune) belongs to the DHH superfamily. The overall survival rate was significantly lower in h-prune-positive cases than in h-prune-negative cases (p\u2009=\u20090.003).\u00a0 h-Prune could be a new prognostic marker and molecular target for CRLM.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":689},{"Name":"Myosin VI (MYO6)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Western blot|qPCR","Usage":"PredictiveBM","Pmid":27044563,"Description":"Myosin VI\u00a0(MYO6)\u00a0is a unique member of the unconventional myosin family, and a reverse-direction motor protein that moves toward the minus-end of actin filaments.\u00a0 These results suggest that MYO6 may promote cell growth and may be used as a potential target for anticancer therapy of CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":690},{"Name":"Rab3D","Molecular type":"Protein","Location":"Rectum, Colon","Source":"Tissue","Assay\/Test":"qRT-PCR|Immunohistochemistry|Western blot","Usage":"PrognosticBM","Pmid":27046094,"Description":"Rab proteins, belonging to a member of the Ras superfamily of monomeric G proteins, localize to distinct cellular compartments and regulate specific steps of intracellular membrane trafficking. We also demonstrated that overall survival is poor in CRC patients with high expression of Rab3D (p<0.001). This study establishes increased Rab3D expression is associated with invasiveness of CRC cells, and Rab3D expression status may serve as a reliable prognostic biomarker in CRC patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":691},{"Name":"Fatty acid-binding proteins 5 (FABP5)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"qRT-PCR|Western blot","Usage":"PrognosticBM|PredictiveBM","Pmid":27047747,"Description":"Fatty acid\u2010binding proteins (FABPs) are members of the intracellular lipid\u2010binding proteins that bind intracellular hydrophobic ligands such as long\u2010chain\u00a0fatty acids. FABP5 might be a promising prognostic or therapeutic biomarker candidate in human colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":692},{"Name":"A-kinase anchor protein (AKAP4)","Molecular type":"Protein","Location":null,"Source":"Blood","Assay\/Test":"RT-PCR|Immunohistochemistry","Usage":"DiagnosticBM","Pmid":27057472,"Description":"AKAP4, a new member of CT antigen protein family, is expressed exclusively in male germ cells during spermatogenesis. AKAP4 protein expression, based on immunoreactivity score (IRS) predicted presence of CRC with 84% sensitivity, 100% specificity, 100% of positive predictive value (PPV) and 83.33% negative predictive value (NPV).\u00a0 AKAP4 may be potential candidate molecule for developing as a biomarker for early diagnosis and immunotherapy of CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":693},{"Name":"Anillin (ANLN)","Molecular type":"Protein","Location":"Rectum, Colon","Source":"Tissue","Assay\/Test":"qRT-PCR|Immunohistochemistry|Western blot","Usage":"PrognosticBM","Pmid":27062703,"Description":"ANLN (Anillin) is a 124 kDa protein, which was initially found as an actin-binding protein in Dorsophilia. ANLN expression is elevated in CRC and has a strong potential to act as a biomarker for the prognosis of CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":694},{"Name":"Glutathione S-transferase alpha 4 (GSTA4)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"qRT\u2013PCR|Immunohistochemistry","Usage":"DiagnosticBM","Pmid":27065323,"Description":"Glutathione S-transferase alpha 4 (GSTA4) is a phase II detoxifying enzyme that metabolizes electrophiles and carcinogens including 4-hydroxy-2-nonenal (4-HNE), an endogenous carcinogen that contributes to colorectal carcinogenesis. GSTA4 is a potential surrogate biomarker for CRC screening and should provide novel approaches for chemoprevention.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":695},{"Name":"microRNA-517a (miR-517a)","Molecular type":"MicroRNA","Location":null,"Source":"Tissue","Assay\/Test":"RT-qPCR|Western blot|Immunohistochemistry","Usage":"PrognosticBM","Pmid":27073521,"Description":"MiR-517a\u00a0is considered to be a novel oncomiR and was observed to be elevated in human\u00a0hepatocellular carcinoma\u00a0(HCC); expression of\u00a0miR-517a\u00a0increased proliferation, migration, and invasion of\u00a0HCC\u00a0cells\u00a0in vitro. MiR-517a is an independent prognostic marker and contributes to cell migration and invasion in human colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":696},{"Name":"combination of CELA1, CTRL","Molecular type":"Protein","Location":"Colon","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"DiagnosticBM","Pmid":27081040,"Description":"Chymotrypsin-like elastase family member 1 (CELA1) also known as elastase-1 (ELA1) is an enzyme that in humans is encoded by the CELA1 gene. Elastases form a subfamily of serine proteases that hydrolyze many proteins in addition to elastin. Centriolin is a protein that in humans is encoded by the CNTRL gene. It was previously known as CEP110. Centriolin is a protein that in humans is encoded by the CNTRL gene. It was previously known as CEP110. The receiver operating characteristic analysis illustrated that the combination of CELA1 and CTRL reached the best diagnostic performance, with 90.0% sensitivity and 80.0% specificity. ","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":697},{"Name":"STEAP1 (six transmembrane epithelial antigen of the prostate 1)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":27104516,"Description":"STEAP1 (six transmembrane epithelial antigen of the prostate 1) is a transmembrane protein that functions as a potential channel or transporter protein.\u00a0 Low STEAP1 expression was correlated with poor overall survival (five-year survival: 33.7% vs. 57.0%, low expression vs. high expression, p = 0.020). We suggest that analysis of STEAP1 expression by immunohistochemical staining could serve as an independent prognostic marker for colorectal patients","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":698},{"Name":"Tumour-associated macrophages (TAMs)","Molecular type":null,"Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry|Morphometrical assay","Usage":"PrognosticBM","Pmid":27105577,"Description":"Tumor-associated macrophages (TAMs) are a type of cell belonging to the macrophage lineage.  A significant correlation was found between TAMs, TAMIA, MVD and EA each other (r ranging from 0.69 to 0.84; P ranging from 0.000 to 0.004). The high level of expression of TAMs and TAMIA in tumour tissue and the significant correlation with both MVD and EA illustrate that TAMs could represent a marker that plays an important role in promoting angiogenesis-mediated CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":699},{"Name":"Serine protease inhibitor Kazal-type 1\u00a0(SPINK1)","Molecular type":"Protein","Location":"Rectum, Colon","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM|PredictiveBM","Pmid":27107100,"Description":"Serine peptidase inhibitor Kazal type-1 (SPINK1), a trypsin kinase inhibitor, has well established associations with inflammation, cancer cell proliferation and carcinogenesis. Kaplan-Meier analyses also showed that patients with high SPINK1 expression had significantly longer overall survival compared with controls (p=0.004). As SPINK1 expression is also an independent prognostic marker in these patients, it has potential use as a biomarker for clinical decision making and for designing personalised targeted therapies.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":700},{"Name":"Pinin (PNN) ","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Western blot|qPCR|Immunohistochemistry|Immunofluorescence","Usage":"PrognosticBM","Pmid":27107420,"Description":"Pinin\u00a0(PNN), a 140 kDa phosphoprotein, was first identified and characterized as a desmosome-associated molecule\u00a0 Kaplan-Meier analysis revealed that a high-level\u00a0PNN\u00a0was associated with a short overall survival of patients with\u00a0CRC\u00a0(p=0.015). Our findings suggested that PNN, as a valuable marker of prognosis, has important influence on the progression of CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":701},{"Name":"microRNA-135a-5p (miR-135a-5p)","Molecular type":"MicroRNA","Location":"Colon, Rectum","Source":"Blood","Assay\/Test":"qRT-PCR","Usage":"DiagnosticBM","Pmid":27126269,"Description":"MicroRNA There was no significant correlation between the relative expression of serum miR-135a-5p and carcinoembryonic antigen ( r2\u2009=\u20090.023, P\u2009=\u20090.293) or carbohydrate antigen 199 ( r2\u2009=\u20090.067, P\u2009=\u20090.068) in colorectal cancer patients. Compared with colorectal polyps group, AUCROC\u00a0of serum miR-135a-5p in colorectal cancer group was 0.832 with 95% CI 0.73-0.93; compared with healthy control group, AUCROC\u00a0was 0.875 with 95% CI 0.80-0.95.\u00a0 serum miR-135a-5p may prove to be an important  biomarker for auxiliary diagnosis of colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":702},{"Name":"Cytokeratin 20 (CK20)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Blood","Assay\/Test":"RT-PCR","Usage":"PrognosticBM","Pmid":27144776,"Description":"Keratin 20, often abbreviated CK20, is a protein that in humans is encoded by the KRT20 gene. In patients positive for CK20 postoperatively both progression-free survival (PFS) and overall survival were significantly shorter than in patients negative for CK20 postoperatively, while the difference between patients positive and negative for CK20 preoperatively was not statistically significant in terms of neither PFS nor overall survival. CK20 expression profile could be a factor in weighting treatment options in CRC patients. In cases where multiple treatment options are possible, patients with positive postoperative CK20 expression could be candidates to receive more aggressive treatment.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":703},{"Name":"Tumour necrosis percentage ","Molecular type":null,"Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":27195424,"Description":"Tumour necrosis is a feature often presented in human solid tumours. Tumour necrosis positively correlated with tumour stage (P=8.5E-4)-especially with T class (4.0E-6)-and inversely correlated with serrated histology (P=0.014) Tumour necrosis percentage is a relevant histomorphological prognostic indicator in CRC. ","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":704},{"Name":"prognostic nutritional index (PNI)","Molecular type":null,"Location":"Colon, Rectum","Source":"Blood","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":27222402,"Description":"The prognostic nutritional index (PNI), which is calculated based on the serum albumin concentration and the peripheral blood lymphocyte count, has been used to assess the immunological and nutritional condition of patients with digestive diseases. Age, American Society of Anesthesiologists (ASA) score, tumor location, number of harvested lymph nodes, venous invasion, perineural invasion, adjuvant treatment and PNI (HR\u2009=\u20091.534, 95%CI: 1.065-2.211, P\u2009=\u20090.022; HR\u2009=\u20091.915, 95%CI: 1.286-2.852, P\u2009=\u20090.001 for DFS and OS, respectively) were independent significant prognostic factors for both DFS and OS. PNI can be a prognostic marker in stage IIA colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":705},{"Name":"NDUFA4L2","Molecular type":"Protein","Location":"Rectum, Colon","Source":"Tissue","Assay\/Test":"RT-PCR|Western blot","Usage":"PrognosticBM","Pmid":27226356,"Description":"NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4-like 2\u00a0is a\u00a0protein\u00a0that in humans is encoded by the NDUFA4L2\u00a0gene. The NDUFA4L2 protein is a subunit of NADH dehydrogenase (ubiquinone), which is located in the mitochondrial inner membrane and is the largest of the five complexes of the electron transport chain. Multivariate analysis indicated that overexpression of NDUFA4L2 was an independent prognostic factor for CRC patients (P\u2009=\u20090.002). NDUFA4L2-negative patients had a higher tumour-free\/overall survival rate than patients with high NDUFA4L2 expression (P\u2009=\u20090.001 and 0.002, respectively). Our data suggest that NDUFA4L2 overexpression is associated with tumour progression and a poor prognosis in CRC patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":706},{"Name":"Transforming acidic coiled-coil protein-3 (TACC3)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry|Quantitative real-time RT-PCR|Western blot","Usage":"PrognosticBM","Pmid":27248823,"Description":"Transforming acidic coiled-coil protein-3 (TACC3), a frequently aberrantly expressed oncogene, is an important biomarker in various human cancers. Patients who had high TACC3 expression had significantly poorer overall survival (OS, P = 0.023) and disease-free survival (DFS, P = 0.019) compared to patients who had low TACC3 expression.  These data indicate that TACC3 promotes CRC progression and could be an independent prognostic factor and a potential therapeutic target for CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":707},{"Name":"PDGFR-\u03b2","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry|Digital image analyses","Usage":"PrognosticBM","Pmid":27248825,"Description":"This gene encodes a typical receptor tyrosine kinase, which is a transmembrane protein consisting of an extracellular ligand binding domain, a transmembrane domain and an intracellular tyrosine kinase domain. The molecular mass of the mature, glycosylated PDGFR\u03b1 protein is approximately 170 kDA. cell surface tyrosine kinase receptor for members of the platelet-derived growth factor family. Low expression of either PDGFR-\u03b1 or PDGFR-\u03b2 was associated with significantly shorter overall survival (OS) (Figure 3A) with median OS 18.2 and 24.1 months for low and high PDGFR-\u03b1 (p = 0.024) and 14.3 and 23.0 months for low and high PDGFR-\u03b2 (p = 0.014), respectively. Perivascular PDGFR-\u03b1 and -\u03b2 were identified as novel independent markers predicting survival in mCRC. ","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":708},{"Name":"PDGFR-\u03b1","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry|Digital image analyses","Usage":"PrognosticBM","Pmid":27248825,"Description":"This gene encodes a typical receptor tyrosine kinase, which is a transmembrane protein consisting of an extracellular ligand binding domain, a transmembrane domain and an intracellular tyrosine kinase domain. The molecular mass of the mature, glycosylated PDGFR\u03b1 protein is approximately 170 kDA. cell surface tyrosine kinase receptor for members of the platelet-derived growth factor family. Low expression of either PDGFR-\u03b1 or PDGFR-\u03b2 was associated with significantly shorter overall survival (OS) (Figure 3A) with median OS 18.2 and 24.1 months for low and high PDGFR-\u03b1 (p = 0.024) and 14.3 and 23.0 months for low and high PDGFR-\u03b2 (p = 0.014), respectively. Perivascular PDGFR-\u03b1 and -\u03b2 were identified as novel independent markers predicting survival in mCRC. ","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":709},{"Name":"Methylated ctDNA (MetctDNA)","Molecular type":"DNA","Location":null,"Source":"Tissue","Assay\/Test":"NGS|PICOLITER DROPLET-dPCR|DATA||STATISTICAL","Usage":"PrognosticBM","Pmid":27251038,"Description":"Methylated DNA immunoprecipitation (MeDIP or mDIP) is a large-scale (chromosome- or genome-wide) purification technique in molecular biology that is used to enrich for methylated DNA sequences. Methylated ctDNA (MetctDNA) was detected in 80% of metastatic CRC and 45% of localized CRC.  These results indicate that MetctDNA could be used as a universal surrogate\u00a0marker\u00a0for tumor follow-up in CRC patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":710},{"Name":"microRNA-31 (miR-31) ","Molecular type":"MicroRNA","Location":null,"Source":"Tissue","Assay\/Test":"RT-PCR","Usage":"PrognosticBM","Pmid":27271609,"Description":"MiR-31 has been characterised as a tumour suppressor miRNA, with its levels varying in breast cancer cells according to the metastatic state of the tumour. Its overexpression significantly predicted poor pathological response (p = 0.018) and worse overall survival (OS) (p = 0.008). The odds ratio for no pathological response among patients with miR-31 overexpression was 0.18 (Confidence Interval = 0.06 to 0.57; p = 0.003). Altogether, miR-31 quantification emerges as a novel valuable clinical tool to predict both pathological response and outcome in LARC patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":711},{"Name":"S100A4","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry|Spheroid assay","Usage":"PrognosticBM","Pmid":27273130,"Description":"S100 calcium-binding protein A4 (S100A4) is a protein that in humans is encoded by the S100A4 gene. In both cohorts, nuclear immunoreactivity was associated with reduced relapse-free (P < 0.001 and P = 0.010) and overall survival (P = 0.046 and P = 0.006) in univariate analysis. In multivariate analysis, nuclear S100A4 was a predictor of poor relapse-free survival in the consecutive series (P = 0.002; HR 1.9) The present study confirms that nuclear S100A4 expression is a negative prognostic biomarker in colorectal cancer","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":712},{"Name":"Y-Box-binding protein-1 (YB-1)","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":27354655,"Description":"Y-Box-binding protein-1 (YB-1), a DNA\/RNA-binding protein, is an important oncogenic transcription and translation factor. High-grade nuclear YB-1 expression was detected in 62.9% of cases and was found to be an independent predictor of poorer overall survival (p<0.001) and relapse-free survival (p<0.001). Nuclear YB-1 expression is a useful prognostic biomarker that correlates with EGFR status in patients with CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":713},{"Name":"Combination of CCR4, TNF-\u03b1","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry|qRT-PCR|Western blot|Chromatin immunoprecipitation","Usage":"PrognosticBM","Pmid":27356745,"Description":"C-C chemokine receptor type 4 is a protein that in humans is encoded by the CCR4 gene. Tumor necrosis factor (TNF, tumor necrosis factor alpha, TNF\u03b1, cachexin, or cachectin) is a cell signaling protein (cytokine) involved in systemic inflammation and is one of the cytokines that make up the acute phase reaction. The expression of TNF-\u03b1 was examined in the TMA and a significant higher level was found in tumor specimens than that in normal specimens (P = 0.002). CRC patients whose tumors with high levels of both CCR4 and TNF-\u03b1 exhibited worst prognoses (OS: P = 0.022, DFS: P = 0.021).  Combination of CCR4 and TNF-\u03b1 is a more powerful prognostic marker for CRC patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":714},{"Name":"Metalloproteases meprin-\u0251 (MEP1A) ","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Reverse transcription PCR|quantitative RT-PCR|Western blot|Immunohistochemistry","Usage":"PrognosticBM","Pmid":27378469,"Description":"Meprin is a member of the astacin family and a zinc metalloendopeptidase that was initially discovered as a protease that was highly expressed at kidney brush border membranes and intestinal epithelial cells.  The expression of MEP1A is an independent prognostic factor for overall survival in CRC (HR 3.643; 95 % CI 0.305-5.842; P\u2009=\u20090.007). MEP1A was not only found to be functionally important, but it might also serve as an important and unique indicator of patient prognosis and therapeutic targeting in CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":715},{"Name":"Carbon atomsC10","Molecular type":"Protein","Location":null,"Source":"Blood","Assay\/Test":"Immunohistochemistry","Usage":"DiagnosticBM","Pmid":27379390,"Description":"carbon atoms Receiver operating characteristic (ROC) curves obtained for the C10 fatty acid gave an area under the curve of 0.8195 along with a sensitivity of 87.8 % and a specificity of 80 % C10 fatty acid gave an area under the curve of 0.8195 along with a sensitivity of 87.8 % and a specificity of 80 %, strongly suggesting that it could be a valuable early diagnostic biomarker of CRC","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":716},{"Name":"Polo-like kinase 2 (Plk2) ","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":27423313,"Description":"Polo-like kinases (Plks) are regulatory serine\/threonin kinases of the cell cycle involved in mitotic entry, mitotic exit, spindle formation, cytokinesis Our data showed a significant correlation between Plk2 expression and tumor size (P\u2009=\u20090.023), extent of invasion (P\u2009=\u20090.022), lymph node metastasis (P\u2009=\u20090.010) and TNM stage (P\u2009=\u20090.006). In conclusion, our data show that Plk2 represents an independent prognostic marker and regulates tumor growth and apoptosis by targeting Fbxw7\/Cyclin E pathway in CRC, suggesting Plk2 as a potential therapeutic target.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":717},{"Name":"microRNA-21 (miR-21) ","Molecular type":"MicroRNA","Location":"Colon, Rectum","Source":"Blood","Assay\/Test":"qRT-PCR","Usage":"DiagnosticBM","Pmid":27432735,"Description":"The sensitivity and specificity of miR-21 was found to be 86.05% and 72.97%, respectively (an area under the ROC curve [AUC] of 0.783).\u00a0 The results of this study indicated that miR-21 expression levels in serum and stool can be considered as a potential diagnostic biomarker for the diagnosis of CRC patients. ","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":718},{"Name":"Leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5)","Molecular type":"DNA","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":27435662,"Description":"Leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5) also known as G-protein coupled receptor 49 (GPR49) or G-protein coupled receptor 67 (GPR67) is a protein that in humans is encoded by the LGR5 gene. For all CRC patients, positive LGR5 mRNA and CD133 expression were associated with classic adenocarcinoma histology type (p\u2009=\u20090.001 and p\u2009=\u20090.014, respectively).  LGR5 mRNA expression is a prognostic factor for CRC stage II patients","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":719},{"Name":"Syndecan-1 (CD138)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Blood","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":27472156,"Description":"The protein encoded by this gene is a transmembrane (type I) heparan sulfate proteoglycan and is a member of the syndecan proteoglycan family. OS determinants were assessed and, based on the final multivariate model, a prognostic score was proposed. Two independent OS prognostic factors were identified: Lactate Dehydrogenase (LDH) high level (p\u2009=\u20090.0066) and log-CD138 high level (p\u2009=\u20090.0190). Our study provides robust evidence in favor of the additional baseline soluble CD138 prognostic value for OS, in mCRC patients. A simple biological scoring system is proposed including LDH and CD138 binary status values. ","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":720},{"Name":"Nucleolar protein 66 (NO66) ","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR|Immunohistochemistry","Usage":"PrognosticBM","Pmid":27473587,"Description":"NO66, one of the JMJD histone demethylases, recognizes both histone H3 at lysine 4 (H3K4me3) and lysine 36 (H3K36) as a substrate, and inhibits the transcription of target genes Multivariate analysis indicated that NO66 was an independent prognostic factor for overall survival. In vitro assays revealed that NO66 expression is closely associated with malignant potential, including proliferation, migration and anti-apoptotic activity. NO66 is an independent prognostic factor in CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":721},{"Name":"Nucleolar protein 66 (NO66 [C14orf169\/MAPJD])","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR|Immunohistochemistry|Western Blot|Gene Set Enrichment","Usage":"PrognosticBM","Pmid":27473587,"Description":"NO66, one of the JMJD histone demethylases, recognizes both histone H3 at lysine 4 (H3K4me3) and lysine 36 (H3K36) as a substrate, and inhibits the transcription of target genes. High expression levels of NO66 were associated with cancer metastatic potential, including lymphatic duct invasion (p = 0.047), venous invasion (p = 0.033), and lymph node metastasis (p = 0.015). NO66 is an independent prognostic factor in CRC. The cancer-selective expression patterns and its involvement in metastatic phenotypes suggest that NO66 is not only a crucial biomarker but is also a promising therapeutic target in CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":722},{"Name":"Hes1 ","Molecular type":"LncRNA ","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":27476040,"Description":"A Notch-induced transcription factor  Patients with loss of nuclear expression of Hes1 had a significantly worse all-cause 5-year survival in both univariate (P = .002) and multivariate (P = .009) analysis. We conclude that loss of nuclear expression of Hes1 occurs in 83% of CRCs when studied in tissue microarray format and is associated with female sex, right-sided location, BRAFV600E mutation, microsatellite instability, larger tumor size, and significantly worse survival.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":723},{"Name":"microRNA-449a (miR-449a)","Molecular type":"MicroRNA","Location":"Colon","Source":"Tissue","Assay\/Test":"RT-PCR|Western blot|Immunohistochemistry|Flow cytometry","Usage":"PrognosticBM","Pmid":27486765,"Description":"Our findings demonstrate the existence of a miR-449a-SATB2 negative feedback loop that maintains low levels of miR-449a as well as high level of SATB2, thereby promoting CRC development.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":724},{"Name":"Chemokine (C-C motif) ligand 15 (CCL15) ","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Quantitative reverse transcription PCR|Western blot|Immunohistochemistry","Usage":"PrognosticBM","Pmid":27492974,"Description":"Chemokine (C-C motif) ligand 15 (CCL15) is a small cytokine belonging to the CC chemokine family that is also known as leukotactin-1, MIP5 and HCC-2. CCL15 is expressed in liver, small intestine, colon, and in certain leukocytes and macrophages of the lung. We also analyzed overall survival (OS) of 81 patients who underwent pulmonary resection (Supplementary Fig. S3A), and found that CCL15 expression tended to correlate with shorter OS although without a significant difference (P = 0.14; Supplementary Fig. S3B). CCL15 can be a biomarker indicating poor prognosis of CRC patients with lung metastases.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":725},{"Name":"CCL15-CCR1\u00a0","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Quantitative reverse transcription PCR|Western blot|Immunohistochemistry","Usage":"PrognosticBM","Pmid":27492974,"Description":"Chemokine (C-C motif) ligand 15 (CCL15) is a small cytokine belonging to the CC chemokine family that is also known as leukotactin-1, MIP5 and HCC-2. CCL15 is expressed in liver, small intestine, colon, and in certain leukocytes and macrophages of the lung. C-C chemokine receptor type 1 is a protein that in humans is encoded by the CCR1 gene. Metastasis frequencies of HCT116 clones to lungs at 28 days after injection. Metastasis frequencies based on the numbers of lungs or the number of mice were shown (Fisher exact test;\u00a0P\u00a0= 0.12 and 0.39, respectively CCL15-CCR1 axis may be a therapeutic target to prevent colorectal cancer lung metastasis.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":726},{"Name":"Seven-gene signature (NHLRC3, ZDHHC21, PRR14L, CCBL1, PTPRB, PNPO,, PPIP5K2)","Molecular type":"DNA","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Gene expression microarray|Gene signature identification","Usage":"PrognosticBM","Pmid":27494884,"Description":"Seven-gene signature We developed a robust seven-gene signature that can predict the OS for CRC patients, providing new insights into identification of CRC patients with high risk of mortality.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":727},{"Name":"Dual-specificity tyrosine-phosphorylation-regulated kinase 2 (DYRK2)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"RT-PCR|Western blot|Cell cycle|Wound-healing|transwell assays|Immunohistochemistry","Usage":"PrognosticBM","Pmid":27532268,"Description":"Dual-specificity tyrosine-phosphorylation-regulated kinase 2 (DYRK2) is a member of dual-specificity kinase family, which could phosphorylate both Ser\/Thr and Tyr substrates. Univariate and multivariate analyses indicated that DYRK2 expression was an independent prognostic factor (P < 0.001). Taking all, we concluded that DYRK2 a novel prognostic biomarker of human colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":728},{"Name":"SA1","Molecular type":"Protein","Location":"Colon","Source":"Tissue","Assay\/Test":"Immunohistochemistry|RT-PCR|Western blot|DNA methylation","Usage":"DiagnosticBM","Pmid":27549371,"Description":"Cohesin subunit SA-1 is a protein that in humans is encoded by the STAG1 gene.   Immunohistochemistry on tissue arrays revealed dramatically decreased SA1 expression in both adenomas (62%; P = 0.001) and adenocarcinomas (75%; P = 0.0001). RT-PCR performed in endoscopically normal rectal biopsies (n = 78) revealed a profound decrease in SA1 expression in adenoma-harboring patients (field carcinogenesis) compared with those who were neoplasia-free (47%; P = 0.03). From a racial perspective, colorectal cancer tissues from Caucasians had 56% higher SA1 expression than in African-Americans. This was mirrored in field carcinogenesis where healthy Caucasians expressed more SA1 at baseline compared with matched African-American subjects (73%; P = 0.003). However, as a biomarker for colorectal cancer risk, the diagnostic performance as assessed by area under ROC curve was greater in African-Americans (AUROC = 0.724) than in Caucasians (AUROC = 0.585). From a biologic perspective, SA1 modulation of high-order chromatin was demonstrated with both biophotonic (nanocytology) and chromatin accessibility [micrococcal nuclease (MNase)] assays in SA1-knockdown HT29 colorectal cancer cells. The functional consequences were underscored by increased proliferation (WST-1; P = 0.0002, colony formation; P = 0.001) in the SA1-knockdown HT29 cells. A tumor suppressor role of SA1 in early colon carcinogenesis and as a risk stratification biomarker giving potential insights into biologic basis of racial disparities in colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":729},{"Name":"Olfactomedin 1 (OLFM1)","Molecular type":"Protein","Location":"Colon","Source":"Tissue","Assay\/Test":"Bioinformatics|RT-qPCR","Usage":"PrognosticBM","Pmid":27555280,"Description":"Olfactomedin 1 (OLFM1), a member of the olfactomedin domain-containing protein family, plays an important role in the development of neurogenic tissues. The results of immunohistochemistry indicated that decreased OLFM1 expression was significantly associated with lymph node status (p = 0.023), distant metastasis (p < 0.001), and AJCC\/TNM stage (p = 0.013), and CRC patients with low OLFM1 expression had consistently poor overall survival (OS; p < 0.001) and progression-free survival (PFS; p < 0.001). VRR data may be an useful biomarker for tailoring surgery and postoperative adjuvant chemotherapy.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":730},{"Name":"microRNA-320 (mir-320)","Molecular type":"MicroRNA","Location":null,"Source":"Tissue","Assay\/Test":"miRNA microarray|Quantitative real-time polymerase chain reaction|Gene expression|miRNA target prediction|Western blot","Usage":"DiagnosticBM","Pmid":27559432,"Description":"In molecular biology mir-320 microRNA is a short RNA molecule. MicroRNAs function to regulate the expression levels of other genes by several mechanisms.  Expressions of all members of the miR-320 family except miR-320e in adenoma were significantly decreased not only in submucosal invasive carcinomas but also in adenomas compared with those in the non-neoplastic mucosa (P < 0.05 and P < 0.01, respectively). MiR-320 family affects colorectal tumor proliferation by targeting CDK6, plays important role in its growth, and is considered to be a biomarker for its early detection.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":731},{"Name":"CD51","Molecular type":"Protein","Location":"Colon","Source":"Tissue","Assay\/Test":"real-time quantitative PCR|Chemoresistance assay|Immunofluorescence|Flow cytometry|cell sorting|Sphere-forming assay|Side population|Side population","Usage":"PredictiveBM","Pmid":27593923,"Description":"CD51 (also called integrin \u03b1v) is a transmembrane glycoprotein responsible for cell-to-matrix binding.  We confirmed that CD51 levels were positively correlated with the Dukes\u2019 grade (P<0.001), the tumor stage (P<0.001) and lymph node metastasis (P<0.001) in these patients. CD51 correlates with the TGF-beta pathway and is a functional marker for colorectal cancer stem cells.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":732},{"Name":"microRNA-188-3p (miR-188-3p) ","Molecular type":"MicroRNA","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Quantitative RT-PCR|Western blot|Cellular assays|In vivo metastases formation|bioluminescence imaging|Luciferase assay","Usage":"PrognosticBM","Pmid":27601590,"Description":"Forced miR-188-3p expression increased migratory behavior of colorectal cancer cells in vitro and metastases formation in vivo (P < 0.05). MiR-188-3p is a novel independent prognostic factor in CRC patients which can be partly explained by its effect on MLLT4 expression and migration of cancer cells.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":733},{"Name":"microRNA-188-3p (miR-188-3p)","Molecular type":"MicroRNA","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":27601590,"Description":"High miR-188-3p expression proves to be an independent prognostic factor [screening cohort: HR = 4.137; 95% confidence interval (CI), 1.568-10.917;\u00a0P\u00a0= 0.004; validation cohort: HR = 1.538; 95% CI, 1.107-2.137;\u00a0P\u00a0= 0.010, respectively]. miR-188-3p is a novel independent prognostic factor in colorectal cancer patients, which can be partly explained by its effect on MLLT4 expression and migration of cancer cells.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":734},{"Name":"LncRNA PANDAR","Molecular type":"LncRNA","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":27629879,"Description":"LncRNA Moreover, multivariate analysis showed that the status of PANDAR expression was an independent prognostic indicator for CRC.\u00a0 Our data suggested that lncRNA PANDAR was a novel molecule involved in CRC progression, which provided a potential prognostic biomarker and therapeutic target for new therapies in patients with CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":735},{"Name":"microRNA-122(miR-122), microRNA-200 (miR-200)","Molecular type":"MicroRNA","Location":"Colon, Rectum","Source":"Blood","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":27632639,"Description":"Increased miR-122 levels were associated with a 'bad' prognostic subtype in metastatic CRC (Odds ratio: 1.563, 95% confidence interval (CI): 1.038-2.347) and a shorter relapse-free survival and overall survival for non-metastatic (Hazard ratio (HR): 1.370, 95% CI: 1.028-1.825; HR: 1.353, 95% CI: 1.002-1.828) and metastatic (HR: 1.264, 95% CI: 1.050-1.520; HR: 1.292, 95% CI: 1.078-1.548) CRC patients. Additionally, several members of the miR-200 family showed associations with patients' prognosis and correlations to clinicopathological characteristics. The here identified miRNA markers, miR-122 and the miR-200 family members, could be of use in the development of a multi-marker blood test for CRC prognosis.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":736},{"Name":"C-reactive protein (CRP)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Blood","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":27696432,"Description":"C-reactive protein (CRP) is an annular (ring-shaped), pentameric protein found in blood plasma, whose levels rise in response to inflammation. Multivariate analysis showed that preoperative CRP >10\u2009mg\/L was a strong predictor of compromised survival (HR\u2009=\u20091.72, 95%CI 1.84-2.50, P\u2009<\u20090.01).  CRP alone is a strong prognostic factor, following curative resection of colorectal liver metastases and should be taken into consideration when selecting treatment strategies in CRLM patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":737},{"Name":"Fecal Bacteria","Molecular type":null,"Location":"Colon","Source":"Feces","Assay\/Test":"Quantitative PCR|Fecal immunochemical test","Usage":"DiagnosticBM","Pmid":27697996,"Description":"Bacteria Improved diagnostic performances of Fn alone (sensitivity 92.8%, specificity 79.8%) and four bacteria (sensitivity 92.8%, specificity 81.5%) were achieved in combination with fecal immunochemical testing for the detection of colorectal cancer. Stool-based CRC-associated bacteria can serve as novel non-invasive diagnostic biomarkers for CRC","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0001988","Id":738},{"Name":"Rassf1a rs2236947","Molecular type":"DNA","Location":null,"Source":"Tissue","Assay\/Test":"PCR","Usage":"PrognosticBM","Pmid":27698403,"Description":"Single nucleotide polymorphism This association was stronger in patients with left-side CRC (hazard ratio (HR): 1.79 (1.01-3.14); P=0.044 and HR: 2.83 (1.14-7.03); P=0.025, for Fire 3 and JACCRO cohorts, respectively).  Rassf1a rs2236947 is a promising biomarker for patients treated with cetuximab plus chemotherapy.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":739},{"Name":"microRNA-203 (miR-203)","Molecular type":"MicroRNA","Location":null,"Source":"Tissue","Assay\/Test":"Quantitative real-time RT-PCR|Immunohistochemistry","Usage":"DiagnosticBM|PrognosticBM","Pmid":27714672,"Description":"The positive expression rates of BIRC5 in CRC and non-tumor tissues were 73.77 % (90\/122) and 30.32 % (37\/122), respectively. The expression intensity of BIRC5 in CRC was significantly higher than that of non-tumor tissues (P < 0.05). MiR-203 is a potential suppressor and predictive biomarker for CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":740},{"Name":"Cysteine-rich angiogenic inducer 61 (CYR61)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Blood","Assay\/Test":"Immunohistochemistry","Usage":"DiagnosticBM","Pmid":27743169,"Description":"Cysteine-rich angiogenic inducer 61 (CYR61) or CCN family member 1 (CCN1), is a matricellular protein that in humans is encoded by the CYR61 gene The serum level of Cyr61 was significantly increased in CRC patients compared with colorectal adenoma patients and healthy controls (p < 0.001).  Cyr61 has potential as a serum biomarker for the diagnosis of CRC and for assessment of the clinicopathological status of CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":741},{"Name":"Thymosin \u03b24","Molecular type":"Protein","Location":"Colon","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":27744656,"Description":"Thymosin \u03b24 is a multi-functional hormone-like polypeptide, being involved in cell migration, angiogenesis, and tumor metastasis. Patients with high expression of thymosin \u03b24 showed poor recurrence-free survival (p = .001) and poor overall survival (p = .005) on multivariate analysis. A high expression level of thymosin \u03b24 indicates poor clinical outcomes and may be a useful prognostic factor in CRC. ","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":742},{"Name":"Thymosin \u03b24","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":27744656,"Description":"Thymosin \u03b24\u00a0is a multi-functional hormone-like polypeptide, being involved in cell migration, angiogenesis, and tumor metastasis. Patients with high expression of thymosin \u03b24\u00a0showed poor recurrence-free survival (p = .001) and poor overall survival (p = .005) on multivariate analysis A high expression level of thymosin \u03b24 indicates poor clinical outcomes and may be a useful prognostic factor in CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":743},{"Name":"Anti-FIRs (PUF60)","Molecular type":"Protein","Location":"Colon","Source":"Tissue","Assay\/Test":"Western blot|AlphaLISA","Usage":"DiagnosticBM","Pmid":27756887,"Description":"Anti-PUF60, poly(U)-binding-splicing factor, autoantibodies are reported to be detected in the sera of dermatomyositis and Sjogren's syndrome that occasionally associated with malignancies. Anti-FIRs antibodies were surely detected in the preoperative sera of 28 colorectal cancer patients (32.2% of positive rates), and the detection rate was significantly higher than that in healthy control sera (Mann-Whitney U test, p < 0.01). Furthermore, the area under the curve of receiver operating characteristic for anti-FIRs antibodies was significantly larger (0.85) than that for anti-p53 antibodies or CA19-9.  The combination of anti-FIRs antibodies with other clinically available tumor markers further improved the specificity and accuracy of cancer diagnosis","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":744},{"Name":"Trefoil factor 3","Molecular type":"Protein","Location":null,"Source":"Blood","Assay\/Test":"Immunohistochemistry","Usage":"DiagnosticBM","Pmid":27760866,"Description":"Trefoil factor 3 (TFF3) belongs to the TFF family, which consists of 3 stable secretory proteins that are expressed together with mucins from epithelial cells of the gastrointestinal tract. At a cutoff value of 5.591 ng\/mL, the diagnostic sensitivity, specificity, and likelihood ratio of serum trefoil factor 3 for colorectal cancer was 74.2%, 94.8%, and 14.25, respectively. Serum trefoil factor 3 is a promising biomarker for the diagnosis of colorectal cancer and prognosis of patients","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":745},{"Name":"microRNA-137 (miR-137)","Molecular type":"MicroRNA","Location":"Colon","Source":"Tissue","Assay\/Test":"RT-PCR|3\u2032-UTR luciferase reporter assay|Methylation-specific polymerase chain reaction (MSP)|Quantitative bisulfite pyrosequencing|Xenograft animal studies|Immunoblotting|Immunohistochemistry","Usage":"PrognosticBM","Pmid":27764771,"Description":"MicorRNA-137 is silenced in human colorectal cancer tissues and colon polyps ROC (receiver operating characteristic curve) analysis suggested that the loss of miR-137 expression in adenomatous polyps shows excellent discrimination for colorectal cancer formation  The investigation of the regulatory mechanism of miR-137-mediated Aurora-A inhibition may shed new light on the early prognosis of cancer therapy for CRC in the future.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":746},{"Name":"CD133+, CD133+CD54+CD44+ cellular subpopulations","Molecular type":null,"Location":"Colon, Rectum","Source":"Blood","Assay\/Test":"Flow cytometry|multivariate","Usage":"PrognosticBM","Pmid":27764803,"Description":"Combined several markers together Sensitivity of 88.2% and a specificity of 92.4%. Meanwhile, it also show accurate predictive value for liver metastasis (OR=2.898, 95% C.I.1.374-6.110). The identification, expression and application of CTC subpopulations will provide an ideal cellular predictive marker for CRC liver metastasis and a potential marker for further investigation.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":747},{"Name":"Cytoplasmic polyadenylation element-binding protein 4 (CPEB4)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":27771769,"Description":"Cytoplasmic polyadenylation element-binding protein 4 (CPEB4), a zinc-finger-containing sequence-specific RNA-binding protein, has been associated with tumor proliferation, invasion, and migration.\u00a0 Through multivariate Cox regression analysis, high expression of CPEB4 was found to be an independent prognostic biomarker for overall survival in CRC patients. High expression of cytoplasmic polyadenylation element-binding protein 4 correlates with poor prognosis of patients with colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":748},{"Name":"Cytoplasmic polyadenylation element-binding protein 4 (CPEB4)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":27771769,"Description":"The cytoplasmic polyadenylation element (CPE), which is present in the 3\u2032-untranslated region (3\u2032-UTRs) in hundreds of mRNAs, is involved in chromosome segregation, cell proliferation, and cell differentiation and mediates regulation of mRNA subpopulations by common cis-acting elements Cox proportional hazard regression model revealed that high expression of CPEB4 is correlated with worse overall survival (log-rank, P < 0.001 and P < 0.0001) High expression of CPEB4 may be an independent and useful biomarker for predicting the poor survival of patients with CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":749},{"Name":"P-selectin ","Molecular type":"Protein","Location":"Colon","Source":"Blood","Assay\/Test":"ELISA determination","Usage":"PrognosticBM","Pmid":27775438,"Description":"P-selectin functions as a cell adhesion molecule (CAM) on the surfaces of activated endothelial cells, which line the inner surface of blood vessels, and activated platelets. In unactivated endothelial cells, it is stored in granules called Weibel-Palade bodies. The highest level of sP-selectin was observed in patients with metastases to the liver (stage IV), and was significantly higher than in patients without metastases (stage I\/II) and with lymph node metastases (stage III), p\u2009=\u20090.02. Our finding show possible involvement of tested selectins in CRC advancement and forming metastasis. Among sL- and E- selectins, P-selectin plays an important role in the progression of CRC and could be an attractive biomarker with clinical significance.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":750},{"Name":"Dieckol","Molecular type":null,"Location":null,"Source":"Tissue","Assay\/Test":"Western blot|Immunohistochemistry","Usage":"PrognosticBM","Pmid":27779676,"Description":"Dieckol is a phlorotannin that can be found in arame (Eisenia bicyclis), in Ecklonia cava or in Ecklonia stolonifera. Therefore, dieckol has the potential to become an attractive therapeutic agent for the treatment of colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":751},{"Name":"carboxypeptidaseA4 (CPA4) ","Molecular type":"Protein","Location":"Colon","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"DiagnosticBM","Pmid":27780921,"Description":"Carboxypeptidase A4 (CPA4) is a member of the metallocarboxypeptidase family, and is aberrantly overexpressed in some types of cancer tissues Sensitivity (90.0%) and specificity (93.8%) for hepatic metastasis detection In this study, we examined CPA4 level in primary colorectal cancer tissue and serum samples, and analyzed the correlation between CPA4 levels and clinicopathological characteristics of CRC patients. We propose that serum CPA4 might be a candidate diagnostic biomarker for colorectal cancer liver metastasis.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":752},{"Name":"carboxypeptidaseA4 (CPA4) ","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":27780921,"Description":"Carboxypeptidase A4 (CPA4) is a member of the metallocarboxypeptidase family, and is aberrantly overexpressed in some types of cancer tissues In leave-one-out-cross-validation, these two markers resulted in sensitivity (90.0%) and specificity (93.8%) for hepatic metastasis detection.  Our results suggest that CPA4 is closely associated with CRC liver metastasis, and serum CPA4 concentration combined with lymph node involvement may be used as accurate predictors of liver metastasis in colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":753},{"Name":"MFHAS1","Molecular type":"Protein","Location":null,"Source":"Tissue","Assay\/Test":"qRT-PCR|Western blot|Gene knockdown|Enzyme-linked immunosorbent assay (ELISA)|Cell counting Kit-8 (CCK-8) assay|Cell migration assay","Usage":"PrognosticBM","Pmid":27783989,"Description":"Malignant fibrous histiocytoma amplified sequence 1 (MFHAS1) is a predicted oncoprotein that demonstrates tumorigenic activity in vivo Our results highlight the role of MFHAS1 as a regulator of macrophages polarization and CRC progress.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":754},{"Name":"microRNA-152 (miR-152)","Molecular type":"MicroRNA","Location":null,"Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":27784461,"Description":"microRNA-152 Univariate Cox regression analysis indicated that lymph node metastasis, degree of differentiation, TNM stage and miR-152 expression level were related to the postoperative survival of colorectal cancer patients (P<0.05).  MiR-152 is a potential marker for prognosis in colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":755},{"Name":"Combination of hERG1 positivity, Glut-1 negativity","Molecular type":null,"Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":27789963,"Description":"the ether-\u00e0-go-go-related gene 1 (hERG1), the glucose transporter 1 (Glut-1) The expressions of hERG1 and Glut-1 were significantly associated (P=0.001). Glut-1 expressed more in patients aged <70 years (42.4% vs 26%; P=0.029) and in left and transverse colon (27.4%, 42.9%, 53.9%, and 25% for right colon, transverse colon, left colon, and rectum, respectively; P=0.019). Glut-1 was less frequently detected in mucinous tumors (P=0.088). The combination of hERG1 positivity and Glut-1 negativity behaves as a prognostic biomarker in radically resected CRC patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":756},{"Name":"FOXP4-AS1","Molecular type":"LncRNA ","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Bioinformatic analyses|qPCR|Flow cytometry|Ethynyl deoxyuridine (Edu)","Usage":"PrognosticBM","Pmid":27790757,"Description":"A novel lncRNA These findings suggest that FOXP4-AS1 plays a crucial role in CRC progression and may be a new biomarker in patients with CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":757},{"Name":"FOXP4-AS1","Molecular type":"LncRNA","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR|Immunohistochemistry","Usage":"PrognosticBM","Pmid":27790757,"Description":"LncRNA We found that FOXP4-AS1 was up-regulated in CRC tissues and cell lines and that its overexpression positively correlated with advanced pathological stages and larger tumour size. Additionally, we found that FOXP4-AS1 knockdown inhibited cell proliferation and induced apoptosis. Furthermore, FOXP4-AS1 knockdown induced marked increase in number of cells in G0\/G1 phase and reduction in number of cells in S phase, in DLD-1, HT-29 and HCT116 cell lines. Consistent with these findings, FOXP4-AS1 silencing inhibited tumour growth in vivo. These findings suggest that FOXP4-AS1 plays a crucial role in CRC progression and may be a new biomarker in patients with CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":758},{"Name":"Fusobacterium nucleatum (Fn)","Molecular type":null,"Location":"Colon","Source":"Feces","Assay\/Test":"Colonoscopy|Quantitative RT-PCR|Faecal immunochemical test","Usage":"DiagnosticBM","Pmid":27797940,"Description":"Fusobacterium nucleatum is an oral bacterium, indigenous to the human oral cavity, that plays a role in periodontal disease.  The abundance was higher for all three individual markers in patients with CRC than controls (p<0.001), and for marker Fn in patients with advanced adenoma than controls (p=0.022). The marker Fn, when combined with FIT, showed superior sensitivity (92.3% vs 73.1%, p<0.001) and area under the receiver-operating characteristic curve (AUC) (0.95 vs 0.86, p<0.001) than stand-alone FIT in detecting CRC in the same patient cohort. This combined test also increased the sensitivity (38.6% vs 15.5%, p<0.001) and AUC (0.65 vs 0.57, p=0.007) for detecting advanced adenoma. The performance gain for both CRC and advanced adenoma was confirmed in the validation cohort (p=0.0014 and p=0.031, respectively). This study identified marker Fn as a valuable marker to improve diagnostic performance of FIT, providing a complementary role to detect lesions missed by FIT alone. ","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0001988","Id":759},{"Name":"Circulating cellular DCLK1 protein (CCDP)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Blood","Assay\/Test":"immunoassay tests|ELISA|IPCR|PLA","Usage":"PrognosticBM","Pmid":27802206,"Description":"Serine\/threonine-protein kinase DCLK1 is an enzyme that in humans is encoded by the DCLK1 gene. The ROC curve showed an AUC of 0.766 (95% CI, 0.680\u20130.852; p <0.001). CCDP could be applied for monitoring purposes in CRC patients","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":760},{"Name":"ING4","Molecular type":"Protein","Location":"Colon","Source":"Tissue","Assay\/Test":"Immunohistochemistry|Western blot|Real time PCR|Tube formation assay|Electrophoretic mobility shift assays (EMSA)|Coimmunoprecipitation (IP)|Luciferase reporter gene assay","Usage":"PrognosticBM|PredictiveBM","Pmid":27806345,"Description":"Cell cycle protein, inhibitor of growth protein 4 (ING4), one member of INGs, possess a common schematic structure, including a Plant Homeo Domain, a Nuclear Localisation Signal and a Novel Conserved Region  Multivariate Cox regression analysis showed that ING4 expression was an independent favourable prognostic factor for CRC (hazard ratio = 0.45, P = 0.001). Our findings imply that reduced ING4 expression in CRC resulted in increased angiogenesis and contributed to CRC metastasis and poor prognosis. Restoration of ING4 may be a novel strategy for the treatment of metastatic CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":761},{"Name":"Interleukin-23 (IL-23)","Molecular type":null,"Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":27807862,"Description":"Interleukin-23 (IL-23) and interleukin-12 (IL-12) are members of a family of proinflammatory heterodimeric cytokines Multivariate adjustment demonstrated a significant association between high IL-23 expression and overall survival (hazard ratio\u2009=\u20091.865, P\u2009=\u20090.041). Elevated IL-23 expression was associated with poor outcome and can be used as a prognostic biomarker for colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":762},{"Name":"Interleukin 23 (IL-23)","Molecular type":null,"Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":27807862,"Description":"Interleukin-23 (IL-23) is a heterodimeric cytokine composed of an IL-12p40 subunit (that is shared with IL-12 ) and the IL-23p19 subunit. TNM stage patients was higher than that for the early TNM stage patients (P\u2009=\u20090.002). Patients with high IL-23 expression were associated with advanced pathological T category (P\u2009<\u20090.001) and late TNM stage (P\u2009=\u20090.003). High IL-23 expression was associated with poor 5-year disease-free survival and overall survival in patients (P\u2009=\u20090.048 and P\u2009=\u20090.028, respectively). Multivariate adjustment demonstrated a significant association between high IL-23 expression and overall survival (hazard ratio\u2009=\u20091.865, P\u2009=\u20090.041). Elevated IL-23 expression was associated with poor outcome and can be used as a prognostic biomarker for colorectal cancer","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":763},{"Name":"C-reactive protein to albumin (CRP\/ALB)","Molecular type":null,"Location":"Colon, Rectum","Source":"Blood","Assay\/Test":"Statistics","Usage":"PrognosticBM","Pmid":27812440,"Description":"C-reactive protein (CRP) is an annular (ring-shaped), pentameric protein found in blood plasma, whose levels rise in response to inflammation. The albumins are a family of globular proteins, the most common of which are the serum albumins. A receiver operating characteristic curve analysis of the C-reactive protein to albumin (CRP\/ALB) ratio in patients with unresectable metastatic colorectal cancer. Area under the curve = 0.655; 95 % confidence interval = 0.539\u20130.772; p = 0.013 The CRP\/ALB ratio is a useful marker for predicting survival and monitoring chemotherapeutic effectiveness in patients with unresectable metastatic colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":764},{"Name":"Dual specificity phosphatase 5 (DUSP5)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Real-time reverse transcription-polymerase chain reaction (RT-PCR)|Western blot|Immunohistochemistry|evaluation","Usage":"PrognosticBM","Pmid":27822421,"Description":"Dual specificity phosphatase 5 (DUSP5) is a negative regulator of Mitogen-activated protein kinase (MAPK) signaling pathway and has recently been identified as a tumor suppressor in several human malignancies. The correlation analysis indicated that DUSP5 expression was negatively correlated N-cadherin and vimentin expression (N-cadherin: r=-0.166, P=0.001; vimentin: r=-0.149, P=0.004), but positively correlated with E-cadherin expression in CRC tissues (r=0.432, P<0.001). Our study proposes that DUSP5 is a promising biomarker for predicting CRC progression and advanced patients with high DUSP5 expression appear to benefit from standard FOLFOX chemotherapy scheme.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":765},{"Name":"microRNA-6826 (miR-6826), microRNA-6875 (miR-6875)","Molecular type":"MicroRNA","Location":"Colon, Rectum","Source":"Blood","Assay\/Test":"qRT-PCR","Usage":"PredictiveBM","Pmid":27878288,"Description":"In contrast, in the HLA-A*2402-unmatched patient group (control group), there was no difference between the patients with high or low plasma miR-6826 expression (P=0.168). Similar results were obtained in the analysis of miR-6875 (P=0.029 and P=0.754, respectively). Moreover, multivariate analysis of the Cox\u00a0regression model indicated that the expression of miR-6826 was the most significant predictor for overall survival (P=0.003, hazard ratio, 3.670).\u00a0 In conclusion, plasma miR-6826 and miR-6875 may be predictive biomarkers for a poor response to vaccine treatment.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":766},{"Name":"microRNA-198 (miR-198), microRNA-765 (miR-765), microRNA-630 (miR-630), microRNA-371-5p (miR-371-5p), microRNA-575 (miR-575), microRNA-202 (miR-202), microRNA-513a-5p (miR-513a-5p)","Molecular type":"MicroRNA","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PredictiveBM","Pmid":27903980,"Description":"Quantitative polymerase chain reaction showed that seven of the candidates were significantly differentially expressed between radiosensitive and insensitive CRC cell lines.\u00a0 These results demonstrated the predictive power of our model and suggested that miR-198, miR-765, miR-630, miR-371-5p, miR-575, miR-202 and miR-513a-5p could be used for predicting the response of CRC to preoperative chemoradiotherapy.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":767},{"Name":"Nicotinamide Nucleotide Transhydrogenase-antisense RNA1 (NNT-AS1)","Molecular type":"LncRNA","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"DiagnosticBM|PrognosticBM","Pmid":27966450,"Description":"LncRNA Multivariate analyses revealed that NNT-AS1 expression was an independent predictor of overall survival (P=0.0174) and progression free survival (P=0.0132) for CRC. NNT-AS1 may be a useful diagnostic and prognostic biomarker and a potential therapeutic target in CRC patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":768},{"Name":"Aurora kinase A (AURKA)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":28013532,"Description":"Aurora kinase A (AURKA), or STK15\/BTAK, is a member of the serine\/threonine kinase family and plays important roles in mitosis and chromosome stability. In a multivariate analysis of PFS, a Cox proportional hazard model confirmed that AURKA expression was an independent and significant prognostic factor in colorectal adenocarcinoma (hazard ratio, 3.944; p < .001). AURKA could serve as an independent factor to predict a poor prognosis in Korean colorectal adenocarcinoma patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":769},{"Name":"microRNA-181c(miR-181c)","Molecular type":"MicroRNA","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":28036302,"Description":"According to multivariate analysis, the higher expression of miR-181c was detected as an independent predictive factor of recurrence (P = 0.001, OR: 9.43, 95% CI: 2.57-34.48). Higher expression of miR-181c may be a useful recurrence predictor of stage II CRC patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":770},{"Name":"WNT5A methylation status","Molecular type":null,"Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM|PredictiveBM","Pmid":28051879,"Description":"WNT5A, a nontransforming WNT protein suppressing the Wnt\/\u03b2-catenin signaling pathway, is frequently detected to be hypermethylated in colorectal cancer (CRC). \u00a0In 5-FU-treated CRC patients, WNT5A methylation status is associated with better drug response and longer progression-free survival, suggesting that 5-FU is more effective in CRC with WNT5A hypermethylation. WNT5A methylation status is prognostic and is useful as a potential drug selection biomarker in CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":771},{"Name":"Periplakin (PPL)","Molecular type":"Protein","Location":"Colon","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PredictiveBM","Pmid":28068625,"Description":"Periplakin (PPL) is a 195 kDa membrane-associated protein and a member of the plakin protein family, which is mainly localized in the desmosomes and interdesmosomal plasma membranes of differentiated epidermal keratinocytes PPL overexpression could reduce metastasis and epithelial-mesenchymal transition (EMT) of HT29 cells, with decreased expression of N-cadherin, Snail, Slug and \u03b1-SMA while increased expression of E-cadherin. On the contrary, the PPL knockdown could promote the cell proliferation, migratory, invasive and EMT ability of HT29 cells. Moreover, enforced expression of PPL induced G1\/G0 cell cycle arrest, with decreased cyclin D1, p-Rb and increased expression of p27kib, which could be reversed by PPL knockdown. In addition, PPL overexpression inhibited the growth of colon cancer allograft in vivo. Taken together, acted as a tumor suppressor in colon cancer progression, PPL could be a new biomarker or potential therapeutic target in colon cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":772},{"Name":"Perineural invasion (PNI)","Molecular type":null,"Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Histopathology","Usage":"PrognosticBM","Pmid":28070726,"Description":"PNI is defined as an invasion spreading in and around the neural tissue In multivariate analyses, PNI+ was an independent negative prognostic factor for 5-year overall survival (hazard ratio [HR] 1.518, 95\u00a0% confidence interval [CI] 1.175-1.961; p\u00a0=\u00a00.001) and 5-year disease-free survival (HR 1.495, 95\u00a0% CI 1.237-1.806; p\u00a0=\u00a00.001). PNI positivity is an independent predictor of aggressive behavior and unfavorable prognosis in CRC. ","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":773},{"Name":"Poly(C)-binding protein 1 (PCBP1)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PredictiveBM","Pmid":28076324,"Description":"Knockdown of PCBP1 sensitized HT-29\/L-OHP and HT-29 cells to L-OHP, while overexpression of PCBP1 increased L-OHP resistance in HT-29 cells. In addition, PCBP1 expression was significantly higher in tumor samples from L-OHP refractory patients than in those from L-OHP responsive patients. In conclusion, our findings suggest that PCBP1 is a molecular marker of L-OHP resistance in colorectal cancer and a promising target for colorectal cancer therapy.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":774},{"Name":"Lysosomal acid phosphatase 2(ACP2)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":28076332,"Description":"Lysosomal acid phosphatase 2 (ACP2), composed of alpha and beta subunits, is a lysosomal enzyme that usually serves as a biochemical marker for this organelle.\u00a0 Multivariate Cox proportion hazard model analysis also revealed ACP2 to be an independent prognostic factor for overall survival (ACP2: p = 0.006; T stage: p = 0.041).\u00a0 Lysosomal acid phosphatase 2 is an unfavorable prognostic factor but is associated with better survival in stage II colorectal cancer patients receiving chemotherapy.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":775},{"Name":"Circulating (CTC) or disseminated tumor cells (DTC) ","Molecular type":null,"Location":"Colon","Source":"Blood","Assay\/Test":"qRT-PCR|Immunohistochemistry","Usage":"PrognosticBM","Pmid":28086834,"Description":"Hereby, tumor cells that can be detected in the peripheral blood are termed circulating tumor cells (CTC), whereas tumor cells found in the bone marrow are termed disseminated tumor cells (DTC). By multivariate analyses only detection of CTC with CK20 RT-PCR in the blood was revealed to be an independent predictor of worse OS (HR1.94; 95% CI 1.0-3.7; p\u2009=\u20090.04) and DFS (HR 1.94; 95% CI 1.1-3.7; p\u2009=\u20090.044). Detection of CTC with CK20 RT-PCR is a highly specific and independent prognostic marker in colon cancer patients. Detection of DTC in the bone marrow with CK20 RT-PCR or immunohistochemistry with anti-EpCAM antibody is not associated with a negative prognostic influence.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":776},{"Name":"The CpG island methylator phenotype (CIMP)","Molecular type":null,"Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"DNA Methylation Assay","Usage":"PrognosticBM","Pmid":28087988,"Description":"CpG island methylator phenotype (CIMP), a distinct molecular subtype of tumors characterized by hypermethylation of DNA When analysis was performed according to anatomical location, more marked survival differences were observed in patients with colon cancer (P\u2009=\u20090.026) than in patients with rectal cancer (P\u2009=\u20090.210). Similarly, the role of CIMP status as a prognostic indicator was more prominent in patients with stage I\/II (P\u2009=\u20090.006) than in patients with stage III\/IV CRC (P\u2009=\u20090.65). DNA methylation status can be considered as a useful predictor of survival after CRC surgery, particularly for patients with stage I\/II disease or colon cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":777},{"Name":"Tumor necrosis factor receptor-associated protein 1 (TRAP1)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":28088229,"Description":"Tumor necrosis factor receptor associated protein 1 (TRAP1) is a molecular chaperone of the 90 kDa heat shock protein (HSP90) family, and is mostly localized to the mitochondrial matrix Multivariate analysis indicated that TRAP1 expression (hazard ratio, 1.947; 95% CI, 1.270 to 2.984; p\u2009=\u20090.002), and pathologic T stage (hazard ratio, 3.190; 95% CI, 1.275 to 7.983; p\u2009=\u20090.013) were independent prognostic factors for colorectal adenocarcinomas. Consequently, our data demonstrated that TRAP1 expression was a good prognostic biomarker for depth of invasion and disease-specific survival in colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":778},{"Name":"Histidine triad nucleotide-binding 2 (HINT2)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR|Immunohistochemistry","Usage":"PrognosticBM","Pmid":28088787,"Description":"Histidine triad nucleotide-binding 2 (HINT2) is a member of the histidine triad superfamily that performs a range of biological functions. HINT2 downregulation increased tumor migration and invasion in vitro, promoted CRC cell metastasis in vivo, and increased expression of epithelial-to-mesenchymal transition (EMT) markers. HINT2 may thus a useful clinical indicator of CRC progression and metastasis risk.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":779},{"Name":"LncRNA SPRY4-IT1","Molecular type":"LncRNA","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":28099409,"Description":"LncRNA Cox regression analysis showed that SPRY4-IT1 could act as an independent prognostic factor in CRC (HR=2.341, 95% CI=1.136-4.826, P=0.021). SPRY4-IT1 might be associated with tumorigenesis and progression of CRC, and it may be a promising biomarker for prognosis in patients with CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":780},{"Name":"BANP ","Molecular type":"RNA","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":28103507,"Description":"Circular RNA RT-PCR result showed that circ-BANP was overexpressed in 35 CRC cancerous tissues. Knockdown of circ-BANP with siRNA significantly attenuate the proliferation of CRC cells. In summary, our findings demonstrated that dysregulated circ-BANP appears to have an important role in CRC cells and could serve as a prognostic and therapeutic marker for CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":781},{"Name":"PANDAR","Molecular type":"LncRNA","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":28106228,"Description":"LncRNA Multivariate Cox regression analysis indicated that PANDAR might be an independent prognostic factor for CRC patients.\u00a0 Our results suggest that high expression of PANDAR was involved in CRC progression and could act as an independent biomarker for prognosis of CRC patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":782},{"Name":"Nm23-H1, p53","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR|Immunohistochemistry","Usage":"PrognosticBM","Pmid":28123532,"Description":"The Nm23-H1 gene is a metastasis suppressor gene, the low expression of which can promote tumor occurrence and metastasis during tumor progression Patients with CRC with Nm23-H1(+)\/p53(-) tumors had increased survival rates, with a five-year overall survival rate of 83.8% and a five-year disease-free survival rate of 70.2%. The five-year overall survival rates in other study cohorts were lower, compared with the Nm23-H1(+)\/p53(-) group (P<0.0125), and this was the same for the five-year disease-free survival rate (P<0.0125). In conclusion, the present study demonstrated that the combined detection of the protein expression of Nm23-H1 and p53 was associated with the long term survival rates of patients with stage II and III CRC; and this may offer potential for use as a predictor of survival rates in patients with CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":783},{"Name":"microRNA-196b (miR-196b)","Molecular type":"MicroRNA","Location":"Colon, Rectum","Source":"Blood","Assay\/Test":"qRT-PCR","Usage":"DiagnosticBM|PrognosticBM","Pmid":28123705,"Description":"Patients with CRC of miR-196b-high status had shorter overall survival and disease-free survival rates compared with those of miR-196b-low status. In conclusion, the results of the present study demonstrated that serum miR-196b is upregulated in CRC, and may have an application as a diagnostic and prognostic biomarker for patients with CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":784},{"Name":"ADAMTS5 ","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":28123746,"Description":"ADAMTS family members contain thrombospondin motifs, cysteine-rich and spacer domains in addition to propeptide, metalloproteinase and disintegrin domains Overall survival and disease-free survival were assessed by the Kaplan-Meier curve with calculation of significance by the log-rank test; however, no significant difference was observed between the ADAMTS5 higher expressing group and the ADAMTS5 lower expressing group (P=0.7490 and P=0.9455, respectively).\u00a0 The present study confirmed high expression of ADAMTS5 as a potent marker for lymphatic invasion and lymphnode metastasis in colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":785},{"Name":"Peroxiredoxin 2 (PRDX2)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR|Immunohistochemistry","Usage":"PrognosticBM","Pmid":28125800,"Description":"Peroxiredoxin2 (PRDX2) is a typical 2-Cys thioredoxin peroxidase, which widely distributed in various tissues and cells. Peroxiredoxin2 (PRDX2) is a typical 2-Cys thioredoxin peroxidase, which widely distributed in various tissues and cells. In conclusion, our findings suggest PRDX2 up-regulation correlates with tumor progression and could serve as a useful marker for the prognosis of CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":786},{"Name":"Transducin (\u03b2)-like 1 X-linked receptor 1 (TBL1XR1)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":28127799,"Description":"Transducin (\u03b2)-like 1 X-linked receptor 1 (TBL1XR1) was initially identified as a component of nuclear receptor corepressor (NCoR) and silencing mediator for retinoid and thyroid hormone receptors (SMRT) complex, which facilitates the recruitment of histone deacetylases to the DNA promoters bound by its interacting transcription factors Both ITC\/LNMM and TBL1XR1 expression were independent prognostic factors for disease relapse or metastasis. Identification of ITC\/LNMM is significant in evaluating clinical outcome and guiding adjuvant chemotherapy for early stage CRC.TBL1XR1 overexpression in CRC tissues can serve as an efficient biomarker to predict the status of ITC\/LNMM. ","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":787},{"Name":"EDNRB","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"DiagnosticBM","Pmid":28140749,"Description":"The results showed that the methylation distribution differences, comparing tumor tissues with their adjacent non-cancerous tissues, were statistically significant in all selected locations within EDNRB gene promoter (P < 0.001); they had also some correlations with tumor stage and grade. Nonetheless, methylation distribution in KISS1 gene CpG rich region revealed no statistically significant differences between CRC and adjacent non-cancerous tissues (P = 0.060).\u00a0 Overall, it can be concluded that aberrant methylated EDNRB can be a promising potential diagnostic biomarker for CRC","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":788},{"Name":"Kallikrein-related peptidase (KLK) ","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":28142115,"Description":"KLK8, also known as neuropsin, is one of fifteen members of the human kallikrein-related peptidase (KLK) gene family, which consists of enzymes with serine protease enzymatic activity. Univariate and multivariate Cox analyses confirmed that KLK8 is a significant independent prognostic factor for both DFS and OS.\u00a0 In conclusion, elevated KLK8 expression was correlated with the progression of CRC and is a potential independent prognostic indicator for CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":789},{"Name":"Enhancer of zeste homolog 2 (EZH2)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR|Immunohistochemistry","Usage":"PrognosticBM","Pmid":28147317,"Description":"The polycomb group protein enhancer of zeste homolog 2 (EZH2) is a methyltransferase that suppresses microRNA-31 (miR-31) in various human malignancies including colorectal cancer. In the result, low EZH2 expression was significantly associated with shorter PFS (log-rank test: P = 0.023) and OS (P = 0.036) in patients with colorectal cancer. In the low-miR-31-expression group and the KRAS (codon 61\/146), NRAS, and BRAF wild-type groups, a significantly shorter PFS (P = 0.022, P = 0.039, P = 0.021, and P = 0.036, respectively) was observed in the EZH2 low-expression groups than in the high-expression groups. In the multivariate analysis, low EZH2 expression was associated with a shorter PFS (P = 0.046), independent of the mutational status and miR-31. EZH2 expression is a prognostic biomarker in patients with colorectal cancer treated with anti-EGFR therapeutics.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":790},{"Name":"Enterotoxigenic Bacteroides fragilis (ETBF)","Molecular type":null,"Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"DiagnosticBM","Pmid":28151975,"Description":"Enterotoxigenic Bacteroides fragilis (ETBF) is a toxin-producing bacteria thought to possibly promote colorectal carcinogenesis by modulating the mucosal immune response and inducing epithelial cell changes. Univariate analysis showed statistically significant associations between ETBF positivity and the presence of low-grade dysplasia (LGD), tubular adenomas (TA), and serrated polyps (P-values of 0.007, 0.027, and 0.007, respectively). We suggest that detection of ETBF may be a potential marker of early colorectal carcinogenesis.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":791},{"Name":"Acyl-CoA synthetases (ACSL)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":28153554,"Description":"Acyl-CoA synthetase long-chain isoform 5 (ACSL5) is one of the lipid metabolizing enzyms that is expressed and synthesized by intestinal epithelial cells [ Using a standardized immunohistochemical approach, colorectal adenocarcinomas with low (n=41; group 1) or high (n=31; group 2) ACSL5 levels were identified. In a one-year follow-up, tumour recurrence was significantly increased in group 1 (p=0.0279). The data indicate that ACSL5 could be an independent prognostic factor for early recurrence of sporadic colorectal adenocarcinoma.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":792},{"Name":"CiRS-7","Molecular type":"Circular RNA","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry  Western blot (WB)","Usage":"PrognosticBM","Pmid":28174233,"Description":"Recently, a novel circular RNA, ciRS-7, was proposed to be a potential miR-7 sponge\uff0cbut the functional and clinical significance of this circular RNA in colorectal cancer remains unexplored. Multivariate survival analysis revealed that ciRS-7 emerged as an independent risk factor for overall survival (P\u00a0= 0.0656 and 0.0324 in the training and validation cohorts, respectively). CiRS-7 is a promising prognostic biomarker in CRC patients and may serve as a therapeutic target for reducing EGFR-RAF1 activity in CRC patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":793},{"Name":"microRNA-19a-3p(miR-19a-3p), microRNA-21-5p(miR-21-5p), microRNA-425-5p(miR-425-5p)","Molecular type":"MicroRNA","Location":"Colon, Rectum","Source":"Blood","Assay\/Test":"qRT-PCR","Usage":"DiagnosticBM","Pmid":28177881,"Description":"We identified that serum levels of miR-19a-3p, miR-21-5p and miR-425-5p were significantly higher in patients with CRC than in NCs. The areas under the receiver operating characteristic (ROC) curve of the three-miRNA panel were 0.86, 0.74 and 0.87 for the training, testing and the external validation stages (30 CRC VS. 18 NCs), respectively.\u00a0 In conclusion, we identified a serum three-miRNA panel for the diagnosis of CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":794},{"Name":"Quaking RNA-binding protein (QKI)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR|Immunohistochemistry","Usage":"PrognosticBM","Pmid":28179294,"Description":"Low QKI expression was observed in 47.7% in CRCs. QKI promoter methylation was detected in 32.1% of patients with CRC, and in these patients mRNA expression in tumor tissue was significantly down-regulated compared to matched normal tissues (p=0.049).\u00a0 Loew QKI expression may be a useful clinical biomarker for predicting recurrence and prognosis.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":795},{"Name":"microRNA-375 (miR-375)","Molecular type":"MicroRNA","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"DiagnosticBM","Pmid":28186962,"Description":"Our results showed that in microRNA-375 over-expressing cells, JAK2\/STAT3 and MAP3K8\/ERK proteins were down-regulated, cell proliferation was inhibited, cell migration rate did not change. These findings suggest miR-375 as a promising diagnostic marker and a therapeutic drug for colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":796},{"Name":"Macrophage inhibitory cytokine 1 (MIC-1\/GDF15)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"DiagnosticBM|PrognosticBM","Pmid":28206963,"Description":"MIC-1 is a 25-kDa secreted protein of\ntransforming growth factor-\u03b2 (TGF-\u03b2) super-family that\nhas been shown to play an important role in carcinogenesis\nrelated activities, including proliferation, migration,\napoptosis, and angiogenesis, as well as to be involved\nin abnormal immune response The sensitivity of serum MIC-1 was 43.8% and 38.5% for CRC diagnosis and early diagnosis, respectively, which were independent of and comparatively higher than for CEA (36.6% and 27.3%) at comparable specificity.\u00a0 MIC-1 was an independent prognostic factor contributing to overall survival. We conclude that MIC-1 can act as a candidate complementary biomarker for screening  early-stage CRC by combination with CEA","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":797},{"Name":"Soluble urokinase plasminogen activator \nreceptor (suPAR)\n","Molecular type":"Protein","Location":"Rectum","Source":"Blood","Assay\/Test":"ELISA","Usage":"PrognosticBM","Pmid":28207142,"Description":"Soluble urokinase plasminogen activator receptor\u00a0(suPAR) is an inflammatory biomarker associated with presence and progression of disease and with increased risk of mortality. In univariate analysis, continuous suPAR was found to be associated with survival (p<0.0001 in both cohorts). Of particular interest was that similar results were obtained for Dukes stage A and B patients when analyzed separately. In multivariate analysis, continuous suPAR was found in both cohorts to be independent of Dukes stage. This study confirms that the preoperative concentration of plasma\nsuPAR contains independent prognostic information on patients with rectal cancer.\n","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":798},{"Name":"microRNA-296 (miR-296)","Molecular type":"MicroRNA","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry|Immunofluorescence (IF)","Usage":"PrognosticBM","Pmid":28209128,"Description":"Underexpression of miR-296 was disclosed in CRC tissues and cells. Its decreased level was evidently correlated with adverse clinical parameters and poor prognosis of CRC patients. miR-296 functions as an anti-metastatic factor mainly by suppressing S100A4 in CRC. It potentially acts as a prognostic predictor and a drug-target for CRC patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":799},{"Name":"Pituitary tumor transforming gene-1 (PTTG1)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry|RT-PCR","Usage":"PrognosticBM","Pmid":28219049,"Description":"Human pituitary tumor transforming gene-1 (PTTG1) is a novel oncogene. The univariate and multivariate analyses suggested PTTG1 overexpression was an independent poor prognostic factor for colorectal cancer patients.\u00a0 In conclusion, PTTG1 is an independent prognostic factor and acts as an oncogene in colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":800},{"Name":"Tissue transglutaminase (TG2)","Molecular type":"Protein","Location":"Colon","Source":"Tissue","Assay\/Test":"Co-immunoprecipitation (co-IP)","Usage":"PrognosticBM","Pmid":28223538,"Description":"The multifunctional enzyme tissue transglutaminase (TG2) is a protein involved in a number of cellular roles, including the post translational modification of proteins, as a scaffold protein in cell adhesion and as a cell signalling protein TG2 inhibition\/knockdown increased interaction between \u03b2-catenin and ubiquitin shown by co-immunoprecipitation, suggesting that TG2 could be important in \u03b2-catenin regulation. \u03b2-Catenin and TG2 was also upregulated in SW620 spheroid cells enriched with cancer stem cell marker CD44 and TG2 inhibition\/knockdown reduced the spheroid forming potential of SW620 cells. Our data suggests that TG2 could hold both prognostic and therapeutic significance in colon cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":801},{"Name":"Soluble HLA-G (sHLA-G)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":28233298,"Description":"HLA-G is a nonclassical major histocompatibility complex(MHC) class Ib molecule9with low polymorphism, expressedin speci \ufb01c cell types and tissues.  High HLA-G expression in tumours was associated with poor cancer specific overall survival in stage II to III (p = 0.01), and with shorter LMFS in stage II patients (p = 0.004).\u00a0 Our findings reveal that sHLA-G levels are associated with distinct progression patterns in consecutive disease stages, indicating a potential value as surrogate marker in the differential prognosis of CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":802},{"Name":"Vascular endothelial growth factor (VEGF)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":28245709,"Description":"The most potent of these cytokines is vascular endothelial growth factor (VEGF-A), a heparin-binding glycoprotein with potent angiogenic, mitogenic, and vascular permeability-enhancing activities specific for endothelial cells. The survival of the patients was significantly longer in the patients for whom biopsies showed negative or weak expression of VEGF in comparison to those with moderate to high expression (p-value = 0.04). In conclusion, VEGF could be related to the survival of the patients with colorectal carcinoma and should be considered as a predictor of the prognosis.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":803},{"Name":"LncRNA upregulated in bladder cancer 1 (linc-UBC1)","Molecular type":"LncRNA","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"DiagnosticBM","Pmid":28260919,"Description":"The present study focused on the lncRNA upregulated in bladder cancer 1 (linc-UBC1), which has a transcript length of 2,616 bp and is located on chromosome 1q32.1. Furthermore, multivariate Cox regression analysis indicated that linc-UBC1 was a significant independent prognostic factor.\u00a0 Taken together, the results of the present study suggest that overexpression of linc-UBC1 promotes proliferation and metastasis in CRC, and may be considered as a novel diagnostic marker of CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":804},{"Name":"microRNA-139-5p (miR-139-5p)","Molecular type":"MicroRNA","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":28262692,"Description":"Moreover, miR-139-5p were also upregulated in the serum of recurrence-positive CRC patients and yielded significantly shorter recurrence-free survival. In conclusion, we identified miR-139-5p as a novel biomarker for tumor recurrence and metastasis in CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":805},{"Name":"Programmed death-ligand 1 (PD-L1)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":28267224,"Description":"The Programmed death-1\/ Programmed death-ligand 1 (PD-L1) pathway is a negative feedback pathway that suppresses the activity of T cells.\u00a0 Patients with high PD-L1 expression on TCs had significantly shorter disease-free survival (DFS) than patients with low expression (hazard ratio [HR] 2.36; 95% confidence interval [CI], 1.21-4.62; P = 0.012). In addition, patients with high PD-L1 expression on TIMCs were associated with longer DFS than patients with low expression (HR 0.40; 95% CI, 0.16-0.98; P = 0.046). These findings suggest that PD-L1 expression status may be a new predictor of recurrence for stage III colorectal cancer patients and highlight the necessity of evaluating PD-L1 expression on TCs and TIMCs separately in tumor microenvironment. ","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":806},{"Name":"Phosphorylase kinase \u03b2 (PHK\u03b2)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"PCR|Immunohistochemistry","Usage":"PrognosticBM","Pmid":28275865,"Description":"Phosphorylase kinase (PHK) is a serine\/threonine protein kinase that phosphorylates and activates PYGL. Positive expression of PHK\u03b2 was significantly correlated with TNM stage and distal metastasis, and elevated expression of PHK\u03b2 was an independent prognostic factor in patients with CRC.\u00a0 PHK\u03b2 affects CRC cell growth and represents a novel prognostic biomarker.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":807},{"Name":"BLACAT1","Molecular type":"LncRNA","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"RNA immunoprecipitation","Usage":"PrognosticBM","Pmid":28277544,"Description":"BLACAT1 (linc-UBC1) is one of the few well-known lincRNAs, with a length of 2616 bp and a functional role in recruiting and binding to polycomb repressive complex 2 (PRC2), first characterized in bladder cancers Mechanistic investigations demonstrated that BLACAT1 had a key role in G1\/G0 arrest, and showed that BLACAT1 can repress p15 expression by binding to EZH2, thus contributing to the regulation of CRC cell cycle and proliferation. Long noncoding RNA BLACAT1 indicates a poor prognosis of colorectal cancer and affects cell proliferation by epigenetically silencing of p15.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":808},{"Name":"H3.3B","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT\u2013PCR","Usage":"PrognosticBM","Pmid":28280610,"Description":"Histone H3 family include a large family of histones that contain H3.1, H3.2, H3.3 (H3F3), CENP-A\/ cenH3 and testis-specific histones like H3t \u00a0Furthermore, statistical analysis represented the significant correlation between the\u00a0H3.3B\u00a0gene expression and some of the clinicopathological characteristics. Our study showed that H3.3B gene expression changes can be useful as a probable prognosis biomarker in the early stages of CRC before it metastasized.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":809},{"Name":"Angiopoietin-2 (Ang-2)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":28289658,"Description":"Ang-2 is part of the Ang\/Tie signaling pathway The stronger the IHC staining for Ang-2 expression was, the shorter the cumulative survival was (P = 0.016). The Ang-2 was correlated with lymph-node metastasis, and high expression of Ang-2 was indicative of poor overall survival. These findings suggest that Ang-2 is a useful prognostic marker in the management of patients with colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":810},{"Name":"E-cadherin","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Blood","Assay\/Test":"Immunohistochemistry","Usage":"PredictiveBM","Pmid":28289897,"Description":"E cadherin, a calcium-dependent transmembrane glycoprotein, is composed of a cytoplasmic domain, a single-pass transmembrane domain and an extracellular domain that consists of five tandemly repeated cadherinmotifs subdomains with putative calcium-binding sites. In CRC cell lines derived from high tumor stages, extracellular domain of E cadherin expression decreased after 5FU treatment whereas it increased in supernatants.\u00a0 The extracellular domain can be defined as a 5FU resistance marker and allow CRC monitoring.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":811},{"Name":"Cellular retinol binding protein 1 (CRBP1)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT\u2013PCR","Usage":"PredictiveBM","Pmid":28291773,"Description":"The cellular retinol binding protein 1 (CRBP1) gene as a candidate gene whose expression represented radiation sensitivity We also confirmed that CRBP1 was epigenetically silenced by hypermethylation of its promoter DNA, and that the quantitative methylation value of CRBP1 significantly correlated with histological response in RC patients with NCRT (P=0.031). Our study identified CRBP1 as a radiation-sensitive predictor in RC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":812},{"Name":"Matrix Metallopeptidase 9 (MMP-9)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT\u2013PCR","Usage":"DiagnosticBM","Pmid":28293015,"Description":"Matrix metalloproteinases participate in regulating the ability of cells to differentiate, proliferate, and in the process of apoptosis, adhesion or migration. We found high levels of expression of MMP9 at each CS, as well as in the tissues at the early stage of CRC. MMP9 gene profile may be a complementary diagnostic marker in CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":813},{"Name":"Homeobox B9 (HOXB9)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT\u2013PCR","Usage":"PredictiveBM","Pmid":28298545,"Description":"Homeobox B9 (HOXB9) belongs to the highly conserved homeobox transcription factor gene family, which is critical for embryonic development. However, patients affected by an HOXB9-negative tumor had a significantly longer PFS compared with those with an HOXB9-positive tumor if treated with a first-line regimen containing bevacizumab (18.0 months vs 10.4 months; HR=2.037; 95% CI=1.006-4.125; P=0.048 Our results candidate HOXB9 as predictive biomarker for selecting colorectal cancer patients for antiangiogenic therapy.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":814},{"Name":"Circulating tumor cells (CTCs)","Molecular type":null,"Location":"Colon, Rectum","Source":"Blood","Assay\/Test":"qRT\u2013PCR","Usage":"DiagnosticBM","Pmid":28314271,"Description":"CTCs are a population of rare cells disseminated from the primary tumor that travel the bloodstream in order to form micrometastases in distant tissues. In the case of VIM we found 76.9% methylated samples, compared to 53.8% in tissue samples. Regarding SFRP2 promoter methylation levels in tissue and CTCs samples, 67.3% and 73.1%, were found methylated respectively. CTCs is a promising diagnostic tool. The combination of genetic mutations and epigenetic aberrations specifically in CTCs, will ameliorate CRC diagnosis in the future.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000178","Id":815},{"Name":"Mitogen-, stress-activated protein kinase 1 (MSK1)","Molecular type":"Protein","Location":"Rectum","Source":"Tissue","Assay\/Test":"qRT\u2013PCR|Immunohistochemistry","Usage":"PrognosticBM","Pmid":28314603,"Description":"Mitogen- and stress-activated protein kinase 1 (MSK1) is a member of a subfamily of MAPK-activated protein kinase, which is activated by extracellular signal regulated kinase 1 and 2 (ERK1\/2) and p38 MAPKs in response to mitogenic signals or cellular stresses CRC patients with high MSK1 expression had shorter overall survival than those with low MSK1 (P=0.033), especially among patients with stage III tumors (P=0.005).  Overexpression of MSK1 is associated with poor prognosis in CRC and is connected to tumor aggressiveness.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":816},{"Name":"Transducin (\u03b2)-like 1 X-linked receptor 1 (TBL1XR1)\u00a0","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT-PCR","Usage":"PrognosticBM","Pmid":28317580,"Description":"Transducin (b)-like 1 X-linked receptor 1 (TBL1XR1) is a core component of the NCoR\/SMRT corepressor complex, which can regulate the switch from gene repression to gene activation of various transcription factors Moreover, high expressions of TBL1XR1 can serve as a predictor for liver metastasis in early stage CRC patients (P = 0.003) TBL1XR1 is a promising biomarker for predicting liver metastasis in early stage CRC patients.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":817},{"Name":"Sulfatase-2 (SULF2)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT\u2010PCR","Usage":"PrognosticBM","Pmid":28320104,"Description":"Sulfatase2 (SULF2), an extracellular heparan endosulfatase, has been found to play critical roles in the initiation and progression of human cancers In vivo tumorigenicity and liver metastasis assays confirmed that SULF2 knockdown significantly reduced the growth and metastatic abilities of HT29 cells in nude mice. Furthermore, SULF2 knockdown reduced the levels of p-Akt and p-Erk1\/2 in HT29 cells, while SULF2 overexpression showed opposite effects on the expressions of these proteins in SW480 cells. In all, SULF2 promotes the growth and metastasis of CRC probably by activating Akt and Erk1\/2 pathways. SULF2 potentially serves as a promising biomarker and therapeutic target in CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":818},{"Name":"Semaphorin 3D (SEMA3D)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT\u2013PCR|Immunohistochemistry","Usage":"DiagnosticBM|PrognosticBM","Pmid":28320475,"Description":"SEMA3D which encodes a\nmember of the semaphorin III family of secreted signaling\nproteins that are involved in axon guidance during neuronal\ndevelopment has a certain correlation with the development\nof breast cancer, glioblastoma, pancreatic cancer,\nthyroid cancer, and other tumors Patients with a higher expression of SEMA3D experienced longer survival (P\u2009=\u20090.002, log-rank [Mantel-Cox]; Kaplan-Meier). In addition, multivariate Cox's proportional hazard model revealed that SEMA3D is an independent prognostic marker (hazard ratio [HR] 1.818, 95% CI 1.063-3.110, P\u2009=\u20090.029).  SEMA3D might become a predictive marker for the diagnosis, metastasis, and prognosis of CRC and provide a novel target for the prevention and treatment of CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":819},{"Name":"DHX32","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT\u2013PCR","Usage":"DiagnosticBM|PrognosticBM","Pmid":28330603,"Description":"DHX32, a novel\nmember of the DEAH family, is up-regulated in CRC and contributes to\nCRC proliferation, apoptosis, migration, and invasion Furthermore, the expression level of DHX32 was positively associated with microvessel density in human CRC and poor outcome of CRC patients. Therefore, the report demonstrates that DHX32 is a pro-angiogenic factor, that inhibition of DHX32-\u03b2-catenin pathway can provide a strategy for CRC treatment, and that the expression level of DHX32 has the potential to serve as a biomarker for CRC diagnosis and prognosis.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":820},{"Name":"TGF\u03b21 R25P","Molecular type":null,"Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Polymorphism screening","Usage":"PredictiveBM","Pmid":28333014,"Description":"The TGF\u03b21 R25P polymorphism was significantly associated with grade \u22653 toxicity (odds ratio [OR] 3.47, P=.04) and, in patients who completed the Bowel Problems Scale, with grade \u22654 toxicity (OR 5.61, P=.02). The latter finding persisted in a multivariable logistic regression model controlling for ethnicity, age, and sex (adjusted OR 1.83, P=.02). We have validated the correlation between the TGF\u03b21 R25P SNP and acute toxicity during CRT in an independent cohort using both clinician- and patient-reported toxicity. ","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":821},{"Name":"KNG1, OLFM4, Sec24C","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"LC\u2013MS\/MS","Usage":"DiagnosticBM","Pmid":28344541,"Description":"KNG1, OLFM4 and Sec24C distributions were validated in tissues and showed different expression levels especially in the two early CRC stages compared to normal and preneoplastic tissues. We highlighted three proteins that require further investigations to better characterise their role in early CRC carcinogenesis and their potential as early CRC markers.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":822},{"Name":"Mismatch repair genes (MMR)","Molecular type":"Protein","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":28345223,"Description":"MMR genes correct mismatched nucleotides and inser-tion\u2013deletion loops (IDLs) in DNA caused by polymerase errors, chemical modi\ufb01cations, and recombination between heterologous DNA sequences We found that the young group of CRC patients with dMMR had higher overall survival (OS) than the young group of patients with proficient MMR (pMMR) (77% vs. 56%, P = 0.03). Middle-aged patients with dMMR also had higher OS than middle-aged group patients with pMMR (78% vs. 68%, P = 0.012). However, we found no statistical difference in OS between dMMR and pMMR status in the older group of patients (75% vs. 71%, P = 0.224). Finally, the middle- and older-aged group set of patients had higher OS than the young group of patients (69% vs. 71% vs. 59%, P = 0.008). These data demonstrated that the age of disease onset can be an important factor to help evaluate the prognosis of CRC when combined with the analysis of MMR status within tumor biopsied tissue.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":823},{"Name":"UMPS 638 CC genotype","Molecular type":null,"Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Pharmacogenetic profiling","Usage":"PredictiveBM","Pmid":28347333,"Description":"Polymorphisms Patients with the UMPS 638 CC genotype experienced significantly more frequent grade 2 or 3 diarrhea (p for trend\u2009=\u20090.018). The UMPS 638 CC genotype might be a candidate biomarker predicting toxicity in patients receiving tegafur-uracil\/leucovorin-based preoperative chemoradiation for locally advanced rectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":824},{"Name":"Interleukin-6 (IL-6)","Molecular type":null,"Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"Immunohistochemistry","Usage":"PrognosticBM","Pmid":28348483,"Description":"Interleukin-6 (IL-6) is an important pro-inflammatory cytokine produced particularly by macrophages but also by other stromal cells such as neutrophils, cancer-associated fibroblasts and endothelial cells, as well as some cancer cells  IL-6 expression was significantly elevated in CRC tissues compared with noncancerous tissues (P < 0.001).  IL-6 might be a useful marker for predicting a poor prognosis in patients with CRC and might be used as a potential therapeutic target in CRC.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":825},{"Name":"Hsa_circRNA_103809, Hsa_circRNA_104700","Molecular type":"RNA","Location":"Colon, Rectum","Source":"Tissue","Assay\/Test":"qRT\u2013PCR|circRNA array","Usage":"DiagnosticBM","Pmid":28349836,"Description":"Circular RNA, a class of non-coding RNA, is a new group of RNAs and is related to tumorigenesis.  The expression levels of hsa_circRNA_103809 ( p\u2009<\u20090.0001) and hsa_circRNA_104700 ( p\u2009=\u20090.0003) were significantly lower in colorectal cancer than in normal tissues. The expression level of hsa_circRNA_103809 was significantly correlated with lymph node metastasis ( p\u2009=\u20090.021) and tumor-node-metastasis stage ( p\u2009=\u20090.011), and the expression level of hsa_circRNA_104700 was significantly correlated with distal metastasis ( p\u2009=\u20090.036).  In conclusion, these results suggest that hsa_circRNA_103809 and hsa_circRNA_104700 may be potentially involved in the development of colorectal cancer and serve as potential biomarkers for the diagnosis of colorectal cancer.","Disease":"Colorectal Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Type":"Molecular Biomarker","In a panel":null,"Evidence level":null,"Molecular ID":null,"Source ID":"UBERON_0000479","Id":826}]